CARDIAC RHYTHM MANAGEMENT

Product Performance Report 2022 First Edition



Letter from Abbott

As a world leader in the development of state-of-the-art technology for cardiac rhythm management devices, Abbott continuously strives to partner with physicians in reducing risks and facilitating the best possible patient outcomes. We understand that our products are implanted in people whose health and well-being depend on their performance. From product design through patient follow-up, Abbott employees are dedicated to product quality and patient safety.

In keeping with this commitment, we publish the Product Performance Report (PPR) semi-annually to ensure that the healthcare community and the patients it serves are informed about the performance of our cardiac devices, which include, implantable cardioverter defibrillators (ICDs), implantable pacemakers, and implantable pacing and defibrillation leads. Abbott recognizes that such performance data must be transparent and consistent.

In order to meet these goals we continue our commitment to the reporting methods described in the 2009 AdvaMed document "Industry Guidance for Uniform Reporting of Clinical Performance of Cardiac Rhythm Management Pulse Generators and Leads", which set standards for lead and pulse generator performance reporting. Determined to provide the highest level of transparency, Abbott goes beyond the AdvaMed recommendations by identifying the root cause of each ICM, ICD, and pacemaker malfunction and providing subcategories of lead malfunctions.

Continuing within this edition of the PPR and consistent with previously published editions, Abbott reports on data from actively monitored studies. Post-Approval Studies are standard practice for Abbott, providing a rich source of actively collected and continuously monitored reliability and performance data for cardiac rhythm management products. This PPR features product performance data from several Abbott post-approval studies encompassing more than 62,000 implants from multiple product families, including leads, ICDs and pacemakers, making it the most comprehensive actively monitored product performance dataset in the industry.

As we continually strive to provide unbiased and reliable information on the performance of our products, Abbott is pleased to release the first edition of the 2022 Product Performance Report containing the latest performance information on our ICDs, pacemakers and lead systems.

Sincerely,

B. Blue

Robert Blunt Divisional Vice President, Quality

Table of Contents

ARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES	
RT ICDS	
Performance Data	1.
Battery Longevity	5
Summary Information	5
RT PACEMAKERS	
Performance Data	6
Summary Information	7
FT-HEART LEADS	
Performance Data	7
Summary Information	9
PLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DEVI	
UAL-CHAMBER	
Performance Data	9
	· · · · · · · · · · · · · · · · · · ·
Performance Data Battery Longevity Summary Information	9 1: 1:
Performance Data Battery Longevity Summary Information	1
Performance Data Battery Longevity Summary Information	1: 1:
Performance Data Battery Longevity Summary Information NGLE-CHAMBER	1. 1. 1.
Performance Data Battery Longevity Summary Information NGLE-CHAMBER Performance Data	1 1 1 1
Performance Data Battery Longevity Summary Information NGLE-CHAMBER Performance Data Battery Longevity Summary Information	1: 1: 1: 1: 1:
Battery Longevity Summary Information INGLE-CHAMBER Performance Data Battery Longevity	1

Table of Contents

ACEMAKERS	
DUAL-CHAMBER	
Performance Data	207
Summary Information	227
SINGLE-CHAMBER	
Performance Data	235
Summary Information	249
ACING LEADS	
Performance Data	256
Summary Information	282
MPLANTABLE CARDIAC MONITORS (ICMS)	
Summary Information	289
OCUS ON CLINICAL PERFORMANCE	
ICD Premature Battery Depletion Advisory Update	292
Update on Riata [®] Lead Performance	295
Update on Durata" Lead Performance	299
Update on Optim [™] Lead Insulation	300
ADVISORIES AND SAFETY ALERTS	302
HEALTHCARE PROFESSIONAL COMMUNICATIONS	326
NDEX	328
NDEX OF PHASED-OUT MODELS	331

Serving Our Mission

Abbott is advancing the treatment of heart and vascular disease through breakthrough medical technologies, allowing people to restore their health and get on with their lives. We focus on improving treatment options for coronary artery disease, cardiac rhythm management, atrial fibrillation, heart failure, structural heart and peripheral artery disease. We are here for the people we serve in their pursuit of healthy lives. This has been the way of Abbott for more than a century—passionately and thoughtfully translating science into lasting contributions to health.

Toward this mission, we maintain a rigorous approach to ensuring the quality of our products. The key elements of this effort include:

- Compliance with U.S. and International quality system standards, such as the U.S. FDA Quality Systems Regulation (21 CFR Part 820) and ISO 13485 (an international standard for the Quality Management System for medical devices)
- Thorough evaluation of product design, including extensive design verification and validation, as well as product qualification testing
- Rigorous control of the design and manufacturing processes
- Inspection and qualification of externally supplied components and materials
- Timely analysis of returned products, including extensive malfunction investigation
- Extensive and frequent internal auditing
- Post market surveillance
- Continuous improvement programs
- Ensuring the highest ethical standards

We continue to be committed to answering your questions and keeping you informed. If you have any questions or concerns, please contact your Abbott Representative or Abbott Technical Services at 1-800-722-3774. Thank you for your input and continued support, allowing Abbott to positively impact the lives of thousands of patients every year.

What's New in This Report

UPDATE ON FORTIFY", FORTIFY ASSURA", QUADRA ASSURA", QUADRA ASSURA MP", UNIFY", UNIFY ASSURA" AND UNIFY QUADRA ICD PREMATURE BATTERY DEPLETION ADVISORY

In order to provide the most up-to-date information, Abbott has included an update on the Fortify™, Fortify Assura™, Quadra Assura™,

Quadra Assura MP^{**}, Unify^{**}, Unify Assura^{**} and Unify Quadra^{**} ICD premature battery depletion advisory (October 2016) in the Focus on Clinical Performance section (see pages 292-294). This section includes an overview on the analysis of products returned to Abbott. Additionally, for advisory models with at least 500 active devices in service, Abbott provides a separate product performance data page per model number.

UPDATE ON RIATA[™] LEAD PERFORMANCE

Since 2011, Abbott continues to include an update on Riata lead performance in the Focus on Clinical Performance section (see pages 295-298). This section provides the latest Riata lead externalized conductor rates from complaint and returns handling, and describes in considerable detail the rates of other types of Riata insulation abrasion failure mechanisms that Abbott has identified from returns analysis.

UPDATE ON DURATA[™] LEAD PERFORMANCE

Durata lead performance continues to meet expectations by all measures. Our confidence in the Durata lead performance is based on combined data from three prospective, actively monitored registries that include approximately 11,000 Optim[™] insulated defibrillation leads. Additionally, this section provides details on the very low rate of abrasion failures that have been identified on Optim insulated defibrillation leads. A statistical analysis of this registry data performed by PHRI, and independent, third-party has been published in December 2021 as a manuscript in the *Heart Rhythm 0² Journal* (heartrhythmopen.com).

UPDATE ON OPTIM[™] LEAD INSULATION

The Abbott Optim lead insulation combines the best characteristics of two established lead insulation materials, polyurethane and silicone. This novel insulation technology imparts lubricity, strength, and abrasion resistance while still maintaining flexibility and biostability. This Product Performance Report provides an up-to-date statistical assessment of the long-term durability of Optim lead insulation on Abbott defibrillation leads (see pages 300-301).

Customer Reported Performance Data

Product performance data derived from customer-initiated complaints and returned products is referred to as Customer Reported Performance Data. While Abbott strongly encourages the submission of any relevant complaints and product returns; this data is not proactively solicited or regularly monitored like data from the Post-Approval studies. Underreporting of events within customer reported performance data is recognized throughout our industry. Abbott is constantly improving the accuracy and utility of the data within this Product Performance Report.

SUMMARY INFORMATION

The Customer Reported Performance Data page for each model or model group includes a table of model-specific information. Several terms from this table that are relevant to performance data calculations are defined below:

Registered U.S. Implants - The total number of U.S. implanted devices for which patient and device information has been provided to Abbott. This total includes devices which have been explanted or are otherwise out of service.

Estimated Active U.S. Implants - The total number of U.S. registered implants that have not been identified to Abbott as explanted or otherwise out of service. An adjustment is made to account for the underreporting of patient mortality. Abbott performed an analysis of the data gathered from multiple clinical studies including some Abbott sponsored studies to determine the mortality rate within the pacemaker and ICD patient population and has factored this into the estimation of the number of active U.S. implants.

Estimated Longevity - The estimated number of years in which a device is expected to reach its Elective Replacement Indicator (ERI), as stated in the product literature. The estimate is based on battery life approximations and empirical battery performance distributions. It is strongly affected by many factors such as programmed parameters, percentage of time paced, internal impedance, etc. For example, the 9.2 year estimated longevity of an Accent[®] DR model PM2110 pacemaker is based on the mean longevity (or 50%) value in the product literature corresponding to pacing at 60 ppm, 2.5V dual-chamber output at 0.4 ms pulse width, 500 ohm lead impedance, 100% DDD pacing, and Stored EGMs On. Actual performance can vary considerably, depending on the actual programmed settings and operations.

Normal Battery Depletion - The condition where a returned device met its electrical specification and reached its elective replacement indicator voltage (1) with an implant duration meeting or exceeding the nominal predicted longevity at default shipped settings, or (2) with an implant duration exceeding 75% of its estimated longevity, based on longevity calculations using information from device usage and the actual device settings. The quantity of normal battery depletions reported is determined directly from laboratory analysis and does not represent any adjustment to account for underreporting.

SURVIVAL CALCULATION GENERAL METHODS

For ICDs, pacemakers, ICMs, and leads, we compile cumulative survival data based on the actuarial (or life-table) method of survival analysis, consistent with ISO 5841-2:2014(E) "Reporting of Clinical Performance of Populations of Pulse Generators and Leads" and the 2009 AdvaMed document "Industry Guidance for Uniform Reporting of Clinical Performance of Cardiac Rhythm Management Pulse Generators and Leads". Product performance is plotted over a maximum range of 20 years, with a minimum of 500 registered implants required for inclusion in the report, and a minimum sample size for each reported time period of 200 devices. "Survival" refers to the proper function of the device, not the survival of the patient, and is intended to illustrate the calculated probability of device survival at a given point in time. A survival probability of 99% at five years, for example, indicates that at five years after implant, the system has a 1% risk of incurring a malfunction and/or normal battery depletion. All domestically implanted devices within each model family are included in the calculations.

With the large size of the U.S. data pool, and the same products are generally used both in the U.S. and internationally, we consider the data in this report to accurately represent each device's performance, regardless of where in the world it was implanted.

The ISO 5841-2:2014(E) "Reporting of Clinical Performance of Populations of Pulse Generators and Leads" was revised in August 2014. The revision clarified survivor definitions and reporting methods, further standardizing product performance reporting across the cardiac rhythm management implantable device and lead manufacturers.

This revision of the ISO standard specifically excludes lead malfunctions confirmed through returned product analysis which were received with no accompanying complaint from the survival probability calculations. However, to provide the highest level of transparency, Abbott continues to include malfunctions not associated with a complaint in the survival probability calculations and in the tabular display of laboratory-confirmed malfunctions.

ICD, PACEMAKER, AND ICM SURVIVAL ANALYSIS

The data used for the analysis of ICDs, pacemakers, and ICMs includes up-to-date device registration information and the laboratory analysis of all domestically implanted devices returned to Abbott. The analysis measures device performance to specification, and does not reflect medical complications, such as infection, erosion, muscle stimulation or inhibition, or units implanted for fewer than 24 hours.

In accordance with ISO 5841-2:2014(E), the survival calculations for ICDs and pacemakers are adjusted to reduce the bias caused by underreporting of malfunctions and normal battery depletions. Abbott compared the malfunctions and normal battery depletion rates calculated from our actively monitored populations to the rates calculated from our passively monitored populations and have adjusted the survival calculations accordingly.

Survival data are presented in a single table and graph. The survival data is separated into "Including Normal Battery Depletion" and "Excluding Normal Battery Depletion" data reflects the frequency of device removal due to normal battery depletion and malfunction of any type. The "Excluding Normal Battery Depletion" category reflects the frequency of device removal due to malfunctions only.

ICD, PACEMAKER, AND ICM MALFUNCTION REPORTING

The quantity and rate of malfunctions recorded for each ICD, pacemaker, and ICM model are presented in a tabular format on both the Customer Reported Performance Data and Actively Monitored Study Data pages. The root cause of all laboratory-confirmed malfunctions is classified into one of eight categories: Electrical Component, Electrical Interconnect, Battery, High Voltage Capacitor (ICDs and CRT-Ds only), Software/Firmware, Mechanical, Possible Early Battery Depletion, or Other. Note that in the rare cases where multiple malfunctions are identified in a single device, a single malfunction category will be selected with priority given in the order of the list above. Consistent with previous performance reports, ICD and Pacemaker malfunctions are further classified as with or without compromised therapy.

ISO 5841-2 (E) was revised in August 2014. This version of the standard (ISO 5841-2:2014 (E)) modified the definitions of device malfunctions with compromised therapy and device malfunctions without compromised therapy from the previous version of the standard (ISO 5841-2:2000 (E)). In Product Performance Reports (PPRs) published prior to July 2021, Abbott used the definitions of these terms included in ISO 5841-2:2000 (E). Beginning with the July 2021 PPR, Abbott is using the revised definitions in ISO 5841-2:2014 (E) to classify device malfunctions. Abbott maintains its commitment to provide the highest level of transparency in reporting.

Malfunction Definitions

Malfunction - failure of a device to meet its performance specifications or otherwise perform as intended.

Malfunction with Compromised Therapy - device malfunction causing compromised pacing or defibrillation therapy (including complete loss or partial degradation) while implanted and in service.

Malfunction without Compromised Therapy - Pulse generator malfunction that did not compromise pacing or defibrillation therapy while implanted and in service.

Note: Therapy is not compromised as long as the critical patient-protective pacing and defibrillation therapies are available. This includes changes in device settings that occur as intended by the design and do not result in loss of critical patient protective therapies but are the reported reasons for explant. Examples include (but are not limited to): reversion to a designed "safe mode", "backup mode", "power-on reset" or other manufacturer specific terminology, error-affecting diagnostic functions, telemetry function, data storage, malfunction of a component that causes battery to lose power quickly enough to cause premature battery depletion, but slowly enough that the condition is detected through normal follow-up before therapy is lost; mechanical problems with connector header that do not affect therapy.

Malfunction Root Cause Category Definitions

Electrical Component - Findings linked to electrical components such as integrated circuits, resistors, low voltage capacitors, diodes, etc. Does not include high voltage capacitors or batteries as those are separately listed.

Electrical Interconnect - Findings linked to the connections between electrical components such as wires, solder joints, wire bonds, feedthroughs, etc.

Battery - Findings linked to the battery and its components.

High Voltage Capacitor - Findings linked to the high voltage capacitor and its components.

Software/Firmware - Findings linked to software or firmware function.

Mechanical - Findings linked to mechanical components such as headers, setscrews, fluid seals, internal supports, the hermetic case, etc.

Possible Early Battery Depletion - Findings where the actual reported implant time is less than 75% of the expected longevity calculated using the available device setting information and no root cause was able to be identified. Additionally, in the absence of a specific root cause finding, returned devices with insufficient device setting information to determine conclusively if battery depletion was normal or premature are conservatively classified as Possible Early Battery Depletion malfunctions.

Other - Findings linked to other components such as packaging and accessories, and findings where analysis is inconclusive, as well as other complications not included above.

LEADS SURVIVAL ANALYSIS

Implanted cardiac leads are subjected to constant, complex flexural and torsional forces, interactions with other leads and/or the pulse generator device, plus other forces associated with cardiac contractions, patient physical activity, posture, and anatomy. Therefore, the functional lifetime of cardiac leads is limited and cannot be predicted with a high degree of confidence. Understanding these limitations, survival estimates are provided for all leads included in this report.

The data used for the survival analysis of leads includes up-to-date lead registration information, chronic complications (>30 days) reported by the field, and the laboratory analysis of all domestically implanted leads returned to Abbott. Complaints reported within 30 days of implant (acute observations), are considered to be related to factors other than lead malfunction, such as patient specific characteristics or implant technique, and are therefore excluded from the survival calculations, consistent with industry practice. If there is laboratory data that determines the lead to have exhibited a malfunction, and the lead is known to have been implanted for more than 24 hours, the lead is counted as a non-survivor. If a lead is the subject of a complaint report, and was implanted for more than 30 days (chronic complication), then the lead is counted as a non-survivor. These criteria are also followed for partial lead returns. This method for non-returned complications is used to ensure a conservative failure estimate for lead performance. Chronic complications commonly associated with non-returned leads and partial lead returns include, but are not limited to, reports of sensing, pacing, and capture anomalies, perforation, and dislodgement.

LEADS OBSERVATION AND COMPLICATION REPORTING

Reporting for recently released lead models provides detail on specific chronic complications (more than 30 days implant), as well as acute observations (post implant to 30 days), that are reported to Abbott as complaints. Each complication and observation is categorized into one of the eleven categories below, irrespective of whether the lead has been returned for analysis. The quantity and rate of each complication and observation type is provided in a tabular format on the Customer Reported Performance Data page. Note that in the rare cases where multiple complaints are identified for a single lead, a single category will be selected with priority given in the order of the list below.

Cardiac Perforation - Penetration of the lead tip through the myocardium, clinically suspected and confirmed by chest x-ray, fluoroscopy, echocardiogram, or visual observation, which results in clinical symptoms, typically degradation of pacing/ICD lead electrical performance (high thresholds), chest pain, or tamponade.

Conductor Fracture - A mechanical break within a lead conductor (includes connectors, coils, cables and/or electrodes) observed visually, electrically, or radiographically.

Lead Dislodgement - Radiographic, electrical or electrocardiographic evidence of electrode displacement from the original implant site or electrode displacement that adversely affects pacing and/or lead performance.

Failure to Capture - Intermittent or complete failure to achieve cardiac stimulation (atrial or ventricular) at programmed output delivered outside of the cardiac refractory period. A sudden and significant increase in the pacing threshold value (elevated thresholds compared to previous measured value) at which 2:1 safety margin can no longer be achieved.

Oversensing - Misinterpretation of cardiac or non-cardiac events as cardiac depolarization, e.g. T-waves, skeletal muscle potentials, and extracardiac electromagnetic interference (EMI).

Failure to Sense (undersensing) - Intermittent or complete loss of sensing or failure to detect intended intrinsic cardiac signals (atrial or ventricular) during non-refractory periods at programmed sensitivity settings.

Insulation Breach - A disruption or break in lead insulation observed visually, electrically, or radiographically.

Abnormal Pacing Impedance - Pacing impedance is typically considered abnormal if a measurement is < 200 Ω or > 2000 Ω (based on lead model and measurement range of the device).

Abnormal Defibrillation Impedance - Defibrillation impedance is typically considered abnormal if a measurement is $< 20 \Omega$ or $> 200 \Omega$ (based on lead model and measurement range of the device).

Extracardiac Stimulation - Clinical observation of inadvertent nerve/muscle stimulation other than cardiac muscle.

Other - Specific proprietary lead mechanical attributes such as lead incorporated sensors, connectors or seal rings which affect a lead's ability to perform as designed or remain in service, as well as other complications not included above.

LEADS MALFUNCTION REPORTING

As a supplement to the survival estimates, the categorization of lead malfunctions emphasizes the root cause of malfunction rather than a functional longevity prediction. In accordance with AdvaMed guidelines, laboratory analysis results of returned leads are categorized into one of the following five categories of malfunctions. The quantity and rate of each malfunction type is provided in a tabular format on the Customer Reported Performance Data and the Actively Monitored Study Data pages. Note that in the rare cases where multiple malfunctions are identified in a single lead, a single malfunction category will be selected with priority given in the order of the list below. The definition for each malfunction type is provided below:

Conductor Fracture - Conductor break with complete or intermittent loss of continuity that could interrupt current flow. This type of malfunction includes any conductor fracture such as those associated with flex-fatigue or clavicular crush damage.

In an effort to further increase customer understanding of Abbott defibrillation and left-heart lead performance, subcategories of conductor fracture are also provided. The definitions of these subcategories are provided below:

Clavicular Crush - Conductor fracture due to strong compression and bending at the approximation of the first rib and clavicle.

In the Pocket - Conductor fracture not within the vascular or cardiac systems, typically within the subcutaneous pocket or associated with the suture sleeve, excluding the mechanism of clavicular crush.

Intravascular - Conductor fracture within the vascular or cardiac systems.

Insulation Breach - Any lead insulation breach, such as: 1) proximal abrasion associated with lead-to-lead or lead-to-can contact in the pocket, 2) mid-lead insulation damage caused by clavicular crush or insulation wear in the region of vein insertion, 3) distal abrasion due to lead-to-lead interactions or contact with anatomic structures, and 4) externalized conductors in the distal region.

Subcategories of insulation breach for defibrillation and left-heart leads are also provided. The definitions of these subcategories are provided below:

Lead-to-Can Contact - Direct contact between the lead and the can (i.e. pacemaker, ICD, or CRT-D) combined with repetitive skeletal movement caused abrasion that resulted in a full thickness outer insulation breach.

Lead-to-Lead Contact - Repetitive contact between two leads caused abrasion that resulted in a full thickness outer insulation breach.

Clavicular Crush - Damage due to strong compression between the first rib and clavicle resulted in a full thickness outer insulation breach.

Externalized Conductors - Abrasion resulted in an outer insulation breach within the vascular or cardiac systems allowing the normally contained conductors to become visible outside the lead body. Externalized conductors were described in our December 2010 and November 2011 communications regarding insulation abrasion failures on silicone Riata[®] and Riata[®] ST lead families (summary on pages 320-321) and in our April 2012 communication regarding insulation abrasion failures on QuickSite[®] and QuickFlex[®] lead families. Additional information regarding externalized conductors on Riata[®] and Riata[®] ST leads can be found at https://www.cardiovascular.abbott/us/en/hcp/product-advisories/riata.html.

Other (Insulation Breach) - Insulation breaches that resulted from a failure mode not represented by the other four categories. This includes a variety of failure modes, such as damage at the suture sleeve and contact with patient anatomy. Also includes insulation breaches for which analysis was unable to isolate a specific cause.

Crimps, Welds and Bonds - Any interruption in the conductor or lead body associated with a point of connection.

Other - Includes specific proprietary lead mechanical attributes, such as lead incorporated sensors, connectors, and seal rings, as well as other analysis results not included in the alternate categories.

Extrinsic Factors - The lead was implanted greater than 30 days, removed from service with an associated complaint and returned for analysis, however analysis was inconclusive because (1) only portions of the lead were available, or (2) the returned lead was damaged by the explanation process, or (3) lab analysis could not determine an out of specification condition (typically with complaints such as dislodgements, perforations, or failure to capture).

Actively Monitored Study Data

SUMMARY INFORMATION

Since 2007 the Product Performance Report has included data from the St. Jude Medical Product Longevity and Performance Registry (SCORE). This comprehensive study provided monitored performance data on pacemakers, ICDs, and leads. With product-specific, post-market registries being standard practice, Abbott complemented the SCORE registry with data from the SJ4 Post-Approval Study, the QuickFlex[®] µ Lead Post-Approval Study, the Quadripolar CRT-D Post-Approval Study, and the OPTIMUM registry. These actively monitored study data sets represent >62,000 implanted devices, and provide a very powerful source of product performance information which complements the data collected from Customer Reported Performance Data. Actively monitored study data is not susceptible to underreporting and provides the most accurate understanding of product performance. The sites participating in these studies individually provided data on the performance of Abbott cardiac rhythm management products using common definitions and criteria. In addition, each of these sites were regularly audited by Abbott personnel to ensure comprehensive reporting. All five studies are now closed per protocol and the enrolled devices and leads continue to be monitored according to the ISO 5841-2:2014(E) standard.

	STUDY DESCRIPTION	STUDY INITIATED	# SITES	# PATIENTS	PRODUCT TYPES/FAMILIES
SCORE (ST. JUDE MEDICAL PRODUCT LONGEVITY AND PERFORMANCE REGISTRY)	Prospective, actively monitored, multicenter registry to evaluate the long-term performance of Abbott market-released cardiac rhythm management products.	September 2007	80	11,247	Pacemakers, ICDs, CRT-Ds, Leads (all types)
SJ4 POST-APPROVAL STUDY	Prospective, actively monitored, multicenter study to evaluate the acute and chronic performance of the Abbott SJ4/DF4 connector and SJ4/DF4 defibrillation leads.	June 2009	58	1,701	ICDs, CRT-Ds, Leads (all types)
QUICKFLEX" µ POST-APPROVAL STUDY	Prospective, actively monitored, multicenter study to evaluate the acute and chronic performance of the Abbott QuickFlex [~] µ1258T left ventricular leads.	September 2010	76	1,930	CRT-Ds, Leads (all types)
QUADRIPOLAR CRT-D POST-APPROVAL STUDY	Prospective, actively monitored, multicenter study to evaluate the acute and chronic performance of the Abbott Quadripolar CRT-D system.	February 2012	71	1,970	Unify Quadra [~] and Quadra Assura [~] CRT-Ds, Leads (all types)
OPTIMUM REGISTRY	Prospective, actively monitored, multicenter registry to evaluate the long-term performance of market-released Abbott leads with Optim" insulation material.	August 2006	241	14,120	Leads (any model with Optim [®] Insulation)

The models included in the actively monitored data set are listed below:

ICDS

Current^{**} + DR (Model CD2211-36) Current^{**} + DR (Model CD2211-36Q) Current[™] + VR (Model CD1211-36Q) Current[™] DR RF (Model 2207-36) Current[™] VR RF (Model 1207-36) Fortify[™] DR (Model CD2231-40) Fortify^{**} DR (Model CD2231-40Q) Fortify" VR (Model CD1231-40Q) Promote[™] + CRT-D (Model CD3211-36) Promote[™] + CRT-D (Model CD3211-36Q) Promote^{^{TT}} RF CRT-D (Model 3207-36) Quadra Assura[™] CRT-D (Model CD3265-40) Quadra Assura[™] CRT-D (Model CD3265-40Q) Quadra Assura[™] CRT-D (Model CD3365-40Q) Quadra Assura MP^{^w} CRT-D (Model CD3369-40Q) Unify Assura[™] CRT-D (Model CD3357-40C) Unify Assura[®] CRT-D (Model CD3357-40Q) Unify Quadra[®] CRT-D (Model CD3249-40) Unify Quadra^{**} CRT-D (Model CD3249-40Q) Unify[®] CRT-D (Model CD3231-40) Unify[™] CRT-D (Model CD3231-40Q)

DEFIBRILLATION LEADS

Durata" (Model 7122) Durata" (Models 7120/7121) Durata" DF4 (Model 7122Q) Durata" DF4 (Models 7120Q/7121Q) Durata" DF4 (Models 7170Q/7171Q) Riata" (Models 1580/1581) Riata" ST (Models 7000/7001) Riata" ST Optim" (Models 7020/7021) Riata" ST Optim" (Models 7070/7071)

CRT LEADS

Quartet" (Model 1458Q) QuickFlex" (Model 1156T) QuickFlex" XL (Model 1158T) QuickFlex" µ (Model 1258T) QuickSite" (Model 1056T) QuickSite" XL (Model 1058T)

PACEMAKERS

Accent[®] DR (Model PM2110) Accent[®] DR RF (Model PM2210) Accent[®] SR RF (Model PM1210) Anthem[®] RF CRT-P (Model PM3210) Identity ADx[®] XL DR (Model 5386) Victory[®] XL DR (Model 5816) Zephyr[®] DR (Model 5820) Zephyr[®] XL DR (Model 5826) Zephyr[®] XL SR (Model 5626)

PACING LEADS

IsoFlex" Optim" (Model 1944) IsoFlex" Optim" (Model 1948) IsoFlex" S (Model 1646) OptiSense" (Model 1699) OptiSense" (Model 1999) Tendril" (Model 1782) Tendril" (Model 1788) Tendril" SDX (Model 1688) Tendril" ST Optim" (Model 1882) Tendril" ST Optim" (Model 1888)

QUALIFYING COMPLICATIONS

When abnormal performance was suspected of an actively monitored study device, the related clinical event and any resulting clinical action were reported to Abbott. A Qualifying Complication was defined to have occurred if the report identified one of the following Clinical Events that resulted in one of the following Clinical Actions. Any Clinical Event without a related Clinical Action was not considered a Qualifying Complication.

QUALIFYING CLINICAL EVENTS

Abnormal Defibrillation Impedance Abnormal Pacing Impedance Cardiac Perforation Conductor Fracture Extracardiac Stimulation Failure to Capture Failure to Capture Failure to Sense Inappropriate Shock Insulation Breach Lead Dislodgement Loss of Telemetry Oversensing Pericardial Effusion Premature Battery Depletion

QUALIFYING CLINICAL ACTION

Generator Pacing Mode Changed Lead Electrically Abandoned/Capped Lead/Generator Explanted Lead/Generator Replaced Lead Polarity Changed Lead Surgically Abandoned/Capped Lead Surgically Repositioned

SURVIVAL CALCULATION METHODS

Survival calculations for actively monitored studies were made in a manner consistent with the ISO 5841-2:2014(E) method used for Customer Reported Performance Data. A minimum of 100 devices were required to have been enrolled, with the latest interval to be reported having a minimum of 50 devices which have been followed for at least six months. Any device with a Qualifying Complication was defined as a non-survivor. Consistent with industry practice, Qualifying Complications for leads were included in the survival calculations for events with an implant duration greater than 30 days. For pacemakers and ICDs, Qualifying Complications were included in the survival calculations for events with an implant duration more than 24 hours. Medical complications unrelated to device performance were not considered as Qualified Complications. Devices included in the actively monitored studies were excluded from the Customer Reported Performance Data throughout the duration of the study. Certain devices and leads, including any which transferred from Customer Reported Performance Data into Actively Monitored Study Data were subsequently excluded from the Customer Reported Performance Data and subject to these Survival Calculation methods. Actively monitored study performance data includes both advisory and non-advisory devices.

MALFUNCTION REPORTING

The Actively Monitored Study Data page contains a table of all device malfunctions. The type, quantity, and rate of all laboratory-confirmed malfunctions are listed using the same categories reported in Customer Reported Performance Data. The malfunction data is not utilized in the actively monitored study survival calculations, but does provide important supplementary information about product performance and reliability.

Medical Advisory Board Review

Abbott has an established and independent Medical Advisory Board (MAB) focused on cardiac rhythm management systems, including pulse generators and leads. One of the important tasks assigned to the MAB is the review of the performance data contained in this report prior to its release and publication on a semi-annual basis. MAB members and their location of practice include:

Dr. Anne Curtis, Buffalo, New York	Dr. Thomas Mattioni, Paradise Valley, Arizona
Dr. Roger Freedman, Salt Lake City, Utah	Dr. Raymond Schaerf, Burbank, California
Dr. Christoph Geller, Bad Berka, Germany	Dr. Bruce Wilkoff, Cleveland, Ohio

Returning Devices to Abbott

To maintain the continued accuracy of our performance reporting, Abbott strongly encourages physicians to notify our Patient Records department (800-550-1648) each time a device is removed from service for any reason. Additionally, all explanted products are requested to be returned to Abbott for laboratory evaluation whether or not a malfunction is suspected. To facilitate the return of explanted devices, Abbott offers a no-cost Returned Products Kit comprised of a postage paid explant box with a shipping address label, a removed device information form, a biohazard bag, and biohazard labels to seal the explant box. This kit, #N0004, can be ordered free of charge by contacting Abbott Customer Service (800-681-9293).


Contact Us

The Abbott team is always ready to respond to questions, comments or suggestions as well as receive product performance feedback. You can reach us by phone at 651-756-2000, on the web at www.abbott.com, or by contacting your local Abbott representative.

Cardiac Resynchronization Therapy (CRT) ICDs

Gallant[™] HF CRT-D MODEL CDHFA500O*

Gallant [®] HF CRT-D MODEL CDHFA500Q*				ICTIONS ROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	July 2020	Electrical Component	0	0.00%	0	0.00%	
Registered US Implants	9,415	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	8,855	Battery	0	0.00%	0	0.00%	
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%	
Normal Battery Depletion	0	Software/Firmware	0	0.00%	0	0.00%	
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	0	0.00%	
		Other	1	0.01%	1	0.01%	
		Total	1	0.01%	1	0.01%	




INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 14 MONTHS
SURVIVAL PROBABILITY	99.95%	99.95%
±1 STANDARD ERROR	0.02%	0.02%
SAMPLE SIZE	5,020	360

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 14 MONTHS
SURVIVAL PROBABILITY	99.95%	99.95%
±1 STANDARD ERROR	0.02%	0.02%

Quadra Assura MP[™] CRT-D MALFUNCTIONS W/ COMPROMISED THERAPY MALFUNCTIONS W/O COMPROMISED THERAPY MODEL CD3369-40Q* RATE RATE QTY QTY US Regulatory Approval February 2016 Electrical Component 7 < 0.01% 12 0.02% Electrical Interconnect 0.01% < 0.01% Registered US Implants 71,361 9 1 Battery 0.00% < 0.01% Estimated Active US Implants 52,378 0 1 Estimated Longevity (see table on page 53) High Voltage Capacitor 0.00% 2 < 0.01% 0 Normal Battery Depletion 89 Software/Firmware 0.00% 0 0.00% 0 Max. Delivered Energy 40 joules Mechanical < 0.01% < 0.01% 5 Number of US Advisories (see pg. 304) Possible Early Battery Depletion 0.00% < 0.01% One 2 0 Other < 0.01% < 0.01% 6 4 Total 21 0.03% 29 0.04%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	AT 68 MONTHS
SURVIVAL PROBABILITY	99.85%	99.82%	99.71%	99.29%	98.44%	98.37%
±1 STANDARD ERROR	0.01%	0.02%	0.02%	0.05%	0.10%	0.11%
SAMPLE SIZE	64,450	49,790	35,090	22,460	11,430	520

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	AT 68 MONTHS
SURVIVAL PROBABILITY	99.86%	99.83%	99.81%	99.78%	99.78%	99.78%
± 1 STANDARD ERROR	0.01%	0.02%	0.02%	0.02%	0.02%	0.02%

Cardiac Resynchronization Therapy (CRT) ICDs ACTIVELY MONITORED STUDY DATA

February 2016

(see table on page 53)

117

0

3,575

40 joules

Quadra Assura MP[™] CRT-D MODEL CD3369-40Q*

US Regulatory Approval

Estimated Longevity

Max. Delivered Energy

Number of Devices Enrolled in Study

Active Devices Enrolled in Study


Cumulative Months of Follow-up

QUALIFYING	COMPLICATIONS
------------	---------------

None Reported


	THERAPY		THE	RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	0	0.00%	0	0.00%
Total	0	0.00%	0	0.00%

MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED



ACTIVELY MONITORED STUDY DATA								
YEAR	1	2	3	AT 41 MONTHS				
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%				
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%				
SAMPLE SIZE	110	90	70	50				

Quadra Assura MP[™] CRT-D MALFUNCTIONS W/ COMPROMISED THERAPY MALFUNCTIONS W/O COMPROMISED THERAPY MODEL CD3369-40C* QTY RATE RATE QTY US Regulatory Approval February 2016 Electrical Component 2 0.02% 0.01% 1 Electrical Interconnect 0.02% 0.00% Registered US Implants 9,160 2 0 Battery 0.00% 0.00% Estimated Active US Implants 6,584 Ω 0 Estimated Longevity (see table on page 53) High Voltage Capacitor 0.01% 0.01% 1 Software/Firmware Normal Battery Depletion 0.00% 0 0.00% 24 Max. Delivered Energy 40 joules Mechanical 0.00% 2 0.02% Number of US Advisories (see pg. 304) Possible Early Battery Depletion 0.00% 0.02% One 2 0 Other 0.01% 0.03% 3 1 Total 0.07% 9 0.10%




INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	AT 66 MONTHS
SURVIVAL PROBABILITY	99.83%	99.55%	99.41%	98.86%	96.80%	96.80%
± 1 STANDARD ERROR	0.05%	0.08%	0.09%	0.17%	0.37%	0.39%
SAMPLE SIZE	8,040	6,060	4,470	3,040	1,630	220

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	AT 66 MONTHS
SURVIVAL PROBABILITY	99.85%	99.58%	99.54%	99.54%	99.45%	99.45%
± 1 STANDARD ERROR	0.04%	0.08%	0.08%	0.08%	0.10%	0.10%

Quadra Assura™ CRT-D MODEL CD3365-40Q* (NON-BA	Quadra Assura™ CRT-D MODEL CD3365-40Q* (NON-BATTERY ADVISORY POPULATION)					MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	June 2013	Electrical Component	2	0.01%	4	0.02%	
Registered US Implants	16,686	Electrical Interconnect	3	0.02%	0	0.00%	
Estimated Active US Implants	10,111	Battery	1	< 0.01%	0	0.00%	
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%	
Normal Battery Depletion	129	Software/Firmware	1	< 0.01%	0	0.00%	
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	4	0.02%	
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	1	< 0.01%	3	0.02%	
		Other	1	< 0.01%	4	0.02%	
		Total	9	0.05%	15	0.09%	



YEARS	AFTER	IMPLAN
-------	-------	--------


INCLUDING NORMAL BATTERY DEPLETION -

YEAR	1	2	3	4	5	6	AT 78 MONTHS
SURVIVAL PROBABILITY	99.85%	99.77%	99.65%	99.07%	97.67%	96.01%	96.01%
± 1 STANDARD ERROR	0.03%	0.04%	0.05%	0.09%	0.14%	0.21%	0.21%
SAMPLE SIZE	15,610	13,780	12,360	11,010	9,420	5,830	280

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 78 MONTHS
SURVIVAL PROBABILITY	99.85%	99.77%	99.72%	99.69%	99.64%	99.62%	99.62%
± 1 STANDARD ERROR	0.03%	0.04%	0.04%	0.05%	0.05%	0.05%	0.05%

Quadra Assura [™] CRT-D MODEL CD3365-40Q* (BATTERY A	Quadra Assura™ CRT-D MODEL CD3365-40Q* (BATTERY ADVISORY POPULATION)						MALFUNCTIONS W/O COMPROMISED THERAPY		
				QTY	RATE		QTY	RATE	
US Regulatory Approval	June 2013		Electrical Component	6	0.02%		14	0.06%	
Registered US Implants	24,081		Electrical Interconnect	10	0.04%		0	0.00%	
Estimated Active US Implants	9,491		Battery	3	0.01%		17	0.07%	
Estimated Longevity	(see table on page 53)		High Voltage Capacitor	1	< 0.01%		0	0.00%	
Normal Battery Depletion	472		Software/Firmware	1	< 0.01%		3	0.01%	
Max. Delivered Energy	40 joules		Mechanical	0	0.00%		2	<0.01%	
Number of US Advisories (see pgs. 304, 305)	Three		Possible Early Battery Depletion	43	0.18%		398	1.65%	
			Other	6	0.02%		7	0.03%	
			Total	70	0.29%		441	1.83%	



INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 99 MONTHS
SURVIVAL PROBABILITY	99.78%	99.40%	98.18%	95.37%	91.58%	85.71%	83.76%	83.24%	83.24%
± 1 STANDARD ERROR	0.03%	0.05%	0.09%	0.16%	0.21%	0.28%	0.30%	0.32%	0.32%
SAMPLE SIZE	22,620	19,960	17,620	15,720	14,240	12,640	8,970	3,390	270

EXCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	AT 99 MONTHS
SURVIVAL PROBABILITY	99.83%	99.54%	98.50%	96.14%	94.06%	92.52%	91.69%	91.56%	91.56%
± 1 STANDARD ERROR	0.03%	0.04%	0.09%	0.14%	0.18%	0.21%	0.23%	0.23%	0.23%

Cardiac Resynchronization Therapy (CRT) ICDs ACTIVELY MONITORED STUDY DATA

Quadra Assura[™] CRT-D MODEL CD3365-40Q*


		QUALIFYING COMPLICATIONS	QTY	RATE
S Regulatory Approval	June 2013	Skin Erosion	1	0.43%
umber of Devices Enrolled in Study	235			
tive Devices Enrolled in Study	0			
umulative Months of Follow-up	10,102			
timated Longevity	(see table on page 53)			
x. Delivered Energy	40 joules			

	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	2	0.85%
Other	0	0.00%	0	0.00%
Total	0	0.00%	2	0.85%



ACTIVELY MONITORED STUDY DATA											
YEAR	1	2	3	4	5	6	AT 74 MONTHS				
SURVIVAL PROBABILITY	99.55%	99.55%	99.55%	99.55%	99.55%	99.55%	99.55%				
±1 STANDARD ERROR	0.44%	0.44%	0.44%	0.44%	0.44%	0.44%	0.44%				
SAMPLE SIZE	220	190	160	120	70	60	50				

Quadra Assura [™] CRT-D MODEL CD3365-40C* (NON-BAT	W/ COMF	NCTIONS PROMISED RAPY	MALFUN W/O COMI THEF	PROMISED		
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	0	0.00%	1	0.04%
Registered US Implants	2,659	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,594	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	2	0.08%	0	0.00%
Normal Battery Depletion	16	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	1	0.04%	0	0.00%
		Total	3	0.11%	1	0.04%



YEARS	AFTER	IMPLAN
-------	-------	--------


INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 75 MONTHS
SURVIVAL PROBABILITY	100.00%	99.81%	99.60%	98.73%	98.43%	96.51%	96.51%
±1 STANDARD ERROR	0.00%	0.09%	0.14%	0.25%	0.28%	0.49%	0.61%
SAMPLE SIZE	2,480	2,180	1,950	1,720	1,380	750	200

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 75 MONTHS
SURVIVAL PROBABILITY	100.00%	99.81%	99.71%	99.59%	99.59%	99.59%	99.59%
±1 STANDARD ERROR	0.00%	0.09%	0.12%	0.14%	0.14%	0.14%	0.14%

Quadra Assura [™] CRT-D MODEL CD3365-40C* (BATTERY A	W/ COMP	AALFUNCTIONS MALFUNCTI COMPROMISED W/O COMPRO THERAPY THERAPY		ROMISED		
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	6	0.11%	2	0.04%
Registered US Implants	5,626	Electrical Interconnect	2	0.04%	0	0.00%
Estimated Active US Implants	2,206	Battery	1	0.02%	1	0.02%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	101	Software/Firmware	0	0.00%	1	0.02%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	8	0.14%	55	0.98%
		Other	3	0.05%	2	0.04%
		Total	20	0.36%	61	1.08%



YEARS AFTER IMPLANT


INCLUDING	NORMAL BATT	ERY DEPLETION	_

YEAR	1	2	3	4	5	6	7	8
SURVIVAL PROBABILITY	99.74%	99.27%	98.38%	96.70%	93.48%	88.29%	86.29%	83.90%
± 1 STANDARD ERROR	0.07%	0.12%	0.19%	0.28%	0.40%	0.56%	0.62%	0.76%
SAMPLE SIZE	5,200	4,440	3,830	3,400	3,090	2,670	1,820	220

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8
SURVIVAL PROBABILITY	99.78%	99.31%	98.42%	97.41%	96.15%	94.90%	94.45%	93.26%
± 1 STANDARD ERROR	0.06%	0.12%	0.19%	0.25%	0.32%	0.37%	0.40%	0.44%

Unify Assura™ CRT-D MODEL CD3357-40Q* (NON-BA	W/ COMP	INCTIONS MALFUNCTION PROMISED W/O COMPROMIS ERAPY THERAPY		PROMISED		
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	0	0.00%	6	0.03%
Registered US Implants	18,171	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	12,390	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	1	< 0.01%	0	0.00%
Normal Battery Depletion	97	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	1	< 0.01%	2	0.01%
		Total	2	0.01%	9	0.05%



YEARS	AFTER	IMPLAN
-------	-------	--------


INCLUDING NORMAL BATTERY DEPLETION -

YEAR	1	2	3	4	5	6	AT 76 MONTHS
SURVIVAL PROBABILITY	99.95%	99.82%	99.45%	98.31%	97.00%	94.58%	94.58%
±1 STANDARD ERROR	0.02%	0.04%	0.07%	0.14%	0.21%	0.42%	0.42%
SAMPLE SIZE	16,400	13,320	10,490	7,490	4,600	1,840	210

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 76 MONTHS
SURVIVAL PROBABILITY	99.95%	99.88%	99.88%	99.82%	99.79%	99.79%	99.79%
± 1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.05%	0.05%	0.05%

Unify Assura™ CRT-D MODEL CD3357-40Q* (BATTERY A		MALFUN W/ COMP THEF		MALFUNCTIONS W/O COMPROMISED THERAPY			
				QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	E	Electrical Component	1	0.02%	2	0.04%
Registered US Implants	5,340	E	Electrical Interconnect	2	0.04%	0	0.00%
Estimated Active US Implants	1,996	E	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 53)	F	High Voltage Capacitor	2	0.04%	0	0.00%
Normal Battery Depletion	180	S	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Ν	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	F	Possible Early Battery Depletion	11	0.21%	69	1.29%
		C	Other	0	0.00%	3	0.06%
		Т	Fotal	16	0.30%	74	1.39%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	1	2	3	4	5	6	7	8
SURVIVAL PROBABILITY	99.78%	99.34%	97.85%	93.55%	87.64%	80.62%	78.86%	78.86%
± 1 STANDARD ERROR	0.06%	0.12%	0.22%	0.40%	0.56%	0.69%	0.74%	0.74%
SAMPLE SIZE	4,980	4,310	3,740	3,290	2,900	2,470	1,630	210

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8
SURVIVAL PROBABILITY	99.90%	99.46%	98.53%	96.55%	94.81%	93.80%	93.39%	93.39%
± 1 STANDARD ERROR	0.04%	0.11%	0.18%	0.30%	0.38%	0.42%	0.45%	0.45%

Cardiac Resynchronization Therapy (CRT) ICDs ACTIVELY MONITORED STUDY DATA

Unify Assura[™] CRT-D MODEL CD3357-40Q*

		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	269		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	10,401		High Voltage Capacitor	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 53)		Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	2	0.74%
			Other	0	0.00%	0	0.00%

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0

0.00%


2

0.74%



ACTIVELY MONITORED ST						
YEAR	1	2	3	4	5	AT 61 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SAMPLE SIZE	250	210	170	130	80	50

Unify Assura™ CRT-D MODEL CD3357-40C* (NON-BA	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	0	0.00%	1	<0.01%
Registered US Implants	16,823	Electrical Interconnect	2	0.01%	1	<0.01%
Estimated Active US Implants	11,044	Battery	0	0.00%	1	<0.01%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	133	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	1	<0.01%
		Other	0	0.00%	4	0.02%
		Total	2	0.01%	9	0.05%



YEARS	AFTER	IMPLAN
-------	-------	--------


INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.93%	99.84%	99.39%	98.13%	95.90%	93.44%	93.44%
± 1 STANDARD ERROR	0.02%	0.03%	0.07%	0.14%	0.24%	0.39%	0.39%
SAMPLE SIZE	15,200	12,330	9,930	7,670	5,220	2,420	260

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.93%	99.89%	99.84%	99.81%	99.81%	99.81%	99.81%
± 1 STANDARD ERROR	0.02%	0.03%	0.04%	0.04%	0.04%	0.04%	0.04%

Unify Assura [™] CRT-D MODEL CD3357-40C* (BATTERY A		W/ COMP	NCTIONS ROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	2	0.02%	3	0.03%
Registered US Implants	9,588	Electrical Interconnect	2	0.02%	1	0.01%
Estimated Active US Implants	3,682	Battery	0	0.00%	6	0.06%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	1	0.01%	0	0.00%
Normal Battery Depletion	319	Software/Firmware	0	0.00%	2	0.02%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	0.01%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	19	0.20%	101	1.05%
		Other	1	0.01%	3	0.03%
		Total	25	0.26%	117	1.22%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.81%	99.44%	97.68%	94.90%	89.93%	82.30%	80.29%	79.52%	79.52%
±1 STANDARD ERROR	0.04%	0.08%	0.17%	0.26%	0.37%	0.49%	0.53%	0.57%	0.57%
SAMPLE SIZE	8,990	7,850	6,810	6,000	5,360	4,680	3,200	1,160	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.89%	99.62%	98.62%	97.01%	95.66%	94.81%	94.25%	93.95%	93.95%
±1 STANDARD ERROR	0.03%	0.07%	0.14%	0.21%	0.26%	0.29%	0.31%	0.34%	0.34%


Cardiac Resynchronization Therapy (CRT) ICDs ACTIVELY MONITORED STUDY DATA

Unify Assura[™] CRT-D MODEL CD3357-40C*

		QUALIFYING C
US Regulatory Approval	June 2013	Premature Batt
Number of Devices Enrolled in Study	232	Skin Erosion
Active Devices Enrolled in Study	0	
Cumulative Months of Follow-up	7,527	
Estimated Longevity	(see table on page 53)	
Max. Delivered Energy	40 joules	


IFYING COMPLICATIONS	QTY	RATE
ture Battery Depletion	4	1.72%
Crosion	1	0.43%

	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	4	1.72%
Other	0	0.00%	0	0.00%
Total	0	0.00%	4	1.72%



ACTIVELY MONITORED ST					
YEAR	1	2	3	4	AT 53 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	97.72%	93.96%
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	1.60%	2.35%
SAMPLE SIZE	210	160	120	80	50

Quadra Assura [™] CRT-D MODEL CD3265-40Q* (BATTERY)	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	Q.	TY RATE
US Regulatory Approval	May 2012	Electrical Component	2	0.01%	(6 0.04%
Registered US Implants	13,540	Electrical Interconnect	1	< 0.01%	(0.00%
Estimated Active US Implants	3,761	Battery	1	< 0.01%	:	7 0.05%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	(0.00%
Normal Battery Depletion	397	Software/Firmware	1	< 0.01%	1	2 0.01%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	÷	3 0.02%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	24	0.18%	10	04 0.77%
		Other	1	< 0.01%	1	< 0.01%
		Total	30	0.22%	12	0.91%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.83%	99.74%	99.38%	97.71%	94.13%	92.34%	88.06%	80.78%	80.09%	80.09%
± 1 STANDARD ERROR	0.04%	0.04%	0.07%	0.15%	0.24%	0.29%	0.36%	0.48%	0.51%	0.51%
SAMPLE SIZE	12,780	11,420	10,290	9,100	8,000	7,100	6,050	4,500	2,090	220


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.87%	99.86%	99.65%	98.88%	97.14%	96.12%	95.61%	95.34%	95.34%	95.34%
±1 STANDARD ERROR	0.03%	0.03%	0.05%	0.11%	0.18%	0.21%	0.23%	0.24%	0.24%	0.24%

Cardiac Resynchronization Therapy (CRT) ICDs ACTIVELY MONITORED STUDY DATA

Quadra Assura[™] CRT-D MODEL CD3265-40Q*

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY
US Regulatory Approval	May 2012	Premature Battery Depletion	1	0.24%	Electrical Component	0
Number of Devices Enrolled in Study	421				Electrical Interconnect	1
Active Devices Enrolled in Study	0				Battery	0
Cumulative Months of Follow-up	19,212				High Voltage Capacitor	0
Estimated Longevity	(see table on page 53)				Software/Firmware	0
Max. Delivered Energy	40 joules				Mechanical	0
					Possible Early Battery Depletion	0
					Other	0



MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

QTY

0

0

0

0

0

0

1

0

1

RATE

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.24%

0.00%

0.24%

RATE

0.00%

0.24%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.24%

1


Total

ACTIVELY MONITORED STUDY DATA									
YEAR	1	2	3	4	5	6	7	AT 85 MONTHS	
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	99.58%	99.58%	99.58%	99.58%	99.58%	
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.42%	0.42%	0.42%	0.42%	0.42%	
SAMPLE SIZE	390	330	270	210	160	140	100	60	

Quadra Assura™ CRT-D	
MODEL CD3265-40 (BATTERY ADVISORY POPULATION)	

US Regulatory Approval	May 2012
Registered US Implants	3,926
Estimated Active US Implants	1,142
Estimated Longevity	(see table on page 53)
Normal Battery Depletion	113
Max. Delivered Energy	40 joules
Number of US Advisories (see pgs. 304, 305)	Three

OPULATION)		W/ COMP	NCTIONS PROMISED RAPY	MALFUNC W/O COMPF THERA	OMISED
		QTY	RATE	QTY	RATE
	Electrical Component	0	0.00%	0	0.00%
	Electrical Interconnect	1	0.03%	0	0.00%
	Battery	0	0.00%	2	0.05%
page 53)	High Voltage Capacitor	0	0.00%	0	0.00%
	Software/Firmware	0	0.00%	1	0.03%
	Mechanical	0	0.00%	0	0.00%
	Possible Early Battery Depletion	5	0.13%	17	0.43%
	Other	7	0.18%	2	0.05%
	Total	13	0.33%	22	0.56%



YEARS AFTER IMPLANT

YEAR	1	2	3	4	5	6	7	8	9	AT 110 MONTHS
SURVIVAL PROBABILITY	99.94%	99.75%	99.62%	98.27%	93.10%	90.80%	87.20%	81.38%	81.38%	81.38%
± 1 STANDARD ERROR	0.04%	0.09%	0.11%	0.25%	0.51%	0.60%	0.71%	0.90%	0.90%	0.90%
SAMPLE SIZE	3,670	3,220	2,870	2,500	2,160	1,890	1,630	1,250	640	220

EXCLUDING NORMAL B	ATTERY DEPLETION
--------------------	------------------

YEAR	1	2	3	4	5	6	7	8	9	AT 110 MONTHS
SURVIVAL PROBABILITY	99.94%	99.82%	99.68%	98.76%	97.84%	96.86%	96.46%	96.46%	96.46%	96.46%
±1 STANDARD ERROR	0.04%	0.07%	0.10%	0.21%	0.28%	0.36%	0.40%	0.40%	0.40%	0.40%

Quadra Assura™ CRT-D MODEL CD3265-40

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	RATE
US Regulatory Approval	May 2012	Premature Battery Depletion	1	1.00%	Electrical Component	0	0.00%
Number of Devices Enrolled in Study	100				Electrical Interconnect	0	0.00%
Active Devices Enrolled in Study	0				Battery	0	0.00%
Cumulative Months of Follow-up	4,828				High Voltage Capacitor	0	0.00%
Estimated Longevity	(see table on page 53)				Software/Firmware	0	0.00%
Max. Delivered Energy	40 joules				Mechanical	0	0.00%
					Possible Early Battery Depletion	1	1.00%
					Other	0	0.00%

MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

QTY

0

0

0

0

0

0

1

0

1

RATE

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

1.00%


0.00%

1.00%

1.00%


1

Total



ACTIVELY MONITORED STUDY DATA								
YEAR	1	2	3	AT 44 MONTHS				
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%				
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%				
SAMPLE SIZE	100	80	60	50				

Unify Assura™ CRT-D MODEL CD3257-40Q* (BATTERY ADVISORY POPULATION)					ICTIONS ROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
				QTY	RATE	QTY	RATE	
US Regulatory Approval	May 2012		Electrical Component	0	0.00%	0	0.00%	
Registered US Implants	2,716		Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	770		Battery	0	0.00%	2	0.07%	
Estimated Longevity	(see table on page 53)		High Voltage Capacitor	0	0.00%	0	0.00%	
Normal Battery Depletion	99		Software/Firmware	1	0.04%	0	0.00%	
Max. Delivered Energy	40 joules		Mechanical	0	0.00%	1	0.04%	
Number of US Advisories (see pgs. 304, 305)	Three		Possible Early Battery Depletion	5	0.18%	12	0.44%	
			Other	2	0.07%	0	0.00%	
			Total	8	0.29%	15	0.55%	



INCLUDING	NORMAL BATTERY	

YEAR	1	2	3	4	5	6	7	8	9
SURVIVAL PROBABILITY	99.92%	99.73%	98.00%	93.52%	88.74%	87.33%	85.17%	79.94%	79.47%
±1 STANDARD ERROR	0.05%	0.11%	0.29%	0.57%	0.77%	0.83%	0.90%	1.09%	1.11%
SAMPLE SIZE	2,510	2,180	1,910	1,640	1,420	1,250	1,090	860	220

YEAR	1	2	3	4	5	6	7	8	9
SURVIVAL PROBABILITY	100.00%	100.00%	99.90%	98.36%	97.59%	96.88%	96.44%	96.44%	96.44%
±1 STANDARD ERROR	0.00%	0.00%	0.07%	0.30%	0.39%	0.45%	0.49%	0.49%	0.49%


*DF4-LLHH connector type.

CUSTOMER REPORTED PERFORMANCE DATA

Unify Assura[™] CRT-D MODEL CD3257-40 (BATTERY ADVISORY POPULATION)

US Regulatory Approval	May 2012
Registered US Implants	6,744
Estimated Active US Implants	1,882
Estimated Longevity	(see table on page 53)
Normal Battery Depletion	300
Max. Delivered Energy	40 joules
Number of US Advisories (see pgs. 304, 305)	Three

POPULATION)		MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COMPR	MALFUNCTIONS W/O COMPROMISED THERAPY		
		QTY	RATE	QTY	RATE		
	Electrical Component	6	0.09%	3	0.04%		
	Electrical Interconnect	1	0.01%	0	0.00%		
	Battery	1	0.01%	1	0.01%		
on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%		
	Software/Firmware	0	0.00%	4	0.06%		
	Mechanical	0	0.00%	0	0.00%		
	Possible Early Battery Depletion	10	0.15%	29	0.43%		
	Other	1	0.01%	1	0.01%		
	Total	19	0.28%	38	0.56%		




YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.81%	99.62%	98.36%	93.89%	87.13%	85.12%	81.61%	75.96%	75.60%	75.60%
±1 STANDARD ERROR	0.05%	0.08%	0.17%	0.34%	0.51%	0.56%	0.62%	0.73%	0.74%	0.74%
SAMPLE SIZE	6,300	5,520	4,880	4,210	3,580	3,080	2,630	2,060	1,070	280

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.90%	99.83%	99.46%	98.56%	97.68%	96.90%	96.75%	96.67%	96.67%	96.67%
±1 STANDARD ERROR	0.03%	0.05%	0.10%	0.16%	0.23%	0.28%	0.29%	0.29%	0.29%	0.29%

Unify Quadra [™] CRT-D MODEL CD3249-40Q* (BATTERY ADVISORY POPULATION)			W/ COMP	ICTIONS ROMISED RAPY	MALFUN W/O COMP THEF	ROMISED
			QTY	RATE	QTY	RATE
US Regulatory Approval	November 2011	Electrical Component	4	0.04%	3	0.03%
Registered US Implants	8,948	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	2,102	Battery	1	0.01%	1	0.01%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	380	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	0.01%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	16	0.18%	36	0.40%
		Other	3	0.03%	0	0.00%
		Total	24	0.27%	41	0.46%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10
SURVIVAL PROBABILITY	99.84%	97.66%	88.54%	79.23%	74.56%
± 1 STANDARD ERROR	0.04%	0.18%	0.43%	0.60%	0.71%
SAMPLE SIZE	7,500	6,120	4,530	3,000	210

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10
SURVIVAL PROBABILITY	99.95%	99.29%	97.56%	96.83%	96.83%
±1 STANDARD ERROR	0.02%	0.11%	0.21%	0.26%	0.26%

*DF4-LLHH connector type.

November 2011

(see table on page 53)

989

50,977

40 joules

0

Unify Quadra[™] CRT-D MODEL CD3249-40Q*

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up


US Regulatory Approval

Estimated Longevity

Max. Delivered Energy

QUALIFYING COMPLICATIONS	QTY	RATE
Premature Battery Depletion	3	0.30%
Skin Erosion	1	0.10%

	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	1	0.10%	3	0.30%
Other	1	0.10%	1	0.10%
Total	2	0.20%	4	0.40%



*DF4-LLHH connector type.


CUSTOMER REPORTED PERFORMANCE DATA

Unify Quadra[™] CRT-D MODEL CD3249-40 (BATTERY ADVISORY POPULATION)

US Regulatory Approval	November 2011	Electrical Con
Registered US Implants	2,523	Electrical Inte
Estimated Active US Implants	651	Battery
Estimated Longevity	(see table on page 53)	High Voltage
Normal Battery Depletion	90	Software/Firm
Max. Delivered Energy	40 joules	Mechanical
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early
		Other

LATION)		THE	RAPY	THER	APY
		QTY	RATE	QTY	RATE
	Electrical Component	0	0.00%	0	0.00%
	Electrical Interconnect	0	0.00%	0	0.00%
	Battery	0	0.00%	0	0.00%
53)	High Voltage Capacitor	0	0.00%	0	0.00%
	Software/Firmware	0	0.00%	0	0.00%
	Mechanical	0	0.00%	1	0.04%
	Possible Early Battery Depletion	0	0.00%	4	0.16%
	Other	1	0.04%	0	0.00%
	Total	1	0.04%	5	0.20%

MALFUNCTIONS W/ COMPROMISED MALFUNCTIONS W/O COMPROMISED



INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 118 MONTHS
SURVIVAL PROBABILITY	99.92%	99.92%	99.60%	97.60%	92.33%	88.66%	87.26%	85.88%	81.77%	81.77%
± 1 STANDARD ERROR	0.06%	0.06%	0.12%	0.36%	0.66%	0.83%	0.89%	0.93%	1.14%	1.14%
SAMPLE SIZE	2,370	2,070	1,840	1,640	1,410	1,190	1,000	830	670	210

YEAR	1	2	3	4	5	6	7	8	9	AT 118 MONTHS
SURVIVAL PROBABILITY	99.92%	99.92%	99.92%	99.80%	99.65%	99.30%	99.12%	99.12%	99.12%	99.12%
±1 STANDARD ERROR	0.06%	0.06%	0.06%	0.10%	0.10%	0.23%	0.26%	0.26%	0.26%	0.26%

Unify Quadra[™] CRT-D MODEL CD3249-40

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	RATE
US Regulatory Approval	November 2011	Skin Erosion	1	0.41%	Electrical Component	0	0.00%
Number of Devices Enrolled in Study	245				Electrical Interconnect	0	0.00%
Active Devices Enrolled in Study	0				Battery	0	0.00%
Cumulative Months of Follow-up	11,372				High Voltage Capacitor	0	0.00%
Estimated Longevity	(see table on page 53)				Software/Firmware	0	0.00%
Max. Delivered Energy	40 joules				Mechanical	0	0.00%
					Possible Early Battery Depletion	0	0.00%
					Other	0	0.00%
					Total	0	0.00%

MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

QTY

0

0

0

0

0

0

0

0

0

RATE

0.00%

0.00%

0.00%

0.00%


0.00%

0.00%

0.00%

0.00%


0.00%



YEAR	1	2	3	4	5	6	7	AT 88 MONTHS
SURVIVAL PROBABILITY	99.57%	99.57%	99.57%	99.57%	99.57%	99.57%	99.57%	99.57%
±1 STANDARD ERROR	0.43%	0.43%	0.43%	0.43%	0.43%	0.43%	0.43%	0.43%
SAMPLE SIZE	230	190	160	130	90	70	60	50

Unifv[™] CRT-D

Unity [™] CRT-D MODEL CD3231-40Q (BATTERY ADVISORY POPULATION)	W/ COM	NCTIONS PROMISED ERAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
	QTY	RATE	QTY	RATE	
US Regulatory Approval May 2010 Electrical Component	2	0.01%	5	0.03%	
Registered US Implants 19,028 Electrical Interconnect	1	< 0.01%	0	0.00%	
Estimated Active US Implants 3,758 Battery	14	0.07%	9	0.05%	
Estimated Longevity (see table on page 53) High Voltage Capacitor	16	0.08%	6	0.03%	
Normal Battery Depletion 1,217 Software/Firmware	0	0.00%	2	0.01%	
Max. Delivered Energy 40 joules Mechanical	1	< 0.01%	2	0.01%	
Number of US Advisories (see pgs. 304, 305) Three Possible Early Battery Depletion	n 56	0.29%	58	0.30%	
Other	8	0.04%	6	0.03%	
Total	98	0.52%	88	0.46%	



INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.67%	97.05%	82.37%	66.64%	64.59%	64.59%
±1 STANDARD ERROR	0.04%	0.14%	0.35%	0.47%	0.49%	0.49%
SAMPLE SIZE	15,650	12,600	9,380	5,850	3,620	260

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.83%	99.22%	97.21%	95.29%	95.29%	95.29%
± 1 STANDARD ERROR	0.03%	0.07%	0.16%	0.22%	0.22%	0.22%


*DF4-LLHH connector type.

Unify[™] CRT-D MODEL CD3231-40Q

US Regulatory Approval	May 2010
Number of Devices Enrolled in Study	1,680
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	103,836
Estimated Longevity	(see table on page 53)
Max. Delivered Energy	40 joules

QUALIFYING COMPLICATIONS	QTY	RATE
Inappropriate Shock	2	0.12%
Premature Battery Depletion	10	0.60%
Skin Erosion	1	0.06%

	W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	1	0.06%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	1	0.06%	1	0.06%
High Voltage Capacitor	1	0.06%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	1	0.06%
Possible Early Battery Depletion	12	0.71%	4	0.24%
Other	2	0.12%	0	0.00%
Total	16	0.95%	7	0.42%




ILAR	1	2	5	4	5	6	/	0	9	AT 116 MONTHS
SURVIVAL PROBABILITY	99.87%	99.72%	99.63%	99.43%	98.98%	98.85%	98.71%	98.71%	98.71%	98.71%
±1 STANDARD ERROR	0.07%	0.14%	0.16%	0.19%	0.31%	0.34%	0.37%	0.37%	0.37%	0.37%
SAMPLE SIZE	1,570	1,360	1,180	1,020	860	750	700	660	480	60

*DF4-LLHH connector type.

Unify[™] CRT-D

VS Regulatory ApprovalMay 2010Electrical Component100.05%50.02%Registered US Implants20,500Electrical Interconnect30.01%00.00%Estimated Active US Implants4.473Battery90.04%30.01%
Registered US Implants20,500Electrical Interconnect30.01%00.00%
Estimated Active US Implants 4 473 Battery 9 0.04% 3 0.01%
Estimated Longevity (see table on page 53) High Voltage Capacitor 7 0.03% 0 0.00%
Normal Battery Depletion 1,417 Software/Firmware 0 0.00% 2 <0.01%
Max. Delivered Energy 40 joules Mechanical 1 <0.01% 1 <0.01%
Number of US Advisories (see pgs. 304, 305)ThreePossible Early Battery Depletion320.16%450.22%
Other 11 0.05% 11 0.05%
Total 73 0.36% 67 0.33%



YEARS	AFTER	IMPLAN1
-------	-------	----------------

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.64%	95.10%	77.62%	66.24%	64.50%	64.50%
± 1 STANDARD ERROR	0.04%	0.18%	0.38%	0.46%	0.47%	0.47%
SAMPLE SIZE	16,570	12,750	9,020	6,000	3,770	230

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.80%	99.13%	97.56%	96.73%	96.73%	96.73%
± 1 STANDARD ERROR	0.03%	0.07%	0.14%	0.18%	0.18%	0.18%

40 joules


Unify[™] CRT-D **MODEL CD3231-40**

Estimated Longevity Max. Delivered Energy

SAMPLE SIZE

		QUALIFYING COMPLICATIONS	QTY	RATE
US Regulatory Approval	May 2010	Premature Battery Depletion	3	0.44%
Number of Devices Enrolled in Study	688	Skin Erosion	1	0.15%
Active Devices Enrolled in Study	0			
Cumulative Months of Follow-up	35,002			
Estimated Longevity	(see table on page 53)			

	MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISE THERAPY	
	QTY	RATE	QTY	RATE
Electrical Component	1	0.15%	0	0.00%
Electrical Interconnect	1	0.15%	0	0.00%
Battery	1	0.15%	2	0.29%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	1	0.15%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	1	0.15%	2	0.29%
Other	0	0.00%	1	0.15%
Total	4	0.58%	6	0.87%



280

220

190

180

120

50


630

510

410

350

Promote [™] + CRT-D MODEL CD3211-36Q*			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	February 2009	Electrical Component	4	0.06%	3	0.04%	
Registered US Implants	6,903	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	876	Battery	9	0.13%	5	0.07%	
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	1	0.01%	0	0.00%	
Normal Battery Depletion	1,325	Software/Firmware	0	0.00%	11	0.16%	
Max. Delivered Energy	36 joules	Mechanical	1	0.01%	0	0.00%	
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	2	0.03%	0	0.00%	
		Other	5	0.07%	6	0.09%	
		Total	22	0.32%	25	0.36%	



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	12	AT 146 MONTHS
SURVIVAL PROBABILITY	98.95%	93.36%	46.54%	20.25%	19.67%	19.67%	19.67%
± 1 STANDARD ERROR	0.12%	0.35%	0.79%	0.59%	0.59%	0.59%	0.59%
SAMPLE SIZE	5,440	4,200	2,590	1,140	970	570	220

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 146 MONTHS
SURVIVAL PROBABILITY	99.45%	98.69%	97.86%	96.90%	96.90%	96.90%	96.90%
± 1 STANDARD ERROR	0.09%	0.16%	0.24%	0.35%	0.35%	0.35%	0.35%


*DF4-LLHH connector type.

Promote[™] + CRT-D MODEL CD3211-36Q*

US Regulatory Approval	February 2009
Number of Devices Enrolled in Study	856
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	50,140
Estimated Longevity	(see table on page 53)
Max. Delivered Energy	36 joules

QTY	RATE
3	0.35%
2	0.23%
2	0.23%
	•


	MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISE THERAPY	
	QTY	RATE	QTY	RATE
Electrical Component	1	0.12%	1	0.12%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	1	0.12%	1	0.12%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	1	0.12%
Possible Early Battery Depletion	2	0.23%	0	0.00%
Other	0	0.00%	0	0.00%
Total	4	0.47%	3	0.35%



ACTIVELY MONITORED ST	UDY DATA					
YEAR	2	4	6	8	10	AT 129 MONTHS
SURVIVAL PROBABILITY	99.19%	99.00%	99.00%	99.00%	99.00%	99.00%
±1 STANDARD ERROR	0.33%	0.38%	0.38%	0.38%	0.38%	0.38%
SAMPLE SIZE	680	480	300	240	210	70

*DF4-LLHH connector type.

Promote [™] + CRT-D MODEL CD3211-36			W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Electrical Component	3	0.03%	3	0.03%
Registered US Implants	8,646	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,063	Battery	11	0.13%	3	0.03%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	2	0.02%	0	0.00%
Normal Battery Depletion	1,485	Software/Firmware	1	0.01%	11	0.13%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	0.01%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	5	0.06%	1	0.01%
		Other	5	0.06%	3	0.03%
		Total	27	0.31%	22	0.25%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.33%	92.56%	42.46%	22.13%	21.70%	21.70%	21.70%
± 1 STANDARD ERROR	0.09%	0.35%	0.73%	0.58%	0.58%	0.58%	0.58%
SAMPLE SIZE	6,710	4,970	2,780	1,320	1,120	710	240

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.72%	98.85%	97.76%	97.12%	97.12%	97.12%	97.12%
± 1 STANDARD ERROR	0.06%	0.14%	0.22%	0.31%	0.31%	0.31%	0.31%

Promote[™] + CRT-D

MODEL CD3211-36

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Skin Erosion	2	0.90%	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	223				Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0				Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	9,516				High Voltage Capacitor	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 53)				Software/Firmware	0	0.00%	3	1.35%
Max. Delivered Energy	36 joules				Mechanical	0	0.00%	0	0.00%
					Possible Early Battery Depletion	0	0.00%	0	0.00%
					Other	0	0.00%	0	0.00%

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0

0.00%

3


1.35%



ACTIVELY MONITORED ST						
YEAR	1	2	3	4	5	AT 61 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	97.01%	97.01%
±1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	2.08%	2.08%
SAMPLE SIZE	210	170	130	100	70	60

Promote[™] **RF CRT-D** N

Promote ¹³⁸ RF CRT-D MODEL 3207-36					W/O COMP	MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	September 2007	Electrical Component	4	0.02%	6	0.02%	
Registered US Implants	24,006	Electrical Interconnect	5	0.02%	3	0.01%	
Estimated Active US Implants	2,236	Battery	19	0.08%	9	0.04%	
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	5	0.02%	1	<0.01%	
Normal Battery Depletion	3,421	Software/Firmware	0	0.00%	15	0.06%	
Max. Delivered Energy	36 joules	Mechanical	3	0.01%	10	0.04%	
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	10	0.04%	6	0.02%	
		Other	17	0.07%	17	0.07%	
		Total	63	0.26%	67	0.28%	



INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.00%	93.92%	55.07%	23.31%	22.17%	22.11%	22.11%
± 1 STANDARD ERROR	0.07%	0.19%	0.47%	0.40%	0.39%	0.39%	0.39%
SAMPLE SIZE	18,430	13,250	7,680	3,100	2,590	2,230	250


YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.51%	98.90%	97.71%	97.05%	97.05%	97.05%	97.05%
± 1 STANDARD ERROR	0.05%	0.08%	0.13%	0.19%	0.19%	0.19%	0.19%

Promote[™] RF CRT-D MODEL 3207-36

US Regulatory Approval	September 2007
Number of Devices Enrolled in Study	672
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	30,394
Estimated Longevity	(see table on page 53)
Max. Delivered Energy	36 joules

QUALIFYING COMPLICATIONS	QTY	RATE
Inappropriate Shock	1	0.15%
Premature Battery Depletion	4	0.60%
Skin Erosion	2	0.30%


	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	1	0.15%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	1	0.15%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	1	0.15%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	1	0.15%
Other	2	0.30%	1	0.15%
Total	2	0.30%	5	0.74%



TEAR	1	2	3	4	5	0	,	AT 85 MORTHS
SURVIVAL PROBABILITY	100.00%	99.82%	99.11%	99.11%	98.70%	98.70%	97.70%	97.70%
±1 STANDARD ERROR	0.00%	0.18%	0.28%	0.45%	0.61%	0.61%	1.16%	1.16%
SAMPLE SIZE	630	540	450	340	240	160	90	60

Atlas[™] + HF CRT-D

Atlas™ + HF CRT-D MODEL V-343			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	November 2004	Electrical Component	3	0.02%	1	< 0.01%
Registered US Implants	18,776	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	684	Battery	40	0.21%	4	0.02%
Estimated Longevity	(see table on page 53)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	3,494	Software/Firmware	0	0.00%	1	<0.01%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories (see pgs. 309, 310)	Two	Possible Early Battery Depletion	7	0.04%	11	0.06%
		Other	10	0.05%	4	0.02%
		Total	60	0.32%	22	0.12%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16
SURVIVAL PROBABILITY	98.61%	82.29%	26.44%	7.89%	7.24%	7.09%	7.09%	7.09%
±1 STANDARD ERROR	0.09%	0.35%	0.48%	0.27%	0.25%	0.25%	0.25%	0.25%
SAMPLE SIZE	14,470	9,380	3,710	1,070	820	760	690	220

YEAR	2	4	6	8	10	12	14	16
SURVIVAL PROBABILITY	99.66%	98.55%	98.15%	97.74%	97.52%	97.52%	97.52%	97.52%
± 1 STANDARD ERROR	0.05%	0.11%	0.15%	0.23%	0.28%	0.28%	0.28%	0.28%

BATTERY LONGEVITY SUMMARY Cardiac Resynchronization Therapy (CRT) ICDs

Battery Longevity (years)

MODELS	FAMILY	NO PACING	25% PACING	50% PACING	100% PACING
CDHFA500Q	Gallant HF CRT-D***	10.6	9.5	8.7	7.4
CD3369-40Q	Quadra Assura MP" CRT-D*	9.5	9.9	8.9	7.4
CD3369-40C	Quadra Assura MP" CRT-D*	8.7	9.9	8.9	7.4
CD3365-40Q	Quadra Assura [™] CRT-D*	7.4	9.9	8.9	7.4
CD3365-40C	Quadra Assura" CRT-D*	11.1	9.9	8.9	7.4
CD3357-40Q	Unify Assura [¨] CRT-D*	11.1	9.9	8.9	7.4
CD3357-40C	Unify Assura [¨] CRT-D*	11.1	9.9	8.9	7.4
CD3265-40Q	Quadra Assura ČRT-D*	11.1	9.9	8.9	7.4
CD3265-40	Quadra Assura [™] CRT-D*	11.1	9.9	8.9	7.4
CD3257-40Q	Unify Assura [¨] CRT-D*	11.1	9.9	8.9	7.4
CD3257-40	Unify Assura [¨] CRT-D*	11.1	9.9	8.9	7.4
CD3249-40Q	Unify Quadra [®] CRT-D*	10.2	9.0	8.1	6.7
CD3249-40	Unify Quadra [®] CRT-D*	10.2	9.0	8.1	6.7
CD3231-40Q	Unify" CRT-D*	10.1	9.0	8.1	6.7
CD3231-40	Unify" CRT-D*	10.1	9.0	8.1	6.7
CD3211-36Q	Promote" + CRT-D**	8.2	7.2	6.5	5.4
CD3211-36	Promote ^{**} + CRT-D**	8.2	7.2	6.5	5.4
3207-36	Promote" RF CRT-D**	8.2	7.2	6.5	5.4
V-343	Atlas" + HF CRT-D**	7.9	7.1	6.4	5.4

Pacing parameters: DDD-BiV, RV 2.5V, LV 2.5V, A 2.5V, 0.5 ms, 60 ppm, 500 ohms

*Battery voltage range: 3.20-2.59. Three maximum charges per year.

**Battery voltage range: 3.20-2.45. Four maximum charges per year as well as monthly charging during the battery's mid-life voltage range.

***Capacitor maintenance interval: 1 charge per every 9 months.

SUMMARY INFORMATION Cardiac Resynchronization Therapy (CRT) ICDs

Survival Probability Summary

INCLUDING NORMAL BATTERY DEPLETION

CDHFA500Q	a 11 - Francisco a		2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
	Gallant HF CRT-D	99.95%									
CD3369-40Q	Quadra Assura MP" CRT-D	99.85%	99.82%	99.71%	99.29%	98.44%					
CD3369-40C	Quadra Assura MP" CRT-D	99.83%	99.55%	99.41%	98.86%	96.80%					
CD3365-40Q	Quadra Assura" CRT-D	99.85%	99.77%	99.65%	99.07%	97.67%	96.01%				
CD3365-40Q	Quadra Assura" CRT-D †	99.78%	99.40%	98.18%	95.37%	91.58%	85.71%	83.76%	83.24%		
CD3365-40C	Quadra Assura" CRT-D	100.00%	99.81%	99.60%	98.73%	98.43%	96.51%				
CD3365-40C	Quadra Assura" CRT-D †	99.74%	99.27%	98.38%	96.70%	93.48%	88.29%	86.29%	83.90%		
CD3357-40Q	Unify Assura" CRT-D	99.95%	99.82%	99.45%	98.31%	97.00%	94.58%				
CD3357-40Q	Unify Assura" CRT-D †	99.78%	99.34%	97.85%	93.55%	87.64%	80.62%	78.86%	78.86%		
CD3357-40C	Unify Assura" CRT-D	99.93%	99.84%	99.39%	98.13%	95.90%	93.44%				
CD3357-40C	Unify Assura" CRT-D †	99.81%	99.44%	97.68%	94.90%	89.93%	82.30%	80.29%	79.52%		
CD3265-40Q	Quadra Assura" CRT-D [†]	99.83%	99.74%	99.38%	97.71%	94.13%	92.34%	88.06%	80.78%	80.09%	
CD3265-40	Quadra Assura" CRT-D †	99.94%	99.75%	99.62%	98.27%	93.10%	90.80%	87.20%	81.38%	81.38%	
CD3257-40Q	Unify Assura" CRT-D †	99.92%	99.73%	98.00%	93.52%	88.74%	87.33%	85.17%	79.94%	79.47%	
CD3257-40	Unify Assura" CRT-D †	99.81%	99.62%	98.36%	93.89%	87.13%	85.12%	81.61%	75.96%	75.60%	
CD3249-40Q	Unify Quadra" CRT-D †	99.87%	99.84%	99.39%	97.66%	92.60%	88.54%	86.76%	79.23%	74.86%	74.56%
CD3249-40	Unify Quadra" CRT-D †	99.92%	99.92%	99.60%	97.60%	92.33%	88.66%	87.26%	85.88%	81.77%	
CD3231-40Q	Unify" CRT-D [†]	99.76%	99.67%	99.00%	97.05%	91.68%	82.37%	71.23%	66.64%	64.99%	64.59%
CD3231-40	Unify" CRT-D [†]	99.79%	99.64%	98.42%	95.10%	88.02%	77.62%	69.16%	66.24%	64.91%	64.50%
CD3211-36Q	Promote" + CRT-D	99.54%	98.95%	97.82%	93.36%	81.51%	46.54%	22.43%	20.25%	19.81%	19.67%
CD3211-36	Promote" + CRT-D	99.53%	99.33%	97.84%	92.56%	75.51%	42.46%	23.88%	22.13%	21.86%	21.70%
3207-36	Promote" RF CRT-D	99.61%	99.00%	97.44%	93.92%	84.34%	55.07%	28.10%	23.31%	22.36%	22.17%
V-343	Atlas" + HF CRT-D	99.66%	98.61%	94.45%	82.29%	56.33%	26.44%	9.94%	7.89%	7.38%	7.24%

†Premature battery depletion advisory population.

Survival Probability Summary

EXCLUDING NORMAL BATTERY DEPLETION

CD3369400Quadra Assura MP CRT-D99.86%99.88%99.81%99.78%99.78%99.78%99.78%99.78%99.78%99.78%99.48%99.48%99.48%91.48%CD3369400Quadra Assura CRT-D99.85%99.75%99.27%99.64%94.64%94.64%92.27%96.92%16.6%1.5.6%<	MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
CD3369-CCQuadra Assura 'CRT-D99.85%99.58%99.54%99.54%99.45%99.45%99.45%99.64%99.62%CD3365-40QQuadra Assura 'CRT-D [†] 99.85%99.57%99.57%99.69%99.65%92.52%99.69%91.56% $$	CDHFA500Q	Gallant" HF CRT-D	99.95%									
CD3365-400Quadra Assura" CRT-D*98,8%99,7%99,7%99,69%96,4%90,62%CD3365-402Quadra Assura" CRT-D*98,8%99,54%98,50%96,14%94,06%92,52%91,69%91,56%	CD3369-40Q	Quadra Assura MP" CRT-D	99.86%	99.83%	99.81%	99.78%	99.78%					
C N C N C N C N C N C N C N C N C N C N	CD3369-40C	Quadra Assura MP" CRT-D	99.85%	99.58%	99.54%	99.54%	99.45%					
CD3365-40C Quadra Assura ² CRT-D 10.00% 99.81% 99.75% 99.55% 99.55% 99.55% 99.55% 99.55% 99.55% 99.55% 99.55% 99.75% 99.85% 99.75% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 99.85% 96.85% 96.85%	CD3365-40Q	Quadra Assura" CRT-D	99.85%	99.77%	99.72%	99.69%	99.64%	99.62%				
CD3365-40CQuadra Assura [®] CRT-D [†] 997%99.3%98.42%97.4%96.1%94.0%94.45%92.2%92.2%CD3357-40QUnify Asura [®] CRT-D [†] 99.95%99.88%99.88%99.82%99.7%97.9%93.39%93.39%53.3%55.5%94.81%98.0%93.39%93.39%55.3%55.5%94.81%98.0%93.39%55.3%93.39%55.3%93.39%55.3%95.35%95.35%94.81%98.0%97.1%	CD3365-40Q	Quadra Assura" CRT-D †	99.83%	99.54%	98.50%	96.14%	94.06%	92.52%	91.69%	91.56%		
Drass7-400Unify Assura °CRT-D9995%99.8%98.8%98.8%98.7%97.9%97.9%97.3%93.3%5.2CD3357-400Unify Assura °CRT-D99.90%94.6%98.5%96.5%94.81%94.81%94.30%93.39%5.25.2CD3357-402Unify Assura °CRT-D [†] 99.93%99.84%98.1%94.1%94.1%94.25%93.5%5.2.4%5.2.4%CD3357-402Unify Assura °CRT-D [†] 99.8%96.2%96.6%96.6%96.4%96.4%96.4%96.4%96.4%96.4%96.4%5.2.4%5.2.4%CD3265-400Quadra Assura °CRT-D [†] 99.8%98.6%96.6%97.8%96.8%96.6%96.6%96.4%96.4%96.4%5.2.4%CD3265-400Unify Assura °CRT-D [†] 99.9%98.8%98.7%97.8%96.8%96.6%96.4%96.4%96.4%5.4.4%CD3265-400Unify Assura °CRT-D [†] 99.9%99.8%98.6%97.8%96.8%96.46%96.4%96.4%5.4.4%CD3265-400Unify Assura °CRT-D [†] 99.9%99.8%98.6%97.6%96.8%96.46%96.4%96.4%5.4.4%CD3265-400Unify Assura °CRT-D [†] 99.9%99.8%98.6%97.6%96.8%96.46%96.4%96.4%96.4%5.4.4%CD3265-400Unify Quadra °CRT-D [†] 99.9%99.8%99.2%98.2%97.6%96.9%96.7%96.7%96.7%96.8%CD324-	CD3365-40C	Quadra Assura" CRT-D	100.00%	99.81%	99.71%	99.59%	99.59%	99.59%				
CD3357-400Unify Assura CRT-D [†] 9990%946%98.5%96.5%94.8%93.8%93.8%93.3%93.3%CD3357-400Unify Assura CRT-D [†] 99.9%99.8%98.4%98.1%98.1%98.1%94.5%93.5%CD3357-400Unify Assura CRT-D [†] 99.8%96.6%96.6%95.6%94.81%94.25%93.95%	CD3365-40C	Quadra Assura" CRT-D †	99.78%	99.31%	98.42%	97.41%	96.15%	94.90%	94.45%	93.26%		
Charter Murrer 99.3% 99.8% 95.6% 94.8% 94.25% 93.5% 53.4%	CD3357-40Q	Unify Assura" CRT-D	99.95%	99.88%	99.88%	99.82%	99.79%	99.79%				
C D3357-40CUnify Asura C RT-D [†] 99.89%99.62%98.62%97.01%95.66%94.81%94.25%93.95%93.95%C D3265-40QQuadra Assura C RT-D [†] 99.87%99.86%96.65%97.14%96.12%95.14%95.34%95.34%95.34%C D3265-40QQuadra Assura C RT-D [†] 99.94%98.82%96.86%97.84%96.66%96.46%96.46%96.46%96.46%C D3257-40QUnify Assura C RT-D [†] 100.00%100.00%99.90%98.36%97.59%96.88%96.44%96.44%96.44%C D3257-40QUnify Assura C RT-D [†] 99.90%99.83%99.65%97.65%96.67%96.67%96.67%96.67%C D3257-40QUnify Quadra C RT-D [†] 99.90%99.85%99.26%97.65%96.90%96.75%96.63%96.83%96.83%C D3249-40QUnify Quadra C RT-D [†] 99.95%99.25%99.85%99.65%97.65%97.15%91.2%91.2%91.2%C D3249-40QUnify C RT-D [†] 99.85%99.85%99.85%98.5%97.65%97.1%91.2%91.2%91.2%C D3249-40QUnify C RT-D [†] 99.85%99.85%99.85%99.85%97.65%97.1%91.2%91.2%91.2%C D3249-40QUnify C RT-D [†] 99.85%99.85%99.85%98.5%97.65%97.5%91.2%91.2%92.9%C D3211-40QUnify C RT-D [†] 99.85%99.65%98.5%98.65%97.65%97.6%<	CD3357-40Q	Unify Assura" CRT-D †	99.90%	99.46%	98.53%	96.55%	94.81%	93.80%	93.39%	93.39%		
Name CD3265-400Number Quadra Assura" CRT-D [†] 99.87%99.86%99.65%98.88%97.14%96.12%95.61%95.34%95.34%CD3265-400Quadra Assura" CRT-D [†] 99.94%99.82%99.68%98.76%97.84%96.86%96.46%96.46%96.46%CD3255-400Unify Assura" CRT-D [†] 100.00%100.00%99.90%98.36%97.59%96.88%96.44%96.44%96.44%CD3257-400Unify Assura" CRT-D [†] 99.90%99.83%99.46%98.56%97.68%96.90%96.75%96.67%96.67%CD3257-400Unify Quadra" CRT-D [†] 99.90%99.95%99.85%99.29%98.52%97.56%97.19%96.83%96.83%96.83%CD3249-400Unify Quadra" CRT-D [†] 99.92%99.92%99.80%99.65%99.30%99.12%99.12%99.12%CD3249-400Unify Quadra" CRT-D [†] 99.92%99.92%99.80%99.65%99.30%99.12%99.12%99.12%CD3231-400Unify" CRT-D [†] 99.88%99.83%99.66%99.22%98.37%97.21%95.79%95.29%95.29%95.29%CD3231-400Unify" CRT-D [†] 99.88%99.80%99.26%99.83%98.66%97.66%97.26%97.02%96.73%96.73%96.73%CD321-36UVinfy" CRT-D [†] 99.84%94.56%98.66%98.66%97.66%97.66%97.26%97.26%96.90%96.90%96.90%CD321-36UPromote"+	CD3357-40C	Unify Assura" CRT-D	99.93%	99.89%	99.84%	99.81%	99.81%	99.81%				
CD 3265-40Quadra Assura "CRT-D [†] 9994%9982%968%98.76%97.84%96.86%96.46%96.46%96.46%CD 3257-40QUnify Assura "CRT-D [†] 100.00%100.00%99.90%98.36%97.59%96.88%96.44%96.44%96.44%CD 3257-40QUnify Assura "CRT-D [†] 99.90%99.83%99.46%98.56%97.68%96.00%96.75%96.67%96.67%CD 3249-40QUnify Quadra" CRT-D [†] 99.95%99.95%99.29%99.25%97.68%99.30%99.12%91.2%91.2%CD 3249-40QUnify Quadra" CRT-D [†] 99.92%99.25%99.28%99.28%99.65%99.30%99.12%91.2%91.2%CD 3249-40QUnify CRT-D [†] 99.98%99.28%99.28%99.28%99.28%99.65%99.30%99.12%91.2%91.2%CD 3241-40QUnify CRT-D [†] 99.88%99.83%99.66%99.22%98.37%97.21%95.7%95.29%95.29%95.29%CD 3231-40QUnify "CRT-D [†] 99.88%99.86%99.25%99.13%98.49%97.56%97.02%96.37%96.37%96.37%CD 3211-36QPromote" + CRT-D99.84%99.65%98.65%98.66%97.66%97.26%97.26%96.90%96.90%96.90%CD 3211-36QPromote" + CRT-D99.79%99.72%99.37%98.85%98.66%97.66%97.76%97.27%97.12%97.12%97.12%97.12%97.12%97.15%<	CD3357-40C	Unify Assura" CRT-D †	99.89%	99.62%	98.62%	97.01%	95.66%	94.81%	94.25%	93.95%		
CD3257-40Q Unify Assura °CRT-D [†] 100.00% 99.90% 98.36% 97.59% 96.88% 96.44% 96.44% 96.44% CD3257-40Q Unify Assura °CRT-D [†] 99.90% 99.83% 99.46% 98.56% 97.68% 96.90% 96.75% 96.67% 96.67% 96.67% 96.67% 96.67% 96.83% 96.83% 96.83% 96.83% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 96.67% 97.5% 97.19% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 96.83% 97.56% 97.19% 96.12% 91.2% 91.2% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% 95.29% <t< td=""><td>CD3265-40Q</td><td>Quadra Assura" CRT-D†</td><td>99.87%</td><td>99.86%</td><td>99.65%</td><td>98.88%</td><td>97.14%</td><td>96.12%</td><td>95.61%</td><td>95.34%</td><td>95.34%</td><td></td></t<>	CD3265-40Q	Quadra Assura" CRT-D †	99.87%	99.86%	99.65%	98.88%	97.14%	96.12%	95.61%	95.34%	95.34%	
CD3257-40Unify Assura CRT-D†99.90%99.83%99.46%98.56%97.68%96.90%96.75%96.67%96.67%96.67%CD3249-40QUnify Quadra CRT-D†99.95%99.95%99.85%99.29%98.52%97.56%97.19%96.83%96.83%96.83%96.83%CD3249-40QUnify Quadra CRT-D†99.92%99.92%99.80%99.65%99.30%99.12%99.12%99.12%CD3231-40QUnify CRT-D†99.88%99.83%99.66%99.22%98.37%97.21%95.97%95.29%95.29%95.29%CD3231-40QUnify CRT-D†99.88%99.80%99.65%99.30%97.56%97.02%96.73%96.73%96.73%95.29%CD3231-40QUnify CRT-D†99.88%99.80%99.52%99.13%98.49%97.56%97.02%96.73%	CD3265-40	Quadra Assura" CRT-D †	99.94%	99.82%	99.68%	98.76%	97.84%	96.86%	96.46%	96.46%	96.46%	
CD3249-40Q Unify Quadra [*] CRT-D [†] 99.95% 99.85% 99.29% 98.52% 97.56% 97.19% 96.83% 96.83% 96.83% CD3249-40Q Unify Quadra [*] CRT-D [†] 99.92% 99.92% 99.80% 99.65% 99.30% 99.12% 97.12% 97.3% 96.33% 96.33% 97.12%	CD3257-40Q	Unify Assura" CRT-D †	100.00%	100.00%	99.90%	98.36%	97.59%	96.88%	96.44%	96.44%	96.44%	
CD3249-400 Difly Quadra CRT-D 9923% 9923% 9923% 9928% 9928% 9926% 98	CD3257-40	Unify Assura" CRT-D †	99.90%	99.83%	99.46%	98.56%	97.68%	96.90%	96.75%	96.67%	96.67%	
CD3231-40Q Unify [°] CRT-D [†] 99.88% 99.66% 99.22% 98.37% 97.21% 95.97% 95.29%	CD3249-40Q	Unify Quadra" CRT-D †	99.95%	99.95%	99.85%	99.29%	98.52%	97.56%	97.19%	96.83%	96.83%	96.83%
CD3231-40 Unify" CRT-D [†] 99.88% 99.80% 99.52% 99.13% 98.49% 97.56% 97.02% 96.73%	CD3249-40	Unify Quadra" CRT-D †	99.92%	99.92%	99.92%	99.80%	99.65%	99.30%	99.12%	99.12%	99.12%	
CD3211-36Q Promote [*] + CRT-D 99.84% 99.06% 98.69% 98.52% 97.86% 97.08% 96.90% 97.10% 97.12% 97.12% 97.15% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05% 97.05%	CD3231-40Q	Unify" CRT-D [†]	99.88%	99.83%	99.66%	99.22%	98.37%	97.21%	95.97%	95.29%	95.29%	95.29%
CD3211-36 Promote" + CRT-D 99.79% 99.72% 99.37% 98.85% 98.66% 97.76% 97.27% 97.12%	CD3231-40	Unify" CRT-D [†]	99.88%	99.80%	99.52%	99.13%	98.49%	97.56%	97.02%	96.73%	96.73%	96.73%
3207-36 Promote [®] RF CRT-D 99.77% 99.51% 99.19% 98.90% 98.58% 97.71% 97.11% 97.05% 97.05% 97.05%	CD3211-36Q	Promote" + CRT-D	99.84%	99.45%	99.06%	98.69%	98.52%	97.86%	97.08%	96.90%	96.90%	96.90%
	CD3211-36	Promote" + CRT-D	99.79%	99.72%	99.37%	98.85%	98.66%	97.76%	97.27%	97.12%	97.12%	97.12%
V-343 Atlas" + HF CRT-D 99.88% 99.66% 99.21% 98.55% 98.40% 98.15% 97.94% 97.74% 97.52% 97.52%	3207-36	Promote" RF CRT-D	99.77%	99.51%	99.19%	98.90%	98.58%	97.71%	97.11%	97.05%	97.05%	97.05%
	V-343	Atlas" + HF CRT-D	99.88%	99.66%	99.21%	98.55%	98.40%	98.15%	97.94%	97.74%	97.52%	97.52%

†Premature battery depletion advisory population.

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR	ELECT		ELECT		BATT	ERY	HIGH VO CAPAO		SOFTV		MECHA	NICAL	BATT DEPLE		от	HER	тот	TAL
MODELS FA	AMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDHFA500Q Ga	allant [®] HF CRT-D	9,415	0.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%	1	0.01%
CD3369-40Q Qu	Quadra Assura MP ⁻ CRT-D	71,361	2.50%	7	<0.01%	9	0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	4	<0.01%	21	0.03%
CD3369-40C Qu	Quadra Assura MP ⁻ CRT-D	9,160	3.20%	2	0.02%	2	0.02%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	1	0.01%	6	0.07%
CD3365-40Q Qu	Quadra Assura [¯] CRT-D	16,686	4.90%	2	0.01%	3	0.02%	1	<0.01%	0	0.00%	1	<0.01%	0	0.00%	1	<0.01%	1	<0.01%	9	0.05%
CD3365-40Q Qu	uadra Assura [¯] CRT-D [†]	24,081	17.30%	6	0.02%	10	0.04%	3	0.01%	1	<0.01%	1	<0.01%	0	0.00%	43	0.18%	6	0.02%	70	0.29%
CD3365-40C Qu	Quadra Assura [¯] CRT-D	2,659	6.20%	0	0.00%	0	0.00%	0	0.00%	2	0.08%	0	0.00%	0	0.00%	0	0.00%	1	0.04%	3	0.11%
CD3365-40C Qu	Quadra Assura ⁻ CRT-D [†]	5,626	20.90%	6	0.11%	2	0.04%	1	0.02%	0	0.00%	0	0.00%	0	0.00%	8	0.14%	3	0.05%	20	0.36%
CD3357-40Q Un	Jnify Assura [®] CRT-D	18,171	4.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	2	0.01%
CD3357-40Q Un	Jnify Assura [®] CRT-D [†]	5,340	21.40%	1	0.02%	2	0.04%	0	0.00%	2	0.04%	0	0.00%	0	0.00%	11	0.21%	0	0.00%	16	0.30%
CD3357-40C Un	Unify Assura" CRT-D	16,823	4.90%	0	0.00%	2	0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.01%
CD3357-40C Un	Unify Assura" CRT-D [†]	9,588	21.50%	2	0.02%	2	0.02%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	19	0.20%	1	0.01%	25	0.26%
CD3265-40Q Qu	Quadra Assura [¯] CRT-D [†]	13,540	16.90%	2	0.01%	1	<0.01%	1	<0.01%	0	0.00%	1	<0.01%	0	0.00%	24	0.18%	1	<0.01%	30	0.22%
CD3265-40 Qu	Quadra Assura ⁻ CRT-D ⁺	3,926	19.30%	0	0.00%	1	0.03%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	5	0.13%	7	0.18%	13	0.33%
CD3257-40Q Un	Unify Assura" CRT-D ⁺	2,716	21.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.04%	0	0.00%	5	0.18%	2	0.07%	8	0.29%
CD3257-40 Un	Unify Assura" CRT-D [†]	6,744	20.10%	6	0.09%	1	0.01%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	10	0.15%	1	0.01%	19	0.28%
CD3249-40Q Un	Jnify Quadra [−] CRT-D [†]	8,948	17.40%	4	0.04%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	16	0.18%	3	0.03%	24	0.27%
CD3249-40 Un	Jnify Quadra [−] CRT-D [†]	2,523	18.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.04%	1	0.04%
CD3231-40Q Un	Jnify" CRT-D [†]	19,028	19.80%	2	0.01%	1	<0.01%	14	0.07%	16	0.08%	0	0.00%	1	<0.01%	56	0.29%	8	0.04%	98	0.52%
CD3231-40 Un	Jnify ⁻ CRT-D [†]	20,500	20.80%	10	0.05%	3	0.01%	9	0.04%	7	0.03%	0	0.00%	1	<0.01%	32	0.16%	11	0.05%	73	0.36%
CD3211-36Q Pro	romote" + CRT-D	6,903	28.10%	4	0.06%	0	0.00%	9	0.13%	1	0.01%	0	0.00%	1	0.01%	2	0.03%	5	0.07%	22	0.32%
CD3211-36 Pro	romote" + CRT-D	8,646	28.20%	3	0.03%	0	0.00%	11	0.13%	2	0.02%	1	0.01%	0	0.00%	5	0.06%	5	0.06%	27	0.31%
3207-36 Pro	romote" RF CRT-D	24,006	27.20%	4	0.02%	5	0.02%	19	0.08%	5	0.02%	0	0.00%	3	0.01%	10	0.04%	17	0.07%	63	0.26%
V-343 Atl	tlas + HF CRT-D	18,776	25.30%	3	0.02%	0	0.00%	40	0.21%	0	0.00%	0	0.00%	0	0.00%	7	0.04%	10	0.05%	60	0.32%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

US Malfunction Summary

WITHOUT COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		TRICAL ONENT		IRICAL ONNECT	BAT	TERY		OLTAGE		WARE/	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	TOT	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDHFA5000) Gallant ["] HF CRT-D	9,415	0.60%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%
CD3369-40Q	Quadra Assura MP ⁻ CRT-D	71,361	2.50%	12	0.02%	1	<0.01%	1	<0.01%	2	<0.01%	0	0.00%	5	<0.01%	2	<0.01%	6	<0.01%	29	0.04%
CD3369-400	Quadra Assura MP ⁻ CRT-D	9,160	3.20%	1	0.01%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	2	0.02%	2	0.02%	3	0.03%	9	0.10%
CD3365-40Q	Quadra Assura ⁻ CRT-D	16,686	4.90%	4	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	0.02%	3	0.02%	4	0.02%	15	0.09%
CD3365-40Q	Quadra Assura [¯] CRT-D [†]	24,081	17.30%	14	0.06%	0	0.00%	17	0.07%	0	0.00%	3	0.01%	2	<0.01%	398	1.65%	7	0.03%	441	1.83%
CD3365-400	Quadra Assura ⁻ CRT-D	2,659	6.20%	1	0.04%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.04%
CD3365-400	Quadra Assura ⁻ CRT-D [†]	5,626	20.90%	2	0.04%	0	0.00%	1	0.02%	0	0.00%	1	0.02%	0	0.00%	55	0.98%	2	0.04%	61	1.08%
CD3357-40Q	Unify Assura" CRT-D	18,171	4.00%	6	0.03%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	2	0.01%	9	0.05%
CD3357-40Q	Unify Assura" CRT-D [†]	5,340	21.40%	2	0.04%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	69	1.29%	3	0.06%	74	1.39%
CD3357-40C	Unify Assura" CRT-D	16,823	4.90%	1	<0.01%	1	<0.01%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%	1	<0.01%	4	0.02%	9	0.05%
CD3357-40C	Unify Assura" CRT-D ⁺	9,588	21.50%	3	0.03%	1	0.01%	6	0.06%	0	0.00%	2	0.02%	1	0.01%	101	1.05%	3	0.03%	117	1.22%
CD3265-40Q	Quadra Assura [¯] CRT-D [†]	13,540	16.90%	6	0.04%	0	0.00%	7	0.05%	0	0.00%	2	0.01%	3	0.02%	104	0.77%	1	<0.01%	123	0.91%
CD3265-40	Quadra Assura⁻CRT-D [†]	3,926	19.30%	0	0.00%	0	0.00%	2	0.05%	0	0.00%	1	0.03%	0	0.00%	17	0.43%	2	0.05%	22	0.56%
CD3257-40Q	Unify Assura" CRT-D ⁺	2,716	21.30%	0	0.00%	0	0.00%	2	0.07%	0	0.00%	0	0.00%	1	0.04%	12	0.44%	0	0.00%	15	0.55%
CD3257-40	Unify Assura" CRT-D †	6,744	20.10%	3	0.04%	0	0.00%	1	0.01%	0	0.00%	4	0.06%	0	0.00%	29	0.43%	1	0.01%	38	0.56%
CD3249-40Q	Unify Quadra [¯] CRT-D [†]	8,948	17.40%	3	0.03%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	1	0.01%	36	0.40%	0	0.00%	41	0.46%
CD3249-40	Unify Quadra ⁻ CRT-D [†]	2,523	18.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.04%	4	0.16%	0	0.00%	5	0.20%
CD3231-40Q	Unify" CRT-D †	19,028	19.80%	5	0.03%	0	0.00%	9	0.05%	6	0.03%	2	0.01%	2	0.01%	58	0.30%	6	0.03%	88	0.46%
CD3231-40	Unify CRT-D ^{\dagger}	20,500	20.80%	5	0.02%	0	0.00%	3	0.01%	0	0.00%	2	< 0.01%	1	<0.01%	45	0.22%	11	0.05%	67	0.33%
CD3211-36Q	Promote" + CRT-D	6,903	28.10%	3	0.04%	0	0.00%	5	0.07%	0	0.00%	11	0.16%	0	0.00%	0	0.00%	6	0.09%	25	0.36%
CD3211-36	Promote" + CRT-D	8,646	28.20%	3	0.03%	0	0.00%	3	0.03%	0	0.00%	11	0.13%	1	0.01%	1	0.01%	3	0.03%	22	0.25%
3207-36	Promote" RF CRT-D	24,006	27.20%	6	0.02%	3	0.01%	9	0.04%	1	<0.01%	15	0.06%	10	0.04%	6	0.02%	17	0.07%	67	0.28%
V-343	Atlas + HF CRT-D	18,776	25.30%	1	<0.01%	0	0.00%	4	0.02%	0	0.00%	1	< 0.01%	1	<0.01%	11	0.06%	4	0.02%	22	0.12%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR	ELECT	RICAL ONENT	ELECT		BAT	TERY		OLTAGE		WARE/ WARE	месни	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	ſAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDHFA500Q	Gallant" HF CRT-D	15,726	0.63%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	1	<0.01%
CD3369-40Q	Quadra Assura MP ⁻ CRT-D	72,066	2.66%	7	<0.01%	9	0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	4	<0.01%	21	0.03%
CD3369-40C	Quadra Assura MP ⁻ CRT-D	9,296	3.73%	2	0.02%	2	0.02%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	1	0.01%	6	0.06%
CD3365-40Q	Quadra Assura [¯] CRT-D	41,046	12.57%	8	0.02%	13	0.03%	4	<0.01%	1	<0.01%	2	< 0.01%	0	0.00%	44	0.11%	7	0.02%	79	0.19%
CD3365-40C	Quadra Assura [¯] CRT-D	8,337	16.97%	6	0.07%	2	0.02%	1	0.01%	2	0.02%	0	0.00%	0	0.00%	8	0.10%	4	0.05%	23	0.28%
CD3357-40Q	Unify Assura" CRT-D	24,036	8.42%	1	<0.01%	2	<0.01%	0	0.00%	3	0.01%	0	0.00%	0	0.00%	11	0.05%	1	<0.01%	18	0.07%
CD3357-40C	Unify Assura" CRT-D	26,906	11.42%	2	<0.01%	4	0.01%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	19	0.07%	1	<0.01%	27	0.10%
CD3265-40Q	Quadra Assura [¬] CRT-D	13,955	17.46%	2	0.01%	2	0.01%	1	<0.01%	0	0.00%	1	<0.01%	0	0.00%	24	0.17%	1	<0.01%	31	0.22%
CD3265-40	Quadra Assura [¯] CRT-D	4,046	20.02%	0	0.00%	1	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	6	0.15%	7	0.17%	14	0.35%
CD3257-40Q	Unify Assura" CRT-D	2,727	22.15%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.04%	0	0.00%	5	0.18%	2	0.07%	8	0.29%
CD3257-40	Unify Assura" CRT-D	6,723	20.68%	6	0.09%	1	0.01%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	10	0.15%	1	0.01%	19	0.28%
CD3249-40Q	Unify Quadra [¯] CRT-D	11,518	15.48%	5	0.04%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	17	0.15%	4	0.03%	27	0.23%
CD3249-40	Unify Quadra ⁻ CRT-D	4,855	11.93%	3	0.06%	2	0.04%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.02%	1	0.02%	7	0.14%
CD3231-40Q	Unify ⁻ CRT-D	20,973	20.29%	3	0.01%	1	<0.01%	15	0.07%	17	0.08%	0	0.00%	1	<0.01%	68	0.32%	10	0.05%	115	0.55%
CD3231-40	Unify" CRT-D	24,031	18.93%	11	0.05%	4	0.02%	10	0.04%	7	0.03%	0	0.00%	1	<0.01%	34	0.14%	11	0.05%	78	0.32%
CD3211-36Q	Promote" + CRT-D	16,097	14.85%	15	0.09%	0	0.00%	14	0.09%	8	0.05%	1	< 0.01%	2	0.01%	8	0.05%	6	0.04%	54	0.34%
CD3211-36	Promote" + CRT-D	21,011	12.83%	14	0.07%	2	< 0.01%	15	0.07%	6	0.03%	1	< 0.01%	0	0.00%	9	0.04%	14	0.07%	61	0.29%
3207-36	Promote" RF CRT-D	25,838	27.05%	5	0.02%	5	0.02%	22	0.09%	5	0.02%	0	0.00%	3	0.01%	10	0.04%	20	0.08%	70	0.27%
V-343	Atlas + HF CRT-D	19,292	25.07%	3	0.02%	0	0.00%	41	0.21%	0	0.00%	0	0.00%	0	0.00%	7	0.04%	10	0.05%	61	0.32%

Definitions of malfunction categories can be found on pages 5-6.

Worldwide Malfunction Summary

WITHOUT COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		IRICAL ONENT		RICAL ONNECT	BAT	TERY		OLTAGE		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	TAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDHFA500Q	Gallant ["] HF CRT-D	15,726	0.63%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
CD3369-40Q	Quadra Assura MP ⁻ CRT-D	72,066	2.66%	12	0.02%	1	<0.01%	1	<0.01%	2	<0.01%	0	0.00%	5	<0.01%	2	<0.01%	6	<0.01%	29	0.04%
CD3369-40C	Quadra Assura MP ⁻ CRT-D	9,296	3.73%	1	0.01%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	2	0.02%	2	0.02%	3	0.03%	9	0.10%
CD3365-40Q	Quadra Assura ⁻ CRT-D	41,046	12.57%	18	0.04%	0	0.00%	17	0.04%	0	0.00%	3	<0.01%	6	0.01%	404	0.98%	11	0.03%	459	1.12%
CD3365-40C	Quadra Assura [¯] CRT-D	8,337	16.97%	3	0.04%	0	0.00%	1	0.01%	0	0.00%	1	0.01%	0	0.00%	55	0.66%	2	0.02%	62	0.74%
CD3357-40Q	Unify Assura" CRT-D	24,036	8.42%	8	0.03%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	72	0.30%	5	0.02%	87	0.36%
CD3357-40C	Unify Assura" CRT-D	26,906	11.42%	4	0.01%	2	<0.01%	7	0.03%	0	0.00%	2	<0.01%	2	<0.01%	106	0.39%	7	0.03%	130	0.48%
CD3265-40Q	Quadra Assura ⁻ CRT-D	13,955	17.46%	6	0.04%	0	0.00%	7	0.05%	0	0.00%	2	0.01%	3	0.02%	105	0.75%	1	<0.01%	124	0.89%
CD3265-40	Quadra Assura [¯] CRT-D	4,046	20.02%	0	0.00%	0	0.00%	2	0.05%	0	0.00%	1	0.02%	0	0.00%	18	0.44%	2	0.05%	23	0.57%
CD3257-40Q	Unify Assura" CRT-D	2,727	22.15%	0	0.00%	0	0.00%	2	0.07%	0	0.00%	0	0.00%	1	0.04%	12	0.44%	0	0.00%	15	0.55%
CD3257-40	Unify Assura" CRT-D	6,723	20.68%	3	0.04%	0	0.00%	1	0.01%	0	0.00%	4	0.06%	0	0.00%	29	0.43%	1	0.01%	38	0.57%
CD3249-40Q	Unify Quadra [¯] CRT-D	11,518	15.48%	3	0.03%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%	42	0.36%	4	0.03%	51	0.44%
CD3249-40	Unify Quadra ⁻ CRT-D	4,855	11.93%	1	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.02%	5	0.10%	0	0.00%	7	0.14%
CD3231-40Q	Unify" CRT-D	20,973	20.29%	6	0.03%	0	0.00%	10	0.05%	6	0.03%	2	<0.01%	3	0.01%	62	0.30%	6	0.03%	95	0.45%
CD3231-40	Unify" CRT-D	24,031	18.93%	7	0.03%	0	0.00%	5	0.02%	0	0.00%	3	0.01%	1	<0.01%	50	0.21%	12	0.05%	78	0.32%
CD3211-36Q	Promote" + CRT-D	16,097	14.85%	6	0.04%	0	0.00%	7	0.04%	0	0.00%	16	0.10%	2	0.01%	4	0.02%	9	0.06%	44	0.27%
CD3211-36	Promote" + CRT-D	21,011	12.83%	8	0.04%	0	0.00%	4	0.02%	0	0.00%	19	0.09%	2	<0.01%	2	<0.01%	9	0.04%	44	0.21%
3207-36	Promote" RF CRT-D	25,838	27.05%	7	0.03%	3	0.01%	10	0.04%	1	<0.01%	17	0.07%	10	0.04%	7	0.03%	18	0.07%	73	0.28%
V-343	Atlas + HF CRT-D	19,292	25.07%	1	< 0.01%	0	0.00%	4	0.02%	0	0.00%	1	<0.01%	1	<0.01%	11	0.06%	4	0.02%	22	0.11%

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE DEVICES	CUMULATIVE MONTHS OF		OPRIATE		SS OF METRY		ARDIAL JSION	BAT	ATURE TERY ETION			то	TAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD3369-40Q	117	0	3,575	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3365-40Q	235	0	10,102	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.43%	1	0.43%
CD3357-40Q	269	0	10,401	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3357-40C	232	0	7,527	0	0.00%	0	0.00%	0	0.00%	4	1.72%	1	0.43%	5	2.16%
CD3265-40Q	421	0	19,212	0	0.00%	0	0.00%	0	0.00%	1	0.24%	0	0.00%	1	0.24%
CD3265-40	100	0	4,828	0	0.00%	0	0.00%	0	0.00%	1	1.00%	0	0.00%	1	1.00%
CD3249-40Q	989	0	50,977	0	0.00%	0	0.00%	0	0.00%	3	0.30%	1	0.10%	4	0.40%
CD3249-40	245	0	11,372	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.41%	1	0.41%
CD3231-40Q	1,680	0	103,836	2	0.12%	0	0.00%	0	0.00%	10	0.60%	1	0.06%	13	0.77%
CD3231-40	688	0	35,002	0	0.00%	0	0.00%	0	0.00%	3	0.44%	1	0.15%	4	0.58%
CD3211-36Q	856	0	50,140	3	0.35%	0	0.00%	0	0.00%	2	0.23%	2	0.23%	7	0.82%
CD3211-36	223	0	9,516	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.90%	2	0.90%
3207-36	672	0	30,394	1	0.15%	0	0.00%	0	0.00%	4	0.60%	2	0.30%	7	1.04%

A list of of complications can be found on page 12.

Actively Monitored Study Data Summary

MALFUNCTIONS WITH COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ IWARE	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD3369-40Q	Quadra Assura [–] CRT-D	117	5.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3365-40Q	Quadra Assura [–] CRT-D	235	19.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3357-40Q	Unify Assura" CRT-D	269	17.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3357-40C	Unify Assura" CRT-D	232	19.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3265-40Q	Quadra Assura [–] CRT-D	421	22.80%	0	0.00%	1	0.24%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.24%
CD3265-40	Quadra Assura [–] CRT-D	100	20.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	1.00%	0	0.00%	1	1.00%
CD3249-40Q	Unify Quadra [¬] CRT-D	989	18.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.10%	1	0.10%	2	0.20%
CD3249-40	Unify Quadra [¬] CRT-D	245	26.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3231-40Q	Unify" CRT-D	1,680	22.50%	0	0.00%	0	0.00%	1	0.06%	1	0.06%	0	0.00%	0	0.00%	12	0.71%	2	0.12%	16	0.95%
CD3231-40	Unify" CRT-D	688	24.30%	1	0.15%	1	0.15%	1	0.15%	0	0.00%	0	0.00%	0	0.00%	1	0.15%	0	0.00%	4	0.58%
CD3211-36Q	Promote" + CRT-D	856	32.80%	1	0.12%	0	0.00%	1	0.12%	0	0.00%	0	0.00%	0	0.00%	2	0.23%	0	0.00%	4	0.47%
CD3211-36	Promote" + CRT-D	223	28.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
3207-36	Promote" RF CRT-D	672	35.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.30%	2	0.30%

MALFUNCI	ALFUNCTIONS WITHOUT COMPROMISED THERAPY Possible early																				
		NUMBER OF DEVICES	PERCENT		IRICAL ONENT		TRICAL CONNECT	BAT	TERY		OLTAGE CITOR		WARE/	MECH	IANICAL		TERY ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD3369-40Q	Quadra Assura [¯] CRT-D	117	5.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3365-40Q	Quadra Assura ⁻ CRT-D	235	19.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.85%	0	0.00%	2	0.85%
CD3357-40Q	Unify Assura" CRT-D	269	17.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.74%	0	0.00%	2	0.74%
CD3357-40C	Unify Assura" CRT-D	232	19.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	1.72%	0	0.00%	4	1.72%
CD3265-40Q	Quadra Assura ⁻ CRT-D	421	22.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.24%	0	0.00%	1	0.24%
CD3265-40	Quadra Assura ⁻ CRT-D	100	20.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	1.00%	0	0.00%	1	1.00%
CD3249-40Q	Unify Quadra ⁻ CRT-D	989	18.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	0.30%	1	0.10%	4	0.40%
CD3249-40	Unify Quadra [¬] CRT-D	245	26.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD3231-40Q	Unify" CRT-D	1,680	22.50%	1	0.06%	0	0.00%	1	0.06%	0	0.00%	0	0.00%	1	0.06%	4	0.24%	0	0.00%	7	0.42%
CD3231-40	Unify" CRT-D	688	24.30%	0	0.00%	0	0.00%	2	0.29%	0	0.00%	1	0.15%	0	0.00%	2	0.29%	1	0.15%	6	0.87%
CD3211-36Q	Promote" + CRT-D	856	32.80%	1	0.12%	0	0.00%	1	0.12%	0	0.00%	0	0.00%	1	0.12%	0	0.00%	0	0.00%	3	0.35%
CD3211-36	Promote" + CRT-D	223	28.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	1.35%	0	0.00%	0	0.00%	0	0.00%	3	1.35%
3207-36	Promote" RF CRT-D	672	35.60%	1	0.15%	0	0.00%	1	0.15%	0	0.00%	1	0.15%	0	0.00%	1	0.15%	1	0.15%	5	0.74%


Definitions of malfunction categories can be found on pages 5-6.

Cardiac Resynchronization Therapy (CRT) Pacemakers

Allure Quadra MP[™] CRT-P MODEL PM3562

US Regulatory Approval	January 2019
Registered US Implants	18,573
Estimated Active US Implants	16,088
Estimated Longevity	8 Years
Normal Battery Depletion	1
Number of US Advisories (see pg. 314)	One

	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTION W/O COMPROMIS THERAPY		
	QTY	RATE	QTY	RATE	
Electrical Component	0	0.00%	0	0.00%	
Electrical Interconnect	0	0.00%	0	0.00%	
Battery	0	0.00%	0	0.00%	
Software/Firmware	0	0.00%	0	0.00%	
Mechanical	0	0.00%	0	0.00%	
Possible Early Battery Depletion	0	0.00%	0	0.00%	
Other	0	0.00%	0	0.00%	
Total	0	0.00%	0	0.00%	



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	AT 32 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	99.80%
± 1 STANDARD ERROR	0.00%	0.00%	0.14%
SAMPLE SIZE	14,330	6,860	390

YEAR	1	2	AT 32 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%	0.00%

Allure Quadra MP[™] CRT-P MODEL PM3262

US Regulatory Approval	February 2016
Registered US Implants	19,957
Estimated Active US Implants	13,400
Estimated Longevity	8 Years
Normal Battery Depletion	141
Number of US Advisories (see pg. 314)	One

		ICTIONS ROMISED RAPY	MALFUN W/O COMF THEF	ROMISED
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	1	<0.01%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	3	0.02%
Mechanical	3	0.02%	9	0.05%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	0	0.00%	1	< 0.01%
Total	3	0.02%	14	0.07%



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	AT 68 MONTHS
SURVIVAL PROBABILITY	99.95%	99.88%	99.69%	98.44%	94.62%	92.74%
± 1 STANDARD ERROR	0.02%	0.02%	0.04%	0.10%	0.27%	0.55%
SAMPLE SIZE	18,950	17,110	14,570	10,280	5,160	210

YEAR	1	2	3	4	5	AT 68 MONTHS
SURVIVAL PROBABILITY	99.95%	99.92%	99.89%	99.76%	99.63%	99.51%
± 1 STANDARD ERROR	0.02%	0.02%	0.02%	0.04%	0.06%	0.11%

Allure[™] RF CRT-P MODEL PM3222

US Regulatory Approval	March 2014
Registered US Implants	10,919
Estimated Active US Implants	6,949
Estimated Longevity	8 Years
Normal Battery Depletion	176
Number of US Advisories (see pg. 314)	One

	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISE THERAPY	D
	QTY	RATE	QTY RATE	
Electrical Component	1	< 0.01%	0 0.00%	
Electrical Interconnect	0	0.00%	0 0.00%	
Battery	0	0.00%	0 0.00%	
Software/Firmware	0	0.00%	0 0.00%	
Mechanical	0	0.00%	7 0.06%	
Possible Early Battery Depletion	0	0.00%	0 0.00%	
Other	0	0.00%	0 0.00%	
Total	1	<0.01%	7 0.06%	



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	AT 86 MONTHS
SURVIVAL PROBABILITY	99.98%	99.72%	99.17%	95.67%	89.68%	84.83%	84.67%	84.67%
± 1 STANDARD ERROR	0.01%	0.05%	0.11%	0.29%	0.52%	0.71%	0.72%	0.72%
SAMPLE SIZE	9,640	7,450	5,710	4,150	2,740	1,570	670	240

YEAR	1	2	3	4	5	6	7	AT 86 MONTHS
SURVIVAL PROBABILITY	99.98%	99.95%	99.95%	99.95%	99.58%	99.46%	99.46%	99.46%
±1 STANDARD ERROR	0.01%	0.02%	0.02%	0.02%	0.11%	0.14%	0.14%	0.14%

Allure Quadra[™] RF CRT-P MODEL PM3242

US Regulatory Approval	March 2014
Registered US Implants	18.365
Estimated Active US Implants	9,457
Estimated Longevity	8 Years
Normal Battery Depletion	446
Number of US Advisories (see pg. 314	e) One

W/ COM	PROMISED	MALFUNCTION W/O COMPROMIS THERAPY	
QTY	RATE	QTY RAT	Е
0	0.00%	2 0.01	%
0	0.00%	0 0.00	9%
0	0.00%	0 0.00)%
0	0.00%	0 0.00	9%
1	< 0.01%	21 0.119	%
0	0.00%	0 0.00)%
0	0.00%	0 0.00	9%
1	<0.01%	23 0.13	%
	W/ COMP THE QTY 0 0 0 0 0 1 0 0 1 0 0	0 0.00% 0 0.00% 0 0.00% 1 <0.01%	W/COMPROMISED THERAPY W/O COMPROMI THERAPY QTY RATE QTY RAT 0 0.00% 2 0.01 0 0.00% 0 0.00 0 0.00% 0 0.00 0 0.00% 0 0.00 0 0.00% 0 0.00 1 <0.01%



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	AT 92 MONTHS
SURVIVAL PROBABILITY	99.92%	99.84%	99.63%	98.82%	95.27%	89.64%	88.45%	88.45%
±1 STANDARD ERROR	0.02%	0.03%	0.04%	0.09%	0.19%	0.29%	0.33%	0.34%
SAMPLE SIZE	17,210	15,350	14,000	12,730	11,280	8,650	4,470	300

YEAR	1	2	3	4	5	6	7	AT 92 MONTHS
SURVIVAL PROBABILITY	99.94%	99.88%	99.86%	99.86%	99.79%	99.59%	99.48%	99.48%
±1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.04%	0.06%	0.06%	0.09%

Anthem[™] RF CRT-P MODEL PM3210

July 2009
20,448
5,502
8 Years
389
Two

	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
	QTY	RATE	QTY	RATE	
Electrical Component	3	0.01%	3	0.01%	
Electrical Interconnect	3	0.01%	1	< 0.01%	
Battery	0	0.00%	1	< 0.01%	
Software/Firmware	0	0.00%	7	0.03%	
Mechanical	0	0.00%	0	0.00%	
Possible Early Battery Depletion	1	< 0.01%	3	0.01%	
Other	0	0.00%	9	0.04%	
Total	7	0.03%	24	0.12%	



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 143 MONTHS
SURVIVAL PROBABILITY	99.71%	97.06%	92.06%	91.43%	91.29%	91.19%
± 1 STANDARD ERROR	0.04%	0.14%	0.24%	0.26%	0.27%	0.28%
SAMPLE SIZE	16,130	12,670	9,740	6,480	2,520	220

YEAR	2	4	6	8	10	AT 143 MONTHS
SURVIVAL PROBABILITY	99.83%	99.69%	99.58%	99.53%	99.46%	99.46%
± 1 STANDARD ERROR	0.03%	0.04%	0.05%	0.06%	0.08%	0.08%

Cardiac Resynchronization Therapy (CRT) Pacemakers ACTIVELY MONITORED STUDY DATA

July 2009

202

5,472

8 Years

0

Anthem[™] RF CRT-P MODEL PM3210

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up


US Regulatory Approval

Estimated Longevity

QUALIFYING	COMPLICATIONS
------------	---------------

None Reported

	W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	0	0.00%	0	0.00%
Total	0	0.00%	0	0.00%




ACTIVELY MONITORED ST			
YEAR	1	2	AT 29 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%	0.00%
SAMPLE SIZE	170	110	50

Cardiac Resynchronization Therapy (CRT) Pacemakers CUSTOMER REPORTED PERFORMANCE DATA

Frontier[™] II CRT-P **MODEL 5586**

US Regulatory Approval	August 2004
Registered US Implants	6,911
Estimated Active US Implants	758
Estimated Longevity	6.5 Years
Normal Battery Depletion	381
Number of US Advisories	None

	W/ COMP	NCTIONS PROMISED RAPY	MALFUNG W/O COMP THER	ROMISED
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	7	0.10%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	7	0.10%
Other	1	0.01%	3	0.04%
Total	1	0.01%	17	0.25%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 172 MONTHS
SURVIVAL PROBABILITY	99.37%	93.63%	76.03%	65.97%	65.05%	65.05%	65.05%	65.05%
± 1 STANDARD ERROR	0.10%	0.38%	0.77%	0.93%	0.95%	0.95%	0.95%	0.95%
SAMPLE SIZE	5,020	3,500	2,200	1,280	900	760	360	200

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 172 MONTHS
SURVIVAL PROBABILITY	99.89%	99.48%	98.99%	98.85%	98.85%	98.85%	98.85%	98.85%
±1 STANDARD ERROR	0.03%	0.11%	0.18%	0.20%	0.20%	0.20%	0.20%	0.20%

SUMMARY INFORMATION Cardiac Resynchronization Therapy (CRT) Pacemakers

Survival Probability Summary

INCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM3562	Allure Quadra MP" CRT-P	100.00%	100.00%								
PM3262	Allure Quadra MP" CRT-P	99.95%	99.88%	99.69%	98.44%	94.62%					
PM3222	Allure" RF CRT-P	99.98%	99.72%	99.17%	95.67%	89.68%	84.83%	84.67%			
PM3242	Allure Quadra" RF CRT-P	99.92%	99.84%	99.63%	98.82%	95.27%	89.64%	88.45%			
PM3210	Anthem" RF CRT-P	99.81%	99.71%	99.11%	97.06%	92.29%	92.06%	91.60%	91.43%	91.43%	91.29%
5586	Frontier" II CRT-P	99.76%	99.37%	97.94%	93.63%	84.63%	76.03%	69.32%	65.97%	65.72%	65.05%

EXCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM3562	Allure Quadra MP" CRT-P	100.00%	100.00%								
PM3262	Allure Quadra MP" CRT-P	99.95%	99.92%	99.89%	99.76%	99.63%					
PM3222	Allure" RF CRT-P	99.98%	99.95%	99.95%	99.95%	99.58%	99.46%	99.46%			
PM3242	Allure Quadra" RF CRT-P	99.94%	99.88%	99.86%	99.86%	99.79%	99.59%	99.48%			
PM3210	Anthem" RF CRT-P	99.87%	99.83%	99.75%	99.69%	99.60%	99.58%	99.53%	99.53%	99.53%	99.46%
5586	Frontier" II CRT-P	99.93%	99.89%	99.71%	99.48%	99.08%	98.99%	98.99%	98.85%	98.85%	98.85%

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		IRICAL ONENT		TRICAL	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	то	DTAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3562	Allure Quadra MP ⁻ CRT-P	18,573	1.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM3262	Allure Quadra MP ⁻ CRT-P	19,957	5.20%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	0.02%	0	0.00%	0	0.00%	3	0.02%
PM3222	Allure" RF CRT-P	10,919	6.30%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
PM3242	Allure Quadra [¬] RF CRT-P	18,365	9.20%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%
PM3210	Anthem RF CRT-P	20,448	19.00%	3	0.01%	3	0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	7	0.03%
5586	Frontier" II CRT-P	6,911	19.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%	1	0.01%

WITHOUT COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		LECTRICAL ELECTRICAL OMPONENT INTERCONNECT		SOFTWARE/ BATTERY FIRMWARE			MECH	ANICAL	BAT	LE EARLY TERY ETION	OTHER		то	DTAL		
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3562	Allure Quadra MP ⁻ CRT-P	18,573	1.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM3262	Allure Quadra MP ⁻ CRT-P	19,957	5.20%	1	<0.01%	0	0.00%	0	0.00%	3	0.02%	9	0.05%	0	0.00%	1	<0.01%	14	0.07%
PM3222	Allure" RF CRT-P	10,919	6.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	7	0.06%	0	0.00%	0	0.00%	7	0.06%
PM3242	Allure Quadra" RF CRT-P	18,365	9.20%	2	0.01%	0	0.00%	0	0.00%	0	0.00%	21	0.11%	0	0.00%	0	0.00%	23	0.13%
PM3210	Anthem RF CRT-P	20,448	19.00%	3	0.01%	1	<0.01%	1	<0.01%	7	0.03%	0	0.00%	3	0.01%	9	0.04%	24	0.12%
5586	Frontier" II CRT-P	6,911	19.60%	7	0.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	7	0.10%	3	0.04%	17	0.25%

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL ONNECT	BAT	TERY		WARE/	MECH	IANICAL	BAT	LE EARLY TERY .ETION	от	HER	тс	DTAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3562	Allure Quadra MP ⁻ CRT-P	44,683	0.74%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
PM3262	Allure Quadra MP [−] CRT-P	35,766	2.91%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	<0.01%	1	<0.01%	0	0.00%	4	0.01%
PM3222	Allure" RF CRT-P	35,424	2.02%	1	<0.01%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%
PM3242	Allure Quadra [¬] RF CRT-P	37,019	4.66%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	0	0.00%	2	<0.01%
PM3210	Anthem" RF CRT-P	21,093	18.21%	3	0.01%	3	0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	7	0.03%

WITHOUT COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL ONNECT	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	тс	DTAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3562	Allure Quadra MP ⁻ CRT-P	44,683	0.74%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	4	<0.01%
PM3262	Allure Quadra MP ⁻ CRT-P	35,766	2.91%	0	0.00%	0	0.00%	0	0.00%	3	<0.01%	9	0.03%	0	0.00%	1	<0.01%	13	0.04%
PM3222	Allure" RF CRT-P	35,424	2.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	7	0.02%	0	0.00%	1	<0.01%	8	0.02%
PM3242	Allure Quadra [¬] RF CRT-P	37,019	4.66%	3	<0.01%	0	0.00%	0	0.00%	0	0.00%	25	0.07%	1	<0.01%	1	<0.01%	30	0.08%
PM3210	Anthem RF CRT-P	21,093	18.21%	3	0.01%	1	< 0.01%	1	< 0.01%	7	0.03%	0	0.00%	3	0.01%	9	0.04%	24	0.11%

Definitions of malfunction categories can be found on pages 5-6.

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE DEVICES	CUMULATIVE MONTHS OF		SS OF METRY		ARDIAL JSION	BAT	ATURE TERY ETION		(IN SION	то	TAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3210	202	0	5472	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

MALFUNCTIONS WITH COMPROMISED THERAPY

														POSSIBI	E EARLY				
		NUMBER OF DEVICES	PERCENT RETURNED FOR		TRICAL ONENT	ELECT INTERC	IRICAL ONNECT	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT DEPL	TERY ETION	OT	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3210	Anthem ⁻ RF	202	30.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

MALFUNCTIONS WITHOUT COMPROMISED THERAPY

														POSSIB	E EARLY				
		NUMBER OF DEVICES	PERCENT RETURNED FOR		RICAL ONENT	ELECT INTERC	IRICAL ONNECT	BAT	TERY		WARE/ WARE	MECH	ANICAL		TERY ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM3210	Anthem ⁻ RF	202	30.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

A list of of complications can be found on page 12. Definitions of malfunction categories can be found on pages 5-6.


CUSTOMER REPORTED PERFORMANCE DATA

Quartet™ MODEL 1458QL

US Regulatory Approval	October 2015
Registered US Implants	16,160
Estimated Active US Implants	11,926
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Quadpolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	1	<0.01%	0	0.00%
Conductor Fracture	0	0.00%	0	0.00%
Lead Dislodgement	32	0.20%	99	0.61%
Failure to Capture	19	0.12%	39	0.24%
Oversensing	0	0.00%	0	0.00%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	2	0.01%	0	0.00%
Abnormal Pacing Impedance	5	0.03%	11	0.07%
Extracardiac Stimulation	27	0.17%	29	0.18%
Other	6	0.04%	6	0.04%
Total	92	0.57%	184	1.14%
Total Returned for Analysis	23		58	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	53	0.33%
Total	53	0.33%



YEAR	1	2	3	4	5	AT 67 MONTHS
SURVIVAL PROBABILITY	99.39%	99.08%	98.93%	98.74%	98.56%	98.56%
±1 STANDARD ERROR	0.06%	0.08%	0.10%	0.11%	0.14%	0.14%
SAMPLE SIZE	14,030	10,330	7,360	4,790	2,470	260


CUSTOMER REPORTED PERFORMANCE DATA

Quartet[™] MODEL 1457Q

US Regulatory Approval	March 2017
Registered US Implants	8,916
Estimated Active US Implants	6,531
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Quadpolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	0	0.00%
Conductor Fracture	1	0.01%	0	0.00%
Lead Dislodgement	43	0.48%	136	1.53%
Failure to Capture	11	0.12%	39	0.44%
Oversensing	1	0.01%	2	0.02%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	0	0.00%	2	0.02%
Abnormal Pacing Impedance	0	0.00%	1	0.01%
Extracardiac Stimulation	15	0.17%	12	0.13%
Other	7	0.08%	6	0.07%
Total	78	0.87%	198	2.22%
Total Returned for Analysis	20		79	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	82	0.92%
Total	82	0.92%



YEAR	1	2	3	4	5	AT 64 MONTHS
SURVIVAL PROBABILITY	98.34%	97.74%	97.22%	97.02%	96.48%	96.48%
±1 STANDARD ERROR	0.15%	0.18%	0.22%	0.25%	0.41%	0.41%
SAMPLE SIZE	7,380	4,870	3,100	1,680	660	210


CUSTOMER REPORTED PERFORMANCE DATA

Quartet[™] MODEL 1456Q

US Regulatory Approval	October 2015
Registered US Implants	12,480
Estimated Active US Implants	9,173
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Quadpolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	2	0.02%	1	<0.01%
Conductor Fracture	2	0.02%	1	<0.01%
Lead Dislodgement	37	0.30%	122	0.98%
Failure to Capture	13	0.10%	39	0.31%
Oversensing	1	<0.01%	1	<0.01%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	1	<0.01%	0	0.00%
Abnormal Pacing Impedance	4	0.03%	1	<0.01%
Extracardiac Stimulation	15	0.12%	20	0.16%
Other	6	0.05%	3	0.02%
Total	81	0.65%	188	1.51%
Total Returned for Analysis	20		92	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	2	0.02%
Lead-to-Can Contact	2	0.02%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	5	0.04%
Extrinsic Factors	88	0.71%
Total	95	0.76%



YEAR	1	2	3	4	5	AT 66 MONTHS
SURVIVAL PROBABILITY	99.02%	98.65%	98.46%	98.15%	97.99%	97.74%
±1 STANDARD ERROR	0.09%	0.12%	0.13%	0.16%	0.19%	0.26%
SAMPLE SIZE	10,690	7,720	5,490	3,470	1,710	280


CUSTOMER REPORTED PERFORMANCE DATA

Quartet[™] MODEL 1458Q

US Regulatory Approval	November 2011
Registered US Implants	174,572
Estimated Active US Implants	100,008
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Quadpolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, <30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	7	<0.01%	5	<0.01%
Conductor Fracture	0	0.00%	37	0.02%
Lead Dislodgement	299	0.17%	1341	0.77%
Failure to Capture	129	0.07%	685	0.39%
Oversensing	4	<0.01%	26	0.01%
Failure to Sense	0	0.00%	2	<0.01%
Insulation Breach	1	<0.01%	17	<0.01%
Abnormal Pacing Impedance	6	< 0.01%	148	0.08%
Extracardiac Stimulation	121	0.07%	237	0.14%
Other	122	0.07%	74	0.04%
Total	689	0.39%	2572	1.47%
Total Returned for Analysis	248		915	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	11	< 0.01%
Clavicular Crush	1	<0.01%
In the Pocket	3	< 0.01%
Intravascular	7	< 0.01%
Insulation Breach	9	< 0.01%
Lead-to-Can Contact	3	< 0.01%
Lead-to-Lead Contact	4	< 0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	2	< 0.01%
Crimps, Welds & Bonds	0	0.00%
Other	15	< 0.01%
Extrinsic Factors	869	0.50%
Total	905	0.52%



YEAR	2	4	6	8	10	AT 121 MONTHS
SURVIVAL PROBABILITY	99.06%	98.68%	98.32%	97.96%	97.76%	97.76%
± 1 STANDARD ERROR	0.02%	0.03%	0.04%	0.05%	0.07%	0.07%
SAMPLE SIZE	130,140	91,940	58,540	22,400	3,220	260


ACTIVELY MONITORED STUDY DATA

Quartet[™] MODEL 1458Q

US Regulatory Approval	November 2011
Number of Devices Enrolled in Study	2,158
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	107,274
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Quadpolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.05%
Extracardiac Stimulation	3	0.14%
Failure to Capture	9	0.42%
Insulation Breach	1	0.05%
Lead Dislodgement	38	1.76%
Oversensing	1	0.05%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	22	1.02%
Total	22	1.02%



*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 81


CUSTOMER REPORTED PERFORMANCE DATA

QuickFlex[™] µ MODEL 1258T

US Regulatory Approval	May 2010
Registered US Implants	48,461
Estimated Active US Implants	20,860
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, <30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	1	<0.01%
Conductor Fracture	0	0.00%	47	0.10%
Lead Dislodgement	65	0.13%	302	0.62%
Failure to Capture	30	0.06%	408	0.84%
Oversensing	0	0.00%	31	0.06%
Failure to Sense	1	<0.01%	3	<0.01%
Insulation Breach	0	0.00%	19	0.04%
Abnormal Pacing Impedance	5	0.01%	95	0.20%
Extracardiac Stimulation	40	0.08%	161	0.33%
Other	16	0.03%	22	0.05%
Total	157	0.32%	1089	2.25%
Total Returned for Analysis	68		282	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	9	0.02%
Clavicular Crush	2	< 0.01%
In the Pocket	3	< 0.01%
Intravascular	4	< 0.01%
Insulation Breach	6	0.01%
Lead-to-Can Contact	1	< 0.01%
Lead-to-Lead Contact	4	< 0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	< 0.01%
Crimps, Welds & Bonds	0	0.00%
Other	1	< 0.01%
Extrinsic Factors	244	0.50%
Total	260	0.54%



YEAR	2	4	6	8	10	AT 139 MONTHS
SURVIVAL PROBABILITY	99.34%	98.98%	98.59%	98.12%	97.65%	97.08%
±1 STANDARD ERROR	0.04%	0.05%	0.06%	0.08%	0.10%	0.18%
SAMPLE SIZE	38,910	31,360	25,450	18,980	9,880	340


ACTIVELY MONITORED STUDY DATA

QuickFlex[™] µ MODEL 1258T

US Regulatory Approval	May 2010
Number of Devices Enrolled in Study	2,375
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	135,823
Insulation	Optim"*
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	7	0.29%
Conductor Fracture	3	0.13%
Extracardiac Stimulation	56	2.36%
Failure to Capture	49	2.06%
Insulation Breach	1	0.04%
Lead Dislodgement	52	2.19%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	0.04%
Clavicular Crush	1	0.04%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	44	1.85%
Total	45	1.89%




CUSTOMER REPORTED PERFORMANCE DATA

QuickFlex[™] MODEL 1156T

US Regulatory Approval	July 2007
Registered US Implants	27,671
Estimated Active US Implants	8,623
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 318)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	1	<0.01%
Conductor Fracture	0	0.00%	10	0.04%
Lead Dislodgement	11	0.04%	147	0.53%
Failure to Capture	5	0.02%	245	0.89%
Oversensing	0	0.00%	20	0.07%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	0	0.00%	53	0.19%
Abnormal Pacing Impedance	1	<0.01%	70	0.25%
Extracardiac Stimulation	14	0.05%	93	0.34%
Other	9	0.03%	9	0.03%
Total	40	0.14%	648	2.34%
Total Returned for Analysis	14		173	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	7	0.03%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	7	0.03%
Insulation Breach	92	0.33%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	4	0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	14	0.05%
Other	74	0.27%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	134	0.48%
Total	233	0.84%



YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.42%	98.71%	97.61%	96.95%	96.48%	95.94%	95.72%
± 1 STANDARD ERROR	0.05%	0.08%	0.12%	0.14%	0.15%	0.17%	0.20%
SAMPLE SIZE	21,380	16,690	13,480	11,360	9,860	6,110	320


ACTIVELY MONITORED STUDY DATA

QuickFlex[™] MODEL 1156T

US Regulatory Approval	July 2007
Number of Devices Enrolled in Study	987
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	53,587
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.10%
Extracardiac Stimulation	18	1.82%
Failure to Capture	10	1.01%
Insulation Breach	1	0.10%
Lead Dislodgement	28	2.84%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	3	0.30%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	3	0.30%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	20	2.03%
Total	23	2.33%



YEAR	2	4	6	8	10	AT 130 MONTHS
SURVIVAL PROBABILITY	95.64%	94.06%	92.94%	91.28%	90.87%	90.87%
±1 STANDARD ERROR	0.69%	0.86%	1.01%	1.24%	1.30%	1.30%
SAMPLE SIZE	750	470	330	260	190	60


CUSTOMER REPORTED PERFORMANCE DATA

QuickFlex[™] XL MODEL 1158T

US Regulatory Approval	July 2007
Registered US Implants	15,341
Estimated Active US Implants	4.859
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 318)	One

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	1	<0.01%
Conductor Fracture	0	0.00%	5	0.03%
Lead Dislodgement	9	0.06%	101	0.66%
Failure to Capture	2	0.01%	158	1.03%
Oversensing	0	0.00%	3	0.02%
Failure to Sense	0	0.00%	1	<0.01%
Insulation Breach	0	0.00%	35	0.23%
Abnormal Pacing Impedance	2	0.01%	28	0.18%
Extracardiac Stimulation	6	0.04%	35	0.23%
Other	6	0.04%	10	0.07%
Total	25	0.16%	377	2.46%
Total Returned for Analysis	13		127	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	5	0.03%
Clavicular Crush	0	0.00%
In the Pocket	1	< 0.01%
Intravascular	4	0.03%
Insulation Breach	59	0.38%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	2	0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	8	0.05%
Other	49	0.32%
Crimps, Welds & Bonds	1	< 0.01%
Other	0	0.00%
Extrinsic Factors	90	0.59%
Total	155	1.01%



YEAR	2	4	6	8	10	12	AT 165 MONTHS
SURVIVAL PROBABILITY	99.35%	98.52%	97.36%	96.62%	96.19%	95.82%	95.72%
± 1 STANDARD ERROR	0.07%	0.11%	0.16%	0.19%	0.21%	0.23%	0.24%
SAMPLE SIZE	11,880	9,370	7,600	6,400	5,540	3,230	280


ACTIVELY MONITORED STUDY DATA

QuickFlex[™] XL MODEL 1158T

US Regulatory Approval	July 2007
Number of Devices Enrolled in Study	553
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	26,942
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Extracardiac Stimulation	9	1.63%
Failure to Capture	10	1.81%
Insulation Breach	1	0.18%
Lead Dislodgement	7	1.27%
Skin Erosion	1	0.18%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	1	0.18%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	1	0.18%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	7	1.27%
Total	8	1.45%



YEAR	2	4	6	8	10	AT 125 MONTHS
SURVIVAL PROBABILITY	96.55%	95.06%	93.93%	93.13%	90.16%	90.16%
±1 STANDARD ERROR	0.79%	1.05%	1.31%	1.53%	2.25%	2.25%
SAMPLE SIZE	410	250	150	110	70	50


CUSTOMER REPORTED PERFORMANCE DATA

QuickSite[™] XL MODEL 1058T

US Regulatory Approval	February 2006
Registered US Implants	9,956
Estimated Active US Implants	2,527
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 318)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	1	0.01%
Conductor Fracture	0	0.00%	8	0.08%
Lead Dislodgement	10	0.10%	35	0.35%
Failure to Capture	3	0.03%	98	0.98%
Oversensing	1	0.01%	4	0.04%
Failure to Sense	0	0.00%	2	0.02%
Insulation Breach	0	0.00%	32	0.32%
Abnormal Pacing Impedance	2	0.02%	22	0.22%
Extracardiac Stimulation	9	0.09%	25	0.25%
Other	1	0.01%	5	0.05%
Total	26	0.26%	232	2.33%
Total Returned for Analysis	11		40	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	2	0.02%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	2	0.02%
Insulation Breach	26	0.26%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	1	0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	6	0.06%
Other	19	0.19%
Crimps, Welds & Bonds	0	0.00%
Other	1	0.01%
Extrinsic Factors	31	0.31%
Total	60	0.60%




YEAR	2	4	6	8	10	12	14	AT 183 MONTHS
SURVIVAL PROBABILITY	99.62%	99.07%	98.08%	96.93%	96.22%	95.61%	94.89%	94.70%
±1 STANDARD ERROR	0.06%	0.11%	0.18%	0.25%	0.29%	0.32%	0.35%	0.38%
SAMPLE SIZE	7,690	5,800	4,470	3,640	3,130	2,790	2,060	210

ACTIVELY MONITORED STUDY DATA

QuickSite[™] XL MODEL 1058T

		QUALIFYING COMPLICATIONS	QTY	RATE
US Regulatory Approval	February 2006	Failure to Capture	4	3.60%
Number of Devices Enrolled in Study	111			
Active Devices Enrolled in Study	0			
Cumulative Months of Follow-up	5,771			
Insulation	Polyurethane/Silicone			
Type and/or Fixation	S-Curve			
Polarity	Bipolar			
Steroid	Yes			

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	0	0.00%
Total	0	0.00%



YEAR	1	2	3	4	AT 49 MONTHS
SURVIVAL PROBABILITY	99.07%	98.01%	96.74%	95.33%	95.33%
±1 STANDARD ERROR	0.92%	1.39%	1.87%	2.31%	2.31%
SAMPLE SIZE	100	90	80	60	50


CUSTOMER REPORTED PERFORMANCE DATA

QuickSite[™] MODEL 1056T

US Regulatory Approval	April 2005
Registered US Implants	32,341
Estimated Active US Implants	7,374
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 318)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	0	0.00%
Conductor Fracture	0	0.00%	13	0.04%
Lead Dislodgement	32	0.10%	174	0.54%
Failure to Capture	15	0.05%	294	0.91%
Oversensing	2	<0.01%	27	0.08%
Failure to Sense	0	0.00%	2	<0.01%
Insulation Breach	1	<0.01%	113	0.35%
Abnormal Pacing Impedance	3	<0.01%	67	0.21%
Extracardiac Stimulation	22	0.07%	108	0.33%
Other	9	0.03%	29	0.09%
Total	84	0.26%	827	2.56%
Total Returned for Analysis	28		213	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	6	0.02%
Clavicular Crush	0	0.00%
In the Pocket	2	< 0.01%
Intravascular	4	0.01%
Insulation Breach	92	0.28%
Lead-to-Can Contact	1	< 0.01%
Lead-to-Lead Contact	11	0.03%
Clavicular Crush	0	0.00%
Externalized Conductors	31	0.10%
Other	49	0.15%
Crimps, Welds & Bonds	0	0.00%
Other	1	< 0.01%
Extrinsic Factors	162	0.50%
Total	261	0.81%



YEAR	2	4	6	8	10	12	14	16	AT 199 MONTHS
SURVIVAL PROBABILITY	99.38%	98.85%	97.82%	96.66%	95.82%	95.32%	94.90%	94.56%	94.49%
±1 STANDARD ERROR	0.05%	0.07%	0.10%	0.14%	0.17%	0.18%	0.20%	0.21%	0.24%
SAMPLE SIZE	25,060	18,800	14,150	11,240	9,440	8,230	6,560	2,490	280


ACTIVELY MONITORED STUDY DATA

QuickSite[™] MODEL 1056T

US Regulatory Approval	April 2005
Number of Devices Enrolled in Study	319
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	15,381
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Bipolar
Steroid	Yes
	105

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.31%
Extracardiac Stimulation	2	0.63%
Failure to Capture	4	1.25%
Lead Dislodgement	5	1.57%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	1	0.31%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.31%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	4	1.25%
Total	5	1.57%




CUSTOMER REPORTED PERFORMANCE DATA

QuickSite[™] MODEL 1056K

US Regulatory Approval	June 2004
Registered US Implants	7,874
Estimated Active US Implants	1,499
Insulation	Polyurethane/Silicone
Type and/or Fixation	S-Curve
Polarity	Unipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBS (POST IMPLA)	ERVATIONS NT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	0	0.00%
Conductor Fracture	0	0.00%	8	0.10%
Lead Dislodgement	10	0.13%	36	0.46%
Failure to Capture	3	0.04%	78	0.99%
Oversensing	0	0.00%	2	0.03%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	0	0.00%	6	0.08%
Abnormal Pacing Impedance	0	0.00%	8	0.10%
Extracardiac Stimulation	10	0.13%	32	0.41%
Other	2	0.03%	11	0.14%
Total	25	0.32%	181	2.30%
Total Returned for Analysis	13		52	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	3	0.04%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	3	0.04%
Insulation Breach	3	0.04%
Lead-to-Can Contact	2	0.03%
Lead-to-Lead Contact	1	0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	53	0.67%
Total	59	0.75%



YEAR	2	4	6	8	10	12	14	16	AT 209 MONTHS
SURVIVAL PROBABILITY	99.26%	98.58%	97.98%	96.93%	95.74%	94.89%	94.59%	94.46%	94.46%
±1 STANDARD ERROR	0.10%	0.15%	0.20%	0.28%	0.36%	0.42%	0.44%	0.45%	0.45%
SAMPLE SIZE	6,100	4,500	3,260	2,430	2,000	1,730	1,540	1,230	280

SUMMARY INFORMATION Left-Heart Leads

Survival Probability Summary

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
1458QL	Quartet	99.39%	99.08%	98.93%	98.74%	98.56%					
1457Q	QuickFlex" µ	98.34%	97.74%	97.22%	97.02%	96.48%					
1456Q	QuickFlex [™] µ	99.02%	98.65%	98.46%	98.15%	97.99%					
1458Q	Quartet	99.30%	99.06%	98.86%	98.68%	98.47%	98.32%	98.14%	97.96%	97.82%	97.76%
1258T	QuickFlex [™] µ	99.55%	99.34%	99.17%	98.98%	98.80%	98.59%	98.32%	98.12%	97.89%	97.65%
1156T	QuickFlex	99.65%	99.42%	99.11%	98.71%	98.19%	97.61%	97.21%	96.95%	96.71%	96.48%
1158T	QuickFlex XL	99.57%	99.35%	98.97%	98.52%	97.85%	97.36%	96.91%	96.62%	96.31%	96.19%
1058T	QuickSite" XL	99.75%	99.62%	99.38%	99.07%	98.76%	98.08%	97.44%	96.93%	96.49%	96.22%
1056T	QuickSite"	99.60%	99.38%	99.17%	98.85%	98.39%	97.82%	97.17%	96.66%	96.18%	95.82%
1056K	QuickSite"	99.50%	99.26%	98.85%	98.58%	98.20%	97.98%	97.48%	96.93%	96.22%	95.74%

Acute Observation Summary POST IMPLANT ≤30 DAYS

	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US		RDIAC		UCTOR		AD GEMENT		JRE TO TURE	OVER	SENSING		LURE		LATION EACH	PA	ORMAL CING DANCE		CARDIAC LATION	от	HER	то	TAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
1458QL	Oct-15	16,160	11,926	1	<0.01%	0	0.00%	32	0.20%	19	0.12%	0	0.00%	0	0.00%	2	0.01%	5	0.03%	27	0.17%	6	0.04%	92	0.57%	23
1457Q	Oct-15	8,916	6,531	0	0.00%	1	0.01%	43	0.48%	11	0.12%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	15	0.17%	7	0.08%	78	0.87%	20
1456Q	Oct-15	12,480	9,173	2	0.02%	2	0.02%	37	0.30%	13	0.10%	1	<0.01%	0	0.00%	1	<0.01%	4	0.03%	15	0.12%	6	0.05%	81	0.65%	20
1458Q	Nov-11	174,572	100,008	7	<0.01%	0	0.00%	299	0.17%	129	0.07%	4	<0.01%	0	0.00%	1	<0.01%	6	<0.01%	121	0.07%	122	0.07%	689	0.39%	248
1258T	May-10	48,461	20,860	0	0.00%	0	0.00%	65	0.13%	30	0.06%	0	0.00%	1	<0.01%	0	0.00%	5	0.01%	40	0.08%	16	0.03%	157	0.32%	68
1156T	Jul-07	27,671	8,623	0	0.00%	0	0.00%	11	0.04%	5	0.02%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	14	0.05%	9	0.03%	40	0.14%	14
1158T	Jul-07	15,341	4,859	0	0.00%	0	0.00%	9	0.06%	2	0.01%	0	0.00%	0	0.00%	0	0.00%	2	0.01%	6	0.04%	6	0.04%	25	0.16%	13
1058T	Feb-06	9,956	2,527	0	0.00%	0	0.00%	10	0.10%	3	0.03%	1	0.01%	0	0.00%	0	0.00%	2	0.02%	9	0.09%	1	0.01%	26	0.26%	11
1056T	Apr-05	32,341	7,374	0	0.00%	0	0.00%	32	0.10%	15	0.05%	2	<0.01%	0	0.00%	1	<0.01%	3	<0.01%	22	0.07%	9	0.03%	84	0.26%	28
1056K	Jun-04	7,874	1,499	0	0.00%	0	0.00%	10	0.13%	3	0.04%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	10	0.13%	2	0.03%	25	0.32%	13

Chronic Complication Summary >30 DAYS

JUDAI	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US		RDIAC DRATION		UCTOR		AD GEMENT		JRE TO TURE	OVERS	SENSING		LURE SENSE		LATION EACH	PA	ORMAL CING DANCE		CARDIAC LATION	OT	HER	тс	TAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
1458QL	Oct-15	16,160	11,926	0	0.00%	0	0.00%	99	0.61%	39	0.24%	0	0.00%	0	0.00%	0	0.00%	11	0.07%	29	0.18%	6	0.04%	184	1.14%	58
1457Q	Oct-15	8,916	6,531	0	0.00%	0	0.00%	136	1.53%	39	0.44%	2	0.02%	0	0.00%	2	0.02%	1	0.01%	12	0.13%	6	0.07%	198	2.22%	79
1456Q	Oct-15	12,480	9,173	1	<0.01%	1	< 0.01%	122	0.98%	39	0.31%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%	20	0.16%	3	0.02%	188	1.51%	92
1458Q	Nov-11	174,572	100,008	5	<0.01%	37	0.02%	1341	0.77%	685	0.39%	26	0.01%	2	<0.01%	17	<0.01%	148	0.08%	237	0.14%	74	0.04%	2572	1.47%	915
1258T	May-10	48,461	20,860	1	<0.01%	47	0.10%	302	0.62%	408	0.84%	31	0.06%	3	<0.01%	19	0.04%	95	0.20%	161	0.33%	22	0.05%	1089	2.25%	282
1156T	Jul-07	27,671	8,623	1	<0.01%	10	0.04%	147	0.53%	245	0.89%	20	0.07%	0	0.00%	53	0.19%	70	0.25%	93	0.34%	9	0.03%	648	2.34%	173
1158T	Jul-07	15,341	4,859	1	<0.01%	5	0.03%	101	0.66%	158	1.03%	3	0.02%	1	<0.01%	35	0.23%	28	0.18%	35	0.23%	10	0.07%	377	2.46%	127
1058T	Feb-06	9,956	2,527	1	0.01%	8	0.08%	35	0.35%	98	0.98%	4	0.04%	2	0.02%	32	0.32%	22	0.22%	25	0.25%	5	0.05%	232	2.33%	40
1056T	Apr-05	32,341	7,374	0	0.00%	13	0.04%	174	0.54%	294	0.91%	27	0.08%	2	<0.01%	113	0.35%	67	0.21%	108	0.33%	29	0.09%	827	2.56%	213
1056K	Jun-04	7,874	1,499	0	0.00%	8	0.10%	36	0.46%	78	0.99%	2	0.03%	0	0.00%	6	0.08%	8	0.10%	32	0.41%	11	0.14%	181	2.30%	52

Definitions of observations and complications can be found on page 7.

US Malfunction Summary

	REGISTERED	PERCENT		OUCTOR		ATION ACH		S, WELDS DNDS	от	HER		INSIC FORS	то	TAL
MODELS	US IMPLANTS	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
1458QL	16,160	5.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	53	0.33%	53	0.33%
1457Q	8,916	6.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	82	0.92%	82	0.92%
1456Q	12,480	9.20%	0	0.00%	2	0.02%	0	0.00%	5	0.04%	88	0.71%	95	0.76%
1458Q	174,572	7.20%	11	<0.01%	9	<0.01%	0	0.00%	15	<0.01%	869	0.50%	904	0.52%
1258T	48,461	12.70%	9	0.02%	6	0.01%	0	0.00%	1	<0.01%	244	0.50%	260	0.54%
1156T	27,671	9.80%	7	0.03%	92	0.33%	0	0.00%	0	0.00%	134	0.48%	233	0.84%
1158T	15,341	11.00%	5	0.03%	59	0.38%	1	<0.01%	0	0.00%	90	0.59%	155	1.01%
1058T	9,956	10.60%	2	0.02%	26	0.26%	0	0.00%	1	0.01%	31	0.31%	60	0.60%
1056T	32,341	10.10%	6	0.02%	92	0.28%	0	0.00%	1	<0.01%	162	0.50%	261	0.81%
1056K	7,874	15.70%	3	0.04%	3	0.04%	0	0.00%	0	0.00%	53	0.67%	59	0.75%

Worldwide Malfunction Summary

	WORLWIDE	PERCENT RETURNED		UCTOR CTURE		LATION EACH		S, WELDS DNDS	от	HER		INSIC FORS	то	TAL
MODELS	SALES	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
1458QL	34,496	2.38%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	67	0.19%	68	0.20%
1457Q	24,716	2.42%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	98	0.40%	98	0.40%
1456Q	36,106	3.17%	0	0.00%	3	0.01%	0	0.00%	8	0.02%	115	0.32%	126	0.35%
1458Q	384,061	3.57%	32	0.01%	17	<0.01%	0	0.00%	30	0.01%	1262	0.33%	1341	0.35%
1258T	186,697	3.95%	51	0.03%	12	0.01%	0	0.00%	5	<0.01%	436	0.23%	504	0.27%

Definitions of malfunction categories can be found on pages 8-9.

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE	CUMULATIVE MONTHS OF	PA	ORMAL CING DANCE		DIAC RATION		UCTOR		CARDIAC	т	LURE TO TURE	1	LURE FO NSE		LATION EACH		AD GEMENT	OVERS	ENSING		ARDIAL ISION		KIN DSION	то	DTAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
1458Q	2,158	0	107,274	1	0.05%	0	0.00%	0	0.00%	3	0.14%	9	0.42%	0	0.00%	1	0.05%	38	1.76%	1	0.05%	0	0.00%	0	0.00%	53	2.46%
1258T	2,375	0	135,823	7	0.29%	0	0.00%	3	0.13%	56	2.36%	49	2.06%	0	0.00%	1	0.04%	52	2.19%	0	0.00%	0	0.00%	0	0.00%	168	7.07%
1156T	987	0	53,587	1	0.10%	0	0.00%	0	0.00%	18	1.82%	10	1.01%	0	0.00%	1	0.10%	28	2.84%	0	0.00%	0	0.00%	0	0.00%	58	5.88%
1158T	553	0	26,942	0	0.00%	0	0.00%	0	0.00%	9	1.63%	10	1.81%	0	0.00%	1	0.18%	7	1.27%	0	0.00%	0	0.00%	1	0.18%	28	5.06%
1058T	111	0	5,771	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	3.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	3.60%
1056T	319	0	15,381	1	0.31%	0	0.00%	0	0.00%	2	0.63%	4	1.25%	0	0.00%	0	0.00%	5	1.57%	0	0.00%	0	0.00%	0	0.00%	12	3.76%

MALFUNCTIONS


	NUMBER OF	PERCENT		OUCTOR		ATION ACH		S, WELDS DNDS	от	HER		TORS	тс	TAL
MODELS	DEVICES	RETURNED FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
1458Q	2,158	6.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	22	1.02%	22	1.02%
1258T	2,375	7.10%	1	0.04%	0	0.00%	0	0.00%	0	0.00%	44	1.85%	45	1.89%
1156T	987	9.40%	0	0.00%	3	0.30%	0	0.00%	0	0.00%	20	2.03%	23	2.33%
1158T	553	6.00%	0	0.00%	1	0.18%	0	0.00%	0	0.00%	7	1.27%	8	1.45%
1058T	111	6.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
1056T	319	8.80%	0	0.00%	1	0.31%	0	0.00%	0	0.00%	4	1.25%	5	1.57%

A list of complications can be found on page 12. Definitions of malfunction categories can be found on pages 8-9.

DUAL-CHAMBER Implantable Cardioverter Defibrillator (ICD) Devices

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices CUSTOMER REPORTED PERFORMANCE DATA

Gallant™ DR MODEL CDDRA500Q*				NCTIONS PROMISED RAPY	MALFUN W/O COMP THER	ROMISED
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2020	Electrical Component	0	0.00%	1	0.01%
Registered US Implants	7,898	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	7,410	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	0	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	0	0.00%
		Total	0	0.00%	1	0.01%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 14 MONTHS
SURVIVAL PROBABILITY	99.97%	99.97%
±1 STANDARD ERROR	0.02%	0.02%
SAMPLE SIZE	4,220	270


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 14 MONTHS
SURVIVAL PROBABILITY	99.97%	99.97%
±1 STANDARD ERROR	0.02%	0.02%

*DF4-LLHH connector type.

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices CUSTOMER REPORTED PERFORMANCE DATA

Ellipse [™] DR MODEL CD2411-36Q*			W/ COM	NCTIONS PROMISED RAPY	W/O COM	NCTIONS IPROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	2	< 0.01%	4	0.01%
Registered US Implants	32,029	Electrical Interconnect	1	< 0.01%	0	0.00%
Estimated Active US Implants	20,223	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	2	< 0.01%	1	< 0.01%
Normal Battery Depletion	62	Software/Firmware	1	< 0.01%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	1	< 0.01%	3	< 0.01%
Number of US Advisories		Possible Early Battery Depletion	0	0.00%	1	<0.01%
(see pgs. 303, 304, 306)	Three	Other	2	< 0.01%	3	<0.01%
		Total	9	0.03%	12	0.04%



YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.91%	99.87%	99.79%	99.74%	99.58%	99.35%	97.03%	94.28%	94.28%
±1 STANDARD ERROR	0.02%	0.02%	0.03%	0.03%	0.05%	0.08%	0.26%	0.56%	0.56%
SAMPLE SIZE	28,910	22,960	17,810	13,380	9,330	5,990	3,320	1,140	250


EXCLUDING NORMAL BATTERY DEPLETION	

YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.92%	99.88%	99.84%	99.83%	99.83%	99.83%	99.83%	99.67%	99.67%
±1 STANDARD ERROR	0.02%	0.02%	0.03%	0.03%	0.03%	0.03%	0.03%	0.12%	0.12%

*DF4-LLHH connector type.

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices CUSTOMER REPORTED PERFORMANCE DATA

Ellipse™ DR MODEL CD2411-36C*				W/ COMPROMISED W/O CO		LFUNCTIONS COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	June 2013	Electrical Component	3	0.03%	5	0.05%	
Registered US Implants	11,081	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	6,280	Battery	0	0.00%	0	0.00%	
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	7	0.06%	1	<0.01%	
Normal Battery Depletion	60	Software/Firmware	0	0.00%	0	0.00%	
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	<0.01%	
Number of US Advisories		Possible Early Battery Depletion	0	0.00%	0	0.00%	
(see pgs. 303, 304, 306)	Four	Other	0	0.00%	4	0.04%	
		Total	10	0.09%	11	0.10%	



INCLUDING	NORMAL	BATTERY	DEPLETI	

YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.78%	99.71%	99.69%	99.47%	99.19%	98.80%	94.89%	88.97%	88.97%
±1 STANDARD ERROR	0.05%	0.05%	0.06%	0.08%	0.11%	0.16%	0.44%	0.96%	0.96%
SAMPLE SIZE	10,160	8,570	7,340	6,220	4,910	3,360	1,930	760	230

EXCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.82%	99.75%	99.75%	99.59%	99.54%	99.41%	99.22%	99.06%	99.06%
±1 STANDARD ERROR	0.04%	0.05%	0.05%	0.07%	0.08%	0.10%	0.14%	0.18%	0.18%

*Parylene coating.

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura™ DR MODEL CD2357-40Q* (NON-BA	MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	3	<0.01%	10	0.02%
Registered US Implants	40,224	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	27,882	Battery	1	< 0.01%	2	<0.01%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	3	<0.01%	1	<0.01%
Normal Battery Depletion	9	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	2	<0.01%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	1	<0.01%
		Other	7	0.02%	1	<0.01%
		Total	14	0.03%	17	0.04%





INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.87%	99.82%	99.77%	99.70%	99.61%	99.56%	99.56%
± 1 STANDARD ERROR	0.02%	0.02%	0.03%	0.04%	0.05%	0.06%	0.06%
SAMPLE SIZE	35,970	27,570	19,920	13,560	8,170	3,470	330

EXCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.89%	99.85%	99.80%	99.74%	99.72%	99.72%	99.72%
± 1 STANDARD ERROR	0.02%	0.02%	0.03%	0.03%	0.04%	0.04%	0.04%

*DF4-LLHH connector type.

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura™ DR MODEL CD2357-40Q* (BATTERY A	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	3	0.02%	9	0.07%
Registered US Implants	12,263	Electrical Interconnect	1	< 0.01%	0	0.00%
Estimated Active US Implants	5,349	Battery	0	0.00%	13	0.11%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	35	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	72	0.59%	559	4.56%
		Other	1	< 0.01%	5	0.04%
		Total	77	0.63%	587	4.79%



YEARS AFTER IMPLANT

INCLUDING	NORMAL B	ATTERY DE	PLETION

YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.79%	99.32%	96.48%	91.18%	85.80%	82.16%	78.71%	76.55%	76.55%
± 1 STANDARD ERROR	0.04%	0.08%	0.18%	0.30%	0.37%	0.42%	0.46%	0.56%	0.56%
SAMPLE SIZE	11,500	10,170	9,060	8,060	7,200	6,290	4,380	1,670	280


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.84%	99.40%	96.62%	91.39%	86.10%	82.78%	79.67%	78.24%	78.24%
± 1 STANDARD ERROR	0.04%	0.07%	0.18%	0.29%	0.37%	0.41%	0.46%	0.51%	0.51%

*DF4-LLHH connector type.

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura™ DR MODEL CD2357-40C* (NON-BA	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	2	0.02%	2	0.02%
Registered US Implants	10,492	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	6,969	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	1	0.01%	0	0.00%
Normal Battery Depletion	3	Software/Firmware	0	0.00%	2	0.02%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	2	0.02%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	0	0.00%
		Total	3	0.03%	6	0.06%



YEARS	AFTER	IMPLAN

INCLUDING	NORMAL	BATTERY	DEPLETION	_

YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	99.90%	99.87%	99.81%	99.73%	99.60%	99.60%	99.60%
± 1 STANDARD ERROR	0.03%	0.04%	0.05%	0.06%	0.09%	0.09%	0.09%
SAMPLE SIZE	9,390	7,520	6,190	4,990	3,350	1,340	260


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	99.90%	99.87%	99.84%	99.84%	99.71%	99.71%	99.71%
±1 STANDARD ERROR	0.03%	0.04%	0.04%	0.04%	0.08%	0.08%	0.08%

*Parylene coating.

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura [™] DR MODEL CD2357-40C* (BATTERY A	DN)	W/ COMP	NCTIONS PROMISED RAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	3	0.04%	2	0.03%
Registered US Implants	6,956	Electrical Interconnect	2	0.03%	1	0.01%
Estimated Active US Implants	3,043	Battery	1	0.01%	5	0.07%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	30	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	32	0.46%	262	3.77%
		Other	2	0.03%	1	0.01%
		Total	40	0.58%	271	3.90%



INCLUDING	NORMAL B	ATTERY I	DEPLETIC	DN	


YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.72%	99.41%	97.41%	92.67%	87.95%	84.97%	81.10%	78.14%	78.14%
±1 STANDARD ERROR	0.06%	0.09%	0.21%	0.36%	0.46%	0.53%	0.61%	0.83%	0.83%
SAMPLE SIZE	6,530	5,760	5,100	4,540	4,050	3,490	2,430	980	200

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.80%	99.58%	97.61%	93.06%	88.63%	85.76%	82.64%	80.78%	80.78%
±1 STANDARD ERROR	0.05%	0.07%	0.20%	0.36%	0.45%	0.52%	0.59%	0.72%	0.72%

*Parylene coating.

Ellipse[™] **DR** MALFUNCTIONS W/ COMPROMISED THERAPY MALFUNCTIONS W/O COMPROMISED THERAPY MODEL CD2311-36Q* RATE RATE QTY QTY US Regulatory Approval May 2012 Electrical Component 3 0.05% 9 0.15% Registered US Implants Electrical Interconnect 0.00% 0.00% 5,898 0 0 Battery 0.00% 0.02% Estimated Active US Implants 1,913 0 1 Estimated Longevity (see table on page 125) High Voltage Capacitor 65 1.10% 140.24% Normal Battery Depletion 186 Software/Firmware 0.02% 0 0.00% Max. Delivered Energy 36 joules Mechanical 0.03% 0.05% 2 3 Number of US Advisories (see pgs. 304, 306) Possible Early Battery Depletion 0.00% 0.00% Two 0 0 Other 0.08% 0.03% 5 2 Total 76 1.29% 29 0.49%




INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.04%	98.02%	97.15%	95.79%	94.79%	92.32%	86.14%	80.34%	79.66%	79.66%
±1 STANDARD ERROR	0.13%	0.19%	0.23%	0.29%	0.33%	0.40%	0.55%	0.67%	0.69%	0.71%
SAMPLE SIZE	5,540	4,940	4,490	4,100	3,730	3,390	3,010	2,390	1,280	220

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.13%	98.17%	97.43%	96.34%	95.80%	95.21%	94.66%	94.26%	94.15%	94.15%
±1 STANDARD ERROR	0.12%	0.18%	0.22%	0.27%	0.29%	0.31%	0.34%	0.36%	0.37%	0.37%

Ellipse™ DR MODEL CD2311-36	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012	Electrical Component	5	0.13%	7	0.19%
Registered US Implants	3,748	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,260	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	22	0.59%	9	0.24%
Normal Battery Depletion	128	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	4	0.11%	3	0.08%
Number of US Advisories (see pgs. 304, 306)	Two	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	5	0.13%	1	0.03%
		Total	36	0.96%	20	0.53%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	98.94%	97.70%	96.98%	96.13%	94.42%	92.34%	85.40%	81.07%	80.20%	80.20%
± 1 STANDARD ERROR	0.17%	0.26%	0.30%	0.34%	0.41%	0.51%	0.70%	0.84%	0.87%	0.87%
SAMPLE SIZE	3,530	3,130	2,800	2,530	2,300	2,100	1,870	1,490	780	230

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.03%	98.03%	97.48%	96.94%	96.31%	96.13%	95.82%	95.70%	95.41%	95.41%
±1 STANDARD ERROR	0.16%	0.24%	0.27%	0.30%	0.34%	0.36%	0.37%	0.39%	0.44%	0.44%

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura [™] DR MODEL CD2257-40Q* (BATTERY A	W/ COMP	NCTIONS PROMISED RAPY	MALFUN W/O COMP THEF	ROMISED		
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012	Electrical Component	5	0.07%	3	0.04%
Registered US Implants	6,798	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	2,510	Battery	1	0.01%	2	0.03%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	47	Software/Firmware	0	0.00%	1	0.01%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	0.01%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	27	0.40%	162	2.38%
		Other	3	0.04%	1	0.01%
		Total	36	0.53%	170	2.50%



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	9	AT 112 MONTHS
SURVIVAL PROBABILITY	99.88%	99.63%	99.11%	96.97%	93.33%	89.98%	87.48%	85.39%	84.48%	84.48%
±1 STANDARD ERROR	0.04%	0.08%	0.13%	0.24%	0.36%	0.45%	0.50%	0.56%	0.60%	0.60%
SAMPLE SIZE	6,410	5,720	5,130	4,590	4,110	3,690	3,300	2,770	1,440	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 112 MONTHS
SURVIVAL PROBABILITY	99.88%	99.72%	99.33%	97.29%	93.74%	90.74%	89.35%	88.17%	87.73%	87.73%
± 1 STANDARD ERROR	0.04%	0.07%	0.11%	0.22%	0.35%	0.44%	0.47%	0.51%	0.53%	0.53%

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura [™] DR MODEL CD2257-40 (BATTERY AD	W/ COMP	NCTIONS PROMISED RAPY	MALFUN W/O COMP THEF	ROMISED		
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012	Electrical Component	2	0.05%	0	0.00%
Registered US Implants	4,235	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,497	Battery	1	0.02%	4	0.09%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	1	0.02%	0	0.00%
Normal Battery Depletion	26	Software/Firmware	0	0.00%	1	0.02%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	n 13	0.31%	75	1.77%
		Other	0	0.00%	3	0.07%
		Total	17	0.40%	83	1.96%



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.85%	99.62%	99.42%	98.01%	95.10%	91.92%	89.09%	87.73%	86.67%	86.67%
± 1 STANDARD ERROR	0.06%	0.10%	0.13%	0.25%	0.41%	0.54%	0.63%	0.68%	0.74%	0.74%
SAMPLE SIZE	3,970	3,510	3,140	2,760	2,430	2,180	1,950	1,630	880	210

EXCLUDING NORM	AL BATTERY	DEPLETION	

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.90%	99.73%	99.53%	98.19%	95.35%	92.55%	90.92%	90.16%	89.72%	89.72%
±1 STANDARD ERROR	0.05%	0.09%	0.12%	0.24%	0.40%	0.52%	0.58%	0.61%	0.65%	0.65%

CUSTOMER REPORTED PERFORMANCE DATA

Fortify™ DR MODEL CD2231-40Q* (BATTERY A	W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY		
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2010	Electrical Component	10	0.04%	9	0.03%
Registered US Implants	26,876	Electrical Interconnect	3	0.01%	2	<0.01%
Estimated Active US Implants	6,599	Battery	28	0.10%	54	0.20%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	5	0.02%	2	<0.01%
Normal Battery Depletion	560	Software/Firmware	1	< 0.01%	2	<0.01%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	164	0.61%	391	1.45%
		Other	16	0.06%	13	0.05%
		Total	227	0.84%	473	1.76%



INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.53%	98.00%	93.24%	85.96%	77.08%	74.82%
±1 STANDARD ERROR	0.04%	0.10%	0.19%	0.28%	0.38%	0.44%
SAMPLE SIZE	22,300	18,120	14,580	11,590	6,920	300

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.76%	98.61%	95.02%	89.37%	88.02%	87.92%
±1 STANDARD ERROR	0.03%	0.08%	0.17%	0.25%	0.27%	0.28%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

Fortify[™] DR MODEL CD2231-40Q*

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	QTY RATE	QTY RATE QTY
gulatory Approval	May 2010	Premature Battery Depletion	7	1.79%	Electrical Component	Electrical Component 0	Electrical Component 0 0.00%	Electrical Component 0 0.00% 0
er of Devices Enrolled in Study	390				Electrical Interconnect	Electrical Interconnect 0	Electrical Interconnect 0 0.00%	Electrical Interconnect 0 0.00% 0
Devices Enrolled in Study	0				Battery	Battery 1	Battery 1 0.26%	Battery 1 0.26% 1
lative Months of Follow-up	24,816				High Voltage Capacitor	High Voltage Capacitor 0	High Voltage Capacitor 0 0.00%	High Voltage Capacitor 0 0.00% 0
ated Longevity	(see table on page 125)				Software/Firmware	Software/Firmware 0	Software/Firmware 0 0.00%	Software/Firmware 0 0.00% 0
Delivered Energy	40 joules				Mechanical	Mechanical 0	Mechanical 0 0.00%	Mechanical 0 0.00% 0
					Possible Early Battery Depletion	Possible Early Battery Depletion 2	Possible Early Battery Depletion 2 0.51%	Possible Early Battery Depletion 2 0.51% 7
					Other	Other 1	Other 1 0.26%	Other 1 0.26% 0

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

1.03%

4

8

2.05%




TEAR	1	2	3	4	5	6	/	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.74%	99.74%	99.74%	99.74%	99.31%	97.14%	96.47%	96.47%	96.47%	96.47%
± 1 STANDARD ERROR	0.26%	0.26%	0.26%	0.26%	0.50%	1.18%	1.35%	1.35%	1.35%	1.35%
SAMPLE SIZE	380	340	300	260	220	180	150	130	100	50

CUSTOMER REPORTED PERFORMANCE DATA

Fortify[™] DR MODEL CD2231-40 (BATTERY ADVISORY P

US Regulatory Approval	May 2010
Registered US Implants	12,092
Estimated Active US Implants	3,079
Estimated Longevity	(see table on page 125)
Normal Battery Depletion	217
Max. Delivered Energy	40 joules
Number of US Advisories (see pgs. 304, 305)	Three

POPULATION)	W/ COMP	NCTIONS PROMISED RAPY	MALFUN W/O COMF THEF	ROMISED
		QTY	RATE	QTY	RATE
1	Electrical Component	9	0.07%	3	0.02%
	Electrical Interconnect	1	< 0.01%	0	0.00%
	Battery	5	0.04%	9	0.07%
on page 125)	High Voltage Capacitor	8	0.07%	2	0.02%
	Software/Firmware	0	0.00%	1	<0.01%
	Mechanical	0	0.00%	1	<0.01%
	Possible Early Battery Depletion	59	0.49%	132	1.09%
	Other	5	0.04%	5	0.04%
	Total	87	0.72%	153	1.27%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 137 MONTHS
SURVIVAL PROBABILITY	99.66%	98.38%	93.59%	86.75%	80.35%	79.25%
± 1 STANDARD ERROR	0.05%	0.13%	0.28%	0.43%	0.55%	0.61%
SAMPLE SIZE	9,870	7,820	6,130	4,840	2,880	270

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 137 MONTHS
SURVIVAL PROBABILITY	99.86%	98.86%	95.57%	91.35%	90.35%	90.35%
± 1 STANDARD ERROR	0.03%	0.11%	0.24%	0.36%	0.39%	0.39%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

100

Fortify[™] DR **MODEL CD2231-40**

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	QTY RATE	QTY RATE QTY
S Regulatory Approval	May 2010	Premature Battery Depletion	2	1.13%	Electrical Component	Electrical Component 0	Electrical Component 0 0.00%	Electrical Component 0 0.00% 0
umber of Devices Enrolled in Study	177				Electrical Interconnect	Electrical Interconnect 0	Electrical Interconnect 0 0.00%	Electrical Interconnect 0 0.00% 0
tive Devices Enrolled in Study	0				Battery	Battery 0	Battery 0 0.00%	Battery 0 0.00% 0
umulative Months of Follow-up	9,249				High Voltage Capacitor	High Voltage Capacitor 0	High Voltage Capacitor 0 0.00%	High Voltage Capacitor 0 0.00% 0
Estimated Longevity	(see table on page 125)				Software/Firmware	Software/Firmware 0	Software/Firmware 0 0.00%	Software/Firmware 0 0.00% 0
Max. Delivered Energy	40 joules				Mechanical	Mechanical 0	Mechanical 0 0.00%	Mechanical 0 0.00% 0
					Possible Early Battery Depletion	Possible Early Battery Depletion 1	Possible Early Battery Depletion 1 0.56%	Possible Early Battery Depletion 1 0.56% 3
					Other	Other 0	Other 0 0.00%	Other 0 0.00% 0

Total


MALFUNCTIONS W/ COMPROMISED THERAPY MALFUNCTIONS W/O COMPROMISED THERAPY

0.56%

1

3


1.69%



70

60

Current™ + DR MODEL CD2211-36Q*	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Electrical Component	6	0.07%	6	0.07%
Registered US Implants	8,148	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,108	Battery	6	0.07%	8	0.10%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	3	0.04%	0	0.00%
Normal Battery Depletion	1,480	Software/Firmware	1	0.01%	23	0.28%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	2	0.02%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	4	0.05%	3	0.04%
		Other	5	0.06%	5	0.06%
		Total	25	0.31%	47	0.58%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 146 MONTHS
SURVIVAL PROBABILITY	99.33%	98.47%	93.48%	32.42%	21.02%	20.90%	20.90%
± 1 STANDARD ERROR	0.10%	0.15%	0.34%	0.69%	0.56%	0.56%	0.56%
SAMPLE SIZE	6,590	5,330	4,320	2,580	1,290	670	230

EXCLUDING NORMAL BAT	TERY DEPLETIO	N					
YEAR	2	4	6	8	10	12	AT 146 MONTHS
SURVIVAL PROBABILITY	99.58%	99.22%	98.54%	95.71%	95.58%	95.58%	95.58%
± 1 STANDARD ERROR	0.08%	0.11%	0.16%	0.35%	0.36%	0.36%	0.36%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

36 joules

Current[™] + DR MODEL CD2211-36Q*


US Regulatory Approval

Max. Delivered Energy

Number of Devices Enrolled in Study Active Devices Enrolled in Study Cumulative Months of Follow-up Estimated Longevity


	QUALIFYING COMPLICATIONS	QTY	RATE
February 2009	Premature Battery Depletion	4	0.48%
835	Skin Erosion	1	0.12%
0			
61,859			
(see table on page 125)			

	W/ COMP	ICTIONS ROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	1	0.12%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	1	0.12%	2	0.24%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	2	0.24%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	1	0.12%
Other	1	0.12%	2	0.24%
Total	2	0.24%	8	0.96%



ACTIVELY MONITORED ST						
YEAR	2	4	6	8	10	AT 131 MONTHS
SURVIVAL PROBABILITY	99.61%	99.44%	99.44%	99.17%	99.17%	99.17%
±1 STANDARD ERROR	0.23%	0.28%	0.28%	0.39%	0.39%	0.39%
SAMPLE SIZE	710	570	440	350	310	50

Current™ + DR MODEL CD2211-36			W/ COMF	NCTIONS PROMISED RAPY	W/O COM	ICTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Electrical Component	3	0.05%	2	0.03%
Registered US Implants	6,271	Electrical Interconnect	2	0.03%	0	0.00%
Estimated Active US Implants	876	Battery	8	0.13%	4	0.06%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	1	0.02%	0	0.00%
Normal Battery Depletion	1,107	Software/Firmware	1	0.02%	16	0.26%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	0.02%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	9	0.14%	4	0.06%
		Other	6	0.10%	2	0.03%
		Total	30	0.48%	29	0.46%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.53%	98.27%	93.02%	28.60%	21.01%	20.96%	20.96%
± 1 STANDARD ERROR	0.09%	0.18%	0.41%	0.76%	0.64%	0.64%	0.64%
SAMPLE SIZE	5,070	4,030	3,220	1,810	980	590	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.76%	98.95%	98.01%	95.88%	95.88%	95.62%	95.62%
± 1 STANDARD ERROR	0.07%	0.14%	0.23%	0.37%	0.37%	0.41%	0.41%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

February 2009

(see table on page 125)

122

6,388

36 joules

0

Current[™] + DR MODEL CD2211-36

US Regulatory Approval

Estimated Longevity

Max. Delivered Energy


Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up


QUALIFYING COMPLICATIONS	QTY	RATE
Inappropriate Shock	1	0.82%
Premature Battery Depletion	1	0.82%

	W/ COMP	NCTIONS ROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	2	1.64%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	1	0.82%	1	0.82%
Total	1	0.82%	3	2.46%



ACTIVELY MONITORED ST	UDY DATA				
YEAR	1	2	3	4	5
SURVIVAL PROBABILITY	99.13%	98.16%	98.16%	98.16%	98.16%
± 1 STANDARD ERROR	0.87%	1.29%	1.29%	1.29%	1.29%
SAMPLE SIZE	120	100	80	60	50

Current [™] DR RF MODEL 2207-36			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	September 2007	Electrical Component	11	0.05%	12	0.05%
Registered US Implants	22,390	Electrical Interconnect	6	0.03%	2	<0.01%
Estimated Active US Implants	2,360	Battery	21	0.09%	9	0.04%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	1	< 0.01%	0	0.00%
Normal Battery Depletion	3,700	Software/Firmware	4	0.02%	48	0.21%
Max. Delivered Energy	36 joules	Mechanical	1	< 0.01%	23	0.10%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	40	0.18%	21	0.09%
		Other	35	0.16%	6	0.03%
		Total	119	0.53%	121	0.54%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 167 MONTHS
SURVIVAL PROBABILITY	99.16%	97.69%	92.52%	37.55%	18.42%	18.15%	18.13%
± 1 STANDARD ERROR	0.07%	0.12%	0.22%	0.46%	0.34%	0.34%	0.34%
SAMPLE SIZE	17,960	14,020	11,030	6,510	3,000	2,470	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 167 MONTHS
SURVIVAL PROBABILITY	99.59%	98.70%	97.83%	94.96%	93.95%	93.88%	93.88%
± 1 STANDARD ERROR	0.05%	0.09%	0.12%	0.22%	0.28%	0.28%	0.28%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

Current[™] DR RF MODEL 2207-36

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	RATE	QTY	I
JS Regulatory Approval	September 2007	Inappropriate Shock	1	0.16%	Electrical Component	0	0.00%	0	
Number of Devices Enrolled in Study	631				Electrical Interconnect	0	0.00%	0	
Active Devices Enrolled in Study	0				Battery	0	0.00%	0	
Cumulative Months of Follow-up	33,069				High Voltage Capacitor	0	0.00%	0	
Estimated Longevity	(see table on page 125)				Software/Firmware	0	0.00%	2	
Max. Delivered Energy	36 joules				Mechanical	0	0.00%	0	
					Possible Early Battery Depletion	1	0.16%	1	
					Other	0	0.00%	0	

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0.16%

1


3

0.48%



SURVIVAL PROBABILITY	99.84%	99.84%	99.84%	99.84%	99.84%	99.84%	99.84%	99.84%	99.84%
±1 STANDARD ERROR	0.16%	0.16%	0.16%	0.16%	0.16%	0.16%	0.16%	0.16%	0.16%
SAMPLE SIZE	600	520	420	340	270	220	170	100	50

Atlas™ II + DR MODEL V-268							
			QTY	RATE	QTY	RATE	
US Regulatory Approval	July 2006	Electrical Component	6	0.04%	4	0.03%	
Registered US Implants	14,713	Electrical Interconnect	4	0.03%	0	0.00%	
Estimated Active US Implants	991	Battery	9	0.06%	3	0.02%	
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	0	0.00%	0	0.00%	
Normal Battery Depletion	2,967	Software/Firmware	0	0.00%	0	0.00%	
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	< 0.01%	
Number of US Advisories (see pg. 309)	One	Possible Early Battery Depletion	19	0.13%	6	0.04%	
		Other	9	0.06%	5	0.03%	
		Total	47	0.32%	19	0.13%	



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 178 MONTHS
SURVIVAL PROBABILITY	99.18%	96.81%	63.59%	11.04%	10.06%	9.92%	9.88%	9.88%
±1 STANDARD ERROR	0.08%	0.17%	0.54%	0.32%	0.30%	0.30%	0.30%	0.30%
SAMPLE SIZE	11,690	8,750	5,780	1,890	1,260	1,110	700	220


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 178 MONTHS
SURVIVAL PROBABILITY	99.68%	99.10%	98.46%	97.99%	97.99%	97.99%	97.99%	97.99%
±1 STANDARD ERROR	0.05%	0.09%	0.13%	0.19%	0.19%	0.19%	0.19%	0.19%

Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA


Atlas[™] II + DR MODEL V-268

MODEL V-268						W/O COM	NCTIONS IPROMISED RAPY
		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	July 2006	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	101		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	3,805		High Voltage Capacitor	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 125)		Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	2	1.98%	0	0.00%
			Total	2	1.98%	0	0.00%



ACTIVELY MONITORED ST			
YEAR	1	2	AT 31 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%
± 1 STANDARD ERROR	0.00%	0.00%	0.00%
SAMPLE SIZE	100	80	50

Atlas™ + DR MODEL V-243			W/ COM	NCTIONS PROMISED ERAPY	W/O COM	NCTIONS IPROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	October 2003	Electrical Component	5	0.02%	3	0.01%
Registered US Implants	21,082	Electrical Interconnect	1	<0.01%	0	0.00%
Estimated Active US Implants	996	Battery	12	0.06%	4	0.02%
Estimated Longevity	(see table on page 125)	High Voltage Capacitor	1	<0.01%	0	0.00%
Normal Battery Depletion	3,712	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	4	0.02%
Number of US Advisories (see pgs. 309, 310, 311)	Three	Possible Early Battery Depletion	6	0.03%	4	0.02%
		Other	17	0.08%	2	< 0.01%
		Total	42	0.20%	17	0.08%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.57%	98.05%	89.49%	32.88%	8.69%	8.04%	7.89%	7.88%	7.88%
±1 STANDARD ERROR	0.05%	0.11%	0.29%	0.50%	0.25%	0.24%	0.24%	0.24%	0.24%
SAMPLE SIZE	16,860	12,670	8,930	4,790	1,570	1,230	1,090	600	200

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.90%	99.61%	99.14%	98.75%	98.58%	98.29%	98.29%	98.29%	98.29%
±1 STANDARD ERROR	0.02%	0.05%	0.08%	0.12%	0.15%	0.21%	0.21%	0.21%	0.21%

BATTERY LONGEVITY SUMMARY Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

Battery Longevity (years)

MODELS	FAMILY	NO PACING	25% PACING	50% PACING	100% PACING
CDDRA500Q	Gallant DR†	10.6	9.9	9.3	8.2
CD2411-36Q	Ellipse" DR*	10.4	9.6	8.9	7.7
CD2411-36C	Ellipse DR*	10.4	9.6	8.9	7.7
CD2357-40Q	Fortify Assura DR**	11.1	10.2	9.5	8.3
CD2357-40C	Fortify Assura DR**	11.1	10.2	9.5	8.3
CD2311-36Q	Ellipse" DR*	10.4	9.6	8.9	7.7
CD2311-36	Ellipse DR*	10.4	9.6	8.9	7.7
CD2257-40Q	Fortify Assura" DR**	11.1	10.2	9.5	8.3
CD2257-40	Fortify Assura DR**	11.1	10.2	9.5	8.3
CD2231-40Q	Fortify" DR**	10.1	9.3	8.6	7.5
CD2231-40	Fortify DR**	10.1	9.3	8.6	7.5
CD2211-36Q	Current" + DR***	8.2	7.5	7.0	6.1
CD2211-36	Current" + DR***	8.2	7.5	7.0	6.1
2207-36	Current" DR RF***	8.2	7.5	7.0	6.1
V-268	Atlas" II + DR***	8.2	7.5	7.0	6.1
V-243	Atlas" + DR***	7.9	7.3	6.9	6.1

Pacing parameters: DDD, 2.5V, 0.5 ms, 60 ppm, 500 ohms

* Battery voltage range 3.20-2.59. Two maximum charges per year.

** Battery voltage range 3.20-2.59. Three maximum charges per year.

*** Battery voltage range: 3.20-2.45. Four maximum charges per year as well as monthly charging during the battery's mid-life voltage range.

+Capacitor maintenance interval: 1 charge per every 9 months

SUMMARY INFORMATION Dual-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

Survival Probability Summary

INCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
CDDRA500Q	Gallant" DR*	99.97%									
CD2411-36Q	Ellipse" DR	99.91%	99.87%	99.79%	99.74%	99.58%	99.35%	97.03%	94.28%		
CD2411-36C	Ellipse" DR	99.78%	99.71%	99.69%	99.47%	99.19%	98.80%	94.89%	88.97%		
CD2357-40Q	Fortify Assura" DR	99.87%	99.82%	99.77%	99.70%	99.61%	99.56%				
CD2357-40Q	Fortify Assura" DR^\dagger	99.79%	99.32%	96.48%	91.18%	85.80%	82.16%	78.71%	76.55%		
CD2357-40C	Fortify Assura" DR	99.90%	99.87%	99.81%	99.73%	99.60%	99.60%				
CD2357-40C	Fortify Assura" DR^{\dagger}	99.72%	99.41%	97.41%	92.67%	87.95%	84.97%	81.10%	78.14%		
CD2311-36Q	Ellipse" DR	99.04%	98.02%	97.15%	95.79%	94.79%	92.32%	86.14%	80.34%	79.66%	
CD2311-36	Ellipse" DR	98.94%	97.70%	96.98%	96.13%	94.42%	92.34%	85.40%	81.07%	80.20%	
CD2257-40Q	Fortify Assura" DR^{\dagger}	99.88%	99.63%	99.11%	96.97%	93.33%	89.98%	87.48%	85.39%	84.48%	
CD2257-40	Fortify Assura" DR^{\dagger}	99.85%	99.62%	99.42%	98.01%	95.10%	91.92%	89.09%	87.73%	86.67%	
CD2231-40Q	Fortify" DR^{\dagger}	99.74%	99.53%	98.94%	98.00%	96.30%	93.24%	89.02%	85.96%	82.37%	77.08%
CD2231-40	Fortify" DR^{\dagger}	99.88%	99.66%	99.16%	98.38%	96.76%	93.59%	89.64%	86.75%	83.86%	80.35%
CD2211-36Q	Current [~] + DR	99.78%	99.33%	98.95%	98.47%	97.10%	93.48%	73.93%	32.42%	21.97%	21.02%
CD2211-36	Current" + DR	99.75%	99.53%	99.15%	98.27%	97.45%	93.02%	68.25%	28.60%	21.78%	21.01%
2207-36	Current" DR RF	99.64%	99.16%	98.52%	97.69%	96.35%	92.52%	76.63%	37.55%	19.92%	18.42%
V-268	Atlas" II + DR	99.52%	99.18%	98.47%	96.81%	90.89%	63.59%	23.11%	11.04%	10.33%	10.06%
V-243	Atlas" + DR	99.79%	99.57%	99.05%	98.05%	95.56%	89.49%	69.08%	32.88%	11.30%	8.69%

†Premature battery depletion advisory population.

Survival Probability Summary

EXCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
CDDRA500Q	Gallant" DR*	99.97%									
CD2411-36Q	Ellipse" DR	99.92%	99.88%	99.84%	99.83%	99.83%	99.83%	99.83%	99.67%		
CD2411-36C	Ellipse" DR	99.82%	99.75%	99.75%	99.59%	99.54%	99.41%	99.22%	99.06%		
CD2357-40Q	Fortify Assura" DR	99.89%	99.85%	99.80%	99.74%	99.72%	99.72%				
CD2357-40Q	Fortify Assura $\ DR^{\dagger}$	99.84%	99.40%	96.62%	91.39%	86.10%	82.78%	79.67%	78.24%		
CD2357-40C	Fortify Assura" DR	99.90%	99.87%	99.84%	99.84%	99.71%	99.71%				
CD2357-40C	Fortify Assura $\ DR^{\dagger}$	99.80%	99.58%	97.61%	93.06%	88.63%	85.76%	82.64%	80.78%		
CD2311-36Q	Ellipse" DR	99.13%	98.17%	97.43%	96.34%	95.80%	95.21%	94.66%	94.26%	94.15%	
CD2311-36	Ellipse" DR	99.03%	98.03%	97.48%	96.94%	96.31%	96.13%	95.82%	95.70%	95.41%	
CD2257-40Q	Fortify Assura" DR^{\dagger}	99.88%	99.72%	99.33%	97.29%	93.74%	90.74%	89.35%	88.17%	87.73%	
CD2257-40	Fortify Assura $\ DR^{\dagger}$	99.90%	99.73%	99.53%	98.19%	95.35%	92.55%	90.92%	90.16%	89.72%	
CD2231-40Q	Fortify $\operatorname{DR}^{\dagger}$	99.87%	99.76%	99.31%	98.61%	97.42%	95.02%	91.89%	89.37%	88.27%	88.02%
CD2231-40	Fortify $\operatorname{DR}^{\dagger}$	99.95%	99.86%	99.48%	98.86%	97.73%	95.57%	93.39%	91.35%	90.69%	90.35%
CD2211-36Q	Current + DR	99.85%	99.58%	99.41%	99.22%	98.82%	98.54%	97.58%	95.71%	95.58%	95.58%
CD2211-36	Current [®] + DR	99.90%	99.76%	99.47%	98.95%	98.76%	98.01%	96.61%	95.88%	95.88%	95.88%
2207-36	Current DR RF	99.75%	99.59%	99.21%	98.70%	98.19%	97.83%	96.99%	94.96%	93.95%	93.95%
V-268	Atlas" II + DR	99.81%	99.68%	99.40%	99.10%	98.82%	98.46%	98.23%	97.99%	97.99%	97.99%
V-243	Atlas" + DR	99.97%	99.90%	99.80%	99.61%	99.40%	99.14%	98.96%	98.75%	98.58%	98.58%

†Premature battery depletion advisory population.

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDDRA500Q	Gallant [®] DR	7,898	0.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD2411-36Q	Ellipse ⁻ DR	32,029	4.50%	2	<0.01%	1	<0.01%	0	0.00%	2	<0.01%	1	< 0.01%	1	<0.01%	0	0.00%	2	<0.01%	9	0.03%
CD2411-36C	Ellipse ⁻ DR	11,081	7.00%	3	0.03%	0	0.00%	0	0.00%	7	0.06%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	10	0.09%
CD2357-40Q	Fortify Assura ⁻ DR	40,224	3.80%	3	<0.01%	0	0.00%	1	<0.01%	3	<0.01%	0	0.00%	0	0.00%	0	0.00%	7	0.02%	14	0.03%
CD2357-40Q	Fortify Assura $\bar{\ } DR^{\dagger}$	12,263	17.50%	3	0.02%	1	< 0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	72	0.59%	1	<0.01%	77	0.63%
CD2357-40C	Fortify Assura ⁻ DR	10,492	4.80%	2	0.02%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	0.03%
CD2357-40C	Fortify Assura $ \mathrm{DR}^{\dagger}$	6,956	19.10%	3	0.04%	2	0.03%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	32	0.46%	2	0.03%	40	0.58%
CD2311-36Q	Ellipse [®] DR	5,898	13.40%	3	0.05%	0	0.00%	0	0.00%	65	1.10%	1	0.02%	2	0.03%	0	0.00%	5	0.08%	76	1.29%
CD2311-36	Ellipse [®] DR	3,748	14.40%	5	0.13%	0	0.00%	0	0.00%	22	0.59%	0	0.00%	4	0.11%	0	0.00%	5	0.13%	36	0.96%
CD2257-40Q	Fortify Assura" DR^{\dagger}	6,798	16.90%	5	0.07%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	27	0.40%	3	0.04%	36	0.53%
CD2257-40	Fortify Assura" DR^{\dagger}	4,235	18.80%	2	0.05%	0	0.00%	1	0.02%	1	0.02%	0	0.00%	0	0.00%	13	0.31%	0	0.00%	17	0.40%
CD2231-40Q	Fortify DR^{\dagger}	26,876	16.80%	10	0.04%	3	0.01%	28	0.10%	5	0.02%	1	<0.01%	0	0.00%	164	0.61%	16	0.06%	227	0.84%
CD2231-40	Fortify DR^{\dagger}	12,092	18.50%	9	0.07%	1	<0.01%	5	0.04%	8	0.07%	0	0.00%	0	0.00%	59	0.49%	5	0.04%	87	0.72%
CD2211-36Q	Current" + DR	8,148	28.90%	6	0.07%	0	0.00%	6	0.07%	3	0.04%	1	0.01%	0	0.00%	4	0.05%	5	0.06%	25	0.31%
CD2211-36	Current" + DR	6,271	29.80%	3	0.05%	2	0.03%	8	0.13%	1	0.02%	1	0.02%	0	0.00%	9	0.14%	6	0.10%	30	0.48%
2207-36	Current DR RF	22,390	28.80%	11	0.05%	6	0.03%	21	0.09%	1	<0.01%	4	0.02%	1	<0.01%	40	0.18%	35	0.16%	119	0.53%
V-268	Atlas II + DR	14,713	29.90%	6	0.04%	4	0.03%	9	0.06%	0	0.00%	0	0.00%	0	0.00%	19	0.13%	9	0.06%	47	0.32%
V-243	Atlas" + DR	21,082	27.40%	5	0.02%	1	<0.01%	12	0.06%	1	<0.01%	0	0.00%	0	0.00%	6	0.03%	17	0.08%	42	0.20%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

US Malfunction Summary

WITHOUT COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR	ELECT COMP	RICAL ONENT		IRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ WARE	MECH	ANICAL	BA	BLE EARLY ITERY LETION	то	HER	тот	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDDRA500Q	Gallant [®] DR	7,898	0.70%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%
CD2411-36Q	Ellipse" DR	32,029	4.50%	4	0.01%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	3	<0.01%	1	<0.01%	3	<0.01%	12	0.04%
CD2411-36C	Ellipse" DR	11,081	7.00%	5	0.05%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	1	<0.01%	0	0.00%	4	0.04%	11	0.10%
CD2357-40Q	Fortify Assura" DR	40,224	3.80%	10	0.02%	0	0.00%	2	<0.01%	1	<0.01%	0	0.00%	2	<0.01%	1	<0.01%	1	<0.01%	17	0.04%
CD2357-40Q	Fortify Assura" DR^{\dagger}	12,263	17.50%	9	0.07%	0	0.00%	13	0.11%	0	0.00%	0	0.00%	1	<0.01%	559	4.56%	5	0.04%	587	4.79%
CD2357-40C	Fortify Assura" DR	10,492	4.80%	2	0.02%	0	0.00%	0	0.00%	0	0.00%	2	0.02%	2	0.02%	0	0.00%	0	0.00%	6	0.06%
CD2357-40C	Fortify Assura" DR^{\dagger}	6,956	19.10%	2	0.03%	1	0.01%	5	0.07%	0	0.00%	0	0.00%	0	0.00%	262	3.77%	1	0.01%	271	3.90%
CD2311-36Q	Ellipse ["] DR	5,898	13.40%	9	0.15%	0	0.00%	1	0.02%	14	0.24%	0	0.00%	3	0.05%	0	0.00%	2	0.03%	29	0.49%
CD2311-36	Ellipse [°] DR	3,748	14.40%	7	0.19%	0	0.00%	0	0.00%	9	0.24%	0	0.00%	3	0.08%	0	0.00%	1	0.03%	20	0.53%
CD2257-40Q	Fortify Assura" DR^{\dagger}	6,798	16.90%	3	0.04%	0	0.00%	2	0.03%	0	0.00%	1	0.01%	1	0.01%	162	2.38%	1	0.01%	170	2.50%
CD2257-40	Fortify Assura" DR^{\dagger}	4,235	18.80%	0	0.00%	0	0.00%	4	0.09%	0	0.00%	1	0.02%	0	0.00%	75	1.77%	3	0.07%	83	1.96%
CD2231-40Q	Fortify DR^{\dagger}	26,876	16.80%	9	0.03%	2	<0.01%	54	0.20%	2	<0.01%	2	<0.01%	0	0.00%	391	1.45%	13	0.05%	473	1.76%
CD2231-40	Fortify DR^{\dagger}	12,092	18.50%	3	0.02%	0	0.00%	9	0.07%	2	0.02%	1	<0.01%	1	<0.01%	132	1.09%	5	0.04%	153	1.27%
CD2211-36Q	Current" + DR	8,148	28.90%	6	0.07%	0	0.00%	8	0.10%	0	0.00%	23	0.28%	2	0.02%	3	0.04%	5	0.06%	47	0.58%
CD2211-36	Current" + DR	6,271	29.80%	2	0.03%	0	0.00%	4	0.06%	0	0.00%	16	0.26%	1	0.02%	4	0.06%	2	0.03%	29	0.46%
2207-36	Current DR RF	22,390	28.80%	12	0.05%	2	<0.01%	9	0.04%	0	0.00%	48	0.21%	23	0.10%	21	0.09%	6	0.03%	121	0.54%
V-268	Atlas" II + DR	14,713	29.90%	4	0.03%	0	0.00%	3	0.02%	0	0.00%	0	0.00%	1	<0.01%	6	0.04%	5	0.03%	19	0.13%
V-243	Atlas" + DR	21,082	27.40%	3	0.01%	0	0.00%	4	0.02%	0	0.00%	0	0.00%	4	0.02%	4	0.02%	2	<0.01%	17	0.08%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	AL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDDRA500Q	Gallant ["] DR	12,992	0.72%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD2411-36Q	Ellipse" DR	32,515	4.63%	2	<0.01%	1	<0.01%	0	0.00%	2	<0.01%	1	<0.01%	1	<0.01%	0	0.00%	2	<0.01%	9	0.03%
CD2411-36C	Ellipse" DR	11,200	7.39%	3	0.03%	0	0.00%	0	0.00%	7	0.06%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	10	0.09%
CD2357-40Q	Fortify Assura [¬] DR	52,794	7.14%	6	0.01%	1	<0.01%	1	<0.01%	3	<0.01%	0	0.00%	0	0.00%	72	0.14%	8	0.02%	91	0.17%
CD2357-40C	Fortify Assura [®] DR	17,647	10.89%	5	0.03%	2	0.01%	1	<0.01%	1	<0.01%	0	0.00%	0	0.00%	32	0.18%	2	0.01%	43	0.24%
CD2311-36Q	Ellipse" DR	5,883	14.96%	3	0.05%	0	0.00%	0	0.00%	65	1.10%	1	0.02%	2	0.03%	0	0.00%	5	0.08%	76	1.29%
CD2311-36	Ellipse" DR	3,749	15.28%	5	0.13%	0	0.00%	0	0.00%	22	0.59%	0	0.00%	4	0.11%	0	0.00%	5	0.13%	36	0.96%
CD2257-40Q	Fortify Assura" DR	6,780	17.26%	5	0.07%	0	0.00%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	27	0.40%	3	0.04%	36	0.53%
CD2257-40	Fortify Assura" DR	4,234	19.34%	2	0.05%	0	0.00%	1	0.02%	1	0.02%	0	0.00%	0	0.00%	13	0.31%	0	0.00%	17	0.40%
CD2231-40Q	Fortify" DR	28,889	16.43%	11	0.04%	3	0.01%	29	0.10%	5	0.02%	1	<0.01%	0	0.00%	172	0.60%	17	0.06%	238	0.82%
CD2231-40	Fortify DR	16,718	14.44%	9	0.05%	2	0.01%	5	0.03%	8	0.05%	0	0.00%	0	0.00%	63	0.38%	6	0.04%	93	0.56%
CD2211-36Q	Current + DR	15,224	18.25%	9	0.06%	1	<0.01%	9	0.06%	8	0.05%	1	<0.01%	0	0.00%	8	0.05%	16	0.11%	52	0.34%
CD2211-36	Current" + DR	13,483	15.12%	8	0.06%	5	0.04%	11	0.08%	4	0.03%	1	<0.01%	0	0.00%	12	0.09%	10	0.07%	51	0.38%
2207-36	Current [®] DR RF	33,051	23.21%	18	0.05%	11	0.03%	30	0.09%	12	0.04%	5	0.02%	2	<0.01%	60	0.18%	47	0.14%	185	0.56%
V-268	Atlas II + DR	25,779	19.57%	15	0.06%	5	0.02%	19	0.07%	1	<0.01%	0	0.00%	0	0.00%	32	0.12%	20	0.08%	92	0.36%
V-243	Atlas + DR	34,105	19.13%	5	0.01%	3	<0.01%	25	0.07%	1	<0.01%	0	0.00%	0	0.00%	14	0.04%	30	0.09%	78	0.23%

Worldwide Malfunction Summary

WITHOUT COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ WARE	MECH	IANICAL	BAT	ELE EARLY ITERY LETION	от	HER	TOT	TAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDDRA500Q	Gallant [¯] DR	12,992	0.72%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
CD2411-36Q	Ellipse ⁻ DR	32,515	4.63%	4	0.01%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	3	<0.01%	1	<0.01%	3	<0.01%	12	0.04%
CD2411-36C	Ellipse ⁻ DR	11,200	7.39%	5	0.04%	0	0.00%	0	0.00%	1	< 0.01%	0	0.00%	1	<0.01%	0	0.00%	4	0.04%	11	0.10%
CD2357-40Q	Fortify Assura" DR	52,794	7.14%	19	0.04%	0	0.00%	15	0.03%	1	< 0.01%	0	0.00%	3	<0.01%	560	1.06%	6	0.01%	604	1.14%
CD2357-40C	Fortify Assura" DR	17,647	10.89%	4	0.02%	1	<0.01%	5	0.03%	0	0.00%	2	0.01%	2	0.01%	262	1.48%	2	0.01%	278	1.58%
CD2311-36Q	Ellipse ⁻ DR	5,883	14.96%	9	0.15%	0	0.00%	1	0.02%	14	0.24%	0	0.00%	3	0.05%	0	0.00%	2	0.03%	29	0.49%
CD2311-36	Ellipse ⁻ DR	3,749	15.28%	7	0.19%	0	0.00%	0	0.00%	9	0.24%	0	0.00%	3	0.08%	0	0.00%	1	0.03%	20	0.53%
CD2257-40Q	Fortify Assura" DR	6,780	17.26%	3	0.04%	0	0.00%	2	0.03%	0	0.00%	1	0.01%	1	0.01%	162	2.39%	1	0.01%	170	2.51%
CD2257-40	Fortify Assura" DR	4,234	19.34%	0	0.00%	0	0.00%	4	0.09%	0	0.00%	1	0.02%	0	0.00%	75	1.77%	3	0.07%	83	1.96%
CD2231-40Q	Fortify" DR	28,889	16.43%	11	0.04%	2	<0.01%	56	0.19%	2	<0.01%	2	<0.01%	0	0.00%	418	1.45%	13	0.04%	504	1.74%
CD2231-40	Fortify ⁻ DR	16,718	14.44%	3	0.02%	0	0.00%	9	0.05%	2	0.01%	1	<0.01%	2	0.01%	151	0.90%	5	0.03%	173	1.03%
CD2211-36Q	Current" + DR	15,224	18.25%	12	0.08%	0	0.00%	11	0.07%	2	0.01%	27	0.18%	3	0.02%	9	0.06%	9	0.06%	73	0.48%
CD2211-36	Current" + DR	13,483	15.12%	2	0.01%	1	<0.01%	4	0.03%	1	<0.01%	20	0.15%	2	0.01%	5	0.04%	6	0.04%	41	0.30%
2207-36	Current DR RF	33,051	23.21%	20	0.06%	5	0.02%	15	0.05%	4	0.01%	109	0.33%	36	0.11%	30	0.09%	12	0.04%	231	0.70%
V-268	Atlas II + DR	25,779	19.57%	7	0.03%	0	0.00%	8	0.03%	1	< 0.01%	0	0.00%	1	<0.01%	9	0.03%	6	0.02%	32	0.12%
V-243	Atlas + DR	34,105	19.13%	6	0.02%	0	0.00%	6	0.02%	0	0.00%	0	0.00%	8	0.02%	6	0.02%	4	0.01%	30	0.09%

Actively Monitored Study Data Summary

	NUMBER OF DEVICES	ACTIVE DEVICES	CUMULATIVE MONTHS OF		ROPRIATE		SS OF METRY		ARDIAL	BAT	ATURE TERY ETION		(IN SION	то	TAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD2231-40Q	390	0	24,816	0	0.00%	0	0.00%	0	0.00%	7	1.79%	0	0.00%	7	1.79%
CD2231-40	177	0	9,249	0	0.00%	0	0.00%	0	0.00%	2	1.13%	0	0.00%	2	1.13%
CD2211-36Q	835	0	61,859	0	0.00%	0	0.00%	0	0.00%	4	0.48%	1	0.12%	5	0.60%
CD2211-36	122	0	6,388	1	0.82%	0	0.00%	0	0.00%	1	0.82%	0	0.00%	2	1.64%
2207-36	631	0	33,069	1	0.16%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.16%
V-268	101	0	3,805	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

QUALIFYING COMPLICATIONS

A list of of complications can be found on page 12.

Actively Monitored Study Data Summary

MALFUNCTIONS WITH COMPROMISED THERAPY


		NUMBER OF DEVICES	PERCENT		TRICAL		TRICAL CONNECT	BAT	TERY		OLTAGE		WARE/ IWARE	MECH	ANICAL	BAT	le early Tery .etion	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD2231-40Q	Fortify" DR	390	23.10%	0	0.00%	0	0.00%	1	0.26%	0	0.00%	0	0.00%	0	0.00%	2	0.51%	1	0.26%	4	1.03%
CD2231-40	Fortify DR	177	21.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.56%	0	0.00%	1	0.56%
CD2211-36Q	Current + DR	835	36.00%	0	0.00%	0	0.00%	1	0.12%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.12%	2	0.24%
CD2211-36	Current + DR	122	36.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.82%	1	0.82%
2207-36	Current [®] DR RF	631	38.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.16%	0	0.00%	1	0.16%
V-268	Atlas II + DR	101	33.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	1.98%	2	1.98%

MALFUNCTIONS WITHOUT COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT		TRICAL		TRICAL CONNECT	BAT	TERY		OLTAGE		WARE/	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	то	TAL
MODELS	FAMILY		FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD2231-40Q	Fortify [®] DR	390	23.10%	0	0.00%	0	0.00%	1	0.26%	0	0.00%	0	0.00%	0	0.00%	7	1.79%	0	0.00%	8	2.05%
CD2231-40	Fortify DR	177	21.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	1.69%	0	0.00%	3	1.69%
CD2211-36Q	Current" + DR	835	36.00%	1	0.12%	0	0.00%	2	0.24%	0	0.00%	2	0.24%	0	0.00%	1	0.12%	2	0.24%	8	0.96%
CD2211-36	Current + DR	122	36.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	1.64%	0	0.00%	0	0.00%	1	0.82%	3	2.46%
2207-36	Current" DR RF	631	38.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.32%	0	0.00%	1	0.16%	0	0.00%	3	0.48%
V-268	Atlas II + DR	101	33.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

SINGLE-CHAMBER Implantable Cardioverter Defibrillator (ICD) Devices

Gallant™ VR MODEL CDVRA500Q*			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	ICTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2020	Electrical Component	0	0.00%	0	0.00%
Registered US Implants	3,649	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	3,433	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	0	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	0	0.00%
		Total	0	0.00%	0	0.00%




INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 13 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%
SAMPLE SIZE	1,940	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	AT 13 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%


Ellipse™ VR MODEL CD1411-36Q*			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	5	0.02%	0	0.00%
Registered US Implants	23,176	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	14,456	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	10	0.04%	4	0.02%
Normal Battery Depletion	16	Software/Firmware	0	0.00%	1	<0.01%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	3	0.01%
Number of US Advisories		Possible Early Battery Depletion	0	0.00%	2	<0.01%
(see pgs. 303, 304, 306)	Three	Other	2	< 0.01%	2	<0.01%
		Total	17	0.07%	12	0.05%



					-		ð	AT 97 MONTHS
SURVIVAL PROBABILITY 99.85	5% 99.69%	99.65%	99.62%	99.40%	99.31%	99.08%	98.74%	98.74%
±1 STANDARD ERROR 0.02	2% 0.04%	0.04%	0.04%	0.07%	0.08%	0.13%	0.22%	0.22%
SAMPLE SIZE 21,21	10 17,450	13,900	10,530	7,550	5,020	2,760	950	240

YEAR	1	2	3	4	5	6	7	8	AT 97 MONTHS
SURVIVAL PROBABILITY	99.87%	99.82%	99.77%	99.75%	99.62%	99.57%	99.43%	99.43%	99.43%
±1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.06%	0.07%	0.10%	0.10%	0.10%

Ellipse™ VR MODEL CD1411-36C*		MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	0	0.00%	3	0.04%
Registered US Implants	7,031	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	4,047	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	0	0.00%	1	0.01%
Normal Battery Depletion	4	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	0.01%
Number of US Advisories	ml	Possible Early Battery Depletion	0	0.00%	0	0.00%
(see pgs. 303, 304, 306)	7,031 4,047 (see table on page 158) 4	Other	0	0.00%	2	0.03%
		Total	0	0.00%	7	0.10%





7

6

AT 94 MONTHS

INCLUDING NORMAL BAT	TERY DEPLETIO	N N				
YEAR	1	2	3	4	5	
SURVIVAL PROBABILITY	99.94%	99.90%	99.86%	99.71%	99.64%	
+ 1 STANDARD FRROR	0.03%	0.04%	0.05%	0.08%	0.09%	


SURVIVAL PROBABILITY	99.94%	99.90%	99.86%	99.71%	99.64%	99.55%	99.41%	99.11%
±1 STANDARD ERROR	0.03%	0.04%	0.05%	0.08%	0.09%	0.11%	0.15%	0.26%
SAMPLE SIZE	6,530	5,660	4,880	3,950	2,950	2,060	1,160	220

EXCLUDING NORMAL BA	ATTERY DEPLETION	1		
YEAR	1	2	3	4

YEAR	1	2	3	4	5	6	7	AT 94 MONTHS
SURVIVAL PROBABILITY	99.94%	99.94%	99.90%	99.80%	99.73%	99.73%	99.73%	99.43%
±1 STANDARD ERROR	0.03%	0.03%	0.04%	0.07%	0.08%	0.08%	0.08%	0.23%

*Parylene coating.

Fortify Assura™ VR MODEL CD1357-40Q* (NON-BA	TTERY ADVISORY POP	ULATION)	W/ COM	NCTIONS PROMISED RAPY	W/O COM	ICTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	2	< 0.01%	3	0.01%
Registered US Implants	24,497	Electrical Interconnect	2	< 0.01%	0	0.00%
Estimated Active US Implants	16,531	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	5	Software/Firmware	0	0.00%	1	<0.01%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	3	0.01%	3	0.01%
		Total	7	0.03%	8	0.03%



YEARS AFTER IMPLANT


INCLUDING NORMAL BA	ATTERY DEPLETION
---------------------	------------------

YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.86%	99.81%	99.79%	99.79%	99.76%	99.76%	99.76%
±1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%
SAMPLE SIZE	22,300	17,960	13,620	9,500	6,000	2,820	300

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 77 MONTHS
SURVIVAL PROBABILITY	99.88%	99.85%	99.85%	99.85%	99.82%	99.82%	99.82%
± 1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.04%	0.04%	0.04%

Fortify Assura™ VR model cd1357-40Q* (battery advisory population)			W/ COM	NCTIONS PROMISED RAPY	W/O COMP	MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	June 2013	Electrical Component	5	0.05%	8	0.08%	
Registered US Implants	10,214	Electrical Interconnect	1	< 0.01%	0	0.00%	
Estimated Active US Implants	4,459	Battery	0	0.00%	5	0.05%	
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	2	0.02%	0	0.00%	
Normal Battery Depletion	10	Software/Firmware	1	< 0.01%	0	0.00%	
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%	
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	68	0.67%	566	5.54%	
		Other	4	0.04%	4	0.04%	
		Total	81	0.79%	583	5.71%	




INCLUDING NORMAL BATTERY DEPLETION	

YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.74%	99.24%	96.67%	90.39%	84.10%	79.66%	76.02%	73.29%	73.29%
± 1 STANDARD ERROR	0.05%	0.09%	0.19%	0.34%	0.43%	0.48%	0.52%	0.65%	0.65%
SAMPLE SIZE	9,570	8,500	7,630	6,790	6,040	5,290	3,680	1,400	250

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	AT 98 MONTHS
SURVIVAL PROBABILITY	99.77%	99.31%	96.73%	90.60%	84.32%	80.00%	76.33%	73.60%	73.60%
± 1 STANDARD ERROR	0.05%	0.08%	0.19%	0.33%	0.42%	0.48%	0.52%	0.65%	0.65%

Fortify Assura™ VR MODEL CD1357-40C* (NON-BA	TTERY ADVISORY POP	ULATION)	W/ COMPROMISED W/O (THERAPY		MALFUN W/O COMP THER	ROMISED
			QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	Electrical Component	0	0.00%	0	0.00%
Registered US Implants	5,567	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	3,552	Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	1	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	1	0.02%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	0	0.00%	1	0.02%
		Other	0	0.00%	0	0.00%
		Total	0	0.00%	2	0.04%





INCLUDING N	NORMAL BATTERY	
--------------------	----------------	--

YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	99.96%	99.87%	99.87%	99.87%	99.87%	99.87%	99.87%
± 1 STANDARD ERROR	0.03%	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%
SAMPLE SIZE	5,130	4,340	3,620	2,690	1,600	690	250


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	99.96%	99.91%	99.91%	99.91%	99.91%	99.91%	99.91%
± 1 STANDARD ERROR	0.03%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%

*Parylene coating.

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura™ VR MODEL CD1357-40C* (BATTERY A	DVISORY POPULATION)	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	June 2013	Electrical Component	3	0.07%	1	0.02%	
Registered US Implants	4,131	Electrical Interconnect	1	0.02%	0	0.00%	
Estimated Active US Implants	1,794	Battery	0	0.00%	4	0.10%	
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	1	0.02%	0	0.00%	
Normal Battery Depletion	6	Software/Firmware	0	0.00%	1	0.02%	
Max. Delivered Energy	40 joules	Mechanical	1	0.02%	0	0.00%	
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	9	0.22%	190	4.60%	
		Other	0	0.00%	2	0.05%	
		Total	15	0.36%	198	4.79%	





INCLUDING NORMAL BAT	TERY DEPLETION	<u> </u>						
YEAR	1	2	3	4	5	6	7	AT 95 MONTHS
SURVIVAL PROBABILITY	99.80%	99.26%	97.07%	91.84%	87.12%	83.14%	79.87%	77.83%
± 1 STANDARD ERROR	0.07%	0.13%	0.28%	0.49%	0.63%	0.71%	0.79%	0.94%
SAMPLE SIZE	3,890	3,430	3,040	2,710	2,400	2,050	1,350	210


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	AT 95 MONTHS
SURVIVAL PROBABILITY	99.90%	99.45%	97.26%	92.02%	87.40%	83.49%	80.34%	78.28%
±1 STANDARD ERROR	0.05%	0.11%	0.27%	0.49%	0.62%	0.71%	0.78%	0.94%

*Parylene coating.

CUSTOMER REPORTED PERFORMANCE DATA

Fortify Assura [™] VR MODEL CD1257-40Q* (BATTERY A	Yortify Assura ^{m} VR NODEL CD1257-40Q* (BATTERY ADVISORY POPULATION)						MALFUNCTIONS W/O COMPROMISED THERAPY		
				QTY	RATE	QTY	RATE		
US Regulatory Approval	May 2012		Electrical Component	1	0.02%	2	0.04%		
Registered US Implants	5,079		Electrical Interconnect	1	0.02%	0	0.00%		
Estimated Active US Implants	2,043		Battery	0	0.00%	3	0.06%		
Estimated Longevity	(see table on page 158)		High Voltage Capacitor	0	0.00%	0	0.00%		
Normal Battery Depletion	11		Software/Firmware	0	0.00%	0	0.00%		
Max. Delivered Energy	40 joules		Mechanical	0	0.00%	0	0.00%		
Number of US Advisories (see pgs. 304, 305)	Three		Possible Early Battery Depletion	20	0.39%	149	2.93%		
			Other	1	0.02%	0	0.00%		
			Total	23	0.45%	154	3.03%		




INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.92%	99.77%	99.33%	97.25%	93.28%	90.10%	87.77%	85.85%	84.36%	84.36%
± 1 STANDARD ERROR	0.04%	0.07%	0.12%	0.26%	0.42%	0.52%	0.58%	0.63%	0.70%	0.70%
SAMPLE SIZE	4,790	4,270	3,820	3,420	3,070	2,770	2,500	2,140	1,160	260

YEAR	1	2	3	4	5	6	7	8	9	AT 111 MONTHS
SURVIVAL PROBABILITY	99.96%	99.87%	99.57%	97.49%	93.57%	90.38%	88.22%	86.42%	85.20%	85.20%
± 1 STANDARD ERROR	0.03%	0.05%	0.10%	0.25%	0.41%	0.51%	0.57%	0.62%	0.68%	0.68%

*DF4-LLHH connector type.

Fortify Assura™ VR MODEL CD1257-40 (BATTERY AD	ortify Assura™ VR odel cd1257-40 (battery advisory population)					
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012	Electrical Component	2	0.09%	0	0.00%
Registered US Implants	2,294	Electrical Interconnect	2	0.09%	0	0.00%
Estimated Active US Implants	914	Battery	1	0.04%	2	0.09%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	0	0.00%	0	0.00%
Normal Battery Depletion	7	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	7	0.31%	43	1.87%
		Other	2	0.09%	1	0.04%
		Total	14	0.61%	46	2.01%




INCLUDING NORMAL BATTERY DEPLETION	
------------------------------------	--

YEAR	1	2	3	4	5	6	7	8	9	AT 110 MONTHS
SURVIVAL PROBABILITY	99.62%	99.51%	98.75%	98.28%	94.86%	92.37%	91.20%	89.76%	88.30%	88.30%
± 1 STANDARD ERROR	0.13%	0.15%	0.25%	0.30%	0.56%	0.70%	0.75%	0.83%	0.95%	0.95%
SAMPLE SIZE	2,130	1,860	1,650	1,490	1,350	1,220	1,100	900	500	210

EXCLUDING NORMAL BATTERY DEPLETION	·

YEAR	1	2	3	4	5	6	7	8	9	AT 110 MONTHS
SURVIVAL PROBABILITY	99.62%	99.62%	99.15%	98.68%	95.68%	93.16%	92.33%	90.87%	89.40%	89.40%
±1 STANDARD ERROR	0.13%	0.13%	0.21%	0.26%	0.52%	0.66%	0.72%	0.80%	0.93%	0.93%

Ellipse™ VR MODEL CD1311-36Q*		W/ COMP	ICTIONS ROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
				QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012		Electrical Component	3	0.06%	3	0.06%
Registered US Implants	4,742		Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,905		Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)		High Voltage Capacitor	38	0.80%	11	0.23%
Normal Battery Depletion	18		Software/Firmware	1	0.02%	0	0.00%
Max. Delivered Energy	36 joules		Mechanical	1	0.02%	0	0.00%
Number of US Advisories (see pgs. 304, 306)	Two		Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	1	0.02%	4	0.08%
			Total	44	0.93%	18	0.38%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.51%	99.11%	98.08%	97.59%	97.23%	96.94%	95.59%	94.36%	93.58%	93.58%
± 1 STANDARD ERROR	0.10%	0.14%	0.22%	0.25%	0.27%	0.29%	0.36%	0.43%	0.47%	0.52%
SAMPLE SIZE	4,460	3,970	3,580	3,240	2,950	2,700	2,460	2,100	1,200	230

EXCLUDING NORMAL I	BATTERY DEPLETION 📥
--------------------	---------------------

YEAR	1	2	3	4	5	6	7	8	9	AT 113 MONTHS
SURVIVAL PROBABILITY	99.51%	99.11%	98.08%	97.59%	97.23%	97.08%	96.66%	96.06%	95.39%	95.39%
±1 STANDARD ERROR	0.10%	0.14%	0.22%	0.25%	0.27%	0.28%	0.31%	0.35%	0.39%	0.45%

*DF4-LLHH connector type.

Ellipse™ VR MODEL CD1311-36		W/ COMP	ICTIONS ROMISED RAPY				
				QTY	RATE	QTY	RATE
US Regulatory Approval	May 2012		Electrical Component	4	0.25%	2	0.12%
Registered US Implants	1,620		Electrical Interconnect	1	0.06%	0	0.00%
Estimated Active US Implants	683		Battery	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)		High Voltage Capacitor	8	0.49%	2	0.12%
Normal Battery Depletion	7		Software/Firmware	0	0.00%	1	0.06%
Max. Delivered Energy	36 joules		Mechanical	2	0.12%	1	0.06%
Number of US Advisories (see pgs. 304, 306)	Two		Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	1	0.06%	0	0.00%
			Total	16	0.99%	6	0.37%






INCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	8	9	AT 109 MONTHS
SURVIVAL PROBABILITY	98.88%	98.28%	97.95%	97.23%	96.65%	96.24%	94.63%	94.37%	94.37%	94.37%
±1 STANDARD ERROR	0.22%	0.32%	0.38%	0.43%	0.51%	0.55%	0.69%	0.71%	0.71%	0.71%
SAMPLE SIZE	1,520	1,340	1,210	1,100	1,000	920	840	720	420	210

EXCLUDI	NG NORMA	L BATTERY	DEPLETION	

YEAR	1	2	3	4	5	6	7	8	9	AT 109 MONTHS
SURVIVAL PROBABILITY	98.88%	98.43%	98.10%	97.38%	96.80%	96.39%	96.15%	96.15%	96.15%	96.15%
±1 STANDARD ERROR	0.22%	0.31%	0.36%	0.42%	0.50%	0.54%	0.56%	0.56%	0.56%	0.56%

Fortify [™] VR MODEL CD1231-40Q* (BATTERY A	ortify™ VR ODEL CD1231-40Q* (BATTERY ADVISORY POPULATION)					MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE	
US Regulatory Approval	May 2010	Electrical Component	7	0.04%	8	0.05%	
Registered US Implants	16,184	Electrical Interconnect	2	0.01%	0	0.00%	
Estimated Active US Implants	5,265	Battery	18	0.11%	47	0.29%	
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	1	< 0.01%	1	<0.01%	
Normal Battery Depletion	82	Software/Firmware	0	0.00%	1	< 0.01%	
Max. Delivered Energy	40 joules	Mechanical	0	0.00%	0	0.00%	
Number of US Advisories (see pgs. 304, 305)	Three	Possible Early Battery Depletion	130	0.80%	389	2.40%	
		Other	9	0.06%	7	0.04%	
		Total	167	1.03%	453	2.80%	



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.66%	97.75%	92.79%	84.96%	80.04%	78.67%
±1 STANDARD ERROR	0.05%	0.13%	0.25%	0.37%	0.44%	0.50%
SAMPLE SIZE	13,310	10,820	8,750	7,010	4,580	270

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 138 MONTHS
SURVIVAL PROBABILITY	99.78%	98.21%	94.00%	86.28%	82.13%	81.03%
±1 STANDARD ERROR	0.04%	0.12%	0.23%	0.36%	0.43%	0.48%

*DF4-LLHH connector type.

Single-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

Fortify[™] VR MODEL CD1231-40Q*

		QUALIFYING COMPLICATIONS	QTY	RATE		QTY	QTY RATE	QTY RATE QTY
US Regulatory Approval	May 2010	Premature Battery Depletion	2	1.25%	Electrical Component	Electrical Component 0	Electrical Component 0 0.00%	Electrical Component 0 0.00% 0
Number of Devices Enrolled in Study	160				Electrical Interconnect	Electrical Interconnect 0	Electrical Interconnect 0 0.00%	Electrical Interconnect 0 0.00% 0
Active Devices Enrolled in Study	0				Battery	Battery 0	Battery 0 0.00%	Battery 0 0.00% 1
Cumulative Months of Follow-up	11,424				High Voltage Capacitor	High Voltage Capacitor 1	High Voltage Capacitor 1 0.63%	High Voltage Capacitor 1 0.63% 0
Estimated Longevity	(see table on page 158)				Software/Firmware	Software/Firmware 0	Software/Firmware 0 0.00%	Software/Firmware 0 0.00% 0
Max. Delivered Energy	40 joules				Mechanical	Mechanical 0	Mechanical 0 0.00%	Mechanical 0 0.00% 0
					Possible Early Battery Depletion	Possible Early Battery Depletion 2	Possible Early Battery Depletion 2 1.25%	Possible Early Battery Depletion 2 1.25% 8
					Other	Other 0	Other 0 0.00%	Other 0 0.00% 0

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

1.88%

3

9

5.63%




YEAR	1	2	3	4	5	6	7	8	AT 107 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	98.63%	97.12%	97.12%
±1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.01%	2.01%
SAMPLE SIZE	160	150	130	110	100	90	80	70	50

*DF4-LLHH connector type.

CUSTOMER REPORTED PERFORMANCE DATA

Fortify[™] VR MALFUNCTIONS W/O COMPROMISED THERAPY MALFUNCTIONS W/ COMPROMISED MODEL CD1231-40 (BATTERY ADVISORY POPULATION) THERAPY RATE QTY QTY US Regulatory Approval Electrical Component 5 0.07% 6 May 2010 Registered US Implants Electrical Interconnect 0.00% 0.00% 6,781 0 0 Battery 0.06% 0.18% Estimated Active US Implants 2,120 4 12 Estimated Longevity (see table on page 158) High Voltage Capacitor 10 0.15% 4 0.06% Normal Battery Depletion Software/Firmware 0 0.00% 0 0.00% 26 Max. Delivered Energy 40 joules Mechanical 0.00% 0.01% 0 1 Possible Early Battery Depletion Number of US Advisories (see pgs. 304, 305) 0.65% 133 Three 44 Other 0.09% 0.09% 6 6 Total 69 1.02% 162 2.39%



RATE

0.09%

1.96%


INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 136 MONTHS
SURVIVAL PROBABILITY	99.63%	97.67%	93.67%	85.66%	81.93%	80.21%
± 1 STANDARD ERROR	0.07%	0.20%	0.38%	0.59%	0.68%	0.75%
SAMPLE SIZE	5,490	4,320	3,410	2,740	1,840	220

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 136 MONTHS
SURVIVAL PROBABILITY	99.89%	98.15%	94.39%	86.57%	83.48%	81.85%
± 1 STANDARD ERROR	0.03%	0.18%	0.36%	0.58%	0.66%	0.74%

Current™ + VR MODEL CD1211-36Q*	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Electrical Component	4	0.09%	3	0.07%
Registered US Implants	4,432	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	718	Battery	5	0.11%	3	0.07%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	1	0.02%	0	0.00%
Normal Battery Depletion	600	Software/Firmware	0	0.00%	2	0.05%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	1	0.02%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	6	0.14%	1	0.02%
		Other	3	0.07%	2	0.05%
		Total	19	0.43%	12	0.27%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 145 MONTHS
SURVIVAL PROBABILITY	99.29%	98.47%	96.42%	87.27%	31.34%	30.74%	30.74%
±1 STANDARD ERROR	0.13%	0.20%	0.35%	0.64%	0.96%	0.96%	0.96%
SAMPLE SIZE	3,590	2,870	2,350	1,910	970	440	230

EXCLUDING	NORMAL	BATTERY	DEPLETI	ON

YEAR	2	4	6	8	10	12	AT 145 MONTHS
SURVIVAL PROBABILITY	99.41%	98.87%	98.21%	98.01%	97.58%	97.58%	97.58%
± 1 STANDARD ERROR	0.12%	0.18%	0.24%	0.26%	0.31%	0.31%	0.31%

*DF4-LLHH connector type.

Single-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA

February 2009

(see table on page 158)

363

26,608

36 joules

0

Current[™] + VR MODEL CD1211-36Q*

US Regulatory Approval

Estimated Longevity

Max. Delivered Energy


Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

QUALIFYING COMPLICATIONS	QTY	RATE
Inappropriate Shock	1	0.28%
Premature Battery Depletion	1	0.28%


	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	1	0.28%	0	0.00%
High Voltage Capacitor	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	1	0.28%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	1	0.28%
Other	0	0.00%	0	0.00%
Total	1	0.28%	2	0.55%



ACTIVELY MONITORED STUDY DATA												
YEAR	2	4	6	8	10	AT 128 MONTHS						
SURVIVAL PROBABILITY	100.00%	99.20%	99.20%	99.20%	99.20%	99.20%						
± 1 STANDARD ERROR	0.00%	0.56%	0.56%	0.56%	0.56%	0.56%						
SAMPLE SIZE	310	230	180	160	140	60						

*DF4-LLHH connector type.

Current™ + VR MODEL CD1211-36	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	February 2009	Electrical Component	3	0.08%	3	0.08%
Registered US Implants	3,641	Electrical Interconnect	2	0.05%	0	0.00%
Estimated Active US Implants	598	Battery	5	0.14%	0	0.00%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	2	0.05%	0	0.00%
Normal Battery Depletion	473	Software/Firmware	0	0.00%	5	0.14%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	0	0.00%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	5	0.14%	2	0.05%
		Other	2	0.05%	1	0.03%
		Total	19	0.52%	11	0.30%




INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	12	AT 148 MONTHS
SURVIVAL PROBABILITY	99.50%	98.40%	96.75%	82.40%	31.43%	31.08%	31.08%
± 1 STANDARD ERROR	0.12%	0.24%	0.37%	0.87%	1.09%	1.08%	1.08%
SAMPLE SIZE	2,960	2,350	1,870	1,490	730	400	200

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 148 MONTHS
SURVIVAL PROBABILITY	99.64%	98.97%	98.68%	97.51%	96.84%	96.84%	96.84%
± 1 STANDARD ERROR	0.10%	0.19%	0.23%	0.33%	0.42%	0.42%	0.42%

Current™ VR RF MODEL 1207-36	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	September 2007	Electrical Component	6	0.05%	10	0.08%
Registered US Implants	13,293	Electrical Interconnect	10	0.08%	0	0.00%
Estimated Active US Implants	1,616	Battery	10	0.08%	5	0.04%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	1	< 0.01%	1	<0.01%
Normal Battery Depletion	1,826	Software/Firmware	1	< 0.01%	18	0.14%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	7	0.05%
Number of US Advisories (see pg. 304)	One	Possible Early Battery Depletion	14	0.11%	18	0.14%
		Other	9	0.07%	9	0.07%
		Total	51	0.38%	68	0.51%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.18%	98.26%	96.10%	87.34%	26.87%	24.20%	24.11%
± 1 STANDARD ERROR	0.08%	0.13%	0.21%	0.40%	0.55%	0.52%	0.52%
SAMPLE SIZE	10,560	8,320	6,690	5,290	2,730	1,670	240


EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.57%	98.92%	98.08%	97.71%	95.50%	95.50%	95.50%
± 1 STANDARD ERROR	0.06%	0.10%	0.15%	0.16%	0.30%	0.30%	0.30%

Single-Chamber Implantable Cardioverter Defibrillator (ICD) Devices ACTIVELY MONITORED STUDY DATA


Current[™] VR RF MODEL 1207-36

MODEL 1207-36				MALFUN W/ COMP THEI	ROMISED	W/O COM	NCTIONS PROMISED RAPY
		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	September 2007	None Reported	Electrical Component	0	0.00%	1	0.25%
Number of Devices Enrolled in Study	395		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	21,879		High Voltage Capacitor	0	0.00%	0	0.00%
Estimated Longevity	(see table on page 158)		Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	0	0.00%	0	0.00%
			Total	0	0.00%	1	0.25%



YEAR	1	2	3	4	5	6	7	8	9	AT 110 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SAMPLE SIZE	380	340	280	210	160	140	120	90	70	50

Atlas™ II VR MODEL V-168						
			QTY	RATE	QTY	RATE
US Regulatory Approval	July 2006	Electrical Component	4	0.04%	3	0.03%
Registered US Implants	10,605	Electrical Interconnect	2	0.02%	0	0.00%
Estimated Active US Implants	887	Battery	10	0.09%	2	0.02%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	1	< 0.01%	0	0.00%
Normal Battery Depletion	1,863	Software/Firmware	0	0.00%	0	0.00%
Max. Delivered Energy	36 joules	Mechanical	1	< 0.01%	4	0.04%
Number of US Advisories (see pg. 309)	One	Possible Early Battery Depletion	10	0.09%	5	0.05%
		Other	10	0.09%	5	0.05%
		Total	38	0.36%	19	0.18%



YEARS AFTER IMPLANT


INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 177 MONTHS
SURVIVAL PROBABILITY	99.27%	97.97%	93.79%	27.89%	13.87%	13.49%	13.46%	13.46%
±1 STANDARD ERROR	0.09%	0.16%	0.31%	0.64%	0.43%	0.43%	0.43%	0.43%
SAMPLE SIZE	8,530	6,450	4,920	2,680	1,150	1,000	620	210

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 177 MONTHS
SURVIVAL PROBABILITY	99.59%	99.20%	98.67%	97.83%	97.56%	97.56%	97.56%	97.56%
±1 STANDARD ERROR	0.06%	0.10%	0.14%	0.19%	0.26%	0.26%	0.26%	0.26%

Atlas™ + VR MODEL V-193			W/ COM	NCTIONS PROMISED RAPY	W/O COM	INCTIONS APROMISED ERAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	October 2003	Electrical Component	2	<0.01%	2	<0.01%
Registered US Implants	20,794	Electrical Interconnect	5	0.02%	1	<0.01%
Estimated Active US Implants	1,335	Battery	9	0.04%	2	<0.01%
Estimated Longevity	(see table on page 158)	High Voltage Capacitor	2	< 0.01%	1	<0.01%
Normal Battery Depletion	2,999	Software/Firmware	0	0.00%	1	< 0.01%
Max. Delivered Energy	36 joules	Mechanical	0	0.00%	5	0.02%
Number of US Advisories (see pgs. 309, 310, 311)	Three	Possible Early Battery Depletion	26	0.13%	5	0.02%
		Other	13	0.06%	7	0.03%
		Total	57	0.27%	24	0.12%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.49%	98.80%	96.06%	83.21%	18.46%	13.01%	12.55%	12.47%	12.47%
±1 STANDARD ERROR	0.05%	0.09%	0.18%	0.39%	0.41%	0.33%	0.33%	0.33%	0.33%
SAMPLE SIZE	16,710	12,650	9,410	6,840	3,140	1,660	1,420	800	210

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.81%	99.59%	98.91%	98.52%	97.99%	97.89%	97.89%	97.89%	97.89%
±1 STANDARD ERROR	0.03%	0.05%	0.10%	0.12%	0.17%	0.19%	0.19%	0.19%	0.19%

BATTERY LONGEVITY SUMMARY Single-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

Battery Longevity (years)

MODELS	FAMILY	NO PACING	25% PACING	50% PACING	100% PACING
CDVRA500Q	Gallant" VR*	11.2	10.8	10.4	9.8
CD1411-36Q	Ellipse VR*	11.1	10.6	10.1	9.4
CD1411-36C	Ellipse" VR*	11.1	10.6	10.1	9.4
CD1357-40Q	Fortify Assura" VR**	11.7	11.3	10.8	10.1
CD1357-40C	Fortify Assura" VR**	11.7	11.3	10.8	10.1
CD1257-40Q	Fortify Assura" VR**	11.7	11.3	10.8	10.1
CD1257-40	Fortify Assura" VR**	11.7	11.3	10.8	10.1
CD1311-36Q	Ellipse VR*	11.1	10.6	10.1	9.4
CD1311-36	Ellipse VR*	11.1	10.6	10.1	9.4
CD1231-40Q	Fortify VR**	10.8	10.3	9.9	9.1
CD1231-40	Fortify VR**	10.8	10.3	9.9	9.1
CD1211-36Q	Current + VR***	8.4	8.0	7.6	7.0
CD1211-36	Current + VR***	8.4	8.0	7.6	7.0
1207-36	Current VR RF***	8.4	8.0	7.6	7.0
V-168	Atlas" II VR***	8.4	8.0	7.6	7.0
V-193	Atlas" + VR***	8.6	8.2	7.9	7.3

Pacing parameters: VVI, 2.5V, 0.5 ms, 60 ppm, 500 ohms

* Battery voltage range 3.20-2.59. Two maximum charges per year.

** Battery voltage range 3.20-2.59. Three maximum charges per year.

*** Battery voltage range: 3.20-2.45. Four maximum charges per year as well as monthly charging during the battery's mid-life voltage range.

SUMMARY INFORMATION Single-Chamber Implantable Cardioverter Defibrillator (ICD) Devices

Survival Probability Summary

INCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
CDVRA500Q	Gallant" VR*	100.00%									
CD1411-36Q	Ellipse" VR	99.85%	99.69%	99.65%	99.62%	99.40%	99.31%	99.08%	98.74%		
CD1411-36C	Ellipse [™] VR	99.94%	99.90%	99.86%	99.71%	99.64%	99.55%	99.41%			
CD1357-40Q	Fortify Assura VR	99.86%	99.81%	99.79%	99.79%	99.76%	99.76%				
CD1357-40Q	Fortify Assura \overline{VR}^{\dagger}	99.74%	99.24%	96.67%	90.39%	84.10%	79.66%	76.02%	73.29%		
CD1357-40C	Fortify Assura" VR	99.96%	99.87%	99.87%	99.87%	99.87%	99.87%				
CD1357-40C	Fortify Assura $\ VR^{\dagger}$	99.80%	99.26%	97.07%	91.84%	87.12%	83.14%	79.87%			
CD1257-40Q	Fortify Assura $\ VR^{\dagger}$	99.92%	99.77%	99.33%	97.25%	93.28%	90.10%	87.77%	85.85%	84.36%	
CD1257-40	Fortify Assura \overline{VR}^{\dagger}	99.62%	99.51%	98.75%	98.28%	94.86%	92.37%	91.20%	89.76%	88.30%	
CD1311-36Q	Ellipse" VR	99.51%	99.11%	98.08%	97.59%	97.23%	96.94%	95.59%	94.36%	93.58%	
CD1311-36	Ellipse VR	98.88%	98.28%	97.95%	97.23%	96.65%	96.24%	94.63%	94.37%	94.37%	
CD1231-40Q	Fortify VR^{\dagger}	99.73%	99.66%	99.12%	97.75%	95.83%	92.79%	88.44%	84.96%	82.33%	80.04%
CD1231-40	Fortify VR^{\dagger}	99.74%	99.63%	99.34%	97.67%	96.25%	93.67%	89.09%	85.66%	83.90%	81.93%
CD1211-36Q	Current" + VR	99.54%	99.29%	98.76%	98.47%	97.13%	96.42%	94.42%	87.27%	50.18%	31.34%
CD1211-36	Current" + VR	99.71%	99.50%	99.08%	98.40%	97.79%	96.75%	94.35%	82.40%	45.41%	31.43%
1207-36	Current VR RF	99.60%	99.18%	98.69%	98.26%	97.59%	96.10%	94.08%	87.34%	52.99%	26.87%
V-168	Atlas" II VR	99.54%	99.27%	98.75%	97.97%	96.46%	93.79%	73.64%	27.89%	14.47%	13.87%
V-193	Atlas" + VR	99.78%	99.49%	99.29%	98.80%	97.90%	96.06%	93.40%	83.21%	48.67%	18.46%

*No survival probability is stated at one year due to the device not meeting the required minimum sample size of 200 U.S. implants with 12 consecutive months of data. Please refer to the individual graphs for data up to one year.

†Premature battery depletion advisory population.

Survival Probability Summary

EXCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
CDVRA500Q	Gallant" VR*	100.00%									
CD1411-36Q	Ellipse" VR	99.87%	99.82%	99.77%	99.75%	99.62%	99.57%	99.43%	99.43%		
CD1411-36C	Ellipse [™] VR	99.94%	99.94%	99.90%	99.80%	99.73%	99.73%	99.73%			
CD1357-40Q	Fortify Assura" VR	99.88%	99.85%	99.85%	99.85%	99.82%	99.82%				
CD1357-40Q	Fortify Assura" VR^{\dagger}	99.77%	99.31%	96.73%	90.60%	84.32%	80.00%	76.33%	73.60%		
CD1357-40C	Fortify Assura" VR	99.96%	99.91%	99.91%	99.91%	99.91%	99.91%				
CD1357-40C	Fortify Assura $\overline{\ } VR^{\dagger}$	99.90%	99.45%	97.26%	92.02%	87.40%	83.49%	80.34%			
CD1257-40Q	Fortify Assura $\overline{\ } VR^{\dagger}$	99.96%	99.87%	99.57%	97.49%	93.57%	90.38%	88.22%	86.42%	85.20%	
CD1257-40	Fortify Assura VR^{\dagger}	99.62%	99.62%	99.15%	98.68%	95.68%	93.16%	92.33%	90.87%	89.40%	
CD1311-36Q	Ellipse" VR	99.51%	99.11%	98.08%	97.59%	97.23%	97.08%	96.66%	96.06%	95.39%	
CD1311-36	Ellipse" VR	98.88%	98.43%	98.10%	97.38%	96.80%	96.39%	96.15%	96.15%	96.15%	
CD1231-40Q	Fortify VR^{\dagger}	99.82%	99.78%	99.35%	98.21%	96.63%	94.00%	89.75%	86.28%	83.84%	82.13%
CD1231-40	Fortify VR^{\dagger}	99.97%	99.89%	99.66%	98.15%	96.93%	94.39%	89.97%	86.57%	85.10%	83.48%
CD1211-36Q	Current + VR	99.66%	99.41%	98.94%	98.87%	98.29%	98.21%	98.21%	98.01%	97.75%	97.58%
CD1211-36	Current + VR	99.71%	99.64%	99.22%	98.97%	98.78%	98.68%	98.04%	97.51%	96.84%	96.84%
1207-36	Current VR RF	99.73%	99.57%	99.18%	98.92%	98.59%	98.08%	97.98%	97.71%	96.15%	95.50%
V-168	Atlas" II VR	99.77%	99.59%	99.44%	99.20%	98.91%	98.67%	98.31%	97.83%	97.56%	97.56%
V-193	Atlas" + VR	99.95%	99.81%	99.74%	99.59%	99.17%	98.91%	98.66%	98.52%	98.41%	97.99%

*No survival probability is stated at one year due to the device not meeting the required minimum sample size of 200 U.S. implants with 12 consecutive months of data. Please refer to the individual graphs for data up to one year.

†Premature battery depletion advisory population.

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		RICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDVRA500Q	Gallant [®] VR	3,649	0.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1411-36Q	Ellipse ⁻ VR	23,176	4.50%	5	0.02%	0	0.00%	0	0.00%	10	0.04%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	17	0.07%
CD1411-36C	Ellipse ⁻ VR	7,031	6.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1357-40Q	Fortify Assura [®] VR	24,497	4.00%	2	<0.01%	2	< 0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	3	0.01%	7	0.03%
CD1357-40Q	Fortify Assura $\bar{\ }VR^{\dagger}$	10,214	16.40%	5	0.05%	1	< 0.01%	0	0.00%	2	0.02%	1	<0.01%	0	0.00%	68	0.67%	4	0.04%	81	0.79%
CD1357-40C	Fortify Assura [®] VR	5,567	5.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1357-40C	Fortify Assura $\bar{\ }VR^{\dagger}$	4,131	18.30%	3	0.07%	1	0.02%	0	0.00%	1	0.02%	0	0.00%	1	0.02%	9	0.22%	0	0.00%	15	0.36%
CD1257-40Q	Fortify Assura $\bar{\ }VR^{\dagger}$	5,079	14.60%	1	0.02%	1	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	20	0.39%	1	0.02%	23	0.45%
CD1257-40	Fortify Assura $\bar{\ } VR^{\dagger}$	2,294	16.90%	2	0.09%	2	0.09%	1	0.04%	0	0.00%	0	0.00%	0	0.00%	7	0.31%	2	0.09%	14	0.61%
CD1311-36Q	Ellipse ⁻ VR	4,742	10.10%	3	0.06%	0	0.00%	0	0.00%	38	0.80%	1	0.02%	1	0.02%	0	0.00%	1	0.02%	44	0.93%
CD1311-36	Ellipse ⁻ VR	1,620	13.00%	4	0.25%	1	0.06%	0	0.00%	8	0.49%	0	0.00%	2	0.12%	0	0.00%	1	0.06%	16	0.99%
CD1231-40Q	Fortify VR^{\dagger}	16,184	16.10%	7	0.04%	2	0.01%	18	0.11%	1	<0.01%	0	0.00%	0	0.00%	130	0.80%	9	0.06%	167	1.03%
CD1231-40	Fortify VR^{\dagger}	6,781	17.20%	5	0.07%	0	0.00%	4	0.06%	10	0.15%	0	0.00%	0	0.00%	44	0.65%	6	0.09%	69	1.02%
CD1211-36Q	Current" + VR	4,432	24.80%	4	0.09%	0	0.00%	5	0.11%	1	0.02%	0	0.00%	0	0.00%	6	0.14%	3	0.07%	19	0.43%
CD1211-36	Current" + VR	3,641	24.10%	3	0.08%	2	0.05%	5	0.14%	2	0.05%	0	0.00%	0	0.00%	5	0.14%	2	0.05%	19	0.52%
1207-36	Current [®] VR RF	13,293	26.30%	6	0.05%	10	0.08%	10	0.08%	1	<0.01%	1	<0.01%	0	0.00%	14	0.11%	9	0.07%	51	0.38%
V-168	Atlas" II VR	10,605	28.10%	4	0.04%	2	0.02%	10	0.09%	1	<0.01%	0	0.00%	1	<0.01%	10	0.09%	10	0.09%	38	0.36%
V-193	Atlas" + VR	20,794	25.70%	2	<0.01%	5	0.02%	9	0.04%	2	<0.01%	0	0.00%	0	0.00%	26	0.13%	13	0.06%	57	0.27%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

US Malfunction Summary

WITHOUT COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR	ELECT COMP	RICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/	месн	ANICAL	BA	BLE EARLY ITERY LETION	то	HER	тот	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDVRA500Q	Gallant [®] VR	3,649	0.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1411-36Q	Ellipse" VR	23,176	4.50%	0	0.00%	0	0.00%	0	0.00%	4	0.02%	1	<0.01%	3	0.01%	2	<0.01%	2	<0.01%	12	0.05%
CD1411-36C	Ellipse ⁻ VR	7,031	6.30%	3	0.04%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	1	0.01%	0	0.00%	2	0.03%	7	0.10%
CD1357-40Q	Fortify Assura [®] VR	24,497	4.00%	3	0.01%	0	0.00%	0	0.00%	0	0.00%	1	< 0.01%	1	<0.01%	0	0.00%	3	0.01%	8	0.03%
CD1357-40Q	Fortify Assura" VR^{\dagger}	10,214	16.40%	8	0.08%	0	0.00%	5	0.05%	0	0.00%	0	0.00%	0	0.00%	566	5.54%	4	0.04%	583	5.71%
CD1357-40C	Fortify Assura [®] VR	5,567	5.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.02%	1	0.02%	0	0.00%	2	0.04%
CD1357-40C	Fortify Assura $\bar{\ }VR^{\dagger}$	4,131	18.30%	1	0.02%	0	0.00%	4	0.10%	0	0.00%	1	0.02%	0	0.00%	190	4.60%	2	0.05%	198	4.79%
CD1257-40Q	Fortify Assura $\bar{\ }VR^{\dagger}$	5,079	14.60%	2	0.04%	0	0.00%	3	0.06%	0	0.00%	0	0.00%	0	0.00%	149	2.93%	0	0.00%	154	3.03%
CD1257-40	Fortify Assura $\bar{\ } VR^{\dagger}$	2,294	16.90%	0	0.00%	0	0.00%	2	0.09%	0	0.00%	0	0.00%	0	0.00%	43	1.87%	1	0.04%	46	2.01%
CD1311-36Q	Ellipse ⁻ VR	4,742	10.10%	3	0.06%	0	0.00%	0	0.00%	11	0.23%	0	0.00%	0	0.00%	0	0.00%	4	0.08%	18	0.38%
CD1311-36	Ellipse ⁻ VR	1,620	13.00%	2	0.12%	0	0.00%	0	0.00%	2	0.12%	1	0.06%	1	0.06%	0	0.00%	0	0.00%	6	0.37%
CD1231-40Q	Fortify VR^{\dagger}	16,184	16.10%	8	0.05%	0	0.00%	47	0.29%	1	<0.01%	1	<0.01%	0	0.00%	389	2.40%	7	0.04%	453	2.80%
CD1231-40	Fortify VR^{\dagger}	6,781	17.20%	6	0.09%	0	0.00%	12	0.18%	4	0.06%	0	0.00%	1	0.01%	133	1.96%	6	0.09%	162	2.39%
CD1211-36Q	Current" + VR	4,432	24.80%	3	0.07%	0	0.00%	3	0.07%	0	0.00%	2	0.05%	1	0.02%	1	0.02%	2	0.05%	12	0.27%
CD1211-36	Current" + VR	3,641	24.10%	3	0.08%	0	0.00%	0	0.00%	0	0.00%	5	0.14%	0	0.00%	2	0.05%	1	0.03%	11	0.30%
1207-36	Current [®] VR RF	13,293	26.30%	10	0.08%	0	0.00%	5	0.04%	1	<0.01%	18	0.14%	7	0.05%	18	0.14%	9	0.07%	68	0.51%
V-168	Atlas" II VR	10,605	28.10%	3	0.03%	0	0.00%	2	0.02%	0	0.00%	0	0.00%	4	0.04%	5	0.05%	5	0.05%	19	0.18%
V-193	Atlas" + VR	20,794	25.70%	2	<0.01%	1	<0.01%	2	<0.01%	1	<0.01%	1	<0.01%	5	0.02%	5	0.02%	7	0.03%	24	0.12%

Definitions of malfunction categories can be found on pages 5-6. †Premature battery depletion advisory population.

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLWIDE	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	AL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDVRA500Q	Gallant [®] VR	7,240	0.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1411-36Q	Ellipse" VR	23,735	4.60%	5	0.02%	0	0.00%	0	0.00%	10	0.04%	0	0.00%	0	0.00%	0	0.00%	2	< 0.01%	17	0.07%
CD1411-36C	Ellipse" VR	7,139	6.85%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
CD1357-40Q	Fortify Assura" VR	35,008	7.80%	7	0.02%	3	<0.01%	0	0.00%	2	<0.01%	1	<0.01%	0	0.00%	68	0.19%	7	0.02%	88	0.25%
CD1357-40C	Fortify Assura [®] VR	9,812	11.48%	3	0.03%	1	0.01%	0	0.00%	1	0.01%	0	0.00%	1	0.01%	9	0.09%	0	0.00%	15	0.15%
CD1257-40Q	Fortify Assura" VR	5,038	15.13%	1	0.02%	1	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	20	0.40%	1	0.02%	23	0.46%
CD1257-40	Fortify Assura" VR	2,298	17.62%	2	0.09%	2	0.09%	1	0.04%	0	0.00%	0	0.00%	0	0.00%	7	0.30%	2	0.09%	14	0.61%
CD1311-36Q	Ellipse [¬] VR	4,912	10.42%	3	0.06%	0	0.00%	0	0.00%	38	0.77%	1	0.02%	1	0.02%	0	0.00%	1	0.02%	44	0.90%
CD1311-36	Ellipse [®] VR	1,628	14.74%	4	0.25%	1	0.06%	0	0.00%	9	0.55%	0	0.00%	2	0.12%	0	0.00%	1	0.06%	17	1.04%
CD1231-40Q	Fortify VR ⁺	18,344	15.09%	8	0.04%	2	0.01%	18	0.10%	2	0.01%	0	0.00%	0	0.00%	145	0.79%	9	0.05%	184	1.00%
CD1231-40	Fortify VR ⁺	10,699	11.91%	9	0.08%	0	0.00%	5	0.05%	10	0.09%	0	0.00%	0	0.00%	48	0.45%	6	0.06%	78	0.73%
CD1211-36Q	Current + VR	16,551	8.28%	15	0.09%	3	0.02%	9	0.05%	7	0.04%	0	0.00%	0	0.00%	8	0.05%	8	0.05%	50	0.30%
CD1211-36	Current" + VR	14,877	6.75%	5	0.03%	4	0.03%	5	0.03%	6	0.04%	0	0.00%	0	0.00%	11	0.07%	11	0.07%	42	0.28%
1207-36	Current VR RF	24,846	17.60%	12	0.05%	31	0.12%	18	0.07%	1	<0.01%	2	<0.01%	1	<0.01%	32	0.13%	12	0.05%	109	0.44%
V-168	Atlas" II VR	23,946	15.45%	8	0.03%	5	0.02%	19	0.08%	1	<0.01%	0	0.00%	1	<0.01%	22	0.09%	21	0.09%	77	0.32%
V-193	Atlas" + VR	39,596	16.43%	6	0.02%	9	0.02%	15	0.04%	5	0.01%	1	<0.01%	1	<0.01%	71	0.18%	32	0.08%	140	0.35%

Worldwide Malfunction Summary

WITHOUT COMPROMISED THERAPY

		WORLWIDE	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL CONNECT	BAT	TERY		OLTAGE		WARE/	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	тот	ΓAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CDVRA500Q	Gallant [®] VR	7,240	0.40%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%
CD1411-36Q	Ellipse ⁻ VR	23,735	4.60%	0	0.00%	0	0.00%	0	0.00%	4	0.02%	1	<0.01%	3	0.01%	2	<0.01%	2	<0.01%	12	0.05%
CD1411-36C	Ellipse ⁻ VR	7,139	6.85%	3	0.04%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	1	0.01%	0	0.00%	2	0.03%	7	0.10%
CD1357-40Q	Fortify Assura [®] VR	35,008	7.80%	11	0.03%	0	0.00%	5	0.01%	0	0.00%	1	<0.01%	1	<0.01%	566	1.62%	7	0.02%	591	1.69%
CD1357-40C	Fortify Assura [®] VR	9,812	11.48%	2	0.02%	0	0.00%	4	0.04%	0	0.00%	1	0.01%	1	0.01%	191	1.95%	2	0.02%	201	2.05%
CD1257-40Q	Fortify Assura" VR	5,038	15.13%	2	0.04%	0	0.00%	3	0.06%	0	0.00%	0	0.00%	0	0.00%	149	2.96%	0	0.00%	154	3.06%
CD1257-40	Fortify Assura [®] VR	2,298	17.62%	0	0.00%	0	0.00%	2	0.09%	0	0.00%	0	0.00%	0	0.00%	43	1.87%	1	0.04%	46	2.00%
CD1311-36Q	Ellipse [®] VR	4,912	10.42%	3	0.06%	0	0.00%	0	0.00%	11	0.22%	0	0.00%	0	0.00%	0	0.00%	4	0.08%	18	0.37%
CD1311-36	Ellipse [¯] VR	1,628	14.74%	2	0.12%	0	0.00%	0	0.00%	2	0.12%	1	0.06%	1	0.06%	0	0.00%	0	0.00%	6	0.37%
CD1231-40Q	Fortify VR^{\dagger}	18,344	15.09%	10	0.05%	1	<0.01%	48	0.26%	1	<0.01%	1	<0.01%	0	0.00%	432	2.35%	7	0.04%	500	2.73%
CD1231-40	Fortify VR^{\dagger}	10,699	11.91%	6	0.06%	0	0.00%	12	0.11%	4	0.04%	0	0.00%	1	<0.01%	144	1.35%	6	0.06%	173	1.62%
CD1211-36Q	Current" + VR	16,551	8.28%	8	0.05%	0	0.00%	7	0.04%	3	0.02%	3	0.02%	1	<0.01%	9	0.05%	14	0.08%	45	0.27%
CD1211-36	Current" + VR	14,877	6.75%	6	0.04%	0	0.00%	3	0.02%	0	0.00%	9	0.06%	0	0.00%	6	0.04%	6	0.04%	30	0.20%
1207-36	Current" VR RF	24,846	17.60%	17	0.07%	3	0.01%	13	0.05%	1	<0.01%	52	0.21%	12	0.05%	29	0.12%	15	0.06%	142	0.57%
V-168	Atlas" II VR	23,946	15.45%	4	0.02%	0	0.00%	6	0.03%	0	0.00%	0	0.00%	12	0.05%	10	0.04%	9	0.04%	41	0.17%
V-193	Atlas" + VR	39,596	16.43%	4	0.01%	3	<0.01%	8	0.02%	1	<0.01%	2	<0.01%	14	0.04%	11	0.03%	13	0.03%	56	0.14%

Actively Monitored Study Data Summary

	NUMBER OF DEVICES	ACTIVE DEVICES	CUMULATIVE MONTHS OF		OPRIATE		SS OF METRY		ARDIAL USION	BAT	ATURE TERY ETION		KIN DSION	то	DTAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD1231-40Q	160	0	11,424	0	0.00%	0	0.00%	0	0.00%	2	1.25%	0	0.00%	2	1.25%
CD1211-36Q	363	0	26,608	1	0.28%	0	0.00%	0	0.00%	1	0.28%	0	0.00%	2	0.55%
1207-36	395	0	21,879	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

QUALIFYING COMPLICATIONS

A list of of complications can be found on page 12.

Actively Monitored Study Data Summary

MALFUNCTIONS WITH COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE		WARE/ IWARE	MECH	ANICAL	BAT	le early Tery .etion	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD1231-40Q	Fortify VR	160	20.60%	0	0.00%	0	0.00%	0	0.00%	1	0.63%	0	0.00%	0	0.00%	2	1.25%	0	0.00%	3	1.88%
CD1211-36Q	Current" + VR	363	32.20%	0	0.00%	0	0.00%	1	0.28%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.28%
1207-36	Current" VR RF	395	36.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

MALFUNCTIONS WITHOUT COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		OLTAGE CITOR		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	то	TAL
MODELS	FAMILY		FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
CD1231-40Q	Fortify VR	160	20.60%	0	0.00%	0	0.00%	1	0.63%	0	0.00%	0	0.00%	0	0.00%	8	5.00%	0	0.00%	9	5.63%
CD1211-36Q	Current" + VR	363	32.20%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.28%	0	0.00%	1	0.28%	0	0.00%	2	0.55%
1207-36	Current" VR RF	395	36.70%	1	0.25%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.25%


CUSTOMER REPORTED PERFORMANCE DATA

Optisure[™] DF4 MODEL LDA230Q

US Regulatory Approval	February 2014
Registered US Implants	1,053
Estimated Active US Implants	611
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 319)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	1	0.09%	0	0.00%
Conductor Fracture	0	0.00%	0	0.00%
Lead Dislodgement	1	0.09%	3	0.28%
Failure to Capture	0	0.00%	5	0.47%
Oversensing	0	0.00%	6	0.57%
Failure to Sense	0	0.00%	1	0.09%
Insulation Breach	0	0.00%	0	0.00%
Abnormal Pacing Impedance	1	0.09%	1	0.09%
Abnormal Defibrillation Impedance	0	0.00%	0	0.00%
Extracardiac Stimulation	1	0.09%	0	0.00%
Other	0	0.00%	0	0.00%
Total	4	0.38%	16	1.52%
Total Returned for Analysis	1		8	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	0.09%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	1	0.09%
Insulation Breach	3	0.28%
Lead-to-Can Contact	1	0.09%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	1	0.09%
Externalized Conductors	0	0.00%
Other	1	0.09%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	8	0.76%
Total	12	1.14%



YEAR	1	2	3	4	5	6	AT 76 MONTHS
SURVIVAL PROBABILITY	98.91%	98.65%	98.36%	98.21%	98.21%	97.54%	97.14%
±1 STANDARD ERROR	0.32%	0.39%	0.44%	0.46%	0.46%	0.66%	0.77%
SAMPLE SIZE	940	790	690	600	490	340	210


CUSTOMER REPORTED PERFORMANCE DATA

Optisure[™] DF4 MODEL LDA220Q

US Regulatory Approval	February 2014
Registered US Implants	12,207
Estimated Active US Implants	7,809
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 319)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	12	0.10%	4	0.03%
Conductor Fracture	0	0.00%	6	0.05%
Lead Dislodgement	52	0.43%	75	0.61%
Failure to Capture	22	0.18%	82	0.67%
Oversensing	5	0.04%	61	0.50%
Failure to Sense	2	0.02%	9	0.07%
Insulation Breach	0	0.00%	2	0.02%
Abnormal Pacing Impedance	0	0.00%	13	0.11%
Abnormal Defibrillation Impedance	5	0.04%	19	0.16%
Extracardiac Stimulation	1	<0.01%	0	0.00%
Other	6	0.05%	4	0.03%
Total	105	0.86%	275	2.25%
Total Returned for Analysis	39		77	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	< 0.01%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	1	< 0.01%
Insulation Breach	7	0.06%
Lead-to-Can Contact	2	0.02%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	2	0.02%
Externalized Conductors	0	0.00%
Other	3	0.02%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	73	0.60%
Total	81	0.66%



YEAR	1	2	3	4	5	6	7	AT 88 MONTHS
SURVIVAL PROBABILITY	99.05%	98.74%	98.40%	98.07%	97.74%	97.21%	97.02%	97.02%
± 1 STANDARD ERROR	0.09%	0.11%	0.13%	0.15%	0.17%	0.22%	0.24%	0.24%
SAMPLE SIZE	10,970	8,910	7,300	5,800	4,370	2,860	1,290	220


CUSTOMER REPORTED PERFORMANCE DATA

Optisure[™] MODEL LDA220

US Regulatory Approval	February 2014
Registered US Implants	605
Estimated Active US Implants	346
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 319)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	1	0.17%	0	0.00%
Conductor Fracture	0	0.00%	0	0.00%
Lead Dislodgement	0	0.00%	5	0.83%
Failure to Capture	0	0.00%	3	0.50%
Oversensing	0	0.00%	5	0.83%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	0	0.00%	0	0.00%
Abnormal Pacing Impedance	0	0.00%	3	0.50%
Abnormal Defibrillation Impedance	0	0.00%	1	0.17%
Extracardiac Stimulation	0	0.00%	0	0.00%
Other	0	0.00%	0	0.00%
Total	1	0.17%	17	2.81%
Total Returned for Analysis	0		4	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	6	0.99%
Total	6	0.99%



YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	98.76%	98.53%	98.28%	97.42%	97.42%	96.97%	96.97%
± 1 STANDARD ERROR	0.50%	0.55%	0.60%	0.78%	0.78%	0.78%	0.89%
SAMPLE SIZE	530	420	380	340	300	250	200

CUSTOMER REPORTED PERFORMANCE DATA

Optisure[™] **DF4** MODEL LDA210Q


US Regulatory Approval	February 2014
Registered US Implants	54,674
Estimated Active US Implants	37,033
Insulation	Optim"*
Type and/or Fixation	Single Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	99	0.18%	23	0.04%
Conductor Fracture	2	< 0.01%	24	0.04%
Lead Dislodgement	186	0.34%	318	0.58%
Failure to Capture	99	0.18%	210	0.38%
Oversensing	40	0.07%	171	0.31%
Failure to Sense	14	0.03%	23	0.04%
Insulation Breach	2	< 0.01%	2	<0.01%
Abnormal Pacing Impedance	9	0.02%	42	0.08%
Abnormal Defibrillation Impedance	10	0.02%	40	0.07%
Extracardiac Stimulation	4	<0.01%	5	<0.01%
Other	19	0.03%	31	0.06%
Total	484	0.89%	889	1.63%
Total Returned for Analysis	172		325	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	7	0.01%
Clavicular Crush	1	< 0.01%
In the Pocket	2	< 0.01%
Intravascular	4	< 0.01%
Insulation Breach	17	0.03%
Lead-to-Can Contact	10	0.02%
Lead-to-Lead Contact	6	0.01%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	<0.01%
Crimps, Welds & Bonds	0	0.00%
Other	5	<0.01%
Extrinsic Factors	311	0.57%
Total	340	0.62%

0.36%

270



±1 STANDARD ERROR 0.04% 0.05% 0.06% 0.07% 0.08% 0.11% 0.15% SAMPLE SIZE 47,410 35,600 19,500 13,270 3,290 26,990 7,910


CUSTOMER REPORTED PERFORMANCE DATA

Optisure[™] MODEL LDA210

US Regulatory Approval	February 2014
Registered US Implants	1,595
Estimated Active US Implants	1,030
Insulation	Optim"*
Type and/or Fixation	Single Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	3	0.19%	0	0.00%
Conductor Fracture	0	0.00%	2	0.13%
Lead Dislodgement	7	0.44%	7	0.44%
Failure to Capture	2	0.13%	11	0.69%
Oversensing	2	0.13%	13	0.82%
Failure to Sense	0	0.00%	0	0.00%
Insulation Breach	0	0.00%	0	0.00%
Abnormal Pacing Impedance	0	0.00%	4	0.25%
Abnormal Defibrillation Impedance	0	0.00%	1	0.06%
Extracardiac Stimulation	0	0.00%	1	0.06%
Other	1	0.06%	2	0.13%
Total	15	0.94%	41	2.57%
Total Returned for Analysis	6		13	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	1	0.06%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	1	0.06%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	15	0.94%
Total	16	1.00%



YEAR	1	2	3	4	5	6	AT 74 MONTHS
SURVIVAL PROBABILITY	98.84%	98.30%	97.86%	97.58%	97.32%	96.33%	96.33%
± 1 STANDARD ERROR	0.27%	0.35%	0.40%	0.46%	0.46%	0.78%	0.78%
SAMPLE SIZE	1,410	1,100	880	660	460	290	220


CUSTOMER REPORTED PERFORMANCE DATA

Durata[™] DF4 MODELS 7170Q & 7171Q

US Regulatory Approval	July 2009
Registered US Implants	7,028
Estimated Active US Implants	3,164
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	6	0.09%	8	0.11%
Conductor Fracture	1	0.01%	31	0.44%
Lead Dislodgement	21	0.30%	33	0.47%
Failure to Capture	14	0.20%	80	1.14%
Oversensing	3	0.04%	71	1.01%
Failure to Sense	0	0.00%	1	0.01%
Insulation Breach	0	0.00%	5	0.07%
Abnormal Pacing Impedance	1	0.01%	23	0.33%
Abnormal Defibrillation Impedance	0	0.00%	21	0.30%
Extracardiac Stimulation	1	0.01%	0	0.00%
Other	1	0.01%	4	0.06%
Total	48	0.68%	277	3.94%
Total Returned for Analysis	22		71	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	5	0.07%
Clavicular Crush	0	0.00%
In the Pocket	2	0.03%
Intravascular	3	0.04%
Insulation Breach	15	0.21%
Lead-to-Can Contact	8	0.11%
Lead-to-Lead Contact	5	0.07%
Clavicular Crush	1	0.01%
Externalized Conductors	0	0.00%
Other	1	0.01%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	54	0.77%
Total	74	1.05%



YEAR	2	4	6	8	10	AT 139 MONTHS
SURVIVAL PROBABILITY	98.56%	97.24%	96.19%	94.49%	93.27%	91.68%
± 1 STANDARD ERROR	0.15%	0.22%	0.28%	0.37%	0.48%	0.79%
SAMPLE SIZE	5,520	4,230	3,100	2,080	1,060	210

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

ACTIVELY MONITORED STUDY DATA

July 2009

115

0

7,749

Optim^{**} Dual Coil, Passive

Bipolar

Yes

Durata[™] DF4 MODELS 7170Q & 7171Q

US Regulatory Approval

Type and/or Fixation

Insulation


Polarity

Steroid

SAMPLE SIZE

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.87%
Conductor Fracture	1	0.87%
Lead Dislodgement	1	0.87%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	0	0.00%
Lead-to-Can Contact	0	0.00%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	2	1.74%
Total	2	1.74%



60

60

50

50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

110

100

80

70

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 175


CUSTOMER REPORTED PERFORMANCE DATA

Durata[™] DF4 MODELS 7120Q & 7121Q

US Regulatory Approval	January 2009
Registered US Implants	139,515
Estimated Active US Implants	62,431
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		CHRONIC COMPLICATIONS (>30 DAYS)	
	QTY	RATE	QTY	RATE
Cardiac Perforation	107	0.08%	47	0.03%
Conductor Fracture	2	<0.01%	261	0.19%
Lead Dislodgement	294	0.21%	713	0.51%
Failure to Capture	142	0.10%	1066	0.76%
Oversensing	54	0.04%	1080	0.77%
Failure to Sense	16	0.01%	103	0.07%
Insulation Breach	0	0.00%	69	0.05%
Abnormal Pacing Impedance	7	<0.01%	233	0.17%
Abnormal Defibrillation Impedance	11	<0.01%	488	0.35%
Extracardiac Stimulation	6	<0.01%	10	<0.01%
Other	44	0.03%	104	0.07%
Total	683	0.49%	4174	2.99%
Total Returned for Analysis	332		1221	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	35	0.03%
Clavicular Crush	5	< 0.01%
In the Pocket	11	< 0.01%
Intravascular	19	0.01%
Insulation Breach	348	0.25%
Lead-to-Can Contact	204	0.15%
Lead-to-Lead Contact	35	0.03%
Clavicular Crush	35	0.03%
Externalized Conductors	0	0.00%
Other	74	0.05%
Crimps, Welds & Bonds	2	<0.01%
Other	38	0.03%
Extrinsic Factors	941	0.67%
Total	1364	0.98%



YEAR	2	4	6	8	10	12	AT 148 MONTHS
SURVIVAL PROBABILITY	98.91%	98.31%	97.44%	96.44%	95.34%	94.33%	93.95%
±1 STANDARD ERROR	0.03%	0.04%	0.05%	0.07%	0.09%	0.14%	0.26%
SAMPLE SIZE	111,860	87,940	67,840	47,990	26,870	6,280	370


ACTIVELY MONITORED STUDY DATA

Durata[™] DF4 MODELS 7120Q & 7121Q

US Regulatory Approval	January 2009
Number of Devices Enrolled in Study	4,322
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	275,708
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Defibrillation Impedance	5	0.12%
Abnormal Pacing Impedance	5	0.12%
Cardiac Perforation	1	0.02%
Conductor Fracture	18	0.42%
Failure to Capture	20	0.46%
Failure to Sense	5	0.12%
Inappropriate Shock	5	0.12%
Insulation Breach	5	0.12%
Lead Dislodgement	39	0.90%
Oversensing	8	0.19%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	5	0.12%
Clavicular Crush	1	0.02%
In the Pocket	2	0.05%
Intravascular	2	0.05%
Insulation Breach	12	0.28%
Lead-to-Can Contact	8	0.19%
Lead-to-Lead Contact	3	0.07%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.02%
Crimps, Welds & Bonds	0	0.00%
Other	1	0.02%
Extrinsic Factors	51	1.18%
Total	69	1.60%



YEAR	2	4	6	8	10	AT 131 MONTHS
SURVIVAL PROBABILITY	98.61%	97.91%	97.00%	96.47%	95.83%	95.83%
±1 STANDARD ERROR	0.18%	0.24%	0.31%	0.35%	0.44%	0.44%
SAMPLE SIZE	3,500	2,630	2,000	1,570	830	80

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 177


CUSTOMER REPORTED PERFORMANCE DATA

Durata[™] DF4 MODEL 7122Q

US Regulatory Approval	January 2009
Registered US Implants	143,710
Estimated Active US Implants	79,881
Insulation	Optim"*
Type and/or Fixation	Single Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	189	0.13%	62	0.04%
Conductor Fracture	3	< 0.01%	114	0.08%
Lead Dislodgement	371	0.26%	746	0.52%
Failure to Capture	193	0.13%	774	0.54%
Oversensing	65	0.05%	671	0.47%
Failure to Sense	14	<0.01%	67	0.05%
Insulation Breach	1	<0.01%	41	0.03%
Abnormal Pacing Impedance	15	0.01%	145	0.10%
Abnormal Defibrillation Impedance	13	<0.01%	151	0.11%
Extracardiac Stimulation	3	<0.01%	11	<0.01%
Other	54	0.04%	103	0.07%
Total	921	0.64%	2885	2.01%
Total Returned for Analysis	371		1022	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	18	0.01%
Clavicular Crush	1	< 0.01%
In the Pocket	9	<0.01%
Intravascular	8	< 0.01%
Insulation Breach	220	0.15%
Lead-to-Can Contact	133	0.09%
Lead-to-Lead Contact	34	0.02%
Clavicular Crush	19	0.01%
Externalized Conductors	0	0.00%
Other	34	0.02%
Crimps, Welds & Bonds	0	0.00%
Other	21	0.01%
Extrinsic Factors	871	0.61%
Total	1130	0.79%




YEAR	2	4	6	8	10	12
SURVIVAL PROBABILITY	98.85%	98.25%	97.44%	96.48%	95.51%	94.51%
± 1 STANDARD ERROR	0.03%	0.04%	0.06%	0.08%	0.13%	0.23%
SAMPLE SIZE	100,290	65,390	40,800	20,320	6,640	260

ACTIVELY MONITORED STUDY DATA

Durata[™] DF4 MODEL 7122Q

		QUALIFYING COMPLICATIONS	QTY	RATE	MA
US Regulatory Approval	January 2009	Abnormal Defibrillation Impedance	3	0.19%	Co
Number of Devices Enrolled in Study	1,561	Conductor Fracture	4	0.26%	
Active Devices Enrolled in Study	0	Failure to Capture	7	0.45%	
Cumulative Months of Follow-up	94,522	Failure to Sense	2	0.13%	
Insulation	Optim"*	Lead Dislodgement	7	0.45%	Ins
Type and/or Fixation	Single Coil, Active	Oversensing	2	0.13%	
Polarity	Bipolar	Pericardial Effusion	2	0.13%	
Steroid	Yes				

MALFUNCTIONS	QTY	RATE
Conductor Fracture	2	0.13%
Clavicular Crush	1	0.06%
In the Pocket	1	0.06%
Intravascular	0	0.00%
Insulation Breach	5	0.32%
Lead-to-Can Contact	4	0.26%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.06%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	15	0.96%
Total	22	1.41%



YEAR	2	4	6	8	10	AT 128 MONTHS
SURVIVAL PROBABILITY	98.84%	98.44%	98.06%	97.78%	97.38%	97.38%
±1 STANDARD ERROR	0.28%	0.34%	0.40%	0.45%	0.60%	0.60%
SAMPLE SIZE	1,260	940	730	470	190	50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 179

CUSTOMER REPORTED PERFORMANCE DATA


Durata™

MODELS 7120 & 7121

US Regulatory Approval	September 2007
Registered US Implants	60,154
Estimated Active US Implants	19,628
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	41	0.07%	18	0.03%
Conductor Fracture	2	<0.01%	174	0.29%
Lead Dislodgement	70	0.12%	190	0.32%
Failure to Capture	25	0.04%	429	0.71%
Oversensing	51	0.08%	880	1.46%
Failure to Sense	5	<0.01%	72	0.12%
Insulation Breach	0	0.00%	76	0.13%
Abnormal Pacing Impedance	2	<0.01%	232	0.39%
Abnormal Defibrillation Impedance	21	0.03%	345	0.57%
Extracardiac Stimulation	0	0.00%	3	<0.01%
Other	21	0.03%	58	0.10%
Total	238	0.40%	2477	4.12%
Total Returned for Analysis	93		625	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	34	0.06%
Clavicular Crush	2	<0.01%
In the Pocket	23	0.04%
Intravascular	9	0.01%
Insulation Breach	210	0.35%
Lead-to-Can Contact	110	0.18%
Lead-to-Lead Contact	40	0.07%
Clavicular Crush	18	0.03%
Externalized Conductors	0	0.00%
Other	42	0.07%
Crimps, Welds & Bonds	1	< 0.01%
Other	9	0.01%
Extrinsic Factors	454	0.75%
Total	708	1.18%



YEAR	2	4	6	8	10	12	AT 167 MONTHS
SURVIVAL PROBABILITY	99.05%	98.30%	97.19%	95.91%	94.76%	93.68%	92.92%
± 1 STANDARD ERROR	0.04%	0.06%	0.08%	0.10%	0.12%	0.15%	0.18%
SAMPLE SIZE	48,330	39,000	31,840	26,130	21,250	14,620	270

ACTIVELY MONITORED STUDY DATA


Durata™

MODELS 7120 & 7121

		· ·
US Regulatory Approval	September 2007	Ab
Number of Devices Enrolled in Study	3,560	Ab
Active Devices Enrolled in Study	0	Co
Cumulative Months of Follow-up	226,815	Fa
Insulation	Optim"*	Fa
Type and/or Fixation	Dual Coil, Active	In
Polarity	Bipolar	In
Steroid	Yes	Le

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Defibrillation Impedance	5	0.14%
Abnormal Pacing Impedance	11	0.31%
Conductor Fracture	17	0.48%
Failure to Capture	15	0.42%
Failure to Sense	2	0.06%
Inappropriate Shock	2	0.06%
Insulation Breach	13	0.37%
Lead Dislodgement	20	0.56%
Oversensing	15	0.42%
Skin Erosion	2	0.06%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	0.03%
Clavicular Crush	0	0.00%
In the Pocket	1	0.03%
Intravascular	0	0.00%
Insulation Breach	13	0.37%
Lead-to-Can Contact	6	0.17%
Lead-to-Lead Contact	6	0.17%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.03%
Crimps, Welds & Bonds	0	0.00%
Other	1	0.03%
Extrinsic Factors	29	0.81%
Total	44	1.24%



YEAR	2	4	6	8	10	12	AT 146 MONTHS
SURVIVAL PROBABILITY	98.80%	98.00%	97.01%	96.12%	95.17%	93.97%	93.97%
±1 STANDARD ERROR	0.19%	0.26%	0.35%	0.44%	0.55%	0.71%	0.71%
SAMPLE SIZE	2,950	2,160	1,500	1,060	710	280	70

CUSTOMER REPORTED PERFORMANCE DATA


Durata™

MODEL 7122

US Regulatory Approval	September 2007
Registered US Implants	16,082
Estimated Active US Implants	6,294
Insulation	Optim"*
Type and/or Fixation	Single Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	12	0.07%	4	0.02%
Conductor Fracture	1	< 0.01%	47	0.29%
Lead Dislodgement	24	0.15%	76	0.47%
Failure to Capture	19	0.12%	118	0.73%
Oversensing	13	0.08%	189	1.18%
Failure to Sense	0	0.00%	13	0.08%
Insulation Breach	1	<0.01%	26	0.16%
Abnormal Pacing Impedance	3	0.02%	53	0.33%
Abnormal Defibrillation Impedance	2	0.01%	47	0.29%
Extracardiac Stimulation	2	0.01%	2	0.01%
Other	4	0.02%	12	0.07%
Total	81	0.50%	587	3.65%
Total Returned for Analysis	37		199	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	16	0.10%
Clavicular Crush	1	< 0.01%
In the Pocket	12	0.07%
Intravascular	3	0.02%
Insulation Breach	73	0.45%
Lead-to-Can Contact	38	0.24%
Lead-to-Lead Contact	24	0.15%
Clavicular Crush	2	0.01%
Externalized Conductors	1	< 0.01%
Other	8	0.05%
Crimps, Welds & Bonds	0	0.00%
Other	4	0.02%
Extrinsic Factors	151	0.94%
Total	244	1.52%



YEAR	2	4	6	8	10	12	AT 161 MONTHS
SURVIVAL PROBABILITY	98.68%	97.81%	96.54%	95.51%	94.59%	93.67%	93.09%
± 1 STANDARD ERROR	0.10%	0.13%	0.18%	0.21%	0.26%	0.31%	0.39%
SAMPLE SIZE	12,840	10,050	7,730	5,670	3,960	2,030	230


ACTIVELY MONITORED STUDY DATA

Durata™

MODEL 7122

		QUALIFYING COMPLICATIONS	QTY	RATE	N
US Regulatory Approval	September 2007	Abnormal Defibrillation Impedance	1	0.22%	0
Number of Devices Enrolled in Study	457	Abnormal Pacing Impedance	5	1.09%	
Active Devices Enrolled in Study	0	Conductor Fracture	6	1.31%	
Cumulative Months of Follow-up	31,078	Failure to Capture	5	1.09%	
Insulation	Optim"*	Failure to Sense	1	0.22%	I
Type and/or Fixation	Single Coil, Active	Insulation Breach	1	0.22%	
Polarity	Bipolar	Lead Dislodgement	5	1.09%	
Steroid	Yes	Oversensing	3	0.66%	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	2	0.44%
Clavicular Crush	0	0.00%
In the Pocket	1	0.22%
Intravascular	1	0.22%
Insulation Breach	3	0.66%
Lead-to-Can Contact	2	0.44%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.22%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	8	1.75%
Total	13	2.84%



YEAR	2	4	6	8	10	AT 128 MONTHS
SURVIVAL PROBABILITY	97.71%	96.20%	93.45%	91.42%	90.35%	90.35%
±1 STANDARD ERROR	0.72%	0.97%	1.40%	1.70%	1.99%	1.99%
SAMPLE SIZE	400	300	220	160	90	50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 183


CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST Optim[™] MODELS 7070 & 7071

US Regulatory Approval	July 2006
Registered US Implants	3,311
Estimated Active US Implants	973
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	3	0.09%	2	0.06%
Conductor Fracture	1	0.03%	28	0.85%
Lead Dislodgement	3	0.09%	13	0.39%
Failure to Capture	6	0.18%	40	1.21%
Oversensing	4	0.12%	69	2.08%
Failure to Sense	3	0.09%	3	0.09%
Insulation Breach	0	0.00%	9	0.27%
Abnormal Pacing Impedance	0	0.00%	16	0.48%
Abnormal Defibrillation Impedance	0	0.00%	22	0.66%
Extracardiac Stimulation	0	0.00%	1	0.03%
Other	0	0.00%	3	0.09%
Total	20	0.60%	206	6.22%
Total Returned for Analysis	6		44	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	2	0.06%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	2	0.06%
Insulation Breach	23	0.69%
Lead-to-Can Contact	9	0.27%
Lead-to-Lead Contact	4	0.12%
Clavicular Crush	2	0.06%
Externalized Conductors	1	0.03%
Other	7	0.21%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	23	0.69%
Total	48	1.45%



YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.09%	97.99%	96.28%	94.57%	92.15%	90.20%	89.46%
± 1 STANDARD ERROR	0.18%	0.28%	0.41%	0.52%	0.67%	0.77%	0.84%
SAMPLE SIZE	2,530	2,000	1,630	1,400	1,190	880	220

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

ACTIVELY MONITORED STUDY DATA

Yes

Riata[™] ST Optim[™] MODELS 7070 & 7071

US Regulatory Approval


Type and/or Fixation

Insulation

Polarity Steroid

	QUALIFYING COMPLICATIONS	QTY	RATE
July 2006	Abnormal Defibrillation Impedance	1	0.35%
288	Abnormal Pacing Impedance	2	0.69%
0	Cardiac Perforation	1	0.35%
19,238	Conductor Fracture	2	0.69%
Optim"*	Failure to Capture	1	0.35%
Dual Coil, Passive	Lead Dislodgement	1	0.35%
Bipolar	Oversensing	1	0.35%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	1	0.35%
Lead-to-Can Contact	1	0.35%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	1	0.35%
Total	2	0.69%



YEAR	2	4	6	8	10	AT 128 MONTHS
SURVIVAL PROBABILITY	98.94%	97.87%	95.82%	94.94%	94.94%	94.94%
±1 STANDARD ERROR	0.61%	0.96%	1.31%	1.73%	1.73%	1.73%
SAMPLE SIZE	240	180	130	100	70	50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 185


CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST Optim[™] MODELS 7020 & 7021

US Regulatory Approval	July 2006
Registered US Implants	14,252
Estimated Active US Implants	3,790
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	33	0.23%	17	0.12%
Conductor Fracture	0	0.00%	67	0.47%
Lead Dislodgement	27	0.19%	66	0.46%
Failure to Capture	17	0.12%	182	1.28%
Oversensing	19	0.13%	293	2.06%
Failure to Sense	8	0.06%	22	0.15%
Insulation Breach	0	0.00%	29	0.20%
Abnormal Pacing Impedance	2	0.01%	62	0.44%
Abnormal Defibrillation Impedance	4	0.03%	116	0.81%
Extracardiac Stimulation	3	0.02%	2	0.01%
Other	0	0.00%	29	0.20%
Total	113	0.79%	885	6.21%
Total Returned for Analysis	53		234	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	11	0.08%
Clavicular Crush	1	< 0.01%
In the Pocket	5	0.04%
Intravascular	5	0.04%
Insulation Breach	65	0.46%
Lead-to-Can Contact	31	0.22%
Lead-to-Lead Contact	7	0.05%
Clavicular Crush	4	0.03%
Externalized Conductors	0	0.00%
Other	23	0.16%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	183	1.28%
Total	259	1.82%



YEAR	2	4	6	8	10	12	14	AT 178 MONTHS
SURVIVAL PROBABILITY	98.54%	97.63%	96.11%	94.13%	92.24%	90.77%	89.31%	89.13%
±1 STANDARD ERROR	0.11%	0.14%	0.20%	0.26%	0.31%	0.35%	0.39%	0.42%
SAMPLE SIZE	11,180	8,770	7,130	5,890	5,000	4,330	2,810	240


ACTIVELY MONITORED STUDY DATA

Riata[™] ST Optim[™] MODELS 7020 & 7021

US Regulatory Approval	July 2006
Number of Devices Enrolled in Study	1,469
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	88,681
Insulation	Optim"*
Type and/or Fixation	Dual Coil, Active
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	6	0.41%
Cardiac Perforation	1	0.07%
Conductor Fracture	9	0.61%
Failure to Capture	16	1.09%
Failure to Sense	1	0.07%
Insulation Breach	2	0.14%
Lead Dislodgement	9	0.61%
Oversensing	6	0.41%
Skin Erosion	1	0.07%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	3	0.20%
Clavicular Crush	0	0.00%
In the Pocket	3	0.20%
Intravascular	0	0.00%
Insulation Breach	4	0.27%
Lead-to-Can Contact	2	0.14%
Lead-to-Lead Contact	0	0.00%
Clavicular Crush	2	0.14%
Externalized Conductors	0	0.00%
Other	0	0.00%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	15	1.02%
Total	22	1.50%



YEAR	2	4	6	8	10	12	AT 157 MONTHS
SURVIVAL PROBABILITY	98.27%	97.87%	96.25%	94.47%	93.12%	92.18%	92.18%
± 1 STANDARD ERROR	0.35%	0.40%	0.62%	0.83%	1.13%	1.30%	1.30%
SAMPLE SIZE	1,180	840	540	350	240	180	50

CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST Optim[™]

ODEL 7022				ERVATIONS NT, ≤30 DAYS)		DMPLICATIONS DAYS)
			QTY	RATE	QTY	RATE
US Regulatory Approval	July 2006	Cardiac Perforation	5	0.34%	3	0.20%
Registered US Implants	1,472	Conductor Fracture	0	0.00%	12	0.82%
Estimated Active US Implants	391	Lead Dislodgement	3	0.20%	11	0.75%
Insulation	Optim"*	Failure to Capture	1	0.07%	17	1.15%
Type and/or Fixation	Single Coil, Active	Oversensing	0	0.00%	33	2.24%
Polarity	Bipolar	Failure to Sense	0	0.00%	1	0.07%
Steroid	Yes	Insulation Breach	0	0.00%	10	0.68%
Number of US Advisories	None	Abnormal Pacing Impedance	2	0.14%	5	0.34%
		Abnormal Defibrillation Impedance	0	0.00%	5	0.34%

Extracardiac Stimulation

Total Returned for Analysis

Other

Total


0.60%

740

0.82%

610

MALFUNCTIONS	QTY	RATE
Conductor Fracture	3	0.20%
Clavicular Crush	0	0.00%
In the Pocket	2	0.14%
Intravascular	1	0.07%
Insulation Breach	13	0.88%
Lead-to-Can Contact	8	0.54%
Lead-to-Lead Contact	3	0.20%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	2	0.14%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	25	1.70%
Total	41	2.79%



1.08%

510

1.18%

440

1.42%

200

0

0

11

0.00%

0.00%

0.75%

1

3

101

35

0.07%

0.20%

6.86%

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

0.29%

1,130

0.45%

900

±1 STANDARD ERROR

SAMPLE SIZE


CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST MODELS 7010 & 7011

US Regulatory Approval	March 2006
Registered US Implants	2,200
Estimated Active US Implants	498
Insulation	Silicone
Type and/or Fixation	Dual Coil, Active
Polarity	Integrated Bipolar
Steroid	Yes
Number of US Advisories (see pg. 320)	One

		SERVATIONS NT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	3	0.14%	3	0.14%
Conductor Fracture	0	0.00%	8	0.36%
Lead Dislodgement	1	0.05%	8	0.36%
Failure to Capture	2	0.09%	14	0.64%
Oversensing	2	0.09%	58	2.64%
Failure to Sense	1	0.05%	3	0.14%
Insulation Breach	0	0.00%	47	2.14%
Abnormal Pacing Impedance	1	0.05%	29	1.32%
Abnormal Defibrillation Impedance	0	0.00%	22	1.00%
Extracardiac Stimulation	0	0.00%	0	0.00%
Other	1	0.05%	3	0.14%
Total	11	0.50%	195	8.86%
Total Returned for Analysis	4		46	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	3	0.14%
Clavicular Crush	0	0.00%
In the Pocket	3	0.14%
Intravascular	0	0.00%
Insulation Breach	44	2.00%
Lead-to-Can Contact	14	0.64%
Lead-to-Lead Contact	19	0.86%
Clavicular Crush	1	0.05%
Externalized Conductors	3	0.14%
Other	7	0.32%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	13	0.59%
Total	60	2.73%



YEAR	2	4	6	8	10	12	14	AT 176 MONTHS
SURVIVAL PROBABILITY	99.31%	98.54%	95.17%	90.12%	85.80%	83.13%	81.60%	81.00%
± 1 STANDARD ERROR	0.19%	0.29%	0.61%	0.92%	1.13%	1.25%	1.33%	1.39%
SAMPLE SIZE	1,700	1,310	1,020	820	680	590	450	230


CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST MODELS 7040 & 7041

US Regulatory Approval	March 2006
Registered US Implants	4,057
Estimated Active US Implants	962
Insulation	Silicone
Type and/or Fixation	Dual Coil, Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	One
(see pg. 320)	

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		CHRONIC COMPLICATIONS (>30 DAYS)	
	QTY	RATE	QTY	RATE
Cardiac Perforation	4	0.10%	3	0.07%
Conductor Fracture	0	0.00%	39	0.96%
Lead Dislodgement	5	0.12%	5	0.12%
Failure to Capture	1	0.02%	56	1.38%
Oversensing	3	0.07%	114	2.81%
Failure to Sense	0	0.00%	16	0.39%
Insulation Breach	0	0.00%	64	1.58%
Abnormal Pacing Impedance	2	0.05%	22	0.54%
Abnormal Defibrillation Impedance	0	0.00%	34	0.84%
Extracardiac Stimulation	0	0.00%	1	0.02%
Other	1	0.02%	10	0.25%
Total	16	0.39%	364	8.97%
Total Returned for Analysis	3		81	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	4	0.10%
Clavicular Crush	0	0.00%
In the Pocket	1	0.02%
Intravascular	3	0.07%
Insulation Breach	69	1.70%
Lead-to-Can Contact	34	0.84%
Lead-to-Lead Contact	21	0.52%
Clavicular Crush	0	0.00%
Externalized Conductors	2	0.05%
Other	12	0.30%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	30	0.74%
Total	103	2.54%



YEAR	2	4	6	8	10	12	14	AT 179 MONTHS
SURVIVAL PROBABILITY	98.99%	97.17%	93.51%	88.39%	85.60%	83.30%	81.61%	80.93%
± 1 STANDARD ERROR	0.17%	0.30%	0.50%	0.71%	0.81%	0.88%	0.95%	0.99%
SAMPLE SIZE	3,170	2,460	1,910	1,520	1,270	1,110	680	200

CUSTOMER REPORTED PERFORMANCE DATA


Riata[™] ST

MODEL 7002

US Regulatory Approval	June 2005
Registered US Implants	2,409
Estimated Active US Implants	543
Insulation	Silicone
Type and/or Fixation	Single Coil, Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories (see pg. 320)	One

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		CHRONIC COMPLICATION (>30 DAYS)	
	QTY	RATE	QTY	RATE
Cardiac Perforation	6	0.25%	5	0.21%
Conductor Fracture	0	0.00%	11	0.46%
Lead Dislodgement	3	0.12%	10	0.42%
Failure to Capture	4	0.17%	27	1.12%
Oversensing	4	0.17%	75	3.11%
Failure to Sense	0	0.00%	3	0.12%
Insulation Breach	0	0.00%	74	3.07%
Abnormal Pacing Impedance	2	0.08%	5	0.21%
Abnormal Defibrillation Impedance	1	0.04%	11	0.46%
Extracardiac Stimulation	0	0.00%	0	0.00%
Other	1	0.04%	8	0.33%
Total	21	0.87%	229	9.51%
Total Returned for Analysis	11		75	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	6	0.25%
Clavicular Crush	0	0.00%
In the Pocket	3	0.12%
Intravascular	3	0.12%
Insulation Breach	81	3.36%
Lead-to-Can Contact	36	1.49%
Lead-to-Lead Contact	18	0.75%
Clavicular Crush	0	0.00%
Externalized Conductors	11	0.46%
Other	16	0.66%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	24	1.00%
Total	111	4.61%



YEAR	2	4	6	8	10	12	14	AT 174 MONTHS
SURVIVAL PROBABILITY	98.37%	96.97%	92.53%	87.08%	84.36%	81.38%	79.74%	78.48%
±1 STANDARD ERROR	0.28%	0.40%	0.69%	0.95%	1.07%	1.19%	1.28%	1.41%
SAMPLE SIZE	1,870	1,490	1,170	910	750	640	420	210

CUSTOMER REPORTED PERFORMANCE DATA

Riata[™] ST MODELS 7000 & 7001

US Regulatory Approval

Registered US Implants

Type and/or Fixation

Number of US Advisories

Insulation

Polarity


Steroid

(see pg. 320)

Estimated Active US Implants

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		CHRONIC COMPLICATIONS (>30 DAYS)	
		QTY	RATE	QTY	RATE
June 2005	Cardiac Perforation	42	0.12%	34	0.10%
34,882	Conductor Fracture	0	0.00%	186	0.53%
7,817	Lead Dislodgement	38	0.11%	60	0.17%
Silicone	Failure to Capture	43	0.12%	396	1.14%
Dual Coil, Active	Oversensing	40	0.11%	997	2.86%
Bipolar	Failure to Sense	7	0.02%	66	0.19%
Yes	Insulation Breach	2	< 0.01%	793	2.27%
One	Abnormal Pacing Impedance	8	0.02%	138	0.40%
One	Abnormal Defibrillation Impedance	4	0.01%	264	0.76%
	Extracardiac Stimulation	3	< 0.01%	6	0.02%
	Other	11	0.03%	102	0.29%
	Total	198	0.57%	3042	8.72%
	Total Returned for Analysis	97		818	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	25	0.07%
Clavicular Crush	4	0.01%
In the Pocket	7	0.02%
Intravascular	14	0.04%
Insulation Breach	668	1.92%
Lead-to-Can Contact	347	0.99%
Lead-to-Lead Contact	179	0.51%
Clavicular Crush	12	0.03%
Externalized Conductors	45	0.13%
Other	85	0.24%
Crimps, Welds & Bonds	1	< 0.01%
Other	1	< 0.01%
Extrinsic Factors	337	0.97%
Total	1032	2.96%



YEAR	2	4	6	8	10	12	14	AT 188 MONTHS
SURVIVAL PROBABILITY	98.90%	97.69%	94.38%	90.16%	86.81%	84.62%	82.51%	80.83%
± 1 STANDARD ERROR	0.06%	0.09%	0.16%	0.22%	0.27%	0.29%	0.32%	0.40%
SAMPLE SIZE	28,120	21,960	17,060	13,260	10,790	9,320	7,190	280

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

ACTIVELY MONITORED STUDY DATA

June 2005

180

0

8,340

Silicone

Bipolar

Yes

Dual Coil, Active

Riata[™] ST MODELS 7000 & 7001

US Regulatory Approval

Type and/or Fixation


Insulation

Polarity

Steroid

QUALIFYING COMPLICATIONS	QTY	RATE
Conductor Fracture	1	0.56%
Insulation Breach	1	0.56%
Lead Dislodgement	1	0.56%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	0	0.00%
Insulation Breach	5	2.78%
Lead-to-Can Contact	3	1.67%
Lead-to-Lead Contact	1	0.56%
Clavicular Crush	0	0.00%
Externalized Conductors	0	0.00%
Other	1	0.56%
Crimps, Welds & Bonds	1	0.56%
Other	0	0.00%
Extrinsic Factors	0	0.00%
Total	6	3.33%




YEAR	1	2	3	4	AT 57 MONTHS
SURVIVAL PROBABILITY	99.43%	98.81%	98.81%	98.81%	98.81%
±1 STANDARD ERROR	0.56%	0.84%	0.84%	0.84%	0.84%
SAMPLE SIZE	170	150	120	90	50

CUSTOMER REPORTED PERFORMANCE DATA

Riata™ i MODELS 1590 & 1591

		MALFUN	ICTIONS	QTY	RATE
US Regulatory Approval	April 2004	Conduct	or Fracture	8	0.089
Registered US Implants	9,700	Clavicu	ılar Crush	1	0.019
Estimated Active US Implants	1,861	In the	Pocket	1	0.019
Insulation	Silicone	Intrava	ıscular	6	0.069
Type and/or Fixation	Dual Coil, Active	Insulatio	on Breach	213	2.209
Polarity	Integrated Bipolar	Lead-te	o-Can Contact	88	0.91%
Steroid	Yes	Lead-to	o-Lead Contact	59	0.61%
Number of US Advisories	One	Clavicu	ılar Crush	2	0.029
(see pg. 320)		Extern	alized Conductors	21	0.22%
		Other		43	0.44%
		Crimps,	Welds & Bonds	0	0.009
		Other		1	0.01%
		Extrinsic	c Factors	59	0.61%
		Total		281	2.90%



YEAR	2	4	6	8	10	12	14	16	AT 200 MONTHS
SURVIVAL PROBABILITY	99.56%	99.22%	97.95%	92.91%	88.62%	85.38%	82.94%	80.79%	80.34%
± 1 STANDARD ERROR	0.07%	0.10%	0.18%	0.38%	0.51%	0.59%	0.65%	0.72%	0.77%
SAMPLE SIZE	7,890	6,160	4,700	3,620	2,870	2,370	2,050	1,280	240


CUSTOMER REPORTED PERFORMANCE DATA

Riata™

MODEL 1582

		MALFUNCTIONS	QTY	RATE
US Regulatory Approval	March 2003	Conductor Fracture	3	0.10%
Registered US Implants	3,132	Clavicular Crush	0	0.009
Estimated Active US Implants	477	In the Pocket	0	0.009
Insulation	Silicone	Intravascular	3	0.10%
Type and/or Fixation	Single Coil, Active	Insulation Breach	183	5.849
Polarity	Bipolar	Lead-to-Can Contact	57	1.829
Steroid	Yes	Lead-to-Lead Contact	32	1.029
Number of US Advisories	One	Clavicular Crush	2	0.069
(see pg. 320)		Externalized Conductors	52	1.669
		Other	40	1.289
		Crimps, Welds & Bonds	0	0.009
		Other	0	0.009
		Extrinsic Factors	35	1.12%

Total



7.06%

221

YEAR	2	4	6	8	10	12	14	16	AT 196 MONTHS
SURVIVAL PROBABILITY	98.66%	96.74%	93.26%	84.82%	76.55%	72.77%	70.38%	66.98%	66.67%
±1 STANDARD ERROR	0.23%	0.37%	0.58%	0.95%	1.20%	1.33%	1.40%	1.54%	1.56%
SAMPLE SIZE	2,440	1,900	1,420	1,030	760	600	490	300	210


CUSTOMER REPORTED PERFORMANCE DATA

Riata™

MODELS 1570 & 1571

		MALFUNCTIONS	QTY	R
US Regulatory Approval	March 2002	Conductor Fracture	6	0.
Registered US Implants	10,279	Clavicular Crush	2	0
Estimated Active US Implants	1,602	In the Pocket	3	0
Insulation	Silicone	Intravascular	1	<0
Type and/or Fixation	Dual Coil, Passive	Insulation Breach	275	2
Polarity	Bipolar	Lead-to-Can Contact	128	1
Steroid	Yes	Lead-to-Lead Contact	47	C
Number of US Advisories	One	Clavicular Crush	2	C
(see pg. 320)		Externalized Conductors	53	0
		Other	45	0
		Crimps, Welds & Bonds	0	C
		Other	0	0
		Extrinsic Factors	69	0

Total



3.41%

350


YEAR	2	4	6	8	10	12	14	16	18	AT 226 MONTHS
SURVIVAL PROBABILITY	99.60%	99.04%	97.50%	93.63%	87.32%	80.97%	76.18%	72.22%	69.79%	69.79%
± 1 STANDARD ERROR	0.07%	0.11%	0.19%	0.34%	0.52%	0.65%	0.75%	0.84%	0.96%	0.96%
SAMPLE SIZE	8,460	6,700	5,130	3,880	3,020	2,350	1,780	1,220	540	200

CUSTOMER REPORTED PERFORMANCE DATA

Riata™

MODELS 1580 & 1581

		MALFUNCTIONS	QTY	RATE
US Regulatory Approval	March 2002	Conductor Fracture	34	0.05%
Registered US Implants	68,403	Clavicular Crush	4	< 0.01%
Estimated Active US Implants	10,740	In the Pocket	11	0.02%
Insulation	Silicone	Intravascular	19	0.03%
Type and/or Fixation	Dual Coil, Active	Insulation Breach	1959	2.86%
Polarity	Bipolar	Lead-to-Can Contact	818	1.20%
Steroid	Yes	Lead-to-Lead Contact	387	0.57%
Number of US Advisories	One	Clavicular Crush	20	0.03%
(see pg. 320)		Externalized Conductors	375	0.55%
		Other	359	0.52%
		Crimps, Welds & Bonds	3	<0.01%
		Other	0	0.00%
		Extrinsic Factors	578	0.84%
		Total	2574	3.76%



YEAR	2	4	6	8	10	12	14	16	18	AT 233 MONTHS
SURVIVAL PROBABILITY	99.39%	98.88%	97.51%	92.62%	86.26%	81.44%	77.73%	74.92%	72.25%	70.89%
±1 STANDARD ERROR	0.03%	0.05%	0.07%	0.14%	0.21%	0.25%	0.28%	0.31%	0.38%	0.51%
SAMPLE SIZE	55,770	43,840	33,500	25,210	19,180	15,330	12,290	8,670	2,700	260

Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

ACTIVELY MONITORED STUDY DATA

March 2002

566

31,733

Silicone

Bipolar

Yes

Dual Coil, Active

0

Riata™

Insulation

Polarity

Steroid


MODELS 1580 & 1581

US Regulatory Approval

Type and/or Fixation

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Defibrillation Impeda	nce 1	0.18%
Conductor Fracture	3	0.53%
Failure to Capture	1	0.18%
Insulation Breach	10	1.77%
Lead Dislodgement	2	0.35%
Oversensing	6	1.06%
Skin Erosion	1	0.18%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	0.18%
Clavicular Crush	0	0.00%
In the Pocket	0	0.00%
Intravascular	1	0.18%
Insulation Breach	24	4.24%
Lead-to-Can Contact	7	1.24%
Lead-to-Lead Contact	7	1.24%
Clavicular Crush	0	0.00%
Externalized Conductors	6	1.06%
Other	4	0.71%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	7	1.24%
Total	32	5.65%



YEAR	2	4	6	8	10	AT 122 MONTHS
SURVIVAL PROBABILITY	99.05%	95.96%	93.16%	92.63%	92.63%	92.63%
±1 STANDARD ERROR	0.36%	1.01%	1.43%	1.52%	1.52%	1.52%
SAMPLE SIZE	470	320	200	130	70	50

SUMMARY INFORMATION Defibrillation Leads

Survival Probability Summary

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
LDA230Q	Optisure" DF4	98.91%	98.65%	98.36%	98.21%	98.21%	97.54%				
LDA220Q	Optisure" DF4	99.05%	98.74%	98.40%	98.07%	97.74%	97.21%	97.02%			
LDA220	Optisure"	98.76%	98.53%	98.28%	97.42%	97.42%	96.97%				
LDA210Q	Optisure" DF4	99.01%	98.75%	98.56%	98.26%	97.93%	97.58%	97.21%			
LDA210	Optisure"	98.84%	98.30%	97.86%	97.58%	97.32%	96.33%				
7170Q/7171Q	Durata" DF4	99.09%	98.56%	98.00%	97.24%	96.84%	96.19%	95.38%	94.49%	93.86%	93.27%
7120Q/7121Q	Durata" DF4	99.18%	98.91%	98.65%	98.31%	97.91%	97.44%	96.88%	96.44%	95.89%	95.34%
7122Q	Durata [®] DF4	99.11%	98.85%	98.57%	98.25%	97.86%	97.44%	96.97%	96.48%	95.92%	95.51%
7120/7121	Durata"	99.38%	99.05%	98.70%	98.30%	97.77%	97.19%	96.50%	95.91%	95.34%	94.76%
7122	Durata	99.17%	98.68%	98.26%	97.81%	97.11%	96.54%	96.02%	95.51%	94.99%	94.59%
7070/7071	Riata" ST Optim"	99.46%	99.09%	98.53%	97.99%	97.00%	96.28%	95.46%	94.57%	93.77%	92.15%
7020/7021	Riata" ST Optim"	98.94%	98.54%	98.17%	97.63%	96.87%	96.11%	95.11%	94.13%	92.96%	92.24%
7022	Riata" ST Optim"	99.08%	98.91%	98.63%	97.65%	97.18%	96.39%	95.41%	94.15%	91.31%	90.78%
7010/7011	Riata" ST	99.43%	99.31%	98.91%	98.54%	97.15%	95.17%	92.89%	90.12%	87.73%	85.80%
7040/7041	Riata" ST	99.37%	98.99%	98.45%	97.17%	95.79%	93.51%	91.06%	88.39%	86.54%	85.60%
7002	Riata [~] ST	98.90%	98.37%	97.68%	96.97%	95.58%	92.53%	90.30%	87.08%	85.71%	84.36%
7000/7001	Riata [®] ST	99.31%	98.90%	98.33%	97.69%	96.48%	94.38%	92.03%	90.16%	88.32%	86.81%
1590/1591	Riata [™] i	99.69%	99.56%	99.45%	99.22%	98.93%	97.95%	95.46%	92.91%	90.87%	88.62%
1582	Riata	99.27%	98.66%	97.89%	96.74%	95.55%	93.26%	89.47%	84.82%	80.39%	76.55%
1570/1571	Riata [™]	99.76%	99.60%	99.37%	99.04%	98.50%	97.50%	95.53%	93.63%	90.99%	87.32%
1580/1581	Riata	99.58%	99.39%	99.18%	98.88%	98.42%	97.51%	95.51%	92.62%	89.43%	86.26%

Acute Observation Summary

POST IMPLANT ≤30 DAYS

	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US		DIAC RATION				GEMENT		URE TO PTURE	OVERS	ENSING		LURE		LATION EACH	PA	ORMAL CING DANCE	DEFIBR	DRMAL ILLATION DANCE		CARDIAC	от	HER	тс	DTAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
LDA230Q	Feb-14	1,053	611	1	0.09%	0	0.00%	1	0.09%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.09%	0	0.00%	1	0.09%	0	0.00%	4	0.38%	1
LDA220Q	Feb-14	12,207	7,809	12	0.10%	0	0.00%	52	0.43%	22	0.18%	5	0.04%	2	0.02%	0	0.00%	0	0.00%	5	0.04%	1	<0.01%	6	0.05%	105	0.86%	39
LDA220	Feb-14	605	346	1	0.17%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.17%	0
LDA210Q	Feb-14	54,674	37,033	99	0.18%	2	<0.01%	186	0.34%	99	0.18%	40	0.07%	14	0.03%	2	<0.01%	9	0.02%	10	0.02%	4	<0.01%	19	0.03%	484	0.89%	172
LDA210	Feb-14	1,595	1,030	3	0.19%	0	0.00%	7	0.44%	2	0.13%	2	0.13%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.06%	15	0.94%	6
7170Q/7171Q	Jul-09	7,028	3,164	6	0.09%	1	0.01%	21	0.30%	14	0.20%	3	0.04%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	1	0.01%	1	0.01%	48	0.68%	22
7120Q/7121Q	Jan-09	139,515	62,431	107	0.08%	2	<0.01%	294	0.21%	142	0.10%	54	0.04%	16	0.01%	0	0.00%	7	<0.01%	11	< 0.01%	6	<0.01%	44	0.03%	683	0.49%	332
7122Q	Jan-09	143,710	79,881	189	0.13%	3	<0.01%	371	0.26%	193	0.13%	65	0.05%	14	< 0.01%	1	<0.01%	15	0.01%	13	< 0.01%	3	<0.01%	54	0.04%	921	0.64%	371
7120/7121	Sep-07	60,154	19,628	41	0.07%	2	<0.01%	70	0.12%	25	0.04%	51	0.08%	5	<0.01%	0	0.00%	2	<0.01%	21	0.03%	0	0.00%	21	0.03%	238	0.40%	93
7122	Sep-07	16,082	6,294	12	0.07%	1	<0.01%	24	0.15%	19	0.12%	13	0.08%	0	0.00%	1	<0.01%	3	0.02%	2	0.01%	2	0.01%	4	0.02%	81	0.50%	37
7070/7071	Jul-06	3,311	973	3	0.09%	1	0.03%	3	0.09%	6	0.18%	4	0.12%	3	0.09%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	20	0.60%	6
7020/7021	Jul-06	14,252	3,790	33	0.23%	0	0.00%	27	0.19%	17	0.12%	19	0.13%	8	0.06%	0	0.00%	2	0.01%	4	0.03%	3	0.02%	0	0.00%	113	0.79%	53
7022	Jul-06	1,472	391	5	0.34%	0	0.00%	3	0.20%	1	0.07%	0	0.00%	0	0.00%	0	0.00%	2	0.14%	0	0.00%	0	0.00%	0	0.00%	11	0.75%	4
7010/7011	Mar-06	2,200	498	3	0.14%	0	0.00%	1	0.05%	2	0.09%	2	0.09%	1	0.05%	0	0.00%	1	0.05%	0	0.00%	0	0.00%	1	0.05%	11	0.50%	4
7040/7041	Mar-06	4,057	962	4	0.10%	0	0.00%	5	0.12%	1	0.02%	3	0.07%	0	0.00%	0	0.00%	2	0.05%	0	0.00%	0	0.00%	1	0.02%	16	0.39%	3
7002	Jun-05	2,409	543	6	0.25%	0	0.00%	3	0.12%	4	0.17%	4	0.17%	0	0.00%	0	0.00%	2	0.08%	1	0.04%	0	0.00%	1	0.04%	21	0.87%	11
7000/7001	Jun-05	34,882	7,817	42	0.12%	0	0.00%	38	0.11%	43	0.12%	40	0.11%	7	0.02%	2	<0.01%	8	0.02%	4	0.01%	3	<0.01%	11	0.03%	198	0.57%	97

Chronic Complication Summary

>30 DAYS

	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US	CAR PERFO	DIAC RATION			LE DISLOD	AD GEMENT		IRE TO TURE	OVERS	ENSING		LURE ENSE		ATION	PAG	DRMAL CING DANCE	DEFIBRI	DRMAL		CARDIAC	от	HER	то	DTAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
LDA230Q	Feb-14	1,053	611	0	0.00%	0	0.00%	3	0.28%	5	0.47%	6	0.57%	1	0.09%	0	0.00%	1	0.09%	0	0.00%	0	0.00%	0	0.00%	16	1.52%	8
LDA220Q	Feb-14	12,207	7,809	4	0.03%	6	0.05%	75	0.61%	82	0.67%	61	0.50%	9	0.07%	2	0.02%	13	0.11%	19	0.16%	0	0.00%	4	0.03%	275	2.25%	77
LDA220	Feb-14	605	346	0	0.00%	0	0.00%	5	0.83%	3	0.50%	5	0.83%	0	0.00%	0	0.00%	3	0.50%	1	0.17%	0	0.00%	0	0.00%	17	2.81%	4
LDA210Q	Feb-14	54,674	37,033	23	0.04%	24	0.04%	318	0.58%	210	0.38%	171	0.31%	23	0.04%	2	<0.01%	42	0.08%	40	0.07%	5	<0.01%	31	0.06%	889	1.63%	325
LDA210	Feb-14	1,595	1,030	0	0.00%	2	0.13%	7	0.44%	11	0.69%	13	0.82%	0	0.00%	0	0.00%	4	0.25%	1	0.06%	1	0.06%	2	0.13%	41	2.57%	13
7170Q/7171Q	Jul-09	7,028	3,164	8	0.11%	31	0.44%	33	0.47%	80	1.14%	71	1.01%	1	0.01%	5	0.07%	23	0.33%	21	0.30%	0	0.00%	4	0.06%	277	3.94%	71
7120Q/7121Q	Jan-09	139,515	62,431	47	0.03%	261	0.19%	713	0.51%	1066	0.76%	1080	0.77%	103	0.07%	69	0.05%	233	0.17%	488	0.35%	10	<0.01%	104	0.07%	4174	2.99%	1221
7122Q	Jan-09	143,710	79,881	62	0.04%	114	0.08%	746	0.52%	774	0.54%	671	0.47%	67	0.05%	41	0.03%	145	0.10%	151	0.11%	11	<0.01%	103	0.07%	2885	2.01%	1022
7120/7121	Sep-07	60,154	19,628	18	0.03%	174	0.29%	190	0.32%	429	0.71%	880	1.46%	72	0.12%	76	0.13%	232	0.39%	345	0.57%	3	<0.01%	58	0.10%	2477	4.12%	625
7122	Sep-07	16,082	6,294	4	0.02%	47	0.29%	76	0.47%	118	0.73%	189	1.18%	13	0.08%	26	0.16%	53	0.33%	47	0.29%	2	0.01%	12	0.07%	587	3.65%	199
7070/7071	Jul-06	3,311	973	2	0.06%	28	0.85%	13	0.39%	40	1.21%	69	2.08%	3	0.09%	9	0.27%	16	0.48%	22	0.66%	1	0.03%	3	0.09%	206	6.22%	44
7020/7021	Jul-06	14,252	3,790	17	0.12%	67	0.47%	66	0.46%	182	1.28%	293	2.06%	22	0.15%	29	0.20%	62	0.44%	116	0.81%	2	0.01%	29	0.20%	885	6.21%	234
7022	Jul-06	1,472	391	3	0.20%	12	0.82%	11	0.75%	17	1.15%	33	2.24%	1	0.07%	10	0.68%	5	0.34%	5	0.34%	1	0.07%	3	0.20%	101	6.86%	35
7010/7011	Mar-06	2,200	498	3	0.14%	8	0.36%	8	0.36%	14	0.64%	58	2.64%	3	0.14%	47	2.14%	29	1.32%	22	1.00%	0	0.00%	3	0.14%	195	8.86%	46
7040/7041	Mar-06	4,057	962	3	0.07%	39	0.96%	5	0.12%	56	1.38%	114	2.81%	16	0.39%	64	1.58%	22	0.54%	34	0.84%	1	0.02%	10	0.25%	364	8.97%	81
7002	Jun-05	2,409	543	5	0.21%	11	0.46%	10	0.42%	27	1.12%	75	3.11%	3	0.12%	74	3.07%	5	0.21%	11	0.46%	0	0.00%	8	0.33%	229	9.51%	75
7000/7001	Jun-05	34,882	7,817	34	0.10%	186	0.53%	60	0.17%	396	1.14%	997	2.86%	66	0.19%	793	2.27%	138	0.40%	264	0.76%	6	0.02%	102	0.29%	3042	8.72%	818

U.S. Malfunction Summary

	REGISTERED	PERCENT RETURNED				ATION ACH		S, WELDS ONDS	от	HER		INSIC TORS	то	TAL
MODELS	US IMPLANTS	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
LDA230Q	1,053	4.30%	1	0.09%	3	0.28%	0	0.00%	0	0.00%	8	0.76%	12	1.14%
LDA220Q	12,207	4.20%	1	<0.01%	7	0.06%	0	0.00%	0	0.00%	73	0.60%	81	0.66%
LDA220	605	5.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	6	0.99%	6	0.99%
LDA210Q	54,674	3.90%	7	0.01%	17	0.03%	0	0.00%	5	<0.01%	311	0.57%	340	0.62%
LDA210	1,595	5.30%	0	0.00%	1	0.06%	0	0.00%	0	0.00%	15	0.94%	16	1.00%
7170Q/7171Q	7,028	5.80%	5	0.07%	15	0.21%	0	0.00%	0	0.00%	54	0.77%	74	1.05%
7120Q/7121Q	139,515	5.50%	35	0.03%	348	0.25%	2	<0.01%	38	0.03%	941	0.67%	1364	0.98%
7122Q	143,710	5.30%	18	0.01%	220	0.15%	0	0.00%	21	0.01%	871	0.61%	1130	0.79%
7120/7121	60,154	6.80%	34	0.06%	210	0.35%	1	<0.01%	9	0.01%	454	0.75%	708	1.18%
7122	16,082	9.90%	16	0.10%	73	0.45%	0	0.00%	4	0.02%	151	0.94%	244	1.52%
7070/7071	3,311	9.20%	2	0.06%	23	0.69%	0	0.00%	0	0.00%	23	0.69%	48	1.45%
7020/7021	14,252	8.20%	11	0.08%	65	0.46%	0	0.00%	0	0.00%	183	1.28%	259	1.82%
7022	1,472	11.70%	3	0.20%	13	0.88%	0	0.00%	0	0.00%	25	1.70%	41	2.79%
7010/7011	2,200	10.10%	3	0.14%	44	2.00%	0	0.00%	0	0.00%	13	0.59%	60	2.73%
7040/7041	4,057	9.30%	4	0.10%	69	1.70%	0	0.00%	0	0.00%	30	0.74%	103	2.54%
7002	2,409	11.40%	6	0.25%	81	3.36%	0	0.00%	0	0.00%	24	1.00%	111	4.61%
7000/7001	34,882	8.40%	25	0.07%	668	1.92%	1	<0.01%	1	<0.01%	337	0.97%	1032	2.96%
1590/1591	9,700	8.50%	8	0.08%	213	2.20%	0	0.00%	1	0.01%	59	0.61%	281	2.90%
1582	3,132	13.00%	3	0.10%	183	5.84%	0	0.00%	0	0.00%	35	1.12%	221	7.06%
1570/1571	10,279	9.70%	6	0.06%	275	2.68%	0	0.00%	0	0.00%	69	0.67%	350	3.41%
1580/1581	68,403	8.90%	34	0.05%	1959	2.86%	3	<0.01%	0	0.00%	578	0.84%	2574	3.76%

Definitions of malfunction categories can be found on pages 8-9.

Worldwide Malfunction Summary

	WORLDWIDE	PERCENT RETURNED				ATION ACH		S, WELDS ONDS	от	HER		INSIC TORS	то	TAL
MODELS	SALES	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
LDA230Q	1,090	4.13%	1	0.09%	3	0.28%	0	0.00%	0	0.00%	8	0.73%	12	1.10%
LDA220Q	17,097	3.12%	1	0.01%	7	0.04%	0	0.00%	1	0.01%	96	0.56%	105	0.61%
LDA210Q	97,462	2.26%	13	0.01%	37	0.04%	0	0.00%	11	0.01%	486	0.50%	547	0.56%
LDA210	1,743	4.82%	0	0.00%	1	0.06%	0	0.00%	0	0.00%	15	0.86%	16	0.92%
7170Q/7171Q	19,410	2.89%	11	0.06%	25	0.13%	2	0.01%	0	0.00%	86	0.44%	124	0.64%
7120Q/7121Q	242,271	3.78%	69	0.03%	464	0.19%	3	<0.01%	96	0.04%	1449	0.60%	2081	0.86%
7122Q	414,383	2.22%	61	0.01%	420	0.10%	2	<0.01%	147	0.04%	1986	0.48%	2616	0.63%
7120/7121	148,097	3.53%	119	0.08%	316	0.21%	1	<0.01%	25	0.02%	865	0.58%	1326	0.90%
7122	81,660	2.95%	120	0.15%	190	0.23%	1	<0.01%	24	0.03%	579	0.71%	914	1.12%

Definitions of malfunction categories can be found on pages 8-9.

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE	CUMULATIVE MONTHS OF	DEFIBR	ORMAL RILLATION	PA	ORMAL CING DANCE		NDIAC DRATION		OUCTOR		CARDIAC JLATION	1	ILURE TO PTURE		ILURE TO ENSE		ROPRIATE		LATION EACH		EAD DGEMENT	OVER	SENSING		ARDIAL		KIN DSION	тс	OTAL
MODELS		ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
7170Q/7171Q	115	0	7,749	0	0.00%	1	0.87%	0	0.00%	1	0.87%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.87%	0	0.00%	0	0.00%	0	0.00%	3	2.61%
7120Q/7121Q	4,322	0	275,708	5	0.12%	5	0.12%	1	0.02%	18	0.42%	0	0.00%	20	0.46%	5	0.12%	5	0.12%	5	0.12%	39	0.90%	8	0.19%	0	0.00%	0	0.00%	111	2.57%
7122Q	1,561	0	94,522	3	0.19%	0	0.00%	0	0.00%	4	0.26%	0	0.00%	7	0.45%	2	0.13%	0	0.00%	0	0.00%	7	0.45%	2	0.13%	2	0.13%	0	0.00%	27	1.73%
7120/7121	3,560	0	226,815	5	0.14%	11	0.31%	0	0.00%	17	0.48%	0	0.00%	15	0.42%	2	0.06%	2	0.06%	13	0.37%	20	0.56%	15	0.42%	0	0.00%	2	0.06%	102	2.87%
7122	457	0	31,078	1	0.22%	5	1.09%	0	0.00%	6	1.31%	0	0.00%	5	1.09%	1	0.22%	0	0.00%	1	0.22%	5	1.09%	3	0.66%	0	0.00%	0	0.00%	27	5.91%
7070/7071	288	0	19,238	1	0.35%	2	0.69%	1	0.35%	2	0.69%	0	0.00%	1	0.35%	0	0.00%	0	0.00%	0	0.00%	1	0.35%	1	0.35%	0	0.00%	0	0.00%	9	3.13%
7020/7021	1,469	0	88,681	0	0.00%	6	0.41%	1	0.07%	9	0.61%	0	0.00%	16	1.09%	1	0.07%	0	0.00%	2	0.14%	9	0.61%	6	0.41%	0	0.00%	1	0.07%	51	3.47%
7000/7001	180	0	8,340	0	0.00%	0	0.00%	0	0.00%	1	0.56%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.56%	1	0.56%	0	0.00%	0	0.00%	0	0.00%	3	1.67%
1580/1581	566	0	31,733	1	0.18%	0	0.00%	0	0.00%	3	0.53%	0	0.00%	1	0.18%	0	0.00%	0	0.00%	10	1.77%	2	0.35%	6	1.06%	0	0.00%	1	0.18%	24	4.24%

A list of complications can be found on page 12.

Actively Monitored Study Data Summary


MALFUNCTIONS

	NUMBER OF DEVICES	PERCENT				ATION ACH		S, WELDS DNDS	OT	HER		INSIC TORS	то	TAL
MODELS	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
7170Q/7171Q	115	7.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	1.74%	2	1.74%
7120Q/7121Q	4,322	7.00%	5	0.12%	12	0.28%	0	0.00%	1	0.02%	51	1.18%	69	1.60%
7122Q	1,561	7.40%	2	0.13%	5	0.32%	0	0.00%	0	0.00%	15	0.96%	22	1.41%
7120/7121	3,560	5.80%	1	0.03%	13	0.37%	0	0.00%	1	0.03%	29	0.81%	44	1.24%
7122	457	7.70%	2	0.44%	3	0.66%	0	0.00%	0	0.00%	8	1.75%	13	2.84%
7070/7071	288	3.80%	0	0.00%	1	0.35%	0	0.00%	0	0.00%	1	0.35%	2	0.69%
7020/7021	1,469	6.80%	3	0.20%	4	0.27%	0	0.00%	0	0.00%	15	1.02%	22	1.50%
7000/7001	180	8.90%	0	0.00%	5	2.78%	1	0.56%	0	0.00%	0	0.00%	6	3.33%
1580/1581	566	9.00%	1	0.18%	24	4.24%	0	0.00%	0	0.00%	7	1.24%	32	5.65%

Definitions of malfunction categories can be found on pages 8-9.

CUSTOMER REPORTED PERFORMANCE DATA

Assurity MRI™ MODEL PM2272			W/ COM	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	January 2017	Electrical Component	2	<0.01%	11	<0.01%
Registered US Implants	281,757	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	219,635	Battery	0	0.00%	0	0.00%
Estimated Longevity	9.4 Years	Software/Firmware	1	<0.01%	32	0.01%
Normal Battery Depletion	40	Mechanical	16	<0.01%	134	0.05%
Number of US Advisories (see pgs. 312, 314)	Two	Possible Early Battery Depletion	0	0.00%	1	<0.01%
		Other	1	<0.01%	4	<0.01%
		Total	20	<0.01%	182	0.06%



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	AT 59 MONTHS
SURVIVAL PROBABILITY	99.97%	99.90%	99.75%	99.29%	98.88%
±1 STANDARD ERROR	0.00%	0.01%	0.01%	0.03%	0.07%
SAMPLE SIZE	237,060	160,340	100,200	50,060	1,000

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	AT 59 MONTHS
SURVIVAL PROBABILITY	99.98%	99.91%	99.80%	99.41%	99.08%
±1 STANDARD ERROR	0.00%	0.01%	0.01%	0.03%	0.05%

CUSTOMER REPORTED PERFORMANCE DATA

Endurity™ DR MODEL PM2160			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2014	Electrical Component	0	0.00%	0	0.00%
Registered US Implants	9,376	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	5,326	Battery	0	0.00%	0	0.00%
Estimated Longevity	9.7 Years	Software/Firmware	0	0.00%	0	0.00%
Normal Battery Depletion	26	Mechanical	0	0.00%	8	0.09%
Number of US Advisories (see pg. 312)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	2	0.02%
		Total	0	0.00%	10	0.11%



INCLUDING NORMAL BATTERY DEPLETION


YEAR	1	2	3	4	5	6	7	AT 91 MONTHS
SURVIVAL PROBABILITY	99.82%	99.77%	99.74%	99.65%	99.55%	99.13%	98.37%	98.26%
±1 STANDARD ERROR	0.04%	0.05%	0.05%	0.06%	0.08%	0.12%	0.17%	0.22%
SAMPLE SIZE	8,870	7,990	7,270	6,610	5,900	4,900	3,080	240

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	1	2	3	4	5	6	7	AT 91 MONTHS
SURVIVAL PROBABILITY	99.85%	99.82%	99.82%	99.79%	99.79%	99.79%	99.65%	99.65%
±1 STANDARD ERROR	0.04%	0.04%	0.04%	0.05%	0.05%	0.05%	0.09%	0.09%

CUSTOMER REPORTED PERFORMANCE DATA

Assurity™ DR RF MODEL PM2240	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2014	Electrical Component	5	<0.01%	18	<0.01%
Registered US Implants	184,596	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	109,208	Battery	0	0.00%	0	0.00%
Estimated Longevity	9.4 Years	Software/Firmware	1	<0.01%	21	0.01%
Normal Battery Depletion	397	Mechanical	64	0.03%	277	0.15%
Number of US Advisories (see pgs. 312, 314)	Two	Possible Early Battery Depletion	3	< 0.01%	4	<0.01%
		Other	0	0.00%	9	<0.01%
		Total	73	0.04%	329	0.18%



YEARS	AFTER	IMPL	AN.
-------	-------	------	-----

INCLUDING NORMAL BATTERY DEPLETION	
------------------------------------	--


YEAR	1	2	3	4	5	6	7	AT 92 MONTHS
SURVIVAL PROBABILITY	99.95%	99.91%	99.83%	99.55%	98.99%	98.27%	97.44%	97.27%
±1 STANDARD ERROR	0.01%	0.01%	0.01%	0.02%	0.03%	0.04%	0.07%	0.08%
SAMPLE SIZE	174,610	157,000	141,970	126,280	105,160	71,170	31,510	450

EXCLUDING NORMAL BATTERY DEPLETION	_
------------------------------------	---

YEAR	1	2	3	4	5	6	7	AT 92 MONTHS
SURVIVAL PROBABILITY	99.96%	99.93%	99.89%	99.73%	99.42%	99.11%	98.91%	98.91%
± 1 STANDARD ERROR	0.00%	0.01%	0.01%	0.01%	0.02%	0.03%	0.04%	0.04%

CUSTOMER REPORTED PERFORMANCE DATA

Accent [™] DR RF MODEL PM2210				NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY	
			QTY	RATE	QTY	RATE
US Regulatory Approval	July 2009	Electrical Component	17	<0.01%	50	0.02%
Registered US Implants	243,113	Electrical Interconnect	8	<0.01%	33	0.01%
Estimated Active US Implants	81,556	Battery	0	0.00%	0	0.00%
Estimated Longevity	8 Years	Software/Firmware	0	0.00%	5	<0.01%
Normal Battery Depletion	1,625	Mechanical	1	<0.01%	22	<0.01%
Number of US Advisories (see pgs. 314, 316)	Two	Possible Early Battery Depletion	7	<0.01%	23	<0.01%
		Other	5	<0.01%	45	0.02%
		Total	38	0.02%	178	0.07%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.86%	99.60%	98.64%	96.92%	96.51%	96.20%	96.20%
±1 STANDARD ERROR	0.01%	0.01%	0.03%	0.05%	0.05%	0.07%	0.07%
SAMPLE SIZE	203,450	166,600	138,420	106,530	46,190	8,430	380

EXCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	AT 149 MONTHS
SURVIVAL PROBABILITY	99.90%	99.79%	99.74%	99.72%	99.70%	99.69%	99.69%
±1 STANDARD ERROR	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0.02%

July 2009

1,773

59,887

8 Years

0

ACTIVELY MONITORED STUDY DATA

Accent[™] DR RF MODEL PM2210

US Regulatory Approval

Estimated Longevity

SAMPLE SIZE


Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

QUALIFYING COMPLICATIONS	QTY	RATE
Premature Battery Depletion	1	0.06%
Skin Erosion	1	0.06%

	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	1	0.06%
Electrical Interconnect	0	0.00%	1	0.06%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	0	0.00%	0	0.00%
Total	0	0.00%	2	0.11%



380

320

260

220

160

60

1,540


1,060

650

450

CUSTOMER REPORTED PERFORMANCE DATA

Accent [™] DR MODEL PM2110			W/ COM	INCTIONS IPROMISED ERAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	July 2009	Electrical Component	2	< 0.01%	3	<0.01%	
Registered US Implants	48,912	Electrical Interconnect	2	< 0.01%	0	0.00%	
Estimated Active US Implants	18,009	Battery	0	0.00%	0	0.00%	
Estimated Longevity	9.2 Years	Software/Firmware	0	0.00%	3	<0.01%	
Normal Battery Depletion	301	Mechanical	0	0.00%	5	0.01%	
Number of US Advisories (see pg. 316)	One	Possible Early Battery Depleti	on 0	0.00%	2	< 0.01%	
		Other	0	0.00%	0	0.00%	
		Total	4	<0.01%	13	0.03%	



YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	AT 143 MONTHS
SURVIVAL PROBABILITY	99.89%	99.61%	98.73%	97.33%	97.18%	96.94%
± 1 STANDARD ERROR	0.02%	0.03%	0.06%	0.10%	0.10%	0.12%
SAMPLE SIZE	40,860	33,380	27,940	21,830	9,690	250

YEAR	2	4	6	8	10	AT 143 MONTHS
SURVIVAL PROBABILITY	99.95%	99.93%	99.90%	99.90%	99.90%	99.90%
±1 STANDARD ERROR	0.01%	0.01%	0.02%	0.02%	0.02%	0.02%

ACTIVELY MONITORED STUDY DATA

Accent[™] DR MODEL PM2110

		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	June 2013	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	228		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	10,196		Software/Firmware	0	0.00%	0	0.00%
Estimated Longevity	9.2 Years		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	0	0.00%	0	0.00%

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0

0.00%

0


0.00%



ACTIVELY MONITORED STUDY DATA								
YEAR	1	2	3	4	5	6	AT 81 MONTHS	
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
±1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
SAMPLE SIZE	210	160	100	90	80	70	50	

CUSTOMER REPORTED PERFORMANCE DATA

Zephyr™ DR MODEL 5820		MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2007	Electrical Component	2	<0.01%	36	0.07%
Registered US Implants	54,402	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	11,453	Battery	0	0.00%	0	0.00%
Estimated Longevity	6.5 Years	Software/Firmware	0	0.00%	9	0.02%
Normal Battery Depletion	2,431	Mechanical	0	0.00%	2	<0.01%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	1	<0.01%
		Other	0	0.00%	92	0.17%
		Total	2	<0.01%	140	0.26%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 171 MONTHS
SURVIVAL PROBABILITY	99.75%	93.84%	79.59%	78.60%	78.48%	78.48%	78.48%	78.48%
±1 STANDARD ERROR	0.02%	0.12%	0.23%	0.24%	0.24%	0.24%	0.24%	0.24%
SAMPLE SIZE	42,580	31,890	20,870	12,620	7,650	3,820	840	200


YEAR	2	4	6	8	10	12	14	AT 171 MONTHS
SURVIVAL PROBABILITY	99.96%	99.65%	99.01%	98.63%	98.54%	98.54%	98.54%	98.54%
±1 STANDARD ERROR	0.01%	0.03%	0.06%	0.08%	0.08%	0.08%	0.08%	0.08%

ACTIVELY MONITORED STUDY DATA

Zephyr[™] DR MODEL 5820

		QUALIFYING COMPLICATIONS	QTY	RATE
US Regulatory Approval	March 2007	Skin Erosion	1	0.35%
Number of Devices Enrolled in Study	284			
Active Devices Enrolled in Study	0			
Cumulative Months of Follow-up	7,986			
Estimated Longevity	6.5 Years			


	MALFUNCTIONS W/ COMPROMISED THERAPY		W/O COM	NCTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	0	0.00%
Electrical Interconnect	0	0.00%	0	0.00%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	0	0.00%
Other	0	0.00%	0	0.00%
Total	0	0.00%	0	0.00%



ACTIVELY MONITORED ST	ACTIVELY MONITORED STUDY DATA								
YEAR	1	2	3	AT 41 MONTHS					
SURVIVAL PROBABILITY	99.62%	99.62%	99.62%	99.62%					
± 1 STANDARD ERROR	0.38%	0.38%	0.38%	0.38%					
SAMPLE SIZE	260	200	120	50					

CUSTOMER REPORTED PERFORMANCE DATA

Victory™ DR MODEL 5810			W/ COM	NCTIONS PROMISED ERAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	December 2005	Electrical Component	1	< 0.01%	89	0.34%	
Registered US Implants	26,313	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	2,174	Battery	0	0.00%	0	0.00%	
Estimated Longevity	6.5 Years	Software/Firmware	0	0.00%	8	0.03%	
Normal Battery Depletion	2,778	Mechanical	0	0.00%	2	<0.01%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	17	0.06%	
		Other	0	0.00%	37	0.14%	
		Total	1	<0.01%	153	0.58%	




YEAR	2	4	6	8	10	12	14	AT 185 MONTHS
SURVIVAL PROBABILITY	99.75%	88.83%	50.06%	42.87%	42.52%	42.48%	42.48%	42.48%
± 1 STANDARD ERROR	0.03%	0.24%	0.44%	0.46%	0.46%	0.46%	0.46%	0.46%
SAMPLE SIZE	20,520	14,170	7,010	3,360	2,560	2,250	1,470	220

EXCLUDING NORMAL	BATTERY	DEPLETION

YEAR	2	4	6	8	10	12	14	AT 185 MONTHS
SURVIVAL PROBABILITY	99.93%	99.15%	97.17%	96.14%	95.78%	95.78%	95.78%	95.78%
± 1 STANDARD ERROR	0.02%	0.07%	0.16%	0.23%	0.25%	0.25%	0.25%	0.25%

CUSTOMER REPORTED PERFORMANCE DATA

Zephyr™ XL DR MODEL 5826	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2007	Electrical Component	1	<0.01%	25	0.02%
Registered US Implants	112,303	Electrical Interconnect	4	<0.01%	0	0.00%
Estimated Active US Implants	21,537	Battery	0	0.00%	0	0.00%
Estimated Longevity	11.7 Years	Software/Firmware	0	0.00%	16	0.01%
Normal Battery Depletion	679	Mechanical	1	<0.01%	9	< 0.01%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	3	< 0.01%
		Other	2	<0.01%	157	0.14%
		Total	8	<0.01%	210	0.19%





YEAR	2	4	6	8	10	12	14	AT 174 MONTHS
SURVIVAL PROBABILITY	99.84%	99.48%	98.12%	96.96%	96.09%	95.20%	95.14%	95.14%
±1 STANDARD ERROR	0.01%	0.02%	0.05%	0.07%	0.09%	0.11%	0.11%	0.11%
SAMPLE SIZE	91,490	71,950	56,670	39,710	26,230	17,490	4,190	260

EXCLUDING NORMAL BATTERY DEPLETIO)N 🕳
-----------------------------------	------

YEAR	2	4	6	8	10	12	14	AT 174 MONTHS
SURVIVAL PROBABILITY	99.93%	99.89%	99.76%	99.29%	98.99%	98.79%	98.75%	98.75%
± 1 STANDARD ERROR	0.01%	0.01%	0.02%	0.04%	0.05%	0.06%	0.06%	0.06%

March 2007

1,516

48,121

11.7 Years

0

ACTIVELY MONITORED STUDY DATA

Zephyr[™] XL DR **MODEL 5826**

US Regulatory Approval

Estimated Longevity


Number of Devices Enrolled in Study

Active Devices Enrolled in Study

Cumulative Months of Follow-up

QUALIFYING	COMPLICATIONS
------------	---------------


		MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISED THERAPY	
QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
None Reported	Electrical Component	0	0.00%	1	0.07%
	Electrical Interconnect	0	0.00%	0	0.00%
	Battery	0	0.00%	0	0.00%
	Software/Firmware	0	0.00%	0	0.00%
	Mechanical	0	0.00%	0	0.00%
	Possible Early Battery Depletion	0	0.00%	0	0.00%
	Other	0	0.00%	0	0.00%
	Total	0	0.00%	1	0.07%



ACTIVELY MONITORED STUDY DATA									
YEAR	1	2	3	4	AT 49 MONTHS				
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%	100.00%				
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%	0.00%				
SAMPLE SIZE	1,440	1,270	900	350	70				

CUSTOMER REPORTED PERFORMANCE DATA

Victory™ XL DR MODEL 5816	MALFUNCTIONS W/ COMPROMISED THERAPY		MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	December 2005	Electrical Component	2	<0.01%	31	0.05%
Registered US Implants	62,724	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	8,207	Battery	0	0.00%	0	0.00%
Estimated Longevity	11.7 Years	Software/Firmware	0	0.00%	8	0.01%
Normal Battery Depletion	1,514	Mechanical	0	0.00%	9	0.01%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	5	<0.01%
		Other	1	<0.01%	92	0.15%
		Total	3	<0.01%	145	0.23%



YEARS AFTER IMPL	AN
------------------	----

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 188 MONTHS
SURVIVAL PROBABILITY	99.83%	99.30%	93.90%	87.03%	86.03%	85.56%	85.34%	85.26%
± 1 STANDARD ERROR	0.02%	0.04%	0.13%	0.20%	0.21%	0.22%	0.22%	0.23%
SAMPLE SIZE	51,370	39,650	30,240	19,590	12,870	9,720	6,060	210

YEAR	2	4	6	8	10	12	14	AT 188 MONTHS
SURVIVAL PROBABILITY	99.95%	99.85%	99.73%	99.15%	98.67%	98.38%	98.30%	98.26%
±1 STANDARD ERROR	0.01%	0.02%	0.03%	0.06%	0.08%	0.10%	0.10%	0.11%

ACTIVELY MONITORED STUDY DATA

Victory[™] XL DR MODEL 5816

		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	December 2005	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	332		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	10,615		Software/Firmware	0	0.00%	0	0.00%
Estimated Longevity	11.7 Years		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%

Other

Total

MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0.00%

0.00%

0


0

0

0

0.00%

0.00%




ACTIVELY MONITORED STUDY DATA										
YEAR	1	2	3	AT 45 MONTHS						
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%						
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%						
SAMPLE SIZE	320	280	200	50						

CUSTOMER REPORTED PERFORMANCE DATA

Verity ADx[™] XL DR MODEL 5356 Verity ADx[™] XL DR M/S MODEL 5357M/S Verity ADx[™] XL DC MODEL 5256

US Regulatory Approval	May 2003
Registered US Implants	17,396
Estimated Active US Implants	2,382
Estimated Longevity	6.9 Years
Normal Battery Depletion	314
Number of US Advisories	None

	W/ COM	NCTIONS PROMISED RAPY	W/O COM	ACTIONS PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	0	0.00%	11	0.06%
Electrical Interconnect	1	< 0.01%	0	0.00%
Battery	0	0.00%	1	< 0.01%
Software/Firmware	0	0.00%	0	0.00%
Mechanical	0	0.00%	0	0.00%
Possible Early Battery Depletion	0	0.00%	1	< 0.01%
Other	0	0.00%	10	0.06%
Total	1	<0.01%	23	0.13%




SURVIVAL PROBABILITY	99.83%	99.46%	96.74%	91.75%	89.14%	88.09%	87.88%	87.24%	87.24%
±1 STANDARD ERROR	0.03%	0.07%	0.18%	0.32%	0.38%	0.41%	0.42%	0.47%	0.47%
SAMPLE SIZE	14,030	10,720	7,930	5,820	4,270	3,090	2,150	1,030	220

YEAR	2	4	6	8	10	12	14	16	AT 208 MONTHS
SURVIVAL PROBABILITY	99.95%	99.91%	99.81%	99.78%	99.64%	99.15%	99.08%	98.85%	98.85%
±1 STANDARD ERROR	0.02%	0.03%	0.04%	0.05%	0.07%	0.14%	0.15%	0.22%	0.22%

CUSTOMER REPORTED PERFORMANCE DATA

Integrity ADx™ DR MODEL 5366			W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	May 2003	Electrical Component	0	0.00%	9	0.11%	
Registered US Implants	8,087	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	737	Battery	0	0.00%	0	0.00%	
Estimated Longevity	6.9 Years	Software/Firmware	0	0.00%	2	0.02%	
Normal Battery Depletion	322	Mechanical	0	0.00%	1	0.01%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	1	0.01%	
		Other	0	0.00%	14	0.17%	
		Total	0	0.00%	27	0.33%	




INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 200 MONTHS
SURVIVAL PROBABILITY	99.94%	99.42%	95.19%	82.80%	73.99%	72.34%	72.01%	72.01%	72.01%
±1 STANDARD ERROR	0.03%	0.10%	0.32%	0.63%	0.81%	0.85%	0.86%	0.86%	0.86%
SAMPLE SIZE	6,650	5,140	3,860	2,720	1,600	1,010	800	410	210

YEAR	2	4	6	8	10	12	14	16	AT 200 MONTHS
SURVIVAL PROBABILITY	100.00%	99.96%	99.91%	99.59%	98.53%	97.02%	96.58%	96.58%	96.58%
±1 STANDARD ERROR	0.00%	0.03%	0.03%	0.11%	0.27%	0.45%	0.50%	0.50%	0.50%

CUSTOMER REPORTED PERFORMANCE DATA

Identity ADx[™] DR MALFUNCTIONS W/ COMPROMISED THERAPY MALFUNCTIONS W/O COMPROMISED THERAPY **MODEL 5380** QTY RATE QTY Electrical Component US Regulatory Approval March 2003 4 < 0.01% 262 Registered US Implants 54,050 Electrical Interconnect < 0.01% 0 1 Battery 0.00% 0 Estimated Active US Implants 2,391 0 Estimated Longevity 3.8 Years Software/Firmware 0 0.00% 2 Normal Battery Depletion Mechanical 0.00% 6 6,222 0 Number of US Advisories One Possible Early Battery Depletion 0.00% 11 0 Other 0.00% 17 0 Total < 0.01% 298 5



RATE

0.48%

0.00%

0.00%

< 0.01%

0.01%

0.02%

0.03%

0.55%

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 212 MONTHS
SURVIVAL PROBABILITY	99.44%	91.66%	46.46%	28.40%	27.80%	27.80%	27.80%	27.80%	27.80%
±1 STANDARD ERROR	0.03%	0.15%	0.33%	0.33%	0.33%	0.33%	0.33%	0.33%	0.33%
SAMPLE SIZE	42,570	29,620	12,430	4,580	3,060	2,580	2,150	1,360	220

YEAR	2	4	6	8	10	12	14	16	AT 212 MONTHS
SURVIVAL PROBABILITY	99.93%	99.22%	96.69%	96.16%	95.93%	95.93%	95.93%	95.93%	95.93%
±1 STANDARD ERROR	0.01%	0.05%	0.13%	0.16%	0.18%	0.18%	0.18%	0.18%	0.18%

CUSTOMER REPORTED PERFORMANCE DATA


Identity ADx[™] XL DR MODEL 5386 Identity ADx[™] XL DC MODEL 5286

US Regulatory Approval	March 2003
Registered US Implants	67,419
Estimated Active US Implants	6,563
Estimated Longevity	6.9 Years
Normal Battery Depletion	3,334
Number of US Advisories	One

		PROMISED RAPY		PROMISED RAPY
	QTY	RATE	QTY	RATE
Electrical Component	2	<0.01%	136	0.20%
Electrical Interconnect	0	0.00%	2	< 0.01%
Battery	0	0.00%	0	0.00%
Software/Firmware	0	0.00%	7	0.01%
Mechanical	0	0.00%	10	0.01%
Possible Early Battery Depletion	0	0.00%	6	< 0.01%
Other	0	0.00%	113	0.17%
Total	2	<0.01%	274	0.41%

MALFUNCTIONS

MALFUNCTIONS



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 214 MONTHS
SURVIVAL PROBABILITY	99.77%	99.21%	94.55%	78.00%	68.08%	67.06%	66.50%	66.44%	66.25%
±1 STANDARD ERROR	0.02%	0.04%	0.11%	0.24%	0.29%	0.30%	0.31%	0.31%	0.32%
SAMPLE SIZE	55,540	43,040	32,200	22,420	12,760	8,240	5,730	3,000	220

YEAR	2	4	6	8	10	12	14	16	AT 214 MONTHS
SURVIVAL PROBABILITY	99.90%	99.85%	99.69%	98.99%	97.18%	96.45%	96.21%	96.17%	95.98%
±1 STANDARD ERROR	0.01%	0.02%	0.03%	0.06%	0.12%	0.15%	0.16%	0.17%	0.21%

ACTIVELY MONITORED STUDY DATA

Identity ADx[™] XL DR **MODEL 5386**

		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	March 2003	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	101		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	3,221		Software/Firmware	0	0.00%	0	0.00%
Estimated Longevity	6.9 Years		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	0	0.00%	0	0.00%

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0

0.00%

0

0.00%



ACTIVELY MONITORED ST			
YEAR	1	2	AT 34 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%
±1 STANDARD ERROR	0.00%	0.00%	0.00%
SAMPLE SIZE	100	80	50

SUMMARY INFORMATION Dual-Chamber Pacemakers

Survival Probability Summary

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM2272	Assurity MRI [~]	99.97%	99.90%	99.75%	99.29%						
PM2160	Endurity [®] DR	99.82%	99.77%	99.74%	99.65%	99.55%	99.13%	98.37%			
PM2240	Assurity" DR RF	99.95%	99.91%	99.83%	99.55%	98.99%	98.27%	97.44%			
PM2210	Accent DR RF	99.92%	99.86%	99.77%	99.60%	99.31%	98.64%	97.03%	96.92%	96.80%	96.51%
PM2110	Accent [®] DR	99.94%	99.89%	99.81%	99.61%	99.38%	98.73%	97.41%	97.33%	97.31%	97.18%
5820	Zephyr [®] DR	99.85%	99.75%	99.02%	93.84%	82.37%	79.59%	78.90%	78.60%	78.54%	78.48%
5810	Victory [®] DR	99.87%	99.75%	98.64%	88.83%	66.23%	50.06%	43.64%	42.87%	42.67%	42.52%
5826	Zephyr ̈ XL DR	99.91%	99.84%	99.74%	99.48%	98.78%	98.12%	97.63%	96.96%	96.43%	96.09%
5816	Victory XL DR	99.91%	99.83%	99.65%	99.30%	97.97%	93.90%	88.46%	87.03%	86.35%	86.03%
5356/5357/5256	Verity $ADx^{*} XL DR/DR(M/S) / DC$	99.89%	99.83%	99.69%	99.46%	98.82%	96.74%	94.42%	91.75%	89.68%	89.14%
5366	Integrity ADx" XL DR	100.00%	99.94%	99.56%	99.42%	98.59%	95.19%	90.12%	82.80%	76.59%	73.99%
5380	Identity ADx DR	99.76%	99.44%	98.17%	91.66%	68.59%	46.46%	32.94%	28.40%	27.88%	27.80%
5386/5286	Identity ADx" XL DR/DC	99.88%	99.77%	99.57%	99.21%	98.28%	94.55%	88.19%	78.00%	70.31%	68.08%

Survival Probability Summary

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM2272	Assurity MRI [~]	99.98%	99.91%	99.80%	99.41%						
PM2160	Endurity [*] DR	99.85%	99.82%	99.82%	99.79%	99.79%	99.79%	99.65%			
PM2240	Assurity" DR RF	99.96%	99.93%	99.89%	99.73%	99.42%	99.11%	98.91%			
PM2210	Accent DR RF	99.95%	99.90%	99.85%	99.79%	99.76%	99.74%	99.72%	99.72%	99.71%	99.70%
PM2110	Accent [®] DR	99.97%	99.95%	99.93%	99.93%	99.93%	99.90%	99.90%	99.90%	99.90%	99.90%
5820	Zephyr [°] DR	99.97%	99.96%	99.92%	99.65%	99.26%	99.01%	98.80%	98.63%	98.57%	98.54%
5810	Victory DR	99.98%	99.93%	99.68%	99.15%	97.61%	97.17%	96.58%	96.14%	95.93%	95.78%
5826	Zephyr [°] XL DR	99.96%	99.93%	99.91%	99.89%	99.83%	99.76%	99.56%	99.29%	99.11%	98.99%
5816	Victory XL DR	99.97%	99.95%	99.91%	99.85%	99.81%	99.73%	99.44%	99.15%	98.79%	98.67%
5356/5357/5256	Verity ADx [*] XL DR/DR(M/S) / DC	99.96%	99.95%	99.93%	99.91%	99.89%	99.81%	99.81%	99.78%	99.74%	99.64%
5366	Integrity ADx [®] XL DR	100.00%	100.00%	99.96%	99.96%	99.96%	99.91%	99.66%	99.59%	99.29%	98.53%
5380	Identity ADx [~] DR	99.96%	99.93%	99.74%	99.22%	97.58%	96.69%	96.55%	96.16%	96.05%	95.93%
5386/5286	Identity ADx " XL DR/DC	99.92%	99.90%	99.87%	99.85%	99.77%	99.69%	99.53%	98.99%	98.09%	97.18%

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		TRICAL		TRICAL CONNECT	BAT	TERY		WARE/	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	тс	DTAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2272	Assurity MRI ⁻	281,757	2.10%	2	<0.01%	0	0.00%	0	0.00%	1	<0.01%	16	<0.01%	0	0.00%	1	<0.01%	20	<0.01%
PM2160	Endurity [®] DR	9,376	4.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM2240	Assurity" DR RF	184,596	4.90%	5	<0.01%	0	0.00%	0	0.00%	1	<0.01%	64	0.03%	3	<0.01%	0	0.00%	73	0.04%
PM2210	Accent DR RF	243,113	12.00%	17	<0.01%	8	<0.01%	0	0.00%	0	0.00%	1	<0.01%	7	<0.01%	5	<0.01%	38	0.02%
PM2110	Accent DR	48,912	10.10%	2	<0.01%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	<0.01%
5820	Zephyr ⁻ DR	54,402	16.20%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%
5810	Victory DR	26,313	19.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
5826	Zephyr [®] XL DR	112,303	19.00%	1	<0.01%	4	<0.01%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	2	<0.01%	8	<0.01%
5816	Victory XL DR	62,724	20.90%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	3	<0.01%
5356/5357/5256	Verity ADx [°] XL DR/ DR(M/S) / DC	17,396	11.90%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
5366	Integrity ADx XL DR	8,087	19.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5380	Identity ADx" DR	54,050	16.20%	4	<0.01%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	5	<0.01%
5386/5286	Identity ADx " XL DR/DC	67,419	19.60%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%

Definitions of malfunction categories can be found on pages 5-6.

US Malfunction Summary

WITHOUT COMPROMISED THERAPY

MODELSMAMILYMAMILYSSQMRATEQTRATE			REGISTERED	PERCENT RETURNED FOR		TRICAL		TRICAL	BAT	TERY		WARE/ WARE	MECH	IANICAL	BA	BLE EARLY TTERY LETION	01	THER	то	TAL
PM2160 Endury DR 9,376 440% 0 0.00% 0 0.00% 2 0.00% 2 0.02% 10 PM2240 Assurity DR RF 184,596 4.90% 18 <0.01% 0 0.00% 21 0.01% 277 0.15% 4 <0.01% 9 <0.01% 329 0 PM2240 Ascent' DR RF 243,113 12.00% 58 <0.01% 52 <0.01% 23 <0.01% 45 0.02% 178 0 PM210 Accent' DR RF 243,113 12.00% 3 <0.01% 0 0.00% 3 <0.01% 52 <0.01% 23 <0.01% 45 0.02% 16 0.01% 3 <0.01% 53 <0.01% 52 <0.01% 52 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% 53 <0.01% </th <th>MODELS</th> <th>FAMILY</th> <th></th> <th></th> <th>QTY</th> <th>RATE</th>	MODELS	FAMILY			QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2240 Assurity DR RF 184,596 4.90% 18 <0.01% 0 0.00% 21 0.01% 277 0.15% 4 <0.01% 9 <0.01% 329 0 PM2240 Accent DR RF 243,113 12.00% 50 0.02% 33 0.01% 0 0.00% 5 <0.01% 22 <0.01% 23 <0.01% 45 0.02% 329 0 PM210 Accent DR RF 243,113 12.00% 50 0.02% 33 0.01% 0 0.00% 5 <0.01% 22 <0.01% 23 <0.01% 45 0.02% 18 0.01% 0 0.00% 0 0.00% 3 <0.01% 22 <0.01% 23 <0.01% 45 0.01% 45 0.01% 45 0.01% 45 0.01% 45 0.01% 45 0.01% 45 0.01% 45 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% <	PM2272	Assurity MRI ⁻	281,757	2.10%	11	<0.01%	0	0.00%	0	0.00%	32	0.01%	134	0.05%	1	<0.01%	4	<0.01%	182	0.06%
PM2210Accent DR RF243,11312.00%500.02%330.01%00.00%5 $<0.01\%$ 22 $<0.01\%$ 23 $<0.01\%$ 450.02%1780PM210Accent DR48.91210.10%3 $<0.01\%$ 00.00%00.00%3 $<0.01\%$ 50.01%22 $<0.01\%$ 23 $<0.01\%$ 450.02%130S820Zephyr DR54.40216.20%360.07%00.00%00.00%90.02%2 $<0.01\%$ 1 $<0.01\%$ 920.11%1400S820Zephyr DR26.31319.00%890.34%00.00%00.00%80.03%2 $<0.01\%$ 1 $<0.01\%$ 920.01%170.06%370.14%1530S820Zephyr XL DR11.30319.00%250.02%00.00%160.01%9 $<0.01\%$ 170.06%370.14%1530S826Zephyr XL DR11.30319.00%250.02%00.00%160.01%90.01%3 $<0.01\%$ 170.06%370.14%160S826Zephyr XL DR11.30319.00%250.02%00.00%80.01%90.01%50.01%130.01%140.14%140.16%140S356/5357/525 $Cr(M/S)/DC$ 1.02%/NCR <t< td=""><td>PM2160</td><td>Endurity⁻ DR</td><td>9,376</td><td>4.40%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>8</td><td>0.09%</td><td>0</td><td>0.00%</td><td>2</td><td>0.02%</td><td>10</td><td>0.11%</td></t<>	PM2160	Endurity ⁻ DR	9,376	4.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	8	0.09%	0	0.00%	2	0.02%	10	0.11%
PM210Accent DR48,91210.0%3 $<0.01\%$ 00.00%00.00%3 $<0.01\%$ 50.01%2 $<0.01\%$ 00.00%1305820Zephyr DR54,40216.20%360.07%00.00%00.00%90.02%2 $<0.01\%$ 1 $<0.01\%$ 920.17%14005810Victory DR26,31319.00%890.34%00.00%00.00%80.03%2 $<0.01\%$ 170.06%370.14%15305826Zephyr XL DR11,23319.00%250.02%00.00%160.01%9 $<0.01\%$ 3 $<0.01\%$ 1570.14%1605816Victory XL DR62,72420.90%310.05%00.00%00.00%80.01%90.01%5 $<0.01\%$ 100.16%140.16%1405366/5357/526Victory AL DR8.08719.0%90.11%00.00%00.00%20.00%10.01%1 $<0.01\%$ 100.06%230.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%10.01%1 <t< td=""><td>PM2240</td><td>Assurity" DR RF</td><td>184,596</td><td>4.90%</td><td>18</td><td><0.01%</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>21</td><td>0.01%</td><td>277</td><td>0.15%</td><td>4</td><td><0.01%</td><td>9</td><td><0.01%</td><td>329</td><td>0.18%</td></t<>	PM2240	Assurity" DR RF	184,596	4.90%	18	<0.01%	0	0.00%	0	0.00%	21	0.01%	277	0.15%	4	<0.01%	9	<0.01%	329	0.18%
5820Zephyr DR54,40216.20%36 $0.07%$ 0 $0.00%$ 0 $0.00%$ 9 $0.02%$ 2 $<0.01%$ 1 $<0.01%$ 92 $0.17%$ 140 00 5810Victory DR26.31319.00%89 $0.34%$ 0 $0.00%$ 0 $0.00%$ 8 $0.03%$ 2 $<0.01%$ 17 $0.06%$ 37 $0.14%$ 153 00 5826Zephyr XL DR11,2.0319.00%25 $0.02%$ 0 $0.00%$ 0 $0.00%$ 16 $0.01%$ 9 $<0.01%$ 3 $<0.01%$ 157 $0.14%$ 210 00 5816Victory XL DR 62.724 $20.90%$ 31 $0.05%$ 0 $0.00%$ 0 $0.00%$ 9 $0.01%$ 9 $<0.01%$ 9 $0.01%$ 9 $0.01%$ 9 $0.01%$ 9 $0.01%$ 9 $0.01%$ 10 $0.06%$ 23 $0.01%$ 10 $0.01%$ 9 $0.01%$ 10	PM2210	Accent DR RF	243,113	12.00%	50	0.02%	33	0.01%	0	0.00%	5	<0.01%	22	<0.01%	23	<0.01%	45	0.02%	178	0.07%
5810 Victory DR 26,313 19.00% 89 0.34% 0 0.00% 0 0.00% 8 0.03% 2 <0.01% 17 0.06% 37 0.14% 153 0 5810 Victory DR 26,313 19.00% 25 0.02% 0 0.00% 0 0.00% 16 0.01% 9 <0.01% 33 <0.01% 153 0.14% 153 0 5826 Zephyr XL DR 112,303 19.00% 25 0.02% 0 0.00% 0 0.00% 16 0.01% 9 <0.01% 3 <0.01% 153 0.14% 153 0 5816 Victory XL DR 62.724 20.90% 31 0.05% 0 0.00% 0 0.00% 8 0.01% 9 0.01% 9 0.01% 9 0.01% 13 0.01% 145 0 5356/5357/526 Victory ADx XL DR/ DR(M/S) / DC 11.90% 19 0.10% 0 0.00% 0 0.00% 2 0.02% 1 0.01% 1 0.	PM2110	Accent [®] DR	48,912	10.10%	3	<0.01%	0	0.00%	0	0.00%	3	<0.01%	5	0.01%	2	<0.01%	0	0.00%	13	0.03%
5826 Zephyr XL DR 112,303 19.00% 25 0.02% 0 0.00% 0 0.01% 9 <0.01% 3 <0.01% 157 0.14% 210 0 5816 Victory XL DR 62,724 20.90% 31 0.05% 0 0.00% 0 0.00% 8 0.01% 9 <0.01% 5 <0.01% 92 0.11% 145 0 5356/5357/526 Verity ADx XL DR/ DR(M/S) / DC 17,396 11.90% 11 0.06% 0 0.00% 1 <0.01% 9 <0.01% 1 <0.01% 2 0.01% 1 <0.01% 2 0.01% 1 <0.01% 1 <0.01% 1 <0.01% 1 <0.01% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% 1 0.01% </td <td>5820</td> <td>Zephyr⁻ DR</td> <td>54,402</td> <td>16.20%</td> <td>36</td> <td>0.07%</td> <td>0</td> <td>0.00%</td> <td>0</td> <td>0.00%</td> <td>9</td> <td>0.02%</td> <td>2</td> <td><0.01%</td> <td>1</td> <td><0.01%</td> <td>92</td> <td>0.17%</td> <td>140</td> <td>0.26%</td>	5820	Zephyr ⁻ DR	54,402	16.20%	36	0.07%	0	0.00%	0	0.00%	9	0.02%	2	<0.01%	1	<0.01%	92	0.17%	140	0.26%
5816 Victory XL DR 62,724 20.90% 31 0.05% 0 0.00% 0 0.00% 8 0.01% 9 0.01% 5 <0.01% 92 0.15% 145 0 5316 Verity ADx* XL DR/ DR(M/S) / DC 17,396 11.90% 11 0.06% 0 0.00% 1 <0.00%	5810	Victory DR	26,313	19.00%	89	0.34%	0	0.00%	0	0.00%	8	0.03%	2	<0.01%	17	0.06%	37	0.14%	153	0.58%
Verity ADx" XL DR/ DR(M/S) / DC 17,396 11.90% 11 0.06% 0 0.00% 1 0.00% 1 <0.01% 0 0.00% 1 <0.01% 10 0.06% 23 0 5366 Integrity ADx" XL DR 8.087 19.70% 9 0.11% 0 0.00% 2 0.02% 1 0.01% 1 0.01% 14 0.17% 27 0 5380 Identity ADx" DR 54.050 16.20% 262 0.48% 0 0.00% 2 <0.01%	5826	Zephyr [®] XL DR	112,303	19.00%	25	0.02%	0	0.00%	0	0.00%	16	0.01%	9	<0.01%	3	<0.01%	157	0.14%	210	0.19%
5356/5357/526 DR(M/S) / DC 17,396 11.90% 11 0.06% 0 0.00% 1 <0.01% 0 0.00% 1 <0.01% 10 0.06% 23 0 5366 Integrity ADx [*] XL DR 8,087 19.70% 9 0.11% 0 0.00% 2 0.02% 1 0.01% 1 0.01% 14 0.17% 27 0 5380 Identity ADx [*] DR 54,050 16.20% 262 0.48% 0 0.00% 2 <0.01%	5816	Victory XL DR	62,724	20.90%	31	0.05%	0	0.00%	0	0.00%	8	0.01%	9	0.01%	5	<0.01%	92	0.15%	145	0.23%
5380 Identity ADx [*] DR 54,050 16.20% 262 0.48% 0 0.00% 2 <0.01% 6 0.01% 11 0.02% 17 0.03% 298 0	5356/5357/5256	, , , , , , , , , , , , , , , , , , ,	17,396	11.90%	11	0.06%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%	10	0.06%	23	0.13%
	5366	Integrity ADx XL DR	8,087	19.70%	9	0.11%	0	0.00%	0	0.00%	2	0.02%	1	0.01%	1	0.01%	14	0.17%	27	0.33%
5386/5286 Identity ADx [*] XL DR/DC 67,419 19,60% 136 0.20% 2 <0.01% 0 0.00% 7 0.01% 10 0.01% 6 <0.01% 113 0.17% 274 0	5380	Identity ADx" DR	54,050	16.20%	262	0.48%	0	0.00%	0	0.00%	2	<0.01%	6	0.01%	11	0.02%	17	0.03%	298	0.55%
	5386/5286	Identity ADx" XL DR/DC	67,419	19.60%	136	0.20%	2	<0.01%	0	0.00%	7	0.01%	10	0.01%	6	<0.01%	113	0.17%	274	0.41%

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL CONNECT	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY LETION	от	HER	TC	DTAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2272	Assurity MRI	645,653	0.93%	4	<0.01%	1	<0.01%	0	0.00%	1	<0.01%	18	<0.01%	0	0.00%	2	<0.01%	26	<0.01%
PM2160	Endurity [®] DR	63,428	0.95%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	3	<0.01%
PM2240	Assurity DR RF	201,978	4.38%	5	<0.01%	0	0.00%	0	0.00%	1	<0.01%	65	0.03%	3	<0.01%	0	0.00%	74	0.04%
PM2210	Accent" DR RF	246,721	11.60%	17	<0.01%	8	<0.01%	0	0.00%	0	0.00%	1	<0.01%	6	<0.01%	5	<0.01%	37	0.01%
PM2110	Accent DR	49,730	9.70%	2	<0.01%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	<0.01%

WITHOUT COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		IRICAL ONNECT	BAT	TERY		IWARE/ /WARE	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	то	TAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2272	Assurity MRI ⁻	645,653	0.93%	24	<0.01%	0	0.00%	0	0.00%	34	<0.01%	139	0.02%	8	<0.01%	7	<0.01%	212	0.03%
PM2160	Endurity ⁻ DR	63,428	0.95%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	13	0.02%	0	0.00%	3	<0.01%	17	0.03%
PM2240	Assurity DR RF	201,978	4.38%	20	<0.01%	0	0.00%	0	0.00%	20	<0.01%	266	0.13%	5	<0.01%	10	<0.01%	321	0.16%
PM2210	Accent" DR RF	246,721	11.60%	53	0.02%	34	0.01%	0	0.00%	5	<0.01%	22	<0.01%	23	<0.01%	44	0.02%	181	0.07%
PM2110	Accent" DR	49,730	9.70%	3	<0.01%	0	0.00%	0	0.00%	3	<0.01%	5	0.01%	2	<0.01%	0	0.00%	13	0.03%

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE DEVICES	CUMULATIVE MONTHS OF		SS OF METRY		ARDIAL JSION	BAT	ATURE TERY ETION			то	TAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2210	1,773	0	59,887	0	0.00%	0	0.00%	1	0.06%	1	0.06%	2	0.11%
PM2110	228	0	10,196	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5820	284	0	7,986	0	0.00%	0	0.00%	0	0.00%	1	0.35%	1	0.35%
5826	1,516	0	48,121	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5816	332	0	10,615	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5386	101	0	3,221	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

A list of of complications can be found on page 12.

Actively Monitored Study Data Summary

MALFUNCTIONS WITH COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL ONNECT	BAT	TERY		RE/ FIRM- ARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2210	Accent DR RF	1,773	24.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM2110	Accent ⁻ DR	228	14.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5820	Zephyr ⁻ DR	284	22.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5826	Zephyr [¯] XL DR	1,516	27.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5816	Victory" XL DR	332	17.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5386	Identity ADx - XL DR	101	18.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%


MALFUNCTIONS WITHOUT COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT RETURNED FOR		TRICAL		TRICAL CONNECT	BAT	TERY		RE/ FIRM- ARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM2210	Accent DR RF	1,773	24.90%	1	0.06%	1	0.06%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.11%
PM2110	Accent DR	228	14.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5820	Zephyr ⁻ DR	284	22.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5826	Zephyr [¯] XL DR	1,516	27.60%	1	0.07%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.07%
5816	Victory XL DR	332	17.50%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5386	Identity ADx [®] XL DR	101	18.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

Definitions of malfunction categories can be found on pages 5-6.

Single-Chamber Pacemakers

Assurity MRI™ MODEL PM1272			W/ COMP	NCTIONS PROMISED RAPY	W/O COM	NCTIONS PROMISED RAPY
			QTY	RATE	QTY	RATE
US Regulatory Approval	January 2017	Electrical Component	0	0.00%	1	<0.01%
Registered US Implants	28,116	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	21,460	Battery	0	0.00%	0	0.00%
Estimated Longevity	13.7 Years	Software/Firmware	0	0.00%	3	0.01%
Normal Battery Depletion	3	Mechanical	0	0.00%	18	0.06%
Number of US Advisories (see pgs. 312, 314)	Two	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	0	0.00%
		Total	0	0.00%	22	0.08%




YEARS AFTER IMPLANT

INCLUDING NORMAL BATTERY DEPLETION -

YEAR	1	2	3	4	AT 58 MONTHS
SURVIVAL PROBABILITY	99.96%	99.92%	99.81%	99.62%	99.03%
±1 STANDARD ERROR	0.01%	0.02%	0.04%	0.06%	0.17%
SAMPLE SIZE	24,100	17,150	11,370	5,960	380

YEAR	1	2	3	4	AT 58 MONTHS
SURVIVAL PROBABILITY	99.96%	99.92%	99.84%	99.67%	99.08%
±1 STANDARD ERROR	0.01%	0.02%	0.03%	0.05%	0.17%

Endurity™ VR MODEL PM1160			W/ COMP	NCTIONS PROMISED RAPY	MALFUN W/O COMF THEF	ROMISED
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2014	Electrical Component	0	0.00%	0	0.00%
Registered US Implants	2,554	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,416	Battery	0	0.00%	0	0.00%
Estimated Longevity	14.6 Years	Software/Firmware	0	0.00%	0	0.00%
Normal Battery Depletion	2	Mechanical	0	0.00%	2	0.08%
Number of US Advisories (see pg. 312)	One	Possible Early Battery Depletion	0	0.00%	0	0.00%
		Other	0	0.00%	1	0.04%
		Total	0	0.00%	3	0.12%




Y	E/	٩RS	AF	TEF	RIN	۱PL	.Α

YEAR	1	2	3	4	5	6	7	AT 88 MONTHS
SURVIVAL PROBABILITY	99.84%	99.84%	99.84%	99.84%	99.70%	99.55%	99.31%	99.31%
± 1 STANDARD ERROR	0.08%	0.08%	0.08%	0.08%	0.12%	0.16%	0.24%	0.24%
SAMPLE SIZE	2,360	2,070	1,900	1,740	1,540	1,240	720	250

EXCLUDING NORMAL BATTERY DEPLETION	EXCLUDING	NORMAL	BATTERY	DEPLETION
------------------------------------	-----------	--------	---------	-----------

YEAR	1	2	3	4	5	6	7	AT 88 MONTHS
SURVIVAL PROBABILITY	99.84%	99.84%	99.84%	99.84%	99.70%	99.70%	99.70%	99.70%
± 1 STANDARD ERROR	0.08%	0.08%	0.08%	0.08%	0.12%	0.12%	0.12%	0.12%

Assurity™ VR MODEL PM1240	•					
			QTY	RATE	QTY	RATE
US Regulatory Approval	March 2014	Electrical Component	0	0.00%	4	0.01%
Registered US Implants	28,638	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	16,855	Battery	0	0.00%	0	0.00%
Estimated Longevity	14.1 Years	Software/Firmware	0	0.00%	2	<0.01%
Normal Battery Depletion	19	Mechanical	2	< 0.01%	23	0.08%
Number of US Advisories (see pgs. 312, 314)	Two	Possible Early Battery Depletion	0	0.00%	1	<0.01%
		Other	0	0.00%	0	0.00%
		Total	2	<0.01%	30	0.10%




YEARS	AFTER	IMPL	AN.
-------	-------	------	-----

INCLUDING	NORMAL R.	ATTERY DEP	

YEAR	1	2	3	4	5	6	7	AT 90 MONTHS
SURVIVAL PROBABILITY	99.98%	99.96%	99.91%	99.80%	99.54%	99.33%	99.19%	99.19%
±1 STANDARD ERROR	0.01%	0.01%	0.02%	0.03%	0.05%	0.07%	0.09%	0.09%
SAMPLE SIZE	26,830	23,840	21,580	19,190	15,750	10,450	4,550	310

YEAR	1	2	3	4	5	6	7	AT 90 MONTHS
SURVIVAL PROBABILITY	99.98%	99.96%	99.94%	99.86%	99.73%	99.59%	99.53%	99.53%
± 1 STANDARD ERROR	0.01%	0.01%	0.01%	0.03%	0.04%	0.05%	0.06%	0.06%

Accent™ SR MODEL PM1110	W/ COMP	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY			
			QTY	RATE	QTY	RATE
US Regulatory Approval	July 2009	Electrical Component	0	0.00%	2	0.01%
Registered US Implants	13,595	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	5,570	Battery	0	0.00%	0	0.00%
Estimated Longevity	12.9 Years	Software/Firmware	0	0.00%	1	< 0.01%
Normal Battery Depletion	15	Mechanical	0	0.00%	0	0.00%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	1	< 0.01%
		Other	0	0.00%	0	0.00%
		Total	0	0.00%	4	0.03%




INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	AT 139 MONTHS
SURVIVAL PROBABILITY	99.87%	99.80%	99.66%	99.54%	99.54%	99.54%
± 1 STANDARD ERROR	0.03%	0.04%	0.06%	0.07%	0.07%	0.07%
SAMPLE SIZE	10,780	8,590	7,250	5,760	2,610	240

YEAR	2	4	6	8	10	AT 139 MONTHS
SURVIVAL PROBABILITY	99.94%	99.92%	99.92%	99.92%	99.92%	99.92%
± 1 STANDARD ERROR	0.02%	0.03%	0.03%	0.03%	0.03%	0.03%

Accent [™] SR RF MODEL PM1210						
			QTY	RATE	QTY	RATE
US Regulatory Approval	July 2009	Electrical Component	3	< 0.01%	11	0.03%
Registered US Implants	39,814	Electrical Interconnect	1	< 0.01%	3	<0.01%
Estimated Active US Implants	15,808	Battery	0	0.00%	1	<0.01%
Estimated Longevity	10.9 Years	Software/Firmware	0	0.00%	1	<0.01%
Normal Battery Depletion	48	Mechanical	0	0.00%	4	0.01%
Number of US Advisories (see pg. 314)	One	Possible Early Battery Depletic	on 2	< 0.01%	3	<0.01%
		Other	0	0.00%	8	0.02%
		Total	6	0.02%	31	0.08%



INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	12	AT 147 MONTHS
SURVIVAL PROBABILITY	99.80%	99.73%	99.42%	99.21%	99.21%	99.17%	99.17%
± 1 STANDARD ERROR	0.02%	0.03%	0.05%	0.06%	0.06%	0.06%	0.06%
SAMPLE SIZE	31,320	24,990	20,920	16,630	7,990	1,680	310

YEAR	2	4	6	8	10	12	AT 147 MONTHS
SURVIVAL PROBABILITY	99.87%	99.81%	99.74%	99.71%	99.71%	99.71%	99.71%
± 1 STANDARD ERROR	0.02%	0.02%	0.03%	0.03%	0.03%	0.03%	0.03%

Single-Chamber Pacemakers

ACTIVELY MONITORED STUDY DATA

Accent[™] SR RF MODEL PM1210

		QUALIFYING COMPLICATIONS		QTY	RATE
US Regulatory Approval	July 2009	None Reported	Electrical C	omponent 0	0.00%
Number of Devices Enrolled in Study	236		Electrical In	iterconnect 0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%
Cumulative Months of Follow-up	6,032		Software/Fi	rmware 0	0.00%
Estimated Longevity	10.9 Years		Mechanical	0	0.00%
			Possible Ea	ly Battery Depletion 0	0.00%

MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

QTY

0

0

0

0

0

0

0

0

0

0

0.00%

0.00%

Other

Total

RATE

0.00%

0.00%


0.00%

0.00%

0.00%


0.00%

0.00%



ACTIVELY MONITORED STUDY DATA									
YEAR	1	2	AT 29 MONTHS						
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%						
±1 STANDARD ERROR	0.00%	0.00%	0.00%						
SAMPLE SIZE	200	120	50						

Zephyr™ XL SR MODEL 5626			W/ COM	NCTIONS PROMISED ERAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	May 2007	Electrical Component	0	0.00%	4	0.02%	
Registered US Implants	20,660	Electrical Interconnect	1	< 0.01%	0	0.00%	
Estimated Active US Implants	5,230	Battery	0	0.00%	0	0.00%	
Estimated Longevity	15.8 Years	Software/Firmware	0	0.00%	0	0.00%	
Normal Battery Depletion	39	Mechanical	0	0.00%	0	0.00%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	0	0.00%	
		Other	1	< 0.01%	12	0.06%	
		Total	2	<0.01%	16	0.08%	



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 170 MONTHS
SURVIVAL PROBABILITY	99.83%	99.63%	99.35%	99.29%	98.88%	98.68%	98.38%	98.38%
±1 STANDARD ERROR	0.03%	0.05%	0.07%	0.08%	0.11%	0.13%	0.25%	0.25%
SAMPLE SIZE	15,500	11,550	9,090	7,430	5,650	3,930	930	230

EXCLUDING NORM	AL BATTERY DEPLETION		
ME A D	2	4	,

YEAR	2	4	6	8	10	12	14	AT 170 MONTHS
SURVIVAL PROBABILITY	99.93%	99.87%	99.83%	99.80%	99.71%	99.59%	99.59%	99.59%
±1 STANDARD ERROR	0.02%	0.03%	0.04%	0.04%	0.06%	0.07%	0.07%	0.07%

Single-Chamber Pacemakers

ACTIVELY MONITORED STUDY DATA

Zephyr[™] XL SR **MODEL 5626**

		QUALIFYING COMPLICATIONS		QTY	RATE	QTY	RATE
US Regulatory Approval	May 2007	None Reported	Electrical Component	0	0.00%	0	0.00%
Number of Devices Enrolled in Study	230		Electrical Interconnect	0	0.00%	0	0.00%
Active Devices Enrolled in Study	0		Battery	0	0.00%	0	0.00%
Cumulative Months of Follow-up	6,626		Software/Firmware	0	0.00%	0	0.00%
Estimated Longevity	15.8 Years		Mechanical	0	0.00%	0	0.00%
			Possible Early Battery Depletion	0	0.00%	0	0.00%
			Other	0	0.00%	0	0.00%

Total


MALFUNCTIONS MALFUNCTIONS W/ COMPROMISED W/O COMPROMISED THERAPY THERAPY

0.00%

0


0

0.00%



ACTIVELY MONITORED STUDY DATA								
YEAR	1	2	3	AT 41 MONTHS				
SURVIVAL PROBABILITY	100.00%	100.00%	100.00%	100.00%				
± 1 STANDARD ERROR	0.00%	0.00%	0.00%	0.00%				
SAMPLE SIZE	220	180	120	50				

Zephyr™ SR MODEL 5620			W/ COM	NCTIONS PROMISED ERAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	March 2007	Electrical Component	0	0.00%	4	0.02%	
Registered US Implants	17,524	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	4,722	Battery	0	0.00%	0	0.00%	
Estimated Longevity	8.8 Years	Software/Firmware	0	0.00%	2	0.01%	
Normal Battery Depletion	208	Mechanical	1	<0.01%	0	0.00%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	0	0.00%	
		Other	0	0.00%	11	0.06%	
		Total	1	<0.01%	17	0.10%	




INCLUDING NORMAL BATTERY DEPLETION -

YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.74%	98.81%	94.01%	93.57%	93.30%	93.22%	93.22%
±1 STANDARD ERROR	0.04%	0.10%	0.26%	0.27%	0.28%	0.29%	0.29%
SAMPLE SIZE	12,640	9,400	7,140	5,030	2,970	1,430	210

YEAR	2	4	6	8	10	12	AT 166 MONTHS
SURVIVAL PROBABILITY	99.94%	99.85%	99.80%	99.64%	99.47%	99.38%	99.38%
± 1 STANDARD ERROR	0.02%	0.04%	0.04%	0.07%	0.10%	0.12%	0.12%

Victory™ SR MODEL 5610				NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
			QTY	RATE	QTY	RATE	
US Regulatory Approval	December 2005	Electrical Component	0	0.00%	25	0.18%	
Registered US Implants	13,690	Electrical Interconnect	0	0.00%	0	0.00%	
Estimated Active US Implants	1,699	Battery	0	0.00%	0	0.00%	
Estimated Longevity	8.8 Years	Software/Firmware	0	0.00%	1	<0.01%	
Normal Battery Depletion	670	Mechanical	0	0.00%	0	0.00%	
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	1	<0.01%	
		Other	1	<0.01%	12	0.09%	
		Total	1	<0.01%	39	0.28%	



YEARS	AFTER	IMPLAN
-------	-------	--------

INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 182 MONTHS
SURVIVAL PROBABILITY	99.63%	98.29%	73.76%	68.43%	67.92%	67.85%	67.85%	67.85%
± 1 STANDARD ERROR	0.06%	0.14%	0.58%	0.64%	0.65%	0.65%	0.65%	0.65%
SAMPLE SIZE	9,940	6,890	4,420	2,630	1,920	1,690	1,110	240

YEAR	2	4	6	8	10	12	14	AT 182 MONTHS
SURVIVAL PROBABILITY	99.96%	99.82%	98.83%	98.22%	97.92%	97.92%	97.92%	97.92%
±1 STANDARD ERROR	0.02%	0.05%	0.14%	0.20%	0.24%	0.24%	0.24%	0.24%


Single-Chamber Pacemakers

CUSTOMER REPORTED PERFORMANCE DATA

Verity ADx[™] XL SR MODEL 5156 Verity ADx[™] XL SR M/S MODEL 5157M/S Verity ADx[™] XL SC MODEL 5056

US Regulatory Approval	May 2003
Registered US Implants	14,516
Estimated Active US Implants	2,741
Estimated Longevity	10.2 Years
Normal Battery Depletion	96
Number of US Advisories	None

	W/ COM	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
	QTY	RATE	QTY	RATE	
Electrical Component	1	<0.01%	4	0.03%	
Electrical Interconnect	0	0.00%	0	0.00%	
Battery	0	0.00%	0	0.00%	
Software/Firmware	0	0.00%	1	<0.01%	
Mechanical	0	0.00%	1	< 0.01%	
Possible Early Battery Depletion	0	0.00%	0	0.00%	
Other	0	0.00%	4	0.03%	
Total	1	<0.01%	10	0.07%	



3,400

10

99.74%

0.07%

2,880

12

99.74%

0.07%

2,180

14

99.66%

0.09%

950

16

99.51%

0.14%

200

AT 208 MONTHS

99.51%

0.14%

10,790

2

99.91%

0.03%

EXCLUDING NORMAL BATTERY DEPLETION

7,700

4

99.91%

0.03%

5,530

6

99.85%

0.04%

4,210

8

99.80%

0.05%


SAMPLE SIZE

SURVIVAL PROBABILITY

±1 STANDARD ERROR

YEAR

Identity ADx™ SR MODEL 5180		W/ COMP	NCTIONS PROMISED RAPY	MALFUN W/O COMI THEF	PROMISED	
			QTY	RATE	QTY	RATE
US Regulatory Approval	May 2003	Electrical Component	0	0.00%	35	0.17%
Registered US Implants	20,872	Electrical Interconnect	0	0.00%	0	0.00%
Estimated Active US Implants	1,678	Battery	0	0.00%	0	0.00%
Estimated Longevity	5.7 Years	Software/Firmware	0	0.00%	6	0.03%
Normal Battery Depletion	1,243	Mechanical	0	0.00%	1	<0.01%
Number of US Advisories	None	Possible Early Battery Depletion	0	0.00%	8	0.04%
		Other	0	0.00%	8	0.04%
		Total	0	0.00%	58	0.28%



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.57%	97.96%	79.13%	54.65%	52.38%	52.32%	52.32%	52.32%	52.32%
± 1 STANDARD ERROR	0.05%	0.12%	0.45%	0.62%	0.64%	0.64%	0.64%	0.64%	0.64%
SAMPLE SIZE	15,190	10,510	6,450	3,230	2,070	1,580	1,200	600	210

YEAR	2	4	6	8	10	12	14	16	AT 202 MONTHS
SURVIVAL PROBABILITY	99.94%	99.78%	99.24%	98.09%	97.75%	97.65%	97.65%	97.65%	97.65%
±1 STANDARD ERROR	0.02%	0.04%	0.09%	0.20%	0.23%	0.24%	0.24%	0.24%	0.24%


Single-Chamber Pacemakers

CUSTOMER REPORTED PERFORMANCE DATA

Microny™ MODELS 2425T, 2525T & 2535K

US Regulatory Approval	April 2001
Registered US Implants	7,948
Estimated Active US Implants	1,486
Estimated Longevity	7.5 Years
Normal Battery Depletion	312
Number of US Advisories	None

	W/ COMF	NCTIONS PROMISED RAPY	MALFUNCTIONS W/O COMPROMISED THERAPY		
	QTY	RATE	QTY	RATE	
Electrical Component	0	0.00%	1	0.01%	
Electrical Interconnect	0	0.00%	0	0.00%	
Battery	0	0.00%	0	0.00%	
Software/Firmware	0	0.00%	0	0.00%	
Mechanical	0	0.00%	0	0.00%	
Possible Early Battery Depletion	0	0.00%	1	0.01%	
Other	0	0.00%	0	0.00%	
Total	0	0.00%	2	0.03%	



INCLUDING NORMAL BATTERY DEPLETION

YEAR	2	4	6	8	10	12	14	AT 181 MONTHS
SURVIVAL PROBABILITY	99.38%	98.36%	97.24%	94.90%	67.15%	52.61%	49.38%	48.49%
±1 STANDARD ERROR	0.10%	0.19%	0.25%	0.43%	1.17%	1.31%	1.38%	1.42%
SAMPLE SIZE	5,280	3,660	2,530	1,760	1,120	630	350	210

YEAR	2	4	6	8	10	12	14	AT 181 MONTHS
SURVIVAL PROBABILITY	99.79%	99.34%	99.21%	98.87%	98.74%	98.74%	98.74%	98.74%
±1 STANDARD ERROR	0.06%	0.12%	0.14%	0.19%	0.22%	0.22%	0.22%	0.22%

SUMMARY INFORMATION Single-Chamber Pacemakers

Survival Probability Summary

INCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM1272	AssurityMRI	99.96%	99.92%	99.81%	99.62%						
PM1160	Endurity SR	99.84%	99.84%	99.84%	99.84%	99.70%	99.55%	99.31%			
PM1240	Assurity" SR	99.98%	99.96%	99.91%	99.80%	99.54%	99.33%	99.19%			
PM1110	Accent SR	99.92%	99.87%	99.85%	99.80%	99.77%	99.66%	99.54%	99.54%	99.54%	99.54%
PM1210	Accent SR RF	99.89%	99.80%	99.76%	99.73%	99.60%	99.42%	99.25%	99.21%	99.21%	99.21%
5626	Zephyr [~] XL SR	99.92%	99.83%	99.73%	99.63%	99.46%	99.35%	99.32%	99.29%	99.15%	98.88%
5620	Zephyr SR	99.86%	99.74%	99.47%	98.81%	95.65%	94.01%	93.78%	93.57%	93.43%	93.30%
5610	Victory [®] SR	99.92%	99.63%	99.40%	98.29%	89.48%	73.76%	69.38%	68.43%	68.14%	67.92%
5156/5157/5056	Verity ADx [*] XL SR/SR(M/S)/SC	99.87%	99.73%	99.60%	99.46%	98.82%	97.93%	97.20%	96.33%	95.92%	95.87%
5180	Identity ADx [°] SR	99.79%	99.57%	99.19%	97.96%	93.70%	79.13%	63.53%	54.65%	52.84%	52.38%
2425T/2525T/2535T	Microny	99.64%	99.38%	98.83%	98.36%	97.52%	97.24%	96.41%	94.90%	86.34%	67.15%

Survival Probability Summary

EXCLUDING NORMAL BATTERY DEPLETION

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
PM1272	AssurityMRI ["]	99.96%	99.92%	99.84%	99.67%						
PM1160	Endurity SR	99.84%	99.84%	99.84%	99.84%	99.70%	99.70%	99.70%			
PM1240	Assurity" SR	99.98%	99.96%	99.94%	99.86%	99.73%	99.59%	99.53%			
PM1110	Accent SR	99.96%	99.94%	99.92%	99.92%	99.92%	99.92%	99.92%	99.92%	99.92%	99.92%
PM1210	Accent SR RF	99.93%	99.87%	99.83%	99.81%	99.76%	99.74%	99.73%	99.71%	99.71%	99.71%
5626	Zephyr" XL SR	99.94%	99.93%	99.93%	99.87%	99.83%	99.83%	99.80%	99.80%	99.74%	99.71%
5620	Zephyr SR	99.97%	99.94%	99.92%	99.85%	99.83%	99.80%	99.77%	99.64%	99.54%	99.47%
5610	Victory [®] SR	99.98%	99.96%	99.91%	99.82%	98.98%	98.83%	98.71%	98.22%	98.02%	97.92%
5156/5157/5056	Verity ADx [*] XL SR/SR(M/S)/SC	99.97%	99.91%	99.91%	99.91%	99.85%	99.85%	99.85%	99.80%	99.80%	99.74%
5180	Identity ADx [°] SR	99.96%	99.94%	99.91%	99.78%	99.59%	99.24%	98.74%	98.09%	97.85%	97.75%
2425T/2525T/2535T	Microny	99.87%	99.79%	99.63%	99.34%	99.21%	99.21%	99.21%	98.87%	98.74%	98.74%

US Malfunction Summary

WITH COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		TRICAL ONENT		TRICAL CONNECT	BAT	TERY		WARE/	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	тс	DTAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1272	Assurity MRI ⁻	28,116	3.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM1160	Endurity SR	2,554	5.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM1240	Assurity SR	28,638	5.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	0	0.00%	2	<0.01%
PM1110	Accent [®] SR	13,595	7.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM1210	Accent [®] SR RF	39,814	7.70%	3	<0.01%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	6	0.02%
5626	Zephyr ⁻ XL SR	20,660	11.50%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	2	<0.01%
5620	Zephyr ⁻ SR	17,524	11.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	0	0.00%	1	<0.01%
5610	Victory SR	13,690	15.70%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	1	<0.01%
5156/5157/5056	Verity ADx ⁻ XL SR/SR(M/S)/SC	14,516	7.80%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
5180	Identity ADx SR	20,872	13.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
2425T/2525T/2535T	Microny	7,948	7.40%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

Definitions of malfunction categories can be found on pages 5-6.

US Malfunction Summary

WITHOUT COMPROMISED THERAPY

		REGISTERED	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY .ETION	от	HER	то	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1272	Assurity MRI ⁻	28,116	3.60%	1	<0.01%	0	0.00%	0	0.00%	3	0.01%	18	0.06%	0	0.00%	0	0.00%	22	0.08%
PM1160	Endurity SR	2,554	5.60%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.08%	0	0.00%	1	0.04%	3	0.12%
PM1240	Assurity SR	28,638	5.90%	4	0.01%	0	0.00%	0	0.00%	2	<0.01%	23	0.08%	1	<0.01%	0	0.00%	30	0.10%
PM1110	Accent [®] SR	13,595	7.90%	2	0.01%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	1	<0.01%	0	0.00%	4	0.03%
PM1210	Accent SR RF	39,814	7.70%	11	0.03%	3	<0.01%	1	<0.01%	1	<0.01%	4	0.01%	3	<0.01%	8	0.02%	31	0.08%
5626	Zephyr ⁻ XL SR	20,660	11.50%	4	0.02%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	12	0.06%	16	0.08%
5620	Zephyr ⁻ SR	17,524	11.80%	4	0.02%	0	0.00%	0	0.00%	2	0.01%	0	0.00%	0	0.00%	11	0.06%	17	0.10%
5610	Victory SR	13,690	15.70%	25	0.18%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	1	<0.01%	12	0.09%	39	0.28%
5156/5157/5056	Verity ADx ⁻ XL SR/SR(M/S)/SC	14,516	7.80%	4	0.03%	0	0.00%	0	0.00%	1	<0.01%	1	<0.01%	0	0.00%	4	0.03%	10	0.07%
5180	Identity ADx SR	20,872	13.40%	35	0.17%	0	0.00%	0	0.00%	6	0.03%	1	<0.01%	8	0.04%	8	0.04%	58	0.28%
2425T/2525T/2535T	Microny	7,948	7.40%	1	0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.01%	0	0.00%	2	0.03%

Worldwide Malfunction Summary

WITH COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY LETION	от	HER	тс	DTAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1272	Assurity MRI	115,807	0.92%	2	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%	0	0.00%	3	<0.01%
PM1160	Endurity ⁻ SR	27,197	0.79%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	<0.01%
PM1240	Assurity SR	32,293	5.04%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	0	0.00%	2	<0.01%
PM1110	Accent [®] SR	58,180	2.17%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
PM1210	Accent SR RF	49,707	6.31%	5	0.01%	1	<0.01%	0	0.00%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	8	0.02%

WITHOUT COMPROMISED THERAPY

		WORLDWIDE	PERCENT RETURNED FOR		TRICAL PONENT		TRICAL CONNECT	BAT	TERY		WARE/ WARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	то	DTAL
MODELS	FAMILY	SALES	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1272	Assurity MRI	115,807	0.92%	2	<0.01%	0	0.00%	0	0.00%	3	<0.01%	19	0.02%	0	0.00%	0	0.00%	24	0.02%
PM1160	Endurity ⁻ SR	27,197	0.79%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	4	0.01%	0	0.00%	1	<0.01%	5	0.02%
PM1240	Assurity SR	32,293	5.04%	5	0.02%	0	0.00%	0	0.00%	2	<0.01%	23	0.07%	1	<0.01%	0	0.00%	31	0.10%
PM1110	Accent ⁻ SR	58,180	2.17%	4	<0.01%	0	0.00%	0	0.00%	2	<0.01%	0	0.00%	1	<0.01%	3	<0.01%	10	0.02%
PM1210	Accent SR RF	49,707	6.31%	14	0.03%	4	< 0.01%	1	<0.01%	1	<0.01%	4	<0.01%	3	<0.01%	10	0.02%	37	0.07%

Definitions of malfunction categories can be found on pages 5-6.

Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF	ACTIVE	CUMULATIVE		SS OF METRY		ARDIAL JSION	BAT	ATURE TERY ETION		IN SION	то	TAL
MODELS	DEVICES ENROLLED	DEVICES ENROLLED	MONTHS OF FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1210	236	0	6,032	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5626	230	0	6,626	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

MALFUNCTIONS WITH COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT RETURNED FOR		IRICAL ONENT		TRICAL	BAT	TERY		.RE/ FIRM- ARE	MECH	ANICAL	BAT	LE EARLY TERY ETION	от	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1210	Accent [™] VR	236	9.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5626	Zephyr™ XL SR	230	14.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

MALFUNCTIONS WITHOUT COMPROMISED THERAPY

		NUMBER OF DEVICES	PERCENT RETURNED FOR		RICAL	ELECT	IRICAL ONNECT	BAT	TERY		RE/ FIRM- ARE	месни	ANICAL	POSSIBL BATT DEPLI		от	HER	то	TAL
MODELS	FAMILY	ENROLLED	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
PM1210	Accent [™] VR	236	9.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
5626	Zephyr™ XL SR	230	14.80%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

A list of of complications can be found on page 12. Definitions of malfunction categories can be found on pages 5-6.


Pacing Leads

Tendril MRI[™] MODEL LPA1200M

US Regulatory Approval	January 2017
Registered US Implants	174,268
Estimated Active US Implants	114,216
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ERVATIONS NT, ≤30 DAYS)		DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	47	0.03%	20	0.01%
Conductor Fracture	3	<0.01%	81	0.05%
Lead Dislodgement	375	0.22%	407	0.23%
Failure to Capture	60	0.03%	238	0.14%
Oversensing	18	0.01%	427	0.25%
Failure to Sense	26	0.01%	39	0.02%
Insulation Breach	1	<0.01%	22	0.01%
Abnormal Pacing Impedance	2	<0.01%	49	0.03%
Extracardiac Stimulation	6	<0.01%	12	<0.01%
Other	62	0.04%	33	0.02%
Total	600	0.34%	1328	0.76%
Total Returned for Analysis	223		384	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	52	0.03%
Insulation Breach	78	0.04%
Crimps, Welds & Bonds	0	0.00%
Other	7	<0.01%
Extrinsic Factors	251	0.14%
Total	388	0.22%




*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

Tendril[™] STS MODEL 2088TC

US Regulatory Approval	May 2009
Registered US Implants	976,047
Estimated Active US Implants	542,247
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	235	0.02%	119	0.01%
Conductor Fracture	10	<0.01%	432	0.04%
Lead Dislodgement	1400	0.14%	2112	0.22%
Failure to Capture	413	0.04%	1716	0.18%
Oversensing	112	0.01%	5615	0.58%
Failure to Sense	60	<0.01%	227	0.02%
Insulation Breach	20	<0.01%	424	0.04%
Abnormal Pacing Impedance	53	<0.01%	384	0.04%
Extracardiac Stimulation	12	<0.01%	72	<0.01%
Other	216	0.02%	323	0.03%
Total	2531	0.26%	11424	1.17%
Total Returned for Analysis	870		3038	

QTY	RATE
94	< 0.01%
1221	0.13%
0	0.00%
33	<0.01%
2037	0.21%
3385	0.35%
	94 1221 0 33 2037



66,890

230

*Optim™ lead insulation is a copolymer of silicone and polyurethane.

435,880

293,920

162,700

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 258

667,150


SAMPLE SIZE

Tendril[™] STS MODEL 2088TC

US Regulatory Approval	May 2009
Number of Devices Enrolled in Study	3,886
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	231,416
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.03%
Cardiac Perforation	1	0.03%
Conductor Fracture	8	0.21%
Extracardiac Stimulation	1	0.03%
Failure to Capture	11	0.28%
Failure to Sense	4	0.10%
Insulation Breach	8	0.21%
Lead Dislodgement	15	0.39%
Oversensing	16	0.41%
Pericardial Effusion	1	0.03%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	0.03%
Insulation Breach	13	0.33%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	13	0.33%
Total	27	0.69%



YEAR	2	4	6	8	10	AT 123 MONTHS
SURVIVAL PROBABILITY	99.20%	98.56%	98.00%	97.30%	97.03%	97.03%
±1 STANDARD ERROR	0.14%	0.22%	0.27%	0.36%	0.42%	0.42%
SAMPLE SIZE	3,250	2,360	1,700	1,140	340	70

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 259

OptiSense[™] MODEL 1999

US Regulatory Approval	May 2007
Registered US Implants	47,482
Estimated Active US Implants	22,019
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	5	0.01%	2	<0.01%
Conductor Fracture	0	0.00%	18	0.04%
Lead Dislodgement	64	0.13%	188	0.40%
Failure to Capture	8	0.02%	100	0.21%
Oversensing	10	0.02%	480	1.01%
Failure to Sense	3	<0.01%	45	0.09%
Insulation Breach	1	<0.01%	57	0.12%
Abnormal Pacing Impedance	0	0.00%	21	0.04%
Extracardiac Stimulation	0	0.00%	2	<0.01%
Other	14	0.03%	26	0.05%
Total	105	0.22%	939	1.98%
Total Returned for Analysis	59		249	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	7	0.01%
Insulation Breach	89	0.19%
Crimps, Welds & Bonds	0	0.00%
Other	7	0.01%
Extrinsic Factors	179	0.38%
Total	282	0.59%




YEAR	2	4	6	8	10	AT 142 MONTHS
SURVIVAL PROBABILITY	99.47%	99.04%	98.61%	98.04%	96.92%	95.70%
±1 STANDARD ERROR	0.03%	0.05%	0.06%	0.08%	0.14%	0.26%
SAMPLE SIZE	40,110	32,990	25,610	16,060	7,560	250

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

OptiSense[™] MODEL 1999

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	October 2009	Abnormal Pacing Impedance	1	0.11%	Conductor Fracture	0	0.00%
Number of Devices Enrolled in Study	877	Conductor Fracture	2	0.23%	Insulation Breach	6	0.68%
Active Devices Enrolled in Study	0	Failure to Sense	2	0.23%	Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	53,426	Insulation Breach	1	0.11%	Other	0	0.00%
Insulation	Optim"*	Lead Dislodgement	11	1.25%	Extrinsic Factors	9	1.03%
Type and/or Fixation	Active	Oversensing	1	0.11%	Total	15	1.71%
Polarity	Bipolar						
Steroid	Yes						



*Optim[™] lead insulation is a copolymer of silicone and polyurethane.


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 261

IsoFlex[™] Optim[™] MODEL 1944

US Regulatory Approval	March 2008
Registered US Implants	19,951
Estimated Active US Implants	9,069
Insulation	Optim"*
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	1	<0.01%
Conductor Fracture	0	0.00%	12	0.06%
Lead Dislodgement	101	0.51%	71	0.36%
Failure to Capture	13	0.07%	53	0.27%
Oversensing	1	<0.01%	162	0.81%
Failure to Sense	3	0.02%	11	0.06%
Insulation Breach	0	0.00%	9	0.05%
Abnormal Pacing Impedance	0	0.00%	5	0.03%
Extracardiac Stimulation	3	0.02%	1	<0.01%
Other	4	0.02%	5	0.03%
Total	125	0.63%	330	1.65%
Total Returned for Analysis	60		53	

QTY	RATE
0	0.00%
19	0.10%
0	0.00%
1	<0.01%
40	0.20%
60	0.30%
	0 19 0 1 40




YEAR	2	4	6	8	10	12	AT 153 MONTHS
SURVIVAL PROBABILITY	99.33%	98.91%	98.54%	97.96%	97.19%	96.35%	95.87%
±1 STANDARD ERROR	0.06%	0.08%	0.10%	0.14%	0.19%	0.32%	0.32%
SAMPLE SIZE	15,370	11,550	8,540	5,640	2,990	1,020	220

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

IsoFlex[™] Optim[™] MODEL 1944

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	March 2008	Lead Dislodgement	1	0.96%	Conductor Fracture	0	0.00%
Number of Devices Enrolled in Study	104				Insulation Breach	0	0.00%
Active Devices Enrolled in Study	0				Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	6,594				Other	0	0.00%
Insulation	Optim"*				Extrinsic Factors	0	0.00%
Type and/or Fixation	Passive				Total	0	0.00%
Polarity	Bipolar						
Steroid	Yes						



TEAR		2	3	5	4	AT 02 MOINTH.
SURVIVAL PROBABILITY	99.02%	99.02%	99.02%	99.02%	99.02%	99.02%
±1 STANDARD ERROR	0.97%	0.97%	0.97%	0.97%	0.97%	0.97%
SAMPLE SIZE	100	80	70	60	60	50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 263

IsoFlex[™] Optim[™] MODEL 1948

US Regulatory Approval	March 2008
Registered US Implants	74,088
Estimated Active US Implants	33,686
Insulation	Optim"*
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	5	<0.01%	12	0.02%
Conductor Fracture	1	<0.01%	121	0.16%
Lead Dislodgement	73	0.10%	91	0.12%
Failure to Capture	49	0.07%	257	0.35%
Oversensing	3	<0.01%	464	0.63%
Failure to Sense	2	<0.01%	5	<0.01%
Insulation Breach	4	<0.01%	105	0.14%
Abnormal Pacing Impedance	1	<0.01%	52	0.07%
Extracardiac Stimulation	2	<0.01%	7	<0.01%
Other	8	0.01%	29	0.04%
Total	148	0.20%	1143	1.54%
Total Returned for Analysis	68		179	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	18	0.02%
Insulation Breach	151	0.20%
Crimps, Welds & Bonds	0	0.00%
Other	1	<0.01%
Extrinsic Factors	104	0.14%
Total	274	0.37%



YEAR	2	4	6	8	10	12	AT 158 MONTHS
SURVIVAL PROBABILITY	99.57%	99.09%	98.55%	97.75%	96.68%	95.60%	95.35%
± 1 STANDARD ERROR	0.03%	0.04%	0.06%	0.08%	0.12%	0.19%	0.25%
SAMPLE SIZE	57,880	43,780	31,720	20,270	10,130	3,310	250


*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

IsoFlex[™] Optim[™] MODEL 1948

US Regulatory Approval	March 2008
Number of Devices Enrolled in Study	765
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	39,100
Insulation	Optim"*
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Failure to Capture	1	0.13%
Insulation Breach	1	0.13%
Lead Dislodgement	2	0.26%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Insulation Breach	5	0.65%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	1	0.13%
Total	6	0.78%



180

50

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

520

300

220

190

SAMPLE SIZE


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 265

OptiSense™ MODELS 1699T & 1699TC

US Regulatory Approval	May 2007
Registered US Implants	22,887
Estimated Active US Implants	7,245
Insulation	Silicone
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		CHRONIC COMPLICA (>30 DAYS)	
	QTY	RATE	QTY	RATE
Cardiac Perforation	1	<0.01%	0	0.00%
Conductor Fracture	0	0.00%	19	0.08%
Lead Dislodgement	4	0.02%	55	0.24%
Failure to Capture	4	0.02%	58	0.25%
Oversensing	3	0.01%	149	0.65%
Failure to Sense	8	0.03%	34	0.15%
Insulation Breach	0	0.00%	11	0.05%
Abnormal Pacing Impedance	0	0.00%	24	0.10%
Extracardiac Stimulation	0	0.00%	3	0.01%
Other	2	<0.01%	11	0.05%
Total	22	0.10%	364	1.59%
Total Returned for Analysis	16		86	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	14	0.06%
Insulation Breach	48	0.21%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	59	0.26%
Total	121	0.53%




YEAR	2	4	6	8	10	12	14	AT 171 MONTHS
SURVIVAL PROBABILITY	99.69%	99.49%	99.05%	98.46%	97.92%	97.52%	96.78%	96.78%
± 1 STANDARD ERROR	0.04%	0.05%	0.08%	0.10%	0.13%	0.15%	0.22%	0.22%
SAMPLE SIZE	18,610	15,090	12,600	10,600	9,120	7,110	1,810	290

OptiSense[™] MODELS 1699T & 1699TC

US Regulatory Approval	May 2007
Number of Devices Enrolled in Study	1,451
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	78,585
Insulation	Silicone
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	1	0.07%
Conductor Fracture	2	0.14%
Failure to Capture	4	0.28%
Insulation Breach	1	0.07%
Lead Dislodgement	8	0.55%
Oversensing	1	0.07%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Insulation Breach	3	0.21%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	6	0.41%
Total	9	0.62%




YEAR	2	4	6	8	10	AT 143 MONTHS
SURVIVAL PROBABILITY	98.99%	98.83%	98.13%	98.13%	98.13%	98.13%
±1 STANDARD ERROR	0.27%	0.32%	0.52%	0.52%	0.52%	0.52%
SAMPLE SIZE	1,160	680	420	330	260	50

Tendril[™] ST Optim[™] MODELS 1888T & 1888TC

US Regulatory Appr	oval	June 2006	
Registered US Impla	ants	302,020	
Estimated Active US	5 Implants	102,266	
Insulation		Optim"*	
Type and/or Fixatio	n	Active	
Polarity		Bipolar	
Steroid		Yes	
Number of US Advis	sories	None	

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	41	0.01%	45	0.01%
Conductor Fracture	8	<0.01%	338	0.11%
Lead Dislodgement	158	0.05%	611	0.20%
Failure to Capture	88	0.03%	1106	0.37%
Oversensing	21	<0.01%	3681	1.22%
Failure to Sense	14	<0.01%	146	0.05%
Insulation Breach	7	<0.01%	498	0.16%
Abnormal Pacing Impedance	10	<0.01%	300	0.10%
Extracardiac Stimulation	5	<0.01%	48	0.02%
Other	42	0.01%	179	0.06%
Total	394	0.13%	6952	2.30%
Total Returned for Analysis	206		1602	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	51	0.02%
Insulation Breach	1163	0.39%
Crimps, Welds & Bonds	1	<0.01%
Other	15	<0.01%
Extrinsic Factors	929	0.31%
Total	2159	0.71%



YEAR	2	4	6	8	10	12	14	AT 179 MONTHS
SURVIVAL PROBABILITY	99.58%	99.13%	98.46%	97.61%	96.64%	95.71%	94.88%	94.76%
±1 STANDARD ERROR	0.01%	0.02%	0.03%	0.04%	0.05%	0.06%	0.09%	0.10%
SAMPLE SIZE	243,800	196,350	160,420	125,590	91,080	54,450	13,390	320


*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

Tendril[™] ST Optim[™] MODELS 1888T & 1888TC

US Regulatory Approval	June 2006
Number of Devices Enrolled in Study	14,505
Active Devices Enrolled in Study	0
Cumulative Months of Follow-up	901,839
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes

QUALIFYING COMPLICATIONS	QTY	RATE
Abnormal Pacing Impedance	7	0.05%
Cardiac Perforation	2	0.01%
Conductor Fracture	10	0.07%
Extracardiac Stimulation	4	0.03%
Failure to Capture	19	0.13%
Failure to Sense	5	0.03%
Insulation Breach	29	0.20%
Lead Dislodgement	58	0.40%
Oversensing	22	0.15%
Skin Erosion	1	< 0.01%

MALFUNCTIONS	QTY	RATE
Conductor Fracture	3	0.02%
Insulation Breach	29	0.20%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	36	0.25%
Total	68	0.47%



*Optim[™] lead insulation is a copolymer of silicone and polyurethane.


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 269

Tendril[™] ST Optim[™] MODELS 1882T & 1882TC

US Regulatory Approval	June 2006
Registered US Implants	49,650
Estimated Active US Implants	20,373
Insulation	Optim"*
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	4	<0.01%	4	<0.01%
Conductor Fracture	0	0.00%	24	0.05%
Lead Dislodgement	49	0.10%	163	0.33%
Failure to Capture	12	0.02%	117	0.24%
Oversensing	6	0.01%	404	0.81%
Failure to Sense	4	<0.01%	32	0.06%
Insulation Breach	0	0.00%	52	0.10%
Abnormal Pacing Impedance	1	<0.01%	33	0.07%
Extracardiac Stimulation	0	0.00%	4	< 0.01%
Other	15	0.03%	33	0.07%
Total	91	0.18%	866	1.74%
Total Returned for Analysis	49		211	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	2	<0.01%
Insulation Breach	102	0.21%
Crimps, Welds & Bonds	0	0.00%
Other	3	<0.01%
Extrinsic Factors	152	0.31%
Total	259	0.52%




TEAR	2	4	8	0	10	12	14	AT 1/2 MONT
SURVIVAL PROBABILITY	99.56%	99.26%	98.76%	98.09%	97.25%	96.33%	95.53%	95.53%
±1 STANDARD ERROR	0.03%	0.04%	0.06%	0.08%	0.12%	0.17%	0.32%	0.32%
SAMPLE SIZE	40,890	33,160	25,600	17,420	10,150	4,490	940	220

*Optim[™] lead insulation is a copolymer of silicone and polyurethane.

Tendril[™] ST Optim[™] MODELS 1882T & 1882TC

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	June 2006	Abnormal Pacing Impedance	1	0.14%	Conductor Fracture	0	0.00%
Number of Devices Enrolled in Study	690	Extracardiac Stimulation	1	0.14%	Insulation Breach	3	0.43%
Active Devices Enrolled in Study	0	Failure to Capture	1	0.14%	Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	43,119	Failure to Sense	1	0.14%	Other	0	0.00%
Insulation	Optim"*	Lead Dislodgement	2	0.29%	Extrinsic Factors	0	0.00%
Type and/or Fixation	Active	Oversensing	2	0.29%	Total	3	0.43%
Polarity	Bipolar	Skin Erosion	1	0.14%			
Steroid	Yes						



*Optim[™] lead insulation is a copolymer of silicone and polyurethane.


ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 271

Tendril™ MODELS 1782T & 1782TC

US Regulatory Approval	February 2006
Registered US Implants	16,412
Estimated Active US Implants	4,761
Insulation	Silicone
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	6	0.04%	0	0.00%
Conductor Fracture	0	0.00%	6	0.04%
Lead Dislodgement	13	0.08%	54	0.33%
Failure to Capture	5	0.03%	57	0.35%
Oversensing	0	0.00%	79	0.48%
Failure to Sense	0	0.00%	9	0.05%
Insulation Breach	0	0.00%	6	0.04%
Abnormal Pacing Impedance	2	0.01%	19	0.12%
Extracardiac Stimulation	1	<0.01%	1	<0.01%
Other	2	0.01%	5	0.03%
Total	29	0.18%	236	1.44%
Total Returned for Analysis	16		73	


MALFUNCTIONS	QTY	RATE
Conductor Fracture	1	<0.01%
Insulation Breach	49	0.30%
Crimps, Welds & Bonds	0	0.00%
Other	0	0.00%
Extrinsic Factors	51	0.31%
Total	101	0.62%



YEAR	2	4	6	8	10	12	14	AT 184 MONTHS
SURVIVAL PROBABILITY	99.71%	99.38%	98.90%	98.24%	97.67%	97.30%	97.04%	96.61%
± 1 STANDARD ERROR	0.04%	0.07%	0.10%	0.14%	0.17%	0.19%	0.21%	0.36%
SAMPLE SIZE	13,250	10,520	8,390	6,850	5,730	4,250	2,200	200

Tendril™ MODELS 1782T & 1782TC

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	February 2006	Oversensing	1	0.61%	Conductor Fracture	0	0.00%
Number of Devices Enrolled in Study	165				Insulation Breach	1	0.61%
Active Devices Enrolled in Study	0				Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	5,930				Other	0	0.00%
Insulation	Silicone				Extrinsic Factors	0	0.00%
Type and/or Fixation	Active				Total	1	0.61%
Polarity	Bipolar						
Steroid	Yes						




YEAR	1	2	3	AT 42 MONTHS
SURVIVAL PROBABILITY	100.00%	100.00%	98.54%	98.54%
±1 STANDARD ERROR	0.00%	0.00%	1.45%	1.45%
SAMPLE SIZE	150	120	80	60

Tendril[™] MODELS 1788T & 1788TC

US Regulatory Approval	February 2006
Registered US Implants	65,265
Estimated Active US Implants	18,230
Insulation	Silicone
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	12	0.02%	8	0.01%
Conductor Fracture	1	<0.01%	39	0.06%
Lead Dislodgement	31	0.05%	80	0.12%
Failure to Capture	31	0.05%	206	0.32%
Oversensing	4	<0.01%	283	0.43%
Failure to Sense	2	<0.01%	25	0.04%
Insulation Breach	1	<0.01%	37	0.06%
Abnormal Pacing Impedance	9	0.01%	57	0.09%
Extracardiac Stimulation	2	<0.01%	7	0.01%
Other	20	0.03%	36	0.06%
Total	113	0.17%	778	1.19%
Total Returned for Analysis	49		169	


MALFUNCTIONS	QTY	RATE
Conductor Fracture	10	0.02%
Insulation Breach	134	0.21%
Crimps, Welds & Bonds	1	<0.01%
Other	1	<0.01%
Extrinsic Factors	107	0.16%
Total	253	0.39%



YEAR	2	4	6	8	10	12	14	AT 184 MONTHS
SURVIVAL PROBABILITY	99.76%	99.54%	99.16%	98.57%	98.15%	97.74%	97.32%	97.13%
± 1 STANDARD ERROR	0.02%	0.03%	0.04%	0.06%	0.08%	0.09%	0.10%	0.11%
SAMPLE SIZE	52,230	40,960	32,910	27,130	23,300	19,640	12,320	310

Tendril™ MODELS 1788T & 1788TC

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	February 2006	Extracardiac Stimulation	1	0.28%	Conductor Fracture	0	0.00%
Number of Devices Enrolled in Study	363	Lead Dislodgement	3	0.83%	Insulation Breach	2	0.55%
Active Devices Enrolled in Study	0				Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	13,446				Other	0	0.00%
Insulation	Silicone				Extrinsic Factors	0	0.00%
Type and/or Fixation	Active				Total	2	0.55%
Polarity	Bipolar						
Steroid	Yes						




SURVIVAL PROBABILITY	98.78%	98.78%	98.78%	98.78%	98.78%	98.78%	98.78%
± 1 STANDARD ERROR	0.61%	0.61%	0.61%	0.61%	0.61%	0.61%	0.61%
SAMPLE SIZE	310	240	170	100	70	60	50

IsoFlex[™] P MODEL 1648T

US Regulatory Approval	April 2005
Registered US Implants	2,836
Estimated Active US Implants	725
Insulation	Polyurethane
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	0	0.00%
Conductor Fracture	0	0.00%	7	0.25%
Lead Dislodgement	2	0.07%	2	0.07%
Failure to Capture	2	0.07%	17	0.60%
Oversensing	0	0.00%	3	0.11%
Failure to Sense	1	0.04%	1	0.04%
Insulation Breach	0	0.00%	14	0.49%
Abnormal Pacing Impedance	0	0.00%	4	0.14%
Extracardiac Stimulation	1	0.04%	0	0.00%
Other	0	0.00%	6	0.21%
Total	6	0.21%	54	1.90%
Total Returned for Analysis	1		8	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Insulation Breach	18	0.63%
Crimps, Welds & Bonds	0	0.00%
Other	2	0.07%
Extrinsic Factors	6	0.21%
Total	26	0.92%




YEAR	2	4	6	8	10	12	14	AT 179 MONTHS
SURVIVAL PROBABILITY	99.62%	99.35%	98.62%	97.80%	96.76%	95.83%	94.92%	94.92%
±1 STANDARD ERROR	0.13%	0.17%	0.28%	0.38%	0.51%	0.59%	0.71%	0.71%
SAMPLE SIZE	2,150	1,660	1,290	1,050	900	800	560	210

IsoFlex[™] S MODEL 1642T

US Regulatory Approval	May 2002
Registered US Implants	27,145
Estimated Active US Implants	6,821
Insulation	Silicone
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

	ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)			MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	0	0.00%	0	0.00%
Conductor Fracture	1	<0.01%	12	0.04%
Lead Dislodgement	49	0.18%	44	0.16%
Failure to Capture	6	0.02%	69	0.25%
Oversensing	0	0.00%	62	0.23%
Failure to Sense	3	0.01%	17	0.06%
Insulation Breach	0	0.00%	7	0.03%
Abnormal Pacing Impedance	3	0.01%	15	0.06%
Extracardiac Stimulation	1	<0.01%	3	0.01%
Other	1	<0.01%	5	0.02%
Total	64	0.24%	234	0.86%
Total Returned for Analysis	39		40	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	0	0.00%
Insulation Breach	40	0.15%
Crimps, Welds & Bonds	1	<0.01%
Other	2	<0.01%
Extrinsic Factors	22	0.08%
Total	65	0.24%




YEAR	2	4	6	8	10	12	14	16	18	AT 218 MONTHS
SURVIVAL PROBABILITY	99.82%	99.65%	99.42%	98.98%	98.58%	98.32%	98.09%	97.61%	97.49%	97.49%
±1 STANDARD ERROR	0.03%	0.04%	0.06%	0.08%	0.11%	0.12%	0.14%	0.18%	0.23%	0.23%
SAMPLE SIZE	21,880	17,510	13,800	11,140	9,080	7,010	4,510	2,150	550	210

IsoFlex[™] S MODEL 1646T

US Regulatory Approval	May 2002
Registered US Implants	90,426
Estimated Active US Implants	21,785
Insulation	Silicone
Type and/or Fixation	Passive
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ACUTE OBSERVATIONS (POST IMPLANT, ≤30 DAYS)		DMPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	4	<0.01%	2	<0.01%
Conductor Fracture	2	<0.01%	126	0.14%
Lead Dislodgement	37	0.04%	36	0.04%
Failure to Capture	35	0.04%	406	0.45%
Oversensing	2	<0.01%	211	0.23%
Failure to Sense	2	<0.01%	14	0.02%
Insulation Breach	2	<0.01%	51	0.06%
Abnormal Pacing Impedance	6	<0.01%	142	0.16%
Extracardiac Stimulation	0	0.00%	7	<0.01%
Other	3	<0.01%	34	0.04%
Total	93	0.10%	1029	1.14%
Total Returned for Analysis	38		129	

MALFUNCTIONS	QTY	RATE
Conductor Fracture	22	0.02%
Insulation Breach	87	0.10%
Crimps, Welds & Bonds	0	0.00%
Other	6	<0.01%
Extrinsic Factors	75	0.08%
Total	190	0.21%




YEAR	2	4	6	8	10	12	14	16	18	AT 221 MONTHS
SURVIVAL PROBABILITY	99.80%	99.58%	99.25%	98.75%	98.26%	97.74%	97.33%	96.89%	96.36%	96.36%
±1 STANDARD ERROR	0.02%	0.02%	0.04%	0.05%	0.07%	0.08%	0.09%	0.12%	0.17%	0.21%
SAMPLE SIZE	71,220	55,200	42,860	34,500	28,510	21,840	14,040	6,600	1,600	270

IsoFlex[™] S MODEL 1646T

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS
US Regulatory Approval	May 2002	Failure to Capture	2	0.31%	Conductor Fracture
Number of Devices Enrolled in Study	641	Lead Dislodgement	1	0.16%	Insulation Breach
ctive Devices Enrolled in Study	0				Crimps, Welds & Bonds
imulative Months of Follow-up	15,884				Other
sulation	Silicone				Extrinsic Factors
pe and/or Fixation	Passive				Total
olarity	Bipolar				
eroid	Yes				

RATE 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%




YEAR	1	2	3	AT 45 MONTHS
SURVIVAL PROBABILITY	99.51%	99.51%	99.51%	99.51%
±1 STANDARD ERROR	0.28%	0.28%	0.28%	0.28%
SAMPLE SIZE	570	410	250	60

Tendril[™] SDX MODELS 1688T & 1688TC

US Regulatory Approval	June 2003
Registered US Implants	491,808
Estimated Active US Implants	140,835
Insulation	Silicone
Type and/or Fixation	Active
Polarity	Bipolar
Steroid	Yes
Number of US Advisories	None

		ERVATIONS NT, ≤30 DAYS)		MPLICATIONS DAYS)
	QTY	RATE	QTY	RATE
Cardiac Perforation	81	0.02%	44	<0.01%
Conductor Fracture	6	<0.01%	625	0.13%
Lead Dislodgement	322	0.07%	640	0.13%
Failure to Capture	203	0.04%	1816	0.37%
Oversensing	24	<0.01%	2300	0.47%
Failure to Sense	34	<0.01%	177	0.04%
Insulation Breach	10	<0.01%	264	0.05%
Abnormal Pacing Impedance	30	<0.01%	678	0.14%
Extracardiac Stimulation	8	<0.01%	52	0.01%
Other	68	0.01%	220	0.04%
Total	786	0.16%	6816	1.39%
Total Returned for Analysis	352		1640	


MALFUNCTIONS	QTY	RATE
Conductor Fracture	222	0.05%
Insulation Breach	1141	0.23%
Crimps, Welds & Bonds	2	< 0.01%
Other	21	<0.01%
Extrinsic Factors	871	0.18%
Total	2257	0.46%



YEAR	2	4	6	8	10	12	14	16	18	AT 220 MONTHS
SURVIVAL PROBABILITY	99.70%	99.41%	98.99%	98.37%	97.73%	97.17%	96.66%	96.08%	95.56%	95.26%
±1 STANDARD ERROR	0.01%	0.01%	0.02%	0.02%	0.03%	0.04%	0.05%	0.06%	0.10%	0.23%
SAMPLE SIZE	398,960	315,290	243,690	180,550	131,590	94,560	62,500	31,710	4,850	280

Tendril[™] SDX MODELS 1688T & 1688TC

		QUALIFYING COMPLICATIONS	QTY	RATE	MALFUNCTIONS	QTY	RATE
US Regulatory Approval	June 2003	Abnormal Pacing Impedance	5	0.19%	Conductor Fracture	1	0.04%
Number of Devices Enrolled in Study	2,645	Conductor Fracture	3	0.11%	Insulation Breach	6	0.23%
Active Devices Enrolled in Study	0	Failure to Capture	3	0.11%	Crimps, Welds & Bonds	0	0.00%
Cumulative Months of Follow-up	102,805	Insulation Breach	3	0.11%	Other	0	0.00%
Insulation	Silicone	Lead Dislodgement	6	0.23%	Extrinsic Factors	5	0.19%
Type and/or Fixation	Active	Oversensing	3	0.11%	Total	12	0.45%
Polarity	Bipolar	Pericardial Effusion	1	0.04%			
Steroid	Yes	Skin Erosion	1	0.04%			



YEAR	2	4	6	8	10	AT 130 MONTHS
SURVIVAL PROBABILITY	99.50%	98.67%	98.33%	97.75%	97.75%	97.75%
±1 STANDARD ERROR	0.14%	0.32%	0.40%	0.48%	0.57%	0.57%
SAMPLE SIZE	1,840	850	460	340	180	60

summary information Pacing Leads

Pacing Leads Survival Probability Summary

MODELS	FAMILY	1 YEAR	2 YEAR	3 YEAR	4 YEAR	5 YEAR	6 YEAR	7 YEAR	8 YEAR	9 YEAR	10 YEAR
LPA1200M	Tendril MRI	99.74%	99.54%	99.35%	99.11%	98.83%	98.44%	98.19%	97.82%	97.06%	
2088TC	Tendril [™] STS	99.68%	99.49%	99.30%	99.09%	98.88%	98.65%	98.41%	98.08%	97.70%	97.13%
1999	OptiSense" Optim"	99.66%	99.47%	99.28%	99.04%	98.82%	98.61%	98.33%	98.04%	97.47%	96.92%
1944	IsoFlex" Optim"	99.58%	99.33%	99.09%	98.91%	98.76%	98.54%	98.23%	97.96%	97.53%	97.19%
1948	IsoFlex" Optim"	99.76%	99.57%	99.34%	99.09%	98.81%	98.55%	98.17%	97.75%	97.35%	96.68%
1699T/TC	OptiSense"	99.80%	99.69%	99.56%	99.49%	99.28%	99.05%	98.80%	98.46%	98.20%	97.92%
1888T/TC	Tendril" ST Optim"	99.76%	99.58%	99.37%	99.13%	98.82%	98.46%	98.06%	97.61%	97.13%	96.64%
1882T/TC	Tendril" ST Optim"	99.70%	99.56%	99.42%	99.26%	99.07%	98.76%	98.43%	98.09%	97.70%	97.25%
1782T/TC	Tendril™	99.82%	99.71%	99.54%	99.38%	99.13%	98.90%	98.63%	98.24%	97.89%	97.67%
1788T/TC	Tendril™	99.84%	99.76%	99.66%	99.54%	99.38%	99.16%	98.85%	98.57%	98.32%	98.15%
1648T	IsoFlex" P	99.76%	99.62%	99.35%	99.35%	99.09%	98.62%	98.27%	97.80%	97.30%	96.76%
1642T	IsoFlex" S	99.88%	99.82%	99.73%	99.65%	99.55%	99.42%	99.16%	98.98%	98.78%	98.58%
1646T	IsoFlex" S	99.86%	99.80%	99.69%	99.58%	99.43%	99.25%	99.01%	98.75%	98.52%	98.26%
1688T/TC	Tendril" SDX	99.82%	99.70%	99.56%	99.41%	99.22%	98.99%	98.73%	98.37%	98.05%	97.73%

Pacing Leads Acute Observation Summary POST IMPLANT ≤30 DAYS

	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US		RDIAC		UCTOR	LE DISLOD	AD GEMENT		JRE TO TURE	OVER	SENSING		LURE SENSE		LATION EACH	PA	ORMAL CING DANCE		CARDIAC	от	HER	то	TAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
LPA1200M	Jan-17	174,268	114,216	47	0.03%	3	< 0.01%	375	0.22%	60	0.03%	18	0.01%	26	0.01%	1	<0.01%	2	<0.01%	6	<0.01%	62	0.04%	600	0.34%	223
2088TC	May-09	976,047	542,247	235	0.02%	10	< 0.01%	1400	0.14%	413	0.04%	112	0.01%	60	<0.01%	20	<0.01%	53	<0.01%	12	<0.01%	216	0.02%	2531	0.26%	870
1999	Oct-09	47,482	22,019	5	0.01%	0	0.00%	64	0.13%	8	0.02%	10	0.02%	3	<0.01%	1	<0.01%	0	0.00%	0	0.00%	14	0.03%	105	0.22%	59
1944	Mar-08	19,951	9,069	0	0.00%	0	0.00%	101	0.51%	13	0.07%	1	<0.01%	3	0.02%	0	0.00%	0	0.00%	3	0.02%	4	0.02%	125	0.63%	60
1948	Mar-08	74,088	33,686	5	<0.01%	1	<0.01%	73	0.10%	49	0.07%	3	<0.01%	2	<0.01%	4	<0.01%	1	<0.01%	2	<0.01%	8	0.01%	148	0.20%	68
1699T/TC	May-07	22,887	7,245	1	<0.01%	0	0.00%	4	0.02%	4	0.02%	3	0.01%	8	0.03%	0	0.00%	0	0.00%	0	0.00%	2	< 0.01%	22	0.10%	16
1888T/TC	Jun-06	302,020	102,266	41	0.01%	8	< 0.01%	158	0.05%	88	0.03%	21	<0.01%	14	<0.01%	7	<0.01%	10	<0.01%	5	<0.01%	42	0.01%	394	0.13%	206
1882T/TC	Jun-06	49,650	20,373	4	<0.01%	0	0.00%	49	0.10%	12	0.02%	6	0.01%	4	<0.01%	0	0.00%	1	<0.01%	0	0.00%	15	0.03%	91	0.18%	49
1782T/TC	Feb-06	16,412	4,761	6	0.04%	0	0.00%	13	0.08%	5	0.03%	0	0.00%	0	0.00%	0	0.00%	2	0.01%	1	<0.01%	2	0.01%	29	0.18%	16
1788T/TC	Feb-06	65,265	18,230	12	0.02%	1	< 0.01%	31	0.05%	31	0.05%	4	<0.01%	2	<0.01%	1	<0.01%	9	0.01%	2	<0.01%	20	0.03%	113	0.17%	49
1648T	Apr-05	2,836	725	0	0.00%	0	0.00%	2	0.07%	2	0.07%	0	0.00%	1	0.04%	0	0.00%	0	0.00%	1	0.04%	0	0.00%	6	0.21%	1
1642T	May-02	27,145	6,821	0	0.00%	1	<0.01%	49	0.18%	6	0.02%	0	0.00%	3	0.01%	0	0.00%	3	0.01%	1	<0.01%	1	< 0.01%	64	0.24%	39
1646T	May-02	90,426	21,785	4	<0.01%	2	< 0.01%	37	0.04%	35	0.04%	2	<0.01%	2	<0.01%	2	<0.01%	6	<0.01%	0	0.00%	3	<0.01%	93	0.10%	38
1688T/TC	Jun-03	491,808	140,835	81	0.02%	6	< 0.01%	322	0.07%	203	0.04%	24	<0.01%	34	<0.01%	10	<0.01%	30	<0.01%	8	<0.01%	68	0.01%	786	0.16%	352

Chronic Complication Summary >30 DAYS

	US REGULATORY	REGISTERED	ESTIMATED ACTIVE US		RDIAC DRATION		UCTOR		GEMENT		IRE TO TURE	OVERS	ENSING		LURE		ATION	PAG	DRMAL CING DANCE		CARDIAC	оті	HER	то	TAL	TOTAL RETURNED FOR
MODELS	APPROVAL	US IMPLANTS	IMPLANTS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	ANALYSIS
LPA1200M	Jan-17	174,268	114,216	20	0.01%	81	0.05%	407	0.23%	238	0.14%	427	0.25%	39	0.02%	22	0.01%	49	0.03%	12	<0.01%	33	0.02%	1328	0.76%	384
2088TC	May-09	976,047	542,247	119	0.01%	432	0.04%	2112	0.22%	1716	0.18%	5615	0.58%	227	0.02%	424	0.04%	384	0.04%	72	<0.01%	323	0.03%	11424	1.17%	3038
1999	Oct-09	47,482	22,019	2	<0.01%	18	0.04%	188	0.40%	100	0.21%	480	1.01%	45	0.09%	57	0.12%	21	0.04%	2	<0.01%	26	0.05%	939	1.98%	249
1944	Mar-08	19,951	9,069	1	<0.01%	12	0.06%	71	0.36%	53	0.27%	162	0.81%	11	0.06%	9	0.05%	5	0.03%	1	<0.01%	5	0.03%	330	1.65%	53
1948	Mar-08	74,088	33,686	12	0.02%	121	0.16%	91	0.12%	257	0.35%	464	0.63%	5	<0.01%	105	0.14%	52	0.07%	7	<0.01%	29	0.04%	1143	1.54%	179
1699T/TC	May-07	22,887	7,245	0	0.00%	19	0.08%	55	0.24%	58	0.25%	149	0.65%	34	0.15%	11	0.05%	24	0.10%	3	0.01%	11	0.05%	364	1.59%	86
1888T/TC	Jun-06	302,020	102,266	45	0.01%	338	0.11%	611	0.20%	1106	0.37%	3681	1.22%	146	0.05%	498	0.16%	300	0.10%	48	0.02%	179	0.06%	6952	2.30%	1602
1882T/TC	Jun-06	49,650	20,373	4	<0.01%	24	0.05%	163	0.33%	117	0.24%	404	0.81%	32	0.06%	52	0.10%	33	0.07%	4	<0.01%	33	0.07%	866	1.74%	211
1782T/TC	Feb-06	16,412	4,761	0	0.00%	6	0.04%	54	0.33%	57	0.35%	79	0.48%	9	0.05%	6	0.04%	19	0.12%	1	<0.01%	5	0.03%	236	1.44%	73
1788T/TC	Feb-06	65,265	18,230	8	0.01%	39	0.06%	80	0.12%	206	0.32%	283	0.43%	25	0.04%	37	0.06%	57	0.09%	7	0.01%	36	0.06%	778	1.19%	169
1648T	Apr-05	2,836	725	0	0.00%	7	0.25%	2	0.07%	17	0.60%	3	0.11%	1	0.04%	14	0.49%	4	0.14%	0	0.00%	6	0.21%	54	1.90%	8
1642T	May-02	27,145	6,821	0	0.00%	12	0.04%	44	0.16%	69	0.25%	62	0.23%	17	0.06%	7	0.03%	15	0.06%	3	0.01%	5	0.02%	234	0.86%	40
1646T	May-02	90,426	21,785	2	<0.01%	126	0.14%	36	0.04%	406	0.45%	211	0.23%	14	0.02%	51	0.06%	142	0.16%	7	<0.01%	34	0.04%	1029	1.14%	129
1688T/TC	Jun-03	491,808	140,835	44	<0.01%	625	0.13%	640	0.13%	1816	0.37%	2300	0.47%	177	0.04%	264	0.05%	678	0.14%	52	0.01%	220	0.04%	6816	1.39%	1640

Definitions of observations and complications can be found on page 7.

Pacing Leads U.S. Malfunction Summary

	REGISTERED	PERCENT RETURNED		OUCTOR		ATION ACH		s, WELDS ONDS	от	HER		INSIC FORS	то	TAL
MODELS	US IMPLANTS	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
LPA1200M	174,268	2.70%	52	0.03%	78	0.04%	0	0.00%	7	<0.01%	251	0.14%	388	0.22%
2088TC	976,047	3.90%	94	<0.01%	1221	0.13%	0	0.00%	33	<0.01%	2037	0.21%	3385	0.35%
1999	47,482	5.20%	7	0.01%	89	0.19%	0	0.00%	7	0.01%	179	0.38%	282	0.59%
1944	19,951	8.10%	0	0.00%	19	0.10%	0	0.00%	1	<0.01%	40	0.20%	60	0.30%
1948	74,088	4.60%	18	0.02%	151	0.20%	0	0.00%	1	<0.01%	104	0.14%	274	0.37%
1699T/TC	22,887	5.70%	14	0.06%	48	0.21%	0	0.00%	0	0.00%	59	0.26%	121	0.53%
1888T/TC	302,020	5.30%	51	0.02%	1163	0.39%	1	<0.01%	15	<0.01%	929	0.31%	2159	0.71%
1882T/TC	49,650	4.50%	2	<0.01%	102	0.21%	0	0.00%	3	<0.01%	152	0.31%	259	0.52%
1782T/TC	16,412	5.70%	1	<0.01%	49	0.30%	0	0.00%	0	0.00%	51	0.31%	101	0.62%
1788T/TC	65,265	5.90%	10	0.02%	134	0.21%	1	<0.01%	1	<0.01%	107	0.16%	253	0.39%
1648T	2,836	6.40%	0	0.00%	18	0.63%	0	0.00%	2	0.07%	6	0.21%	26	0.92%
1642T	27,145	5.70%	0	0.00%	40	0.15%	1	<0.01%	2	<0.01%	22	0.08%	65	0.24%
1646T	90,426	5.40%	22	0.02%	87	0.10%	0	0.00%	6	<0.01%	75	0.08%	190	0.21%
1688T/TC	491,808	5.50%	222	0.05%	1141	0.23%	2	<0.01%	21	<0.01%	871	0.18%	2257	0.46%

Pacing Leads Worldwide Malfunction Summary

	WORLDWIDE	PERCENT RETURNED				ATION ACH		S, WELDS ONDS	от	HER		INSIC TORS	то	TAL
MODELS	SALES	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
LPA1200M	493,373	1.10%	82	0.02%	140	0.03%	0	0.00%	17	<0.01%	363	0.07%	602	0.12%
2088TC	3,321,760	1.21%	129	<0.01%	1503	0.05%	0	0.00%	87	<0.01%	2684	0.08%	4403	0.13%
1888T/TC	1,152,604	1.66%	75	0.01%	1369	0.12%	1	< 0.01%	34	<0.01%	1316	0.11%	2795	0.24%

Definitions of malfunction categories can be found on pages 8-9.

Pacing Leads Actively Monitored Study Data Summary

QUALIFYING COMPLICATIONS

	NUMBER OF DEVICES	ACTIVE	CUMULATIVE MONTHS OF	PA	ORMAL CING DANCE		DIAC PRATION		OUCTOR		CARDIAC JLATION		LURE TO TURE	1	LURE FO INSE		LATION		AD GEMENT	OVERS	ENSING		ARDIAL JSION		KIN DSION	то	DTAL
MODELS	ENROLLED	ENROLLED	FOLLOW-UP	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
2088	3,886	0	231,416	1	0.03%	1	0.03%	8	0.21%	1	0.03%	11	0.28%	4	0.10%	8	0.21%	15	0.39%	16	0.41%	1	0.03%	0	0.00%	66	1.70%
1999	877	0	53,426	1	0.11%	0	0.00%	2	0.23%	0	0.00%	0	0.00%	2	0.23%	1	0.11%	11	1.25%	1	0.11%	0	0.00%	0	0.00%	18	2.05%
1944	104	0	6,594	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.96%	0	0.00%	0	0.00%	0	0.00%	1	0.96%
1948	765	0	39,100	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.13%	0	0.00%	1	0.13%	2	0.26%	0	0.00%	0	0.00%	0	0.00%	4	0.52%
1699T/TC	1,451	0	78,585	1	0.07%	0	0.00%	2	0.14%	0	0.00%	4	0.28%	0	0.00%	1	0.07%	8	0.55%	1	0.07%	0	0.00%	0	0.00%	17	1.17%
1888T/TC	14,505	0	901,839	7	0.05%	2	0.01%	10	0.07%	4	0.03%	19	0.13%	5	0.03%	29	0.20%	58	0.40%	22	0.15%	0	0.00%	1	<0.01%	157	1.08%
1882T/TC	690	0	43,119	1	0.14%	0	0.00%	0	0.00%	1	0.14%	1	0.14%	1	0.14%	0	0.00%	2	0.29%	2	0.29%	0	0.00%	1	0.14%	9	1.30%
1782T/TC	165	0	5,930	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	1	0.61%	0	0.00%	0	0.00%	1	0.61%
1788T/TC	363	0	13,446	0	0.00%	0	0.00%	0	0.00%	1	0.28%	0	0.00%	0	0.00%	0	0.00%	3	0.83%	0	0.00%	0	0.00%	0	0.00%	4	1.10%
1646T	641	0	15,884	0	0.00%	0	0.00%	0	0.00%	0	0.00%	2	0.31%	0	0.00%	0	0.00%	1	0.16%	0	0.00%	0	0.00%	0	0.00%	3	0.47%
1688T/TC	2,645	0	102,805	5	0.19%	0	0.00%	3	0.11%	0	0.00%	3	0.11%	0	0.00%	3	0.11%	6	0.23%	3	0.11%	1	0.04%	1	0.04%	25	0.95%

Pacing Leads Actively Monitored Study Data Summary

MALFUNCTIONS

	NUMBER OF DEVICES	PERCENT RETURNED				ATION ACH		S, WELDS DNDS	от	HER		INSIC TORS	тот	TAL
MODELS	ENROLLED	FOR ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
2088TC	3,886	5.70%	1	0.03%	13	0.33%	0	0.00%	0	0.00%	13	0.33%	27	0.69%
1999	877	7.50%	0	0.00%	6	0.68%	0	0.00%	0	0.00%	9	1.03%	15	1.71%
1944	104	2.90%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
1948	765	7.10%	0	0.00%	5	0.65%	0	0.00%	0	0.00%	1	0.13%	6	0.78%
1699T/TC	1,451	4.10%	0	0.00%	3	0.21%	0	0.00%	0	0.00%	6	0.41%	9	0.62%
1888T/TC	14,505	4.70%	3	0.02%	29	0.20%	0	0.00%	0	0.00%	36	0.25%	68	0.47%
1882T/TC	690	5.40%	0	0.00%	3	0.43%	0	0.00%	0	0.00%	0	0.00%	3	0.43%
1782T/TC	165	6.10%	0	0.00%	1	0.61%	0	0.00%	0	0.00%	0	0.00%	1	0.61%
1788T/TC	363	5.50%	0	0.00%	2	0.55%	0	0.00%	0	0.00%	0	0.00%	2	0.55%
1646T	641	2.30%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
1688T/TC	2,645	7.60%	1	0.04%	6	0.23%	0	0.00%	0	0.00%	5	0.19%	12	0.45%

Implantable Cardiac Monitors (ICM) Devices

Implantable Cardiac Monitors (ICMs) Devices

US Malfunction Summary

		REGISTERED	PERCENT RETURNED FOR		TRICAL		TRICAL CONNECT	BAT	TERY		WARE/ WARE	MECH	IANICAL	BAT	LE EARLY ITERY LETION	01	THER	тс	TAL
MODELS	FAMILY	US IMPLANTS	ANALYSIS	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE	QTY	RATE
DM4500	Jot Dx [™] ICM	2,024	0.10%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
DM3500	Confirm Rx [™] ICM	80,753	4.30%	7	<0.01%	10	0.01%	0	0.00%	0	0.00%	2	<0.01%	7	<0.01%	4	<0.01%	30	0.04%
DM2102	SJM Confirm™ ICM	5,814	13.00%	19	0.33%	0	0.00%	1	0.02%	0	0.00%	0	0.00%	1	0.02%	5	0.09%	26	0.45%
DM2100	SJM Confirm [™] ICM	18,687	17.70%	15	0.08%	1	< 0.01%	20	0.11%	10	0.05%	0	0.00%	7	0.04%	42	0.22%	95	0.51%

Definitions of malfunction categories can be found on pages 5-6.

ICD Premature Battery Depletion Advisory Update – June 2022

Since the original October 11, 2016 communication, Abbott (formerly St. Jude Medical) has continued to analyze and review the performance data from the affected device population. The rates reported below summarize performance data through February 28, 2022.

Importantly, the information contained in this notice has not altered our previously communicated patient management recommendations. This information is intended to keep you informed of our continuous analysis of all products returned to the company.

RATES


The table below summarizes the updated worldwide experience for the affected devices that were returned for product analysis due to premature battery depletion (PBD). The table includes the updated data through February 28, 2022.

WORLDWIDE PATIENT IMPACT	NUMBER / RATE THROUGH FEBRUARY 28, 2022
No Harm Reported/Additional Surgery Only*	8,895/2.231%
Loss of Pacing – Minor (Dizziness)	60/0.015%
Loss of Pacing – Major (Syncope)	29/<0.01%
Loss of Defibrillation – Emergency	4/<0.01%
Loss of Defibrillation – Death	2/<0.01%
Grand Total	8,990/2.255%
Total Units Sold	398,740

*All impacts in this table were related to a replacement surgery, as the data are from units explanted and returned for analysis. The category "No Harm Reported/Additional Surgery Only" means there was no associated report of patient symptoms in addition to the replacement of the affected unit.

Note: The calculation also includes investigations associated with the Battery Performance Alert notifications. These are reflected in the "No Harm Reported/Additional Surgery Only" category.

Estimated Performance of Affected Fortify[™] Implantable Cardioverter Defibrillator (ICD), Fortify Assura[™] ICD, Quadra Assura[™] Cardiac Resynchronization Therapy Defibrillator (CRT-D), Unify[™] CRT-D, Unify Assura[™] CRT-D and Unify Quadra[™] CRT-D Devices



SURVIVAL CALCULATION GENERAL METHODS


Internal modeling based on an analysis of field returns related to premature battery depletions associated with lithium clusters; updated with data through February 28, 2022.

Non-Advisory Population Update

Fortify[™], Fortify Assura[™], Quadra Assura[™], Quadra Assura MP[™], Unify[™], Unify Assura[™] and Unify Quadra[™] Devices manufactured after May 23, 2015 were built with an improved battery design with additional insulation and thus not included in the advisory population. Through February 2022 there have been zero (N=0) occurrences, worldwide, of premature depletion due to Li clusters with the improved design.

In the US there have been ~ 218,600 implanted devices with the improved battery design with no occurrences of premature depletion associated with Li clusters. Of the implanted US population, ~94% (or ~204,500) have exceed 1 year of implant duration and ~81% (or ~177,000) have exceed 2.0 years of implant duration with no occurrences of premature depletion due to Li clusters.

SURVIVAL PLOT FOR NON-ADVISORY POPULATION KAPLAN-MEIER METHOD CENSORING FOR NON-ADVISORY POPULATION WITH CLUSTER




Update on Riata[™] Lead Performance

CUSTOMER REPORTED PERFORMANCE DATA

Abbott understands that the passive system of complaint reporting and returned product analysis results in under-reporting and hence underestimates the true failure rate associated with any given failure mechanism. This is especially true for externalized conductors since most manifest as visual anomalies only with normal electrical performance. While acknowledging these limitations, Abbott provides externalized conductor rates from the passive data system to maintain continuity with previously published data and to provide full disclosure of the data available to Abbott. As of February 28, 2022, there were 6,592 cases of externalized conductors reported to Abbott worldwide on Riata[™] (8F) and Riata[™] ST (7F) silicone defibrillation leads, equating to a 3.54% (5,523/156,000) incidence rate for Riata (8F) and 1.51% (1,069/70,600) for Riata ST (7F) leads. Of these 6,592 leads, 4,811 were not returned and 1,781 were returned for analysis.

As with any lead, there are failure mechanisms other than externalized conductors which result from insulation abrasion. Historically, the rate of all-cause insulation abrasion failures has been reported in the range of 3 to 10% (Kleemann et al., Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter Defibrillators over a Period > 10 years, Circulation 2007; 115:2474-2480). The most common form of insulation abrasion has been lead-to-can abrasion occurring in the pocket area. Externalization of conductors is another manifestation of insulation abrasion. It is most commonly caused by a mechanism referred to as inside-out abrasion, where the conductor cables become visible outside the insulation body. Approximately 87% of confirmed externalized conductors from product returns analysis are caused by inside-out abrasion, while 13% result from external sources of abrasion.

A flow diagram depicting specific insulation abrasion failure mechanisms for Riata" and Riata" ST silicone leads is shown in the following figure.



FLOW DIAGRAM OF INSULATION ABRASION TYPES AND FAILURE MECHANISMS

*Determined by returned product analysis.

**Includes cases determined by returned product analysis as well as cases identified only by fluoroscopy or visualization of explanted leads.

Definitions of the failure mechanisms are provided below:

- External Abrasion: Abrasion resulting from direct contact with an implanted device (e.g., pulse generator can, another lead), calcified anatomy, or anatomical structure that results in an outer insulation breach.
- Internal Abrasion: "Inside-out" abrasion between a lead conductor and the outer insulation that results in an insulation breach.
- Intravascular Abrasion External: Direct contact with a foreign body (e.g., another lead), calcified anatomy, or cardiac structure within the vascular system or the heart that results in an outer insulation breach. The nature of the breach does not result in the conductors becoming visible outside the lead body. Determined by returned product analysis.
- Externalized Conductors External Source of Abrasion: Direct contact with a foreign body (e.g., another lead), calcified anatomy, or cardiac structure within the vascular system or the heart that results in an outer insulation breach and the normally contained conductors becoming visible outside the lead body. Includes cases determined by returned product analysis as well as cases identified only by fluoroscopy or visualization of explanted leads. For those cases not returned, the assignment of an external source of abrasion is based on the fraction of externalized conductor cases identified by returned product analysis as external.
- Lead-to-Can Abrasion: Direct contact between the lead and the can (i.e. pacemaker, ICD, or CRT-D) that results in an outer insulation breach. Determined by returned product analysis.
- Insulation Damage: Insulation breaches that result from external mechanisms, including clavicular crush and outside-in abrasion by lead conductors. Determined by returned product analysis.
- Intravascular Abrasion Inside Out: "Inside-out" abrasion between a lead conductor and the outer insulation within the vascular system or the heart that results in an outer insulation breach. The nature of the breach does not result in the conductors becoming visible outside the lead body. Determined by returned product analysis.
- Externalized Conductors Inside-Out: Outward abrasion of conductors that results in an outer insulation breach within the vascular system or heart and the normally contained conductors becoming visible outside the lead body. Includes cases determined by returned product analysis as well as cases identified only by fluoroscopy or visualization of explanted leads. For those cases not returned, the assignment of an inside-out source of abrasion is based on the fraction of externalized conductor cases identified by returned product analysis as inside-out.
- Internal Abrasion Short under RV Shock Coil: Outward abrasion of the conductor cables under the RV shock coil that results in breaches of the outermost silicone insulation and the ETFE cable insulator, allowing the exposed metal surface of the conductor cables to make direct contact with, and potentially short against, the overlying RV shock coil. Determined by returned product analysis.
- Internal Abrasion Short under SVC Shock Coil: Outward abrasion of the conductor cables under the SVC shock coil that results in breaches of the outermost silicone insulation and the ETFE cable insulator, allowing the exposed metal surface of the conductor cables to make direct contact with, and potentially short against, the overlying SVC shock coil. Determined by returned product analysis.

The table below summarizes the incidence of insulation abrasion failure mechanisms confirmed by returns analysis of Riata^{**} and Riata^{**} ST leads. Approximately 15,120 Riata and Riata ST leads have been returned for analysis worldwide through February 28, 2022. Returned leads may exhibit more than one failure mechanism; hence the incidence rates presented in the table are not mutually exclusive. Note that the rates for externalized conductors also include visual-only observations that have been reported for leads remaining implanted.

RIATA[®] (8F) AND RIATA[®] ST (7F) LEAD INSULATION ABRASION FAILURE MECHANISMS FROM COMPLAINTS AND RETURNS

INSULATION FAILURE MECHANISM	ABRASION TYPE	RIATA (8F) WORLDWIDE (WW) INCIDENCE RATE (WW SALES = 156,100)	RIATA ST (7F) WORLDWIDE (WW) INCIDENCE RATE (WW SALES = 70,600)
Intravascular – External*	External Abrasion	0.55%	0.58%
Externalized Conductors – External**	External Abrasion	0.42%	0.21%
Lead-to-Can*	External Abrasion	1.07%	0.97%
Insulation Damage*	External Abrasion	0.11%	0.07%
Intravascular - Inside Out*	Internal Abrasion	0.64%	0.44%
Externalized Conductors - Inside Out**	Internal Abrasion	3.18%	1.31%
Internal Abrasion Short Under RV Shock Coil*	Internal Abrasion	0.13%	0.05%
Internal Abrasion Short Under SVC Shock Coil*	Internal Abrasion	0.13%	0.021%

*Determined by returned product analysis.

**Includes cases determined by returned product analysis as well as cases identified only by fluoroscopy or visualization of explanted leads.

Update on Durata[™] Lead Performance

CUSTOMER REPORTED PERFORMANCE DATA

While large active registry data are robust for determining the true incidence rate of failures, passively collected data from worldwide complaints and returns analysis provides an important data source for better understanding the root cause of lead failures, as well as an appropriate method for comparing relative incidence rates of failure between lead models. The table below summarizes the incidence of insulation abrasion failure mechanisms confirmed by returns analysis of RiataTM ST OptimTM and DurataTM leads. Approximately 28,460 Riata ST Optim and Durata leads have been returned for analysis worldwide through February 28, 2022. Returned leads may exhibit more than one failure mechanism; hence the incidence rates presented in the table are not mutually exclusive.

DURATA™ (WW SALES 939,693) AND RIATA™ ST OPTIM™ (WW SALES = 33,109) LEADS INSULATION FAILURE MECHANISMS FROM COMPLAINTS AND RETURNS ANALYSIS

INSULATION FAILURE MECHANISM	ABRASION TYPE	OPTIM DEFIB LEAD WORLDWIDE (WW) INCIDENCE RATE (WW SALES = 972,802)
Intravascular – External*	External Abrasion	0.034%
Externalized Conductors – External**	External Abrasion	0.007%
Lead-to-Can*	External Abrasion	0.104%
Insulation Damage*	External Abrasion	0.026%
Intravascular - Inside Out*	Internal Abrasion	0.00216%***
Externalized Conductors - Inside Out**	Internal Abrasion	0.00041%***
Internal Abrasion Short Under RV Shock Coil*	Internal Abrasion	0.015%
Internal Abrasion Short Under SVC Shock Coil*	Internal Abrasion	0.009%

*Determined by returned product analysis.

**Includes cases determined by returned product analysis as well as cases identified only by fluoroscopy or visualization of explanted leads.

***These values reflect returns with a silicone insulation breach due to inside-out abrasion in the short region not protected by Optim insulation.

These incidence rates from complaints and returns analysis demonstrate the effectiveness of the Riata ST Optim and Durata lead design changes in reducing insulationrelated failures when compared to the same type of data for Riata and Riata ST silicone leads (see page 298).

Update on Optim[™] Lead Insulation

In 2006 Abbott brought to the cardiac rhythm management (CRM) market the first novel insulation technology in over 20 years: a silicone-polyurethane co-polymer known as Optim[®] lead insulation, now featured in IsoFlex[®] Optim[®], Tendril[®] STS, OptiSense[®], QuickFlex[®] µ, Quartet[®], Durata[®], and Optisure[®] lead families. Optim lead insulation consolidates the best characteristics of two established CRM lead insulation materials, polyurethane and silicone.

The polyurethane content of Optim lead insulation imparts lubricity, strength, and abrasion resistance while the nearly 50% silicone content imparts flexibility and biostability.^{1,2} The clinical performance of >8.0 million Optim insulated pacing and tachycardia leads implanted worldwide continues to be excellent. All aspects of Optim lead insulation performance can be appreciated by referring to the Acute Observation, Chronic Complication, Lead Malfunction, and Survival Probability data found in this Product Performance Report. One noteworthy reliability benefit of Optim lead insulation is a significant reduction in the most common mode of lead malfunction: insulation abrasion.³ Insulation abrasion can occur as a result of lead motion and contact with pacemakers, ICDs, adjacent leads, or anatomical structures and can occur in the subcutaneous, intravascular, or intracardiac areas of the lead. Abrasion within a lead can occur as a result of contact between internal components, as noted in our November 2011 Riata[™] lead advisory. The clinical effects associated with all types of insulation abrasion malfunctions can include sensing noise and changes in both pacing and defibrillation impedances and thresholds. As indicated in our December 2010 Riata communication, the presence of Optim[™] lead insulation on the Riata[™] ST Optim[™] and Durata[™] defibrillation lead family has greatly reduced the quantity of all abrasion types.


This Product Performance Report provides an up-to-date statistical assessment of the benefits of Optim lead insulation on Abbott tachycardia leads. A Kaplan-Meier analysis including all U.S. data through December 31, 2021 was performed on two groups of leads: (1) tachycardia leads with silicone insulation [Riata and Riata ST lead families], and (2) tachycardia leads with Optim lead insulation [Riata ST Optim and Durata lead families]. For each group, the U.S. registration and tracking data was combined with data from all U.S. confirmed abrasion malfunctions. This analysis does not include data from prospective registries or non-returned complaints. A Kaplan-Meier curve representing freedom from abrasion for both groups is provided below. The longest implant duration that is common to both model groups was 183 months. To provide a direct comparison of both model groups, the probability of an abrasion malfunction by 183 months of implant time is also presented in graphical format below.

¹ C. Jenney, J. Tan, A. Karicherla, J. Burke, and J. Helland, "A New Insulation Material for Cardiac Leads with Potential for Improved Performance," HRS 2005, HeartRhythm, 2, S318-S319 (2005). 2 J. Tan and C. Jenney, "Comparative In Vivo Biostability Study of A New Lead Insulation Material Versus Polyurethanes," HRS2006, Heart Rhythm, 3, S146 (2006).

³ T. Kleemann, T. Becker, K. Doenges, M. Vater, J. Senges, S. Schneider, W. Saggau, U. Weisse, and K. Seidl, "Annual Rate of Transvenous Defibrillation Lead Defects in Implantable Cardioverter-Defibrillators Over a Period of >10 Years," Circulation, 115, 2474-2480 (2007).

The data show that the presence of Optim[®] lead insulation dramatically reduces the probability of abrasion malfunction in tachycardia leads at 183 months by 80%, which was confirmed to be statistically significant (p<0.001) by a log-rank test.

OPTIM^{TE} LEAD INSULATION EFFECTS ON ABBOTT TACHYCARDIA LEAD ABRASION KAPLAN-MEIER ANALYSIS OF U.S. RETURNS ANALYSIS DATA



The following table summarizes advisories and safety alerts regarding Abbott implantable device systems since 2005. These advisories and alerts have been previously communicated to physicians. For more information please access our Product Advisory web page at <u>Cardiovascular Product Advisories | Abbott</u> or contact Abbott Technical Services at 1-800-722-3774.

ICD AND CRT-D DEVICES

Subset of Ellipse" (Models CD24II-36C, CD1277-36, CD1377-36C, Class II in affected devices. This solution does not present additional risk to patients and device explant is not required for the up of the solution is available in Merlin" PCS Programmer software Model 3330 v24.6.1 or later and Abbott will assist in updati of Ellipse" Implantable Cardioverter Defibrillators Abbott is notifying physicians that a small number of Ellipse" Implantable Cardioverter Defibrillators programmer software and restoring wireless RF communication for these devices. (CD3) may lose wireless radiofrequency (RF) We recommend working with your Abbott representative to help correct affected devices during the patient's next regular software.	MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
	Subset of Ellipse ¹⁴ (Models CD2411-36C, CD1277-36, CD1377-36C,	Class II Abbott is notifying physicians that a small number of Ellipse" Implantable Cardioverter Defibrillators (ICDs) may lose wireless radiofrequency (RF) communication. Devices will continue to function normally, but remote monitoring and data	We recommend working with your Abbott representative to help correct affected devices during the patient's next regularly

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
GLOBAL MODELS Ellipse™ (Models CD1411-36Q, CD2411-36Q, CD2411-36C)	6/21/2019 Class I The potential for electrical failures was identified in implantable cardioverter defibrillators (ICDs) due to a manufacturing error with aluminum wires. The affected ICDs may contain electrical wire connections which may not be completely insulated. The potential patient impact could be the inability to deliver high voltage therapy. There is no available option to verify the vulnerability status for implanted devices.	On June 20, 2019 Abbott began voluntarily recalling a small number (204 devices globally) of Ellipse implantable cardioverter defibrillators (ICDs) from our customers and hospitals to prevent implant of devices that may have a latent vulnerability in the electronics circuitry. We have currently received zero (0) product performance complaints related to this issue. On June 21, 2019, hand-delivery of Urgent Medical Device Recall Notices to physicians supporting implanted patients commenced. Device explant and replacement are recommended. Customers were advised to: 1) Review the device model and serial numbers in the appendix of the customer letter to identify the impacted patients and return the acknowledgement form to the Abbott sales representative; and 2) Device explant and replacement are recommended. A copy of this letter is available on <u>Cardiovascular Product Advisories</u> [Abbott. Customers with additional questions are encouraged to call 1-800-727-7846 (Opt3), 8:30am - 5:30pm Central Time, Monday thru Friday. Current Status (December 31, 2021): No occurrences of failure to deliver high voltage therapy have been reported following the field communication. Potentially affected devices have been or are planned for explant per recommendations.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
GLOBAL MODELS Current" (Models 1207-30, 1207-36, 2207-30, 2207-36, CD1211-36, CD1211-36Q, CD1215-36, CD1215-36Q, CD1217-36, CD1219-36, CD1219-36Q, CD2211-36, CD2211-360, CD2215-36, CD2215-36Q, CD2217-36, CD2219-36Q, CD2219-36Q, Ellipse" (Models CD1275-36, CD1275-36Q, CD1277-36, CD1277-36Q, CD1377-36C, CD1377-36C, CD1377-36Q, CD1	ADVISORY 4/16/2018 Class II Abbott released a planned upgrade to the firmware installed on our implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) devices. The cybersecurity firmware update provides an additional layer of protection against unauthorized device access.	 FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY Prophylactic replacement of affected devices is not recommended. Recommendations for Devices Eligible for Firmware Upgrade While not intended to serve as a substitute for your professional judgment, we, along with our Medical Advisory Boards, recommend the firmware upgrade for all eligible patients at the next regularly scheduled visit or when appropriate depending on the preferences of the patient and physician. Please consider the following: Discuss the risks and benefits of the firmware update with your patients. As part of this discussion, it is important to consider patient specific issues such as pacemaker dependence, frequency of high voltage therapy, age of device, and patient preference. If deemed appropriate, install this firmware update following the instructions on the programmer. The update should be performed with appropriate monitoring and external defibrillation equipment available. Recommendations for Current[*] & Promote[*] Devices not Eligible for Cybersecurity Firmware Update If you have any concerns relating to device cybersecurity for those patients implanted with Current[*]/Promote[*] devices, you do have the option to permanently disable the RF communication capability in the device. However, if you choose that option, the patient can no longer be monitored remotely using an RF Merlin@home transmitter. For most patients, permanently disabling RF is not advisable given the prove henefits and proven benefits of remote monitoring with your patients at the next regularly scheduled vist. If deemed appropriate, RF communication may be permanently disabled during an in-clinic device interrogation with Merlin programmer software version 24.2.x or later by selecting the RF icon in the upper left corner of the FastPath summary screen. Current Status (D

ABBOTT PRODUCT PERFORMANCE REPORT 2022 FIRST EDITION / PAGE 304

Quadra Assura MP" (Models CD3269-40, CD3269-40Q, CD3271-40, CD3271-40Q, CD3369-40C, CD3369-40Q, CD3371-40, CD3371-40C,

Quadra Assura^w (Models CD3265-40, CD3265-40Q, CD3267-40, CD3267-40Q, CD3365-40C, CD3365-40Q, CD3367-40, CD3367-40C, CD3367-40Q,

Unify Assura[™] (Models CD3257-40, CD3257-40Q, CD3261-40, CD3261-40Q, CD3357-40C, CD3357-40Q, CD3361-40, CD3361-40C, CD3361-40Q,

Unify Quadra^w (Models CD3249-40, CD3249-40Q, CD3251-40, CD3251-40Q) Unify^w (Models CD3231-40, CD3231-40Q, CD3235-40, CD3235-40Q)

Unify Quadra MP¹¹ (Models CD3255-40, CD3255-40Q)

CD3371-40Q, CD3371-40QC)

CD3367-40QC)

CD3361-40QC)

ICD AND CRT-D DEVICES

CD3361-40, CD3361-40C, CD3361-40Q, CD3361-40QC)

Unify Quadra MP⁻ (Models CD3255-40, CD3255-40Q)

Unify (Models CD3231-40, CD3231-40Q, CD3235-40,

Unify Quadra" (Models CD3249-40, CD3249-40Q,

CD3251-40, CD3251-40Q)

CD3235-40Q)

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
GLOBAL MODELS Excelis Quadra" (Models CD3281-40, CD3281-400)	10/11/2016 Class I	In consultation with our Medical Advisory Board, we recommend the following:
Excelis quadra (Models CD3281 10, CD3281 10Q) Excelis" + (Models CD3389-40C, CD3389-40QC)		Do not implant unused affected devices.
Excelis" CRT-D (Models CD3297-40, CD3297-40Q)	High voltage devices (ICDs and CRT-Ds) that	Conduct patient follow-up per standard practice.
Fortify Assura ⁻ DR (Models CD2257-40, CD2257-40Q,	utilize Lithium-based battery chemistries are	• Prophylactic device replacement is NOT recommended because complications following replacement have been reported to occur at
CD2259-40, CD2259-40Q, CD2357-40C, CD2357-40Q,	subject to Lithium cluster formation during high	a greater rate than the rate of harm associated with premature battery depletion due to lithium cluster induced shorts (see below for
CD2359-40, CD2359-40C, CD2359-40Q, CD2359-40QC)	voltage charging. Depending on their location,	selected references).
Fortify Assura ST DR (Models CD2263-40, CD2263-40Q,	Lithium clusters may cause a short circuit that	• In the event of an ERI indicator in these devices, immediate device change is recommended. At this time there is no factor, method or test
CD2363-40C, CD2363-40Q)	can lead to premature battery depletion. Our	to identify devices with this form of premature battery depletion approaching ERI or to accurately predict remaining battery life once
Fortify Assura ST VR (Models CD1263-40, CD1263-40Q,	investigation indicates that if a short circuit occurs,	ERI appears.
CD1363-40C, CD1363-40Q)	battery depletion can occur in these devices within	Physicians should reaffirm the availability of home monitoring to avoid or minimize time without device therapy for bradycardia and task available to avoid or minimize time without device therapy for bradycardia and
Fortify Assura [®] VR (Models CD1257-40, CD1257-40Q, CD	a day to a few weeks, which may result in the inability to deliver therapy.	tachycardia events. • Dered a structure in Markin nor" Dationt Caro Network (DCN) utilizing the "Direct Marto" feature to provide you wish an immediate alart
CD1259-40, CD1259-40Q, CD1357-40C, CD1357-40Q, CD1359-40, CD1359-40C, CD1359-40Q, CD1359-40QC)	maonity to deriver therapy.	 Enroll patients in Merlin.net[®] Patient Care Network (PCN) utilizing the "DirectAlerts[®] feature to provide you with an immediate alert notification in the event ERI is reached. For patients currently enrolled in Merlin.net PCN, remind them of the importance of using
Fortify" DR (Models CD2231-40, CD2231-40Q, CD2233-40,		remote monitoring.
CD2233-400)		Review the most recent Programmed Parameters printout.
Fortify ST DR (Models CD2235-40, CD2235-40Q,		 • Ensure that under the "Trigger Alerts When" section, that the "Device at ERI" parameter is ON (it is normally ON) for both "Show on
CD2241-40, CD2241-40Q)		FastPath" and "Notify Patient" selections.
Fortify ST VR (Models CD1235-40, CD1235-40Q,	8/28/2017	• If the "Device at ERI" alert is OFF, we recommend that the patient be seen promptly to program this parameter ON.
CD1241-40, CD1241-40Q)	Class I	• Advise patients that an ERI indication triggers a vibratory alert. At the next scheduled office visit:
Fortify VR (Models CD1231-40, CD1231-40Q, CD1233-40,		• Interrogate the patient's device to determine if an ERI alert has been triggered. Premature battery depletion can be identified by
CD1233-40Q)	Customers were made aware of the availability	physicians through home monitoring showing ERI or more advanced battery depletion.
HeartMinder" + DR (Models CD2391-40C, CD2391-40QC)	of a new battery performance management tool	 Perform a patient notifier test to confirm that the patient feels and recognizes the vibratory alert.
HeartMinder" + VR (Models CD1391-40C, CD1391-40QC)	for detection of abnormal battery performance in	 Patients who cannot feel the vibratory alert may experience loss of battery and/or loss of device function without their awareness.
HeartMinder [®] ST DR (Models CD2299-40, CD2299-40Q)	devices subject to the October 2016 advisory.	• Advise the patient to contact your office promptly should they feel a vibratory alert.
HeartMinder" ST VR (Models CD1299-40, CD1299-40Q)		• In-office evaluation should be performed to determine the reason for the alert as other non-critical events can also trigger a vibratory
Quadra + Excelis" (Models CD3385-40C, CD3385-40QC)		alert.
Quadra Assura MP ⁻ (Models CD3269-40, CD3269-40Q, CD3271-40, CD3271-40Q, CD3371-40, CD3371-40C,		The following additional recommendations were communicated in April 2018 follow up advisory:
CD3271-40Q, CD3271-40Q, CD3371-40C, CD3371-40C, CD3371-40Q, CD3371-40QC)	A follow up was provided on April 16, 2018	 Patients receiving the firmware update should be advised that the device-based Battery Performance Alert (BPA) will trigger a
Quadra Assura" (Models CD3265-40, CD3265-40Q,	regarding the availability of a firmware upgrade for	 rateristicerving the initiate update should be advised that the device-based battery refrontiance Activity with trigger a vibratory alert.
CD3267-40, CD3267-40Q, CD3365-40C, CD3365-40Q,	devices subject to the October 2016 advisory which	In the absence of a BPA being triggered in a patient's device, through Merlin.net or the Merlin programmer, we continue to recommend
CD3367-40, CD3367-40C, CD3367-40Q, CD3367-40QC)	provides further detection capability for premature	adhering to the original patient management recommendations from the 2016 Premature Battery Depletion advisory. However, if the
Unify Assura [®] (Models CD3257-40, CD3257-40Q,	battery depletion.	BPA is triggered, immediate device explant and replacement is recommended.
CD3261-40, CD3261-40Q, CD3357-40C, CD3357-40Q,		

Device Replacement Complication Publications

- John W. Moore III, William Barrington, et. al.; "Complications of replacing implantable devices in response to advisories: A single center experience"; International Journal of Cardiology 134 (2009) 42–46 (5.5% overall, 2.1% major complications)
- 2. Paul A. Gould, MBBS, PhD, Lorne J. Gula, MD, et. al., "Outcome of advisory implantable cardioverter- defibrillator replacement: One-year follow-up"; Heart Rhythm, Vol 5, No 12, December 2008 (9.1% overall, 5.9% major complications, including two deaths)
- 3. Krystina B. Lewis, Dawn Stacey, R.N., Ph.D., et. al.; "Estimating the Risks and Benefits of Implantable Cardioverter Defibrillator Generator Replacement: A Systematic Review; PACE, Vol. 39, July 2016 (7.5% overall, 4.0% major complications)

Current Status (February 28, 2022): At the time of the advisory, 841 returned devices (0.21%) of 398,740 devices worldwide had premature depletion in association with lithium clusters, including 549 in the US. As of February 28, 2022, there were additional occurrences for a cumulative worldwide total of 8,990 and the rate is now 2.26%.

For additional information and to determine if a device serial number is subject to this advisory, please go to the following website: Cardiovascular Product Advisories | Abbott,

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Ellipse [*] and Ellipse ST VR/DR US: CD1309, CD1311*, CD1409, CD1411*, CD2309, CD2311*, CD2409, CD2411* (all -36, -36Q, -36C and -36QC suffixes). *Denotes models also sold OUS. OUS: CD1277, CD1279, CD1293, CD1295, CD1377, CD1393, CD2295, CD2377, CD2293, CD2295, CD2377, CD2393 (all -36, -36Q, -36C and -36QC suffixes).	8/19/2014 Class II Extended Charge Time may result in delayed delivery of high voltage therapy or prevent delivery of part or all of a programmed high voltage therapy shock. The anomaly most commonly presents as a vibratory patient notification and upon interrogation, a programmer or Merlin.net [®] Patient Care Network (PCN) alert indicating a [®] Capacitor Charge Time Limit reached [®] message. This may occur during a capacitor maintenance or charging for high voltage therapy. The anomaly occurs as a result of internal damage to the capacitors used in the high voltage charging circuitry of the subject devices, which may result in an extended charge time. As designed, the device will deliver the available energy on the capacitors once the charge time limit of 32 seconds is reached, even if the energy is less than the programmed value. This condition is detectable as the device will initiate a vibratory patient alert and, for patients enrolled and actively being	 Abbott recommends that patients with affected devices be enrolled in Merlin.net Patient Care Network (PCN) so that any extended charge time alert ("Capacitor Charge Time Limit reached" message) will be transmitted to Merlin.net PCN for patients being actively monitored and can be viewed by your clinic staff. If your patient has received a vibratory notification and/or if a programmer or Merlin.net alert for an extended charge time has been observed: Schedule your Ellipse ICD patient for an in-office follow-up evaluation as soon as possible. Interrogate the Ellipse ICD and perform a manual capacitor maintenance charge. Note the charge time to full charge; it should be approximately 15 seconds or less. Contact Abbott CRM Technical Services Department at 800-722-3774 to review the results of the capacitor maintenance test and discuss if additional evaluation is required. A device that has experienced repeated extended charge time out warnings should be considered for replacement. As the large majority of the extended charge time events have presented at the routine 6 month automatic capacitor maintenance interval, programming the interval to every 4 months at your patient's next scheduled follow up visit may provide an earlier indication of this potential anomaly. It should be noted that changing the device programming to a 4 month capacitor maintenance interval will reduce device longevity by approximately 9%. Device replacement is not recommended for an Ellipse device exhibiting normal charge times, and patients should continue to be followed at routine follow up intervals, per HRS/EHRA Expert Consensus on Monitoring Cardiovascular Implantable Electronic Devices (CIED), April 2008.
	followed, a Merlin, net PCN notification. Additionally, upon device interrogation, an alert message will indicate "Capacitor Charge Time Limit reached" on a specific date. Approximately 97% of Ellipse ICD extended charge time events reported to Abbott have been detected during capacitor maintenance	Current Status (December 31, 2021) : At the time of the advisory, the worldwide event rate of extended charge time on the affected population was 0.42%, based on 179 extended charge time events out of 43,000 worldwide sales. As of December 31, 2021, there were additional reports and the rate is now 1.48%. There have been no reports of serious injury or death within this population.

with the remainder detected during defibrillation threshold (DFT) testing. There have been no reported cases of an Ellipse device failing to deliver high voltage therapy to a patient when

needed.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION

AnalyST Accel⁻ DR RF

ADVISORY

1/23/2014 Outside US only

(Models CD2219-36, CD2219-36Q) AnalyST Accel⁻ VR RF (Models CD1219-36, CD1219-36Q) Current Accel⁻ DR RF (Models CD2215-36, CD2215-36Q) Current Accel VR RF (Models CD1215-36, CD1215-36Q) Current⁻ DR (Model 2207-36) Current VR (Model 1207-36) Ellipse" DR (Models CD2277-36, CD2277-36Q, CD2377-36, CD2377-36Q, CD2377-36C, CD2377-36QC) Ellipse VR (Models CD1277-36, CD1277-36Q, CD1377-36, CD1377-36Q, CD1377-36C, CD1377-36QC) Fortify Assura DR (Models CD2259-40, CD2259-40Q, CD2359-40, CD2359-40Q, CD2359-40C, CD2359-40QC) Fortify Assura VR (Models CD1259-40, CD1259-400, CD1359-40, CD1359-400, CD1359-40C, CD1359-40QC) Fortify ST DR (Models CD2235-40, CD2235-40Q) Fortify ST VR (Models CD1235-40, CD1235-40Q) Promote Accel" RF (Models CD3215-36, CD3215-36Q) Promote Quadra" (Models CD3239-40, CD3239-40Q) Promote" (Model 3213-36) Quadra Assura" (Models CD3267-40, CD3267-40Q, CD3367-40, CD3367-40Q, CD3367-40C, CD3367-40QC) Quadra Assura MP" (Models CD3371-40, CD3371-40Q, CD3371-40C, CD3371-40QC) Unify Assura (Models CD3261-40. CD3261-400, CD3361-40, CD3361-400, CD3361-40C, CD3361-40QC) Unify Quadra" (Models CD3251-40, CD3251-40Q) Unify (Models CD3235-40, CD3235-40Q)

In November 2013, Abbott released the Merlin[®] Programmer Software version 17.2.2 rev. 0 (herein after referred to as 17.2.2) as an upgrade to existing programmers. Testing has shown that, when using a programmer with the 17.2.2 software, an incorrect value for sinus redetection, potentially affecting the high voltage therapy delivery sequence can occur when a device is programmed to a single VF detection zone. The issue can be introduced during programming of certain families of Abbott ICD/CRTD devices. The issue is not present when a device is programmed to a two or three zone configuration. When using the 17.2.2 software and any parameter is programmed as part of a single VF detection zone configuration, the sinus redetection value will be inappropriately set to zero milliseconds. As a result, any intrinsic activity following the first shock will be considered a "sinus rate" and the device will diagnose "return to sinus". Therefore, if the arrhythmia was not terminated by the initial high voltage therapy, the ongoing arrhythmia would be considered a new episode causing the next high voltage therapy to also be delivered at the first programmed energy level. For example, if the first shock is programmed to 20 joules and subsequent shocks are programmed to higher energy values, the only HV therapy the patient would receive if the arrhythmia continues and is redetected, would be 20 joules, rather than the increasing HV energy levels as programmed.

FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY

Immediate Resolution Steps:

- Review your SJM⁻ ICD/CRT-D patient records for patients with affected devices implanted or seen in clinic starting in September 2013
 and programmed to a single VF detection zone with the 17.2.2 software. For patients identified during this review we recommend that you
 schedule an immediate follow-up visit. The programmer software version is printed on the bottom of each report page.
- For patient devices programmed as described above with 17.2.2 software, a new software version 17.2.3 will correct this issue and is expected to be available by February 2014. Your Abbott representative will assist you with obtaining and installing the 17.2.3 software on your programmer. Using this software, programming any parameter will reset the return to sinus criteria to normal function.
- If a patient is seen before the 17.2.3 software is installed, then program the device to a two or three zone configuration, even if one of the zones is strictly a monitor zone. This will resolve the issue when using a programmer with 17.2.2 software.

Current Status (December 31, 2021): Software version 17.2.3 which corrected the issue was released in early 2014. No occurrences have been reported or are expected following the field communication and correction.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Fortify` ST (Models CD1235-40, CD1235-40Q, CD2235-40, CD2235-40Q)	4/18/2013 Outside US only The Merlin [®] PCS programmer software Model 3330 versions 14.2.2, 16.2.1 and 17.2.1.1 provide new features for Abbott ICDs, including an option to enhance the ST diagnostic features in Abbott Fortify [®] ST ICD models CD1235-40, CD1235-40Q, CD2235-40 and CD2235-40Q via a device software upgrade. During a device software upgrade, implanted devices are temporarily placed into the back-up pacing (BVV) and back-up defibrillation only (BDFO) mode. The back-up mode parameter settings will be in effect for the two minute upgrade process. Once the upgrade successfully completes, the device will revert to the previously programmed parameter settings. Depending on the individual patient, this temporary change in parameter values while in back-up defibrillation on wode could make the device susceptible to oversening and potentially deliver high voltage therapy during the upgrade procedure.	In order to prevent the potential for inappropriate therapy during the software upgrade process, consider programming the "Tachy Therapy Enabled/Disabled" function to Disabled prior to proceeding with the software upgrade. It is imperative to re-interrogate the device and program the "Tachy Therapy Enabled/Disabled" function to Enabled after the upgrade has been successfully completed. As with any device evaluation and programming, ECG monitoring and availability of back up external defibrillation equipment is recommended during the entire software upgrade process. Current Status (December 31, 2021) : At the time of the advisory there were 20 devices confirmed to be affected by this issue. As of December 31, 2021 there were an additional 52 devices confirmed with this issue. There have been no reports of serious injury or death.

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Convert [*] + (Model V-195)	5/6/2010 Outside US only	If a patient's device is already programmed to a two zone configuration with a Merlin [¬] PCS programmer running version 7.2.1, 8.2.1 or 10.2.0, a follow-up visit should be scheduled to perform the recommendations outlined below:
	A condition where devices programmed to a two-zone tachy therapy configuration, using a Merlin [®] Patient Care System (PCS) programmer running version 7.2.1, 8.2.1 or 10.2.0 software, can result in the VT Therapy Timeout parameter being	A permanent correction is available in the new release of the Merlin [®] PCS programmer software version 10.2.2 which has received regulatory approval. Subsequently using a Merlin [®] programmer with 10.2.2 (or later) software and following the steps outlined below will ensure that the VT Therapy Timeout parameter is programmed ON.
	programmed OFF and HV therapy not being available if ATP therapies are unsuccessful.	 Interrogate the Convert+ ICD and verify that it is programmed to a two zone configuration. Program the device to a single zone, fibrillation only tachycardia mode. This action will program the VT Therapy Timeout parameter ON.
		3. Re-program the device to the desired two zone configuration. (VT Therapy Timeout will remain ON).
		If your patient's device is programmed to a single zone (fib only) there is no need to perform any reprogramming action.
		As these actions fully correct the potential issue there is no need to consider any device explant.
		Current Status (December 31, 2021): At the time of the advisory there was one report of this issue out of approximately 330 Convert+ Model V-195 ICDs distributed in Europe and Asia. As of December 31, 2021. there have been no additional reports associated with this

advisory.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Epic ⁻ ICDs	1/16/2008	A simple programmer software/device firmware upgrade will resolve the issue and prevent a future occurrence. Patients who are followed
(Models V-197, V-235, V-337,	Class II	on a routine basis with scheduled follow-up visits every three to six months should continue with their scheduled visit. Upon interrogation
V-338, V-339),		of one of the subject devices, the Merlin Patient Care System and Model 3510 programmers with the newly provided software will
Epic" + ICDs	A very rare condition (incidence of eight in 143,000 devices	automatically identify a device that can benefit from a firmware upgrade and will instruct the clinician that an upgrade is available.
(Models V-196, V-233, V-236,	worldwide; six in the US and two outside the US) that could	
V-239, V-350)	lead to a ventricular sensing anomaly in Epic" and Atlas" family	Abbott, along with our independent Medical Advisory Board members, has determined that no other action is recommended.
Epic" II ICDs	of implantable cardioverter defibrillators (ICDs) has been	
(Models V-158, V-255, V-258,	identified. A loss of ventricular sensing would prevent an ICD	Current Status (December 31, 2021): At the time of the advisory, there were 8 worldwide (6 U.S.) devices confirmed to have been affected by
V-355, V-356, V-357)	from being able to detect an arrhythmia. The loss of ventricular	this issue. As of December 31, 2021 there have been no additional devices confirmed to have this issue since the time of the advisory.
Atlas" + ICDs	sensing anomaly can only occur when the device's software	
(Model V-340, V-341, V-343,	writes to a particular memory location and only if there is a	
V-193, V-242, V-243)	precise alignment of two timing parameters that normally do	
Atlas" II ICDs	not coincide during routine operation of the device. The precise	
(Models V-168, V-265, V-268,	alignment requires the software write to occur at the exact time	
V-365, V-366, V-367)	that a comparison is made during a specific 61 microsecond	
	(µsec) window.	

MODEL IDENTIFICATION

Photon[®] DR (V-230HV) (certain serial numbers), Photon[®] Micro VR/DR (Models V-194, V-232), Atlas[®] VR/DR (Models V-199, V-240)

10/7/2005 Class II

ADVISORY

A particular vendor-supplied memory chip can be affected at a low frequency rate by background levels of atmospheric ionizing cosmic radiation ("background cosmic radiation"). The anomaly can trigger a temporary loss of pacing function and permanent loss of defibrillation support.

FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY

In the unlikely event that a device chip is affected by background cosmic radiation, the high current drain condition will deplete the battery voltage rapidly. This can result in loss of output for a period up to approximately 48 hours. During this period, the patient would be without pacing or defibrillation therapy. After this initial period, the battery will reach a voltage level at which the device will enter its "Hardware Reset Mode." This safety mode is designed to preserve the device's ability to provide VVI pacing support. A device that has been reset to the Hardware Reset Mode will operate in the VVI mode at 60 ppm, but will not be capable of providing tachycardia detection or therapy. This will be noted by a warning message on the programmer screen upon device interrogation.

To assist in your patient care and following discussions with our independent Medical Advisory Board, Abbott recommends: If it is not already your current practice, physicians should perform routine device monitoring every three months for patients with the affected models listed above.

In determining whether additional patient management or follow up may be needed, consider the low failure rate for the anomaly and the unique medical needs and situation of each individual patient, including whether the patient is pacemaker dependent or at high risk for life-threatening arrhythmias.

If a patient's device is found in the Hardware Reset Mode, you should arrange for device replacement as soon as possible.You should continue to provide patients with the usual admonitions to keep scheduled appointments and to report all changes in symptoms.

Current Status (December 31, 2021): At the time of the advisory, there were 60 worldwide (38 U.S.) devices confirmed to have been affected by this issue. As of December 31, 2021 there were an additional 42 worldwide (28 U.S.) devices confirmed with this issue. This is within the 95% confidence interval prediction made at the time of the advisory. There have been no reports of serious injury or death.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Epic [°] DR/HF (V-233, V-337, V-338), Epic [°] Plus DR/VR/HF (V-236, V-239, V-196, V-239T, V-196T, V-350), Atlas [°] DR (V-242), and Atlas [°] Plus DR/VR/HF (V-243, V-193, V-193C, V-340, V-341, V-343)	 6/13/2005 Class II Two anomalies have been identified: Due to a device software anomaly, it is possible that when the device's battery is nearing its elective replacement indicator (ERI), a charging cycle may be skipped. After a capacitor charge, if a rate responsive pacing mode (e.g., DDDR, VVIR, etc.) is programmed "On," this "noise" may be interpreted by the device's accelerometer (activity sensor) as physical activity, causing a temporary increase in the pacing rate that may persist after charging is completed. 	Two anomalies were discovered during routine product monitoring. Neither of these anomalies presents a significant clinical risk to your patients, and no clinical complications have been reported to Abbott. Both are easily corrected by performing a simple, automated softwar download to the device. This potentially affects approximately 30,000 implanted ICDs in the United States and includes the following model numbers: Epic [°] DR/HF (V-233/V-337/V-338), Epic [°] Plus DR/VR/HF (V-236/V-239/V-196/V-239T/V-196T/V-350), Atlas [°] DR (V-242), and Atlas [°] Plus DR/VR/HF (V-243/V-193/V-193C/V-340/V-341/V-343). The first anomaly can one or the affected devices attempts to deliver multiple shocks in rapid succession. Due to a device software anomaly, it is possible that when the device's battery is nearing its elective replacement indicator (ERI), a charging cycle may be skipped. If this were to occur, the first shock will always be delivered as programmed and, if needed, the next shock in the programmed sequence would be delivered after a delay of only two to four seconds. A skipped charge would result in less than the full number of programmed shocks being available for delivery during that episode, but all delivered shocks would be at their programmed energy. This behavior was discovered as an incidental finding during analysis of one returned device that has delivered a large number of high-voltage shocks over a short time period.

been observed during the performance of manual capacitor maintenance, has been traced back to a component supplied to Abbott by one vendor; therefore, only the subset of the device models listed above that were manufactured with the affected component (device serial numbers below 141000 for any model) will exhibit this behavior. Abbott has developed **programmer software that will automatically detect the affected ICDs and download device software that will correct the "skipped charge" anomaly and mitigate the response to electrical noise. Once the upgrade is performed, the potential for a skipped charge will be eliminated. Additionally, once the upgrade is performed if a rate responsive mode is programmed "On," devices with serial numbers below 141000 will have their rate response functions suspended for the time period during which the electrical noise could be present (i.e., while significant residual voltage remains on the high-voltage capacitors); non-rate responsive pacing at the programmed base rate will continue to be provided as appropriate. This period during which rate response is suspended may last anywhere from a few minutes up to approximately 90 minutes. If rate responsive pacing was ongoing prior to charging, the pacing rate will gradually decrease**

A second anomaly is caused by electrical "noise" generated as a result of the charging of the device's high-voltage capacitors. After a capacitor charge, if a rate responsive pacing mode (e.g., DDDR, VVIR, etc.) is programmed "On," this "noise" may be interpreted by the device's accelerometer (activity sensor) as physical activity, causing a temporary increase in the pacing rate that may persist after charging is completed. The degree and duration of the rate increase will depend on a variety of factors, but the rate will never exceed the programmed Maximum Sensor Rate, and the device will gradually return to the appropriate rate. The anomalous behavior, which has

The software download for potentially affected devices will automatically be initiated the next time the patient's device is interrogated with the v4.8.5 programmer software. Since a skipped charge is more likely to occur in devices that are closer to their elective replacement indicator (ERI), Abbott recommends that if the next patient follow-up is not scheduled to occur within the next six months that the patient be seen within this time period.

to the base pacing rate according to the normal rate response recovery algorithm and will remain there while rate responsive pacing is suspended. The rate response behavior for devices with serial numbers greater than 141000 will not be affected by the software download.

In addition, if devices are programmed to pacing settings that result in high current consumption, such as high output bi-ventricular pacing, consideration should be given to scheduling the patient for a follow-up visit within three months if it is not scheduled to occur within that time period. As always, Abbott defers to your clinical judgment on any decisions regarding the management of your patients.

Current Status (December 31, 2021): There have been no implanted devices confirmed to have been affected by this issue since the time of the advisory.

ICD AND CRT-D DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Epic ⁻ (V-197, V-235),	3/10/2005	During routine product evaluation, Abbott Quality Assurance identified that a software parameter that affects the sensitivity of the reed
Epic (V-197, V-235), Epic ⁺ + (V-196, V-236),	S/10/2005 Class II	switch in the listed devices was being set to an incorrect value during manufacturing beginning in late November of last year. This has
Epic [®] HF CRT-D (V-338),	61855 11	the effect of preventing these devices from entering the magnet mode to inhibit tachy therapy when an external magnet is applied. This
Epic"+ HF CRT-D (V-350),	A software parameter that affects the sensitivity of the reed	is a software controlled parameter that can be easily corrected via the programmer. All other bradycardia pacing and tachvarrhythmia
Atlas"+ (V-193, V-243),	switch in the listed devices was being set to an incorrect value	detection and therapy features are not affected in devices subject to this notification. Until the magnet sensitivity parameter is corrected vi
Atlas" + HF CRT-D (V-340),	which could prevent these devices from entering the magnet	the programmer, tachy therapy may not be properly inhibited as is customary with placement of an external magnet, but can be inhibited
or Atlas" (model V-242) ICDs	mode to inhibit tachy therapy when an external magnet is applied.	by using the programmer to program the device to Defib Off, and then back On as needed.
		The affected devices were manufactured during a three month period beginning November 22, 2004. To date, there have been no field reports of any magnet mode failures, nor have there been any clinical complications reported associated with this issue. Magnet mode

reports of any magnet mode failures, nor have there been any clinical complications reported associated with this issue. Magnet mode application is usually used to inhibit tachycardia therapy such as when a patient is subjected to electrocautery during a surgical procedure. In order to remedy this situation, in addition to this notification, Abbott Sales Representatives and Field Clinical Engineers have been provided with a simple software tool that can be used to set, via the programmer, the reed switch's magnet sensitivity to the proper value. You may contact them to schedule this reprogramming at the patient's next scheduled follow-up visit or at your discretion.

Current Status (December 31, 2021): There have been no implanted devices confirmed to have been affected by this issue since the time of the advisory.

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
A subset of Assurity™ (Models PM1240, PM2240), Assurity™ + (Model PM2260), Assurity MRI™ (Models PM1272,	3/15/2021 Class I	Recognizing that each patient requires individual consideration by their physician, in consultation with Abbott CRM's Medical Advisory Board (MAB), Abbott provides the following guidelines:
Assurity MRT (Models PM1160, PM2272), Endurity''' (Models PM1160, PM2160), Endurity''' Core (Models PM1152, PM2152), Endurity MRT''' (Models PM1172, PM2172)	Abbott informed customers of an issue which may affect a subset of Assurity [™] and Endurity [™] pacemakers. The issue is caused by intermittent incomplete mixing of epoxy during manufacture, which may introduce a risk of moisture ingress and interruption of device functionality. Abbott provided a follow up safety notification on October 5, 2021 to communicate additional units in the advisory and the availability of a new Electronics Performance Indicator (EPI) tool to assist in patient management for those pacemakers monitored with Merlin. net. The EPI tool supplements information available on Merlin.net to identify abnormal electrical system performance resulting from moisture ingress.	 Prophylactic generator replacement is not recommended. This is due to the very low rate of occurrence, and the low potential for patient harm when replacement is performed following an EPI notification or an ERI/EOS alert. Routine follow-up should remain as per standard of care and clinical protocol. Review device function including measured battery voltage or any unexpected change in battery consumption. Also, evaluate the potential for risk in patients who are pacemaker dependent and are unable to be reliably followed using remote monitoring. Prompt replacement for devices that receive an EPI notification, reach ERI/EOS, or experience one of these clinical impacts (loss of telemetry, reduced battery longevity, loss of pacing, or reduced ERI to EOS duration), commensurate with the patient's underlying clinical condition. When possible, monitor patients using Merlin.net to benefit from alert monitoring between routine device checks. For patients currently enrolled in Merlin.net, remind them of the importance of using remote monitoring, which provides daily monitoring of ERI and EOS alerts and includes monitoring of the safety notification population by the EPI tool. Current Status (December 31, 2021): 278 devices of the 337,990 worldwide (0.082%) have exhibited moisture ingress into the pulse generator, resulting in a loss of functionality.
		To determine if a device serial number is subject to this advisory, please go to the following website: <u>https://www.cardiovascular.abbott/us/en/hcp/product-advisories/pacemaker-lookup.html.</u>

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Nanostim™ Leadless Cardiac Pacemaker (Model S1DLCP)	11/17/2017 Outside US and US Investigational Device Exemption (IDE) only	The following patient management recommendations have been developed in consultation with our Leadless Steering Committee membe after discussions detailing the occurrences and the potential clinical impact associated with detached docking buttons:
	Abbott was made aware of docking button detachments that have occurred following implant or during attempted retrieval of Nanostim" Leadless Cardiac Pacemaker (LCP) devices. The docking button is a small component (3.6 mm diameter) and is connected to the end of the LCP by two cables. This component is necessary for docking the LCP to the retrieval catheter during a retrieval procedure.	 Continue following patients as per recommendations of the October 2016 Battery Malfunction for Nanostim[™] LCP advisory. Retrieval of an implanted Nanostim[™] LCP with an intact docking button confirmed radiographically remains an option, but should only be considered if the procedure can be performed as per the specifications contained in the instructions for use. If a detached docking button has been identified, Nanostim[™] LCP retrieval is not recommended. In the rare situation where retrieval is the only management option, Abbott recommends the procedure be performed by physicians experienced in foreign body removal, including using the femoral approach. Please contact the Abbott Clinical Study Team for further guidance. Prophylactic imaging for the sole purpose of determining if the docking button is intact is not recommended due to the effects of radiatic and lack of any clear clinical actions based on results of imaging alone. If the option of Nanostim[™] LCP retrieval is being considered, fina imaging decisions should take into account the individual patient circumstances and preferences.

• If a detached docking button is identified, continue to follow the patient as per the Clinical Study Protocol and report the incident to Abbott and relevant Competent Authority, as appropriate.

Current Status: (December 31, 2021): At the time of advisory, three (0.21%) of 1,423 devices implanted worldwide have been reported to have a detached docking button. As of December 31, 2021, a total of 7 have been reported and the rate remains at 0.5% (7/1,423). There have been no reports of serious injury or death.

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Global Models	8/28/2017	Patient Management Recommendations
Accent MRI [™] (Model PM1224) Accent [™] DR RF (Models PM2210,	Class II	Prophylactic replacement of affected devices is not recommended.
PM2212)	New pacemaker firmware was developed to further mitigate the	
Accent MRI [™] (Models PM2218, PM2224)	risk of unauthorized access to our pacemakers that utilize radio frequency (RF) communications. The firmware update provides	While not intended to serve as a substitute for your professional judgment as to whether the firmware update is advisable for a particula patient, we, along with our Cyber Security Medical
Accent [™] SR RF	an additional layer of security against unauthorized access to	Advisory Board, recommend the following:
(Model (PM1210)	these devices that further reduces the potential for a successful	
Accent [™] ST DR RF	cybersecurity attack.	Discuss the risks and benefits of the cybersecurity vulnerabilities and associated firmware update with your patients at the next regula
(Models PM2216, PM2222)		scheduled visit. As part of this discussion, it is important to consider patient specific issues such as pacemaker dependence, age of devi
Accent™ ST MRI DR RF (Model		and patient preference and provide them with the "Patient Communication".
PM2226) Accent [™] ST MRI SR RF (Model		 Determine if the update is appropriate given the risk of update for the patient. If deemed appropriate, install this firmware update following the instructions on the programmer (and listed below).
PM1226)		 For pacing dependent patients, consider performing the cybersecurity firmware update in a facility where temporary pacing and
Accent [™] ST SR RF (Model PM1222)		pacemaker generator change are readily available, due to the very small estimated risk of firmware update malfunction.
Allure Quadra™ RF CRT-P		
(Model PM3242)		Current Status (December 31, 2021): We have received no reports of device compromise related to the cybersecurity vulnerabilities in
Allure™ RF CRT-P (Model PM3222)		implanted devices impacted by this communication.
Anthem [™] RF CRT-P		
(Models PM3210, PM3212)		If you have any questions about the cybersecurity firmware update you can contact your Abbott representative or our dedicated custom technical support hotline at 1-800-722-3774 (U.S.).
Assurity [™] + DR RF (Model PM2260) Assurity [™] + SR RF (Model PM1260)		technical support nonline at $1-800-/22-3//4$ (U.S.).
Assurity [™] DR RF (Model PM2240)		Additional materials, including a Patient Communication, can be found on Cardiovascular Product Advisories Abbott.
Assurity MRI™ (Model PM2272)		
Assurity™ SR RF (Model PM1240)		
Assurity MRI™ (Model PM1272)		
Nuance [™] DR RF (Model PM2214)		
Nuance [™] MRI DR RF (Model PM2230)		
Nuance [™] MRI SR RF (Model PM1230) Nuance [™] SR RF (Model PM1214)		
Nuance [™] ST DR RF (Model PM2228)		
Nuance [™] ST SR RF (Model PM1228)		
Quadra Allure MP™ (Model PM3562)		
Quadra Allure MP™ RF CRT-P		
(Model PM3262)		
Quadra Allure™ (Model PM3542)		
Quadra Relieve MP™ (Model PM3564) Quadra Relieve MP™ RF CRT-P		
(Model PM3264)		
Quadra Relieve [™] (Model PM3544)		
Quadra Relieve™ RF CRT-P		
(Model PM3244)		
Relieve™ RF CRT-P (Model PM3224)		
Zenex [™] + DR RF (Model PM2270)		
Zenex [™] + SR RF (Model PM1270)		
Zenex™ DR RF (Model PM2250) Zenex™ DR RF MRI (Model PM2282)		
ZEITEA DIA AF MIAI (MOUGH PM2282)		

Zenex¹⁵⁸ SR RF (Model PM1250) Zenex¹⁵⁸ SR RF MRI (Model PM1282)

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Nanostim" Leadless Cardiac Pacemaker (Model SIDLCP)	10/28/2016 Outside US and US Investigational Device Exemption (IDE) only Abbott was made aware of seven (7) reports worldwide of lost telemetry and pacing output as a result of a battery malfunction associated with Nanostim Leadless Cardiac Pacemaker	 In consultation with our Leadless II IDE and our Leadless Postmarket Study Steering Committees we recommend the following: Do not implant unused devices and return them to Abbott. Do not rely on the RRT indicator to identify a battery that may potentially malfunction. However, if the RRT indicator does trigger, replace the device per standard practice. Do not perform AV Node ablation in patients with an existing Nanostim LCP without another functional pacing system implanted. For patients who have not previously been documented to be pacemaker dependent, re-assess patients in-office for pacemaker dependent.
	(LCP) devices. Due to these events, we have decided to pause Nanostim LCP implants in the Leadless II IDE/CAP study. Analysis of returned units has found decreased battery capacity due to reduced electrolyte, resulting in high internal battery resistance. This disrupts the required capacity for proper device function and reduces device longevity.	 dependence. For non-pacemaker dependent patients with devices of implant duration ≥ 24 months, more intensive follow-up and monitoring is recommended. Implant Duration ≥ 24 months: Request follow-up as soon as possible to assess the status of the battery. Then, monthly follow-up is recommended through in-office visits or a reliable method of tele-monitoring of heart rate and electrocardiogram. Implant Duration < 24 months: Continue follow up per protocol. For pacemaker dependent patients, device replacement is recommended (priority should be for patients with implants of longer duration).
	Referring to a previously measured battery voltage may not provide an indication of continued normal operation as battery voltage remains normal under these circumstances. The Recommended Replacement Time (RRT) indicator will not be triggered as the battery voltage will remain above RRT in these devices. Battery malfunction may be indicated with a loss of telemetry/communication with the implanted device and/or loss of pacing and magnet mode operation.	 Identify and treat patients as quickly as possible. Identify and treat patients as quickly as possible. Interrogate the device and identify the ability to communicate with the device and the patient's underlying rhythm. Determine the strategy for management, including a decision whether to retrieve or abandon the Nanostim LCP, based on the individual patient's clinical history and overall medical condition. Use a temporary pacemaker for backup pacing while replacing the Nanostim device where clinically indicated. If the device is to be retrieved, use the Nanostim retrieval system as per the standard procedure described in the instructions for use. If the device will not be retrieved or if retrieval was attempted and not possible, implant a new pacemaker lead (bipolar) at a distance from the existing LCP to prevent long-term mechanical and electrical interactions. Confirm the location using multiple radiographic views. After implantation of the new pacing system, if it is possible to communicate with the LCP, turn "OFF" the abandoned LCP system. If the LCP device cannot be turned "OFF", consider programming the newly implanted system a minimum of 5 bpm faster than the LCP in order to inhibit the Nanostim device.

Current Status: (December 31, 2021): At the time of advisory, seven (7) reported devices (0.50%) of 1,423 implanted devices worldwide have exhibited battery malfunction at 29-37 months after implant. As of December 31, 2021, there were additional reports and the rate is now 24.88%. There have been no reports of serious injury or death.

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Accent [~] SR (Model PM1110) Accent [~] DR (Model PM2112)	12/7/2012 Outside US Only Due to an incorrect software setting, a specific subset of the Accent" SR and Accent" DR devices shipped to certain countries outside the US will not provide a change in the sensor driven (rate responsive) pacing rates in response to patient physical activity. All other programmed parameters, features	 Abbott makes the following recommendations: Identify affected patient Review your patient's clinical indications for pacing and determine the clinical need for rate responsive, sensor driven pacing. In the event that a patient requires rate responsive sensor driven activity pacing and exhibits clinical symptoms due to the lack of increased pacing rates with exercise, please contact your local Sales Representative or our Technical Support Continue to follow patients on their standard follow-up schedule.
	and functions operate as designed, e.g. an Accent DR device programmed to DDDR will appropriately track atrial activity and properly function in the DDD mode. A non-invasive programmer software solution that will correct the issue in all affected, implanted devices will be available once regulatory approval has been completed.	Current Status (December 31, 2021): The programmer software update was released in April 2013. At the time of the advisory, approximately 6,000 affected devices were implanted. There have been no additional devices confirmed to have this issue since the time of the software release in April 2013.

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Accent ⁻ DR (Models PM2110, PM2112, PM2210, PM2212), Anthem ⁻ CRT-P (Models PM3110, PM3112, PM3210, PM3212)	9/22/2011 Class II A small amount of electrical charge may accumulate within an internal capacitor which results in a low or varying pacing lead impedance (PLI) value during the automatic daily	In order to prevent a false reading, a new Merlin [¬] Patient Care System programmer software version is available. When used to interrogate an Accent DR or Anthem CRT-P pacemaker this software will eliminate the potential for this anomaly to occur. With the new software, the programmer will automatically activate circuitry in the pacemaker during the interrogation process to ensure that any residual charge on the capacitor is discharged prior to performing the daily PLI measurement. The onetime upgrade is performed automatically on affected devices and will not change the operation of the implanted device. Your Abbott Sales Representative will assist you in loading the new programmer software onto your Merlin programmer.
	measurements. An out of range lead impedance measurement may result in a patient notifier alert, a remote monitoring Merlin.net [•] Patient Care Network alert, or a prior alert message to be displayed on the programmer screen at the next in-clinic	If you are following any patients implanted with Accent DR pacemakers or Anthem CRT-P devices, Abbott makes the following recommendations, which are consistent with standard best practices:
	follow-up.	 Ensure that the new programmer software version is loaded on your programmers as soon as practical.
		• Continue to follow patients on their standard follow-up schedule. Since the likelihood of the low lead impedance measurement is low, the device interrogation can be performed at the patient's next regular scheduled follow-up visit.
		• In the event that a patient receives a low lead impedance alert before the new programmer software has been loaded we suggest that you

In the event that a patient receives a low lead impedance alert before the new programmer software has been loaded, we suggest that you
evaluate the device as you normally would for any such instance. If the daily pacing lead impedance value is out-of range, re-interrogate
the device's measured data and look at the lead impedance values. This "in-clinic" measurement is not affected by the aforementioned
capacitor charge build-up and will provide an accurate lead impedance measurement.

Current Status (December 31, 2021): Worldwide, 13 Accent DR (<0.01%) and 225 Anthem CRT-P (1.6%) devices have exhibited this diagnostic anomaly.

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
of battery voltage, expected battery longevity and elective replacement indicator (ERI) status in Abbott Identity ⁻ pacemakers. The anomaly does not affect the device ⁴ actual battery voltage, longevity or functionality, but could result in inaccurate reporting of the status of these measured data parameters. This software anomaly can appear in the Abbott Identity ⁻ family of pacemakers when programmed by	Class II A programmer software anomaly can lead to incorrect reporting of battery voltage, expected battery longevity and elective	No follow-up is recommended at the time of advisory. Devices do not need to be replaced. A programmer software update, pending FDA an other regulatory agency approval, will mitigate this anomaly when the device is interrogated. Before the programmer software update is available, any subsequent measured data update that is performed during the session would be valid and the device operating magnet rate would be up-to-date. After the programmer software update is available, any device affected by this issue will be automatically corrected via the normal interrogation process.
	Identity [®] pacemakers. The anomaly does not affect the device's actual battery voltage, longevity or functionality, but could result in inaccurate reporting of the status of these measured data parameters. This software anomaly can appear in the Abbott Identity [®] family of pacemakers when programmed by the Abbott APS [®] III Model 3500/3510 or Merlin [®] Patient Care	Current Status (December 31, 2021): At the time of the advisory, there were 53 worldwide (50 U.S.) devices confirmed to have been affected by this issue. As of December 31, 2021 there were an additional 78 worldwide (65 U.S.) devices confirmed with this issue, all prior to the distribution of the software fix.

LEFT-HEART LEADS

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
QuickSite" (Models 1056T, 1058T) QuickFlex" (Models 1156T, 1158T)	 4/3/2012 Class II Abrasion of the silicone insulation in the distal portion of QuickSite and QuickFlex leads has led to visual observations of externalized conductors. There have been no reports of death or serious injury associated with the externalized conductors; likewise there have been no electrical dysfunctions attributable to the externalized conductors. The reported rate of externalized conductors in the QuickSite and QuickFlex leads is 0.023%, based on 39 confirmed cases of externalized conductors in a population of approximately 82,000 QuickSite and 89,000 QuickFlex leads sold worldwide. This issue is under-detected because these cases are visual observations without any signs of electrical dysfunction and fluoroscopic/xray imaging is not routine. Based on a review of returned leads and available fluoroscopic and x-ray images of patients with QuickSite and QuickFlex leads (1,219 leads), it is estimated that the incidence of conductor externalization on these leads may be 3% to 4%. 	Abbott and its Medical Advisory Board recommend that physicians continue to monitor their patient's implanted system at regularly scheduled intervals with attention paid to diagnostic information related to LV pacing performance, in particular LV lead impedance and capture thresholds. Programming of alerts that monitor lead impedance changes outside of the nominal range and enabling the patient notifier should be considered. A special X-ray or fluoroscopic imaging is not recommended for LV CRT leads with normal electrical function. CRT pacing functionality should be evaluated during routine device checks and only leads exhibiting electrical anomalies that cannot be reprogrammed to deliver effective CRT pacing should be considered for replacement.

DEFIBRILLATION LEADS

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Optisure [®] Defibrillation Lead (Models LDA220, LDA220Q, LDA230Q,	11/3/2015 Class I	Abbott recommends the following actions depending on the device the affected patients have implanted. According to our records the vast majority of patients with the subject leads have devices with the DynamicTx ⁻ feature that provides additional protection to help ensure
LDP220Q)	618551	insports of participation of a compromised lead.
1012200	A limited number of dual coil Optisure defibrillation leads may	
	have been compromised during the manufacturing process.	For patients implanted with a potentially-impacted Optisure lead connected to a device WITH DynamicTx ^{-*} technology, we recommend:
	A trim technique to remove excess medical adhesive around	
	the SVC shock coil may have introduced damage to the lead's	Review the Patient Records:
	insulation.	1. Ensure DynamicTx ⁻ technology is programmed "On"
		2. Enroll these patients in our Merlin.net [®] Patient Care Network
	A thorough investigation has determined the probability of	3. Monitor patients as normal, with no additional testing or follow-up needed.
	a lead malfunction as a result of this trim technique is very	
	low. A total of 447 leads subjected to the trim technique were distributed globally. Of those, 278 were implanted in the United	For patients implanted with a potentially-impacted Optisure lead connected to a device WITHOUT DynamicTx [*] technology we recommend:
	States. Abbott is not aware of any adverse clinical events related	1. Enroll these patients in our Merlin.net [¬] Patient Care Network
	to this matter. Furthermore, an analysis of patients implanted	2. Where clinically appropriate, consider turning off the SVC coil (select RV-to-Can vector)
	with the subject leads that are being actively monitored via	3. If dual coil shocking configuration is desired, consider performing a high voltage test using maximum energy.
	Merlin.net" Patient Care Network has shown that none of these	a. If shock delivery is normal - no additional testing is required
	patients have experienced any recorded electrical issues.	b. If shock delivery identifies a short circuit – consider lead replacement
		 DynamicTx⁻ technology automatically adjusts shock configurations to ensure the delivery of high-voltage therapy even if an electrical short were to occur.
		We recommend at your patient's next follow-up visit an Abbott representative be present to program an alert message into the implanted
		device. This will provide clinicians following patients with impacted subject lead an alert message on the Merlin [®] Programmer upon interrogation, ensuring that future caregivers assessing the diagnostics of these devices receive the latest information and be made aware of this corrective action. We believe such actions will further the ability of our clinician partners to most optimally manage the care of their
		of this corrective action, we believe such actions will further the ability of our chinician partners to most optimally manage the care of their partners to most optimally manage the care of the car

patients.

DEFIBRILLATION LEADS

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Riata" Defibrillation Lead (Models 1570, 1571, 1572, 1580, 1581, 1582) Riata" i Defibrillation Lead (Models	11/28/2011 Class I	Abbott and its Medical Advisory Board (MAB) make the following recommendations, which are consistent with standard best practices and our December 2010 product communication.
Ison, 15on, 15on, 15on, 15on, 15o2) Riata [¬] ST Defibrillation Lead (Models 7000, 7001, 7002, 7010, 7011, 7040, 7041, 7042)	Externalized conductors occur when an abrasion results in an outer insulation breach, allowing the normally contained conductors to become visible outside the lead body. Even though causality cannot be established, when externalized conductors	Whenever possible, monitor devices and leads remotely and advise your patients of the importance of contacting you should they experience any adverse events. Abbott ⁻ remote monitoring features can be used to detect electrical changes early that may be associated with externalized conductors.
	are accompanied by reports of electrical malfunction, these reports typically include pacing or defibrillation impedance changes, inappropriate therapy, noise and oversensing, and pacing threshold rise. Externalized conductors have not been	Continue to monitor your patient's implanted system at regularly scheduled intervals with particular attention to diagnostic information related to defibrillation lead performance. The recommendations for frequency of in-person are a follow-up period of every 3 - 6 months for ICD/CRT-D devices per the HRS/EHRA consensus.
	observed in Riata ST Optim [°] and Durata [°] models due to the presence of an abrasion resistant outer Optim [°] lead insulation sheath.	Review lead measurements including pacing and high voltage lead impedances per your standard follow-up procedures in particular looking for significant changes from the patient's previous follow-up visits.
	A summary of the types and incidence rates of Riata lead abrasion malfunctions is presented on pages 295-298 of this Product Performance Report.	If there is evidence of a lead electrical failure, manage the patient per standard practice. ¹ This may include x-ray or fluoroscopy. Additional testing, if necessary, could include provocative methods such as shoulder and arm movements and deep respiration while looking at the surface ECG and intracardiac electrograms with the programmer, which may reveal an intermittent problem associated with any source of lead electrical failure if one exists.
		The value of routine x-ray or fluoroscopy for patients with leads having no electrical abnormalities is unknown at this time and is therefore not recommended.
		In addition, prophylactic explant or replacement of a lead without electrical dysfunction is not recommended.
		Currently there is no expert consensus regarding whether patients undergoing pulse generator replacement should undergo fluoroscopy or lead replacement should an externalized conductor without electrical anomalies be present. This is, in part, because the risk versus benefit of replacing a lead in such a patient may vary from patient to patient and center to center. Clinical decisions in this setting should be individualized based on specific patient conditions and circumstances.
		Based on input from the MAB, Abbott continues to monitor post-market surveillance data to evaluate further the incidence of externalized conductors and the long-term performance of leads with externalized conductors that do not exhibit electrical abnormalities.
		Comment Status (February 28, 2022). As the sime of the advisory there was a worldwide reported all excession involution abunction rate of 0.620

Current Status (February 28, 2022): At the time of the advisory there was a worldwide reported all-cause insulation abrasion rate of 0.63% for Riata silicone leads. The worldwide reported rate for the subcategory of externalized conductors in Riata silicone leads was 0.10%. As of February 28, 2022, there have been additional reports. The worldwide reported rates of all-cause abrasion and externalized conductors for Riata silicone leads was 4.85% and 2.93% respectively. The latest information related to the silicone Riata lead advisory, including the final results of the Cardiac Lead Assessment Study (CLAS) and references to independent studies of Riata lead performance, can be obtained at https://www.cardiovascular.abbott/us/en/hep/product-advisories/riata.html.

1 Epstein, A.E. "Troubleshooting of Implantable Cardioverter-Defibrillators." *Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy, 4th ed.* Eds. Ellenbogen, K.A., Kay G.N., Lau, C-P., Wilkoff, B.L. Philadelphia: Elsevier, 2011. 889-910.

DEFIBRILLATION LEADS

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Riata" Defibrillation Lead (Models	12/15/2010	Continue to monitor your patient's implanted system at regularly scheduled intervals with particular attention to diagnostic information
1570, 1571, 1572, 1580, 1581, 1582) Riata [°] i Defibrillation Lead (Models	Outside US Only	related to defibrillation lead performance. The recommendations for frequency of in-person or remote monitoring are a follow-up period of every 3 - 6 months for ICD/CRT-D devices per the HRS/EHRA consensus.
1560, 1561, 1562, 1590, 1591, 1592)	Abrasion of silicone defibrillation leads is acknowledged within	
Riata ⁻ ST Defibrillation Lead (Models 7000, 7001, 7002, 7010, 7011, 7040, 7041, 7042)	the clinical community as a well known clinical risk and is documented in the literature as the number one cause of lead failure across the industry with reported failure rates ranging	Review lead measurements including pacing and high voltage lead impedances per your standard follow-up procedure in particular looking for significant changes from the patient's previous follow-up visits.
	from 3 to 10%. After more than 9 years of clinical use and approximately 227,000 implants, silicone insulated Riata [®] , Riata [®]	If there is evidence of a lead electrical failure, manage the patient per standard practice. ¹ This may include x-ray or fluoroscopy. Additional testing if necessary could include provocative methods such as shoulder and arm movements and deep respiration while looking at the

testing if necessary could include provocative methods such as shoulder and arm movements and deep respiration while looking at the surface ECG and intracardiac electrograms with the programmer, which may reveal an intermittent problem if one exists.

Consider remote monitoring and advise your patients of the importance of contacting you if they experience any adverse events.

Current Status (February 28, 2022): At the time of the advisory there was a worldwide insulation abrasion rate of 0.47% for Riata silicone leads. As of February 28, 2022, there have been additional reports and the worldwide reported insulation abrasion rate is 4.85%.

A summary of the types and incidence rates of Riata lead abrasion malfunctions is presented on pages 295-298 of this Product Performance Report.

i, and Riata" ST defibrillation leads have exhibited an insulation

abrasion rate of 0.47% (inclusive of confirmed returns and complaints/observations with no associated return).

There are several factors that can contribute to lead abrasion

in implanted pacing and defibrillation systems, including physiological stresses placed on the lead due to patient anatomy,

implant orientation, and mechanical stresses applied from

concomitant devices in the body.

1 Epstein, A.E. "Troubleshooting of Implantable Cardioverter-Defibrillators." Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy, 4th ed. Eds. Ellenbogen, K.A., Kay G.N., Lau, C-P., Wilkoff, B.L. Philadelphia: Elsevier, 2011. 889-910.

ICM DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
MODEL IDENTIFICATION Confirm Rx'" (Model DM3500)	ADVISORY 5/18/2018 Class II US Only Abbott advised physicians that exposure to sub-freezing temperatures during our supply chain process caused a transient battery voltage drop for a small number of Confirm Rx [~] Model DM3500 Insertable Cardiac Monitoring (ICM) devices.	 FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY Prophylactic replacement of affected devices is not recommended. To correct implanted devices or detect affected units before implant, it is required to update to Merlin" programmer software version 24.2.x or later. If you do not yet have this software version, you may contact your Abbott representative to facilitate in upgrading your programmer(s). Recommendations for Patients with Implanted Devices Abbott reviewed data in Merlin.net" Patient Care Network to identify implanted devices with an incorrect low battery indicator. Patients confirmed to be impacted can be found in the enclosed Patient List. Additionally, implanted patients who could not be assessed for this condition through data available in Merlin.net" PCN are included in this list. We recommend performing the following actions at the patient's next regularly scheduled visit: For patients confirmed to be impacted, contact Abbott Technical Services to assist in correcting the battery indicator. For Confirm Rx" device patients requiring further assessment to determine potential impact, review post-implant programmer printouts or session records to determine whether a low battery indicator is present. If a low battery indicator is observed, contact Abbott Technical Services to assist in confirmation and correction of the battery indicator display. Recommendations for Devices not yet Implanted For new implants, Merlin" programmer software version 24.2.x or later will detect this incorrect low battery indicator condition. Interrogate all new Confirm Rx devices prior to implant. If the notification pop-up is displayed, follow the on-screen instructions to proceed with contacting Abbott Technical Services an alternate device for the implant.
		Current Status (December 31, 2021): At the time of the advisory, 0.41% devices distributed worldwide have been reported to have experienced incorrect display of low battery indicator. As of December 31, 2021 there have been no additional reports of low battery indicator and the rate remains at 0.283%. There have been no reports of serious injury or death.

If you have any questions about this communication or the patient management recommendations, please contact your Abbott representative or Abbott Technical Support at 1-800-722-3774 (U.S.). Additional materials, can be found on <u>Cardiovascular Product</u> <u>Advisories | Abbott.</u>

ICM DEVICES

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
SJM Confirm ⁻ ICM (Models DM2100, DM2102)	3/11/2011 Class II US and Germany	If you are following any patients implanted with the SJM Confirm ICM Models DM2100 or DM2102 and their device was upgraded using the Merlin programmer with the above mentioned software versions it is recommended to determine the patient's clinical reason for the implant and their continued need for the device:
	A product firmware upgrade using the Merlin [®] Patient Care System (PCS) programmer running software versions 10.1.1.3, 10.1.1.2, or 11.2.2 leaves the implantable cardiac monitor device in a state which results in increased current usage. If not corrected this state could result in premature battery depletion.	 If the device has previously been used to record and assist in the diagnosis of an arrhythmia and is no longer needed, no further action required. The device will exhaust its battery capacity prior to the 3 year expected longevity. If the unit is still indicated for diagnosing a potential clinical arrhythmia, contact your Field Clinical Engineer and he/she will assist in calculating the projected remaining longevity. If appropriate, the microprocessor operation can be reset to the nominal current drain. If the device is no longer indicated it can be left implanted until such time that a routine explant is desired.
		If the device is determined to be necessary and is experiencing increased current usage as described above, it can be corrected with assistance from your Sales Representative or Abbott Technical Services.

Current Status (December 31, 2021): At the time of the advisory, 83 implanted devices world-wide were identified as having undergone the problematic firmware upgrade. All of these devices have been corrected using the Merlin PCS programmer or were determined by the clinician to not require further action because the device had already provided the necessary diagnostic information and was no longer required. There have been no additional implanted devices confirmed to have been affected by this issue. Updated Merlin PCS programmer software has been implemented which prevents this issue from occurring in the future.

REMOTE MONITORING/TRANSMITTERS

MODEL IDENTIFICATION	ADVISORY	FOLLOW-UP RECOMMENDATIONS AT TIME OF ADVISORY
Merlin@home** Software Model EX2000 v8.2.2 for Merlin@home** Transmitter (Models EX1150, EX1150W, EX1100, EX1100W)	4/3/2017 Class II In recognition of the changing cybersecurity landscape, and the increased public attention on medical device cyber risks, we have informed the clinical community about available updates to Merlin@home" transmitter software. The Merlin@home" patient transmitter software version 8.2.2 includes security updates that complement the company's existing security measures and further reduce the already extremely low cybersecurity risks.	 Patients should ensure that their Merlin@home" transmitter is plugged in and connected via cellular adapter, wi-fi or landline so the transmitter can receive these and any future updates. Health Care Providers should continue to conduct patient management using the Merlin.net" Patient Care Network (PCN) and inoffice follow-ups per normal routine with patients who have an implantable cardiac device that is monitored using the Merlin@home" transmitter. For further information, health care providers can contact their local sales representative. In addition, both health care providers and patients can visit <u>Connectivity and Remote Care for Cardiac Rhythm Management Abbott (cardiovascularabbott)</u> for answers to questions and additional information regarding Abbott's implantable cardiac rhythm devices, or the Merlin@home" transmitter. Current Status (December 31, 2021): We have received no reports of device compromise related to the cybersecurity vulnerabilities in the implanted devices impacted by this communication.

REMOTE MONITORING/TRANSMITTERS

Transmitter EX1150 Class II A Merany according to the set of	Merlinghome transmitter software has been modified to prevent this issue from occurring and has received FDA approval. exiton from you or your patients. No changes to your patient's remote or in-clinic follow up schedules are required patients with ande dovices not menitored above, patients who are being remotely followed with inductive telemetry (wand directly over the device) patients not being followed remotely are not affected by this issue. Pert Status (December 31, 2021): In December 2014, the worldwide event rate of Merlinghome transmitters initiating a software resulting in hackup operation for Ellipse, Fortify Assuru, Unify Assura and Quadra Assura TLDs was 20,00% based on 83,000 ees followed via Merlin.ene Patient Care Network (Merlin remote monitoring). For Assurity and Allure pacemakers, the rate of increa was 0.00% based on 12,000 devices followed remotely. As of December 31, 2021, the cumulative incidence rate based on dwide sales for Ellipse, Fortify Assura, Unify Assura and Quadra Assura TLDs was 20,00% based on 83,000 dwide sales for Ellipse, Fortify Assura, Unify Assura and Quadra Assura TLDs was 20,00% based on 12,000 devices followed via Merlinghome software indexe and patient as a status and the sale and the sale at 0.19%.

Healthcare Professional Communications

Healthcare Professional Communications

PACEMAKER AND CRT-P DEVICES

MODEL IDENTIFICATION	COMMUNICATION	DETAILS
Affinity", Entity", Integrity", Identity", Sustain", Frontier", Victory" and Zephyr" models	1/29/2014 Worldwide As part of Abbott's commitment to communications on device performance, and in consultation with our Medical Advisory Board, we provided Health Care Professionals information regarding possible effects of electrocautery on older generation Abbott pacemakers.	Abbott has reviewed incident reports on specific older generation pacemaker models exposed to electrocautery. When devices from these pacemaker families are exposed to electrocautery (as well as the PEAK PlasmaBlade'blade), they may exhibit a temporary change in function that could persist for 30 seconds or longer after the electrocautery exposure has been terminated. The duration of the effect depends on several factors including the battery voltage of the device, the energy of the electrocautery output, and the distance from the electrocautery source to the implanted system. The most clinically significant observation has been loss of capture due to a transient reduction in the pacing output voltage. Placing a magnet over the device or programming to an asynchronous pacing mode will not prevent this temporary reduction in pacing output. The effects of electrocautery on cardiac implantable electronic device operation are well documented in the scientific literature and most, if not all, pacemaker and implantable cardioverter defibrillator (ICD) User's Manuals include labeling about the use of electrosurgery equipment and its possible effects on the operational characteristics and/or internal circuitry of these devices. As is the case with all perioperative assessments in patients with cardiac implantable electrocautery or employ appropriate precautions to ensure that the heart rate will be supported in the presence of electrocautery. Consideration of placing a temporary transvenous pacemaker is appropriate. ¹² All Abbott pacemaker and ICD User's Manuals provide Warnings and Precautions regarding the use of electrosurgical devices in the vicinity of an implanted device. Importantly, the more recent families of Abbott pacemakers (Accent and Anthem) and all ICDs are not subject to this temporary change in function from the extended effects of electrocautery.
		References:

¹ Hayes and Friedman, Cardiac Pacing, Defibrillation and Resynchronization, 2nd Edition, p. 192
² Ellenbogen and Wood, Cardiac Pacing and ICDs, 4th Edition, p. 227

Index

Index

	D.C.		
	PG	ICDS	PG
Allure Quadra MP [®] CRT-P (PM3262)	65	Current [®] + DR (CD2211-36)	117
Allure Quadra MP [®] CRT-P (PM3562)	64	Current [®] + DR (CD2211-36Q)	115
Allure Quadra [®] RF CRT-P (PM3242)	67	Current [™] + VR (CD1211-36)	152
Allure [®] RF CRT-P (PM3222)	66	Current [™] + VR (CD1211-36Q)	150
Anthem [®] RF CRT-P (PM3210)	68	Current [™] DR RF (2207-36)	119
Atlas [®] + HF CRT-D (V-343)	51	Current [®] VR RF (1207-36)	153
Frontier [®] II CRT-P (5586)	70	Ellipse [™] DR (CD2311-36)	108
Gallant [™] HF CRT-D (CDHFA500Q)	16	Ellipse [™] DR (CD2311-36Q)	107
Promote [™] + CRT-D (CD3211-36)	47	Ellipse [¬] DR (CD2411-36C)	102
Promote ^{**} + CRT-D (CD3211-36Q)	45	Ellipse [®] DR (CD2411-36Q)	101
Promote" RF CRT-D (3207-36)	49	Ellipse [®] VR (CD1311-36)	146
Quadra Assura [®] CRT-D (CD3265-40)	33	Ellipse [®] VR (CD1311-36Q)	145
Quadra Assura [®] CRT-D (CD3265-40Q)	31	Ellipse [®] VR (CD1411-36C)	138
Quadra Assura [®] CRT-D (CD3365-40C)	23	Ellipse [®] VR (CD1411-36Q)	137
Quadra Assura" CRT-D (CD3365-40Q)	20	Fortify Assura [®] DR (CD2257-40)	110
Quadra Assura MP ^{^{**}} CRT-D (CD3369-40C)	19	Fortify Assura" DR (CD2257-40Q)	109
Quadra Assura MP ^{^{**}} CRT-D (CD3369-40Q)	17	Fortify Assura" DR (CD2357-40C)	105
Unify Assura" CRT-D (CD3257-40)	36	Fortify Assura" DR (CD2357-40Q)	103
Unify Assura" CRT-D (CD3257-40Q)	35	Fortify Assura" VR (CD1257-40)	144
Unify Assura" CRT-D (CD3357-40C)	28	Fortify Assura" VR (CD1257-40Q)	143
Unify Assura" CRT-D (CD3357-40Q)	25	Fortify Assura" VR (CD1357-40C)	141
Unify Quadra [®] CRT-D (CD3249-40)	39	Fortify Assura" VR (CD1357-40Q)	139
Unify Quadra [®] CRT-D (CD3249-40Q)	37	Fortify" DR (CD2231-40)	113
Unify" CRT-D (CD3231-40)	43	Fortify" DR (CD2231-40Q)	111
Unify" CRT-D (CD3231-40Q)	41	Fortify" VR (CD1231-40)	149
		Fortify" VR (CD1231-40Q)	147
LEFT-HEART LEADS	PG	Gallant [®] DR (CDDRA500Q)	100
Quartet [®] (1456Q)	79	Gallant [®] VR (CDVRA500Q)	136
Quartet ^{**} (1457Q)	78	dunune (n (OD (100000))	100
Quartet [®] (1458Q)	80	DEFIBRILLATION LEADS	PG
Quartet (1458QL)	77	Durata" (7120, 7121)	180
QuickFlex" (1156T)	84	Durata" (7122)	180
QuickFlex [®] µ (1258T)	82	Durata [®] DF4 (7120Q, 7121Q)	102
QuickFlex [®] XL (1158T)	86	Durata [®] DF4 (7122Q)	178
QuickSite" (1056K)	92	Durata [®] DF4 (7170Q, 7171Q)	176
QuickSite [®] (1056T)	90	Optisure" (LDA210)	174
QuickSite [®] XL (1058T)	88	Optisure" (LDA220)	175
Quickone ML (10001)	00	Optisure (LDA220) Optisure DF4 (LDA210Q)	171
ICDS	PG	Optisure [®] DF4 (LDA210Q)	172
Atlas" + DR (V-243)	123	Optisure" DF4 (LDA220Q)	1/0
Atlas" + $VR(V-243)$ Atlas" + $VR(V-193)$	123		169
Atlas" II + DR (V-268)	130	Riata" (1570, 1571) Biota" (1580, 1581)	196
Atlas [®] II VR (V-168)	121	Riata" (1580, 1581)	197
Auas 11 VIX (V-100)	100		

Index

300 295

DEFIBRILLATION LEADS	PG	PACING LEADS
Riata [®] (1582)	195	IsoFlex [®] Optim [®] (1944)
Riata" i (1590, 1591)	194	IsoFlex [®] Optim [®] (1948)
Riata [®] ST (7000, 7001)	192	IsoFlex [®] P (1648T)
Riata [®] ST (7002)	191	IsoFlex [®] S (1642T)
Riata [®] ST (7010, 7011)	189	IsoFlex [®] S (1646T)
Riata [®] ST (7040, 7041)	190	OptiSense" (1699T, 1699TC)
Riata [®] ST Optim [®] (7020, 7021)	186	OptiSense" (1999)
Riata [®] ST Optim [®] (7022)	188	Tendril [®] (1782T, 1782TC)
Riata [®] ST Optim [®] (7070, 7071)	184	Tendril [®] (1788T, 1788TC)
		Tendril MRI [™] (LPA1200M)
PACEMAKERS	PG	Tendril [®] SDX (1688T, 1688TC)
Accent [®] DR (PM2110)	213	Tendril [®] ST Optim [®] (1882T, 1882TC)
Accent [™] DR RF (PM2210)	211	Tendril [®] ST Optim [®] (1888T, 1888TC)
Accent [®] SR (PM1110)	239	Tendril [®] STS (2088TC)
Accent [®] SR RF (PM1210)	240	
Assurity" DR RF (PM2240)	210	FOCUS ON CLINICAL PERFORM
Assurity MRI [®] (PM1272)	236	ICD Premature Battery Depletion Ac
Assurity MRI [®] (PM2272)	208	Update on Durata [®] Lead Performanc
Assurity" VR (PM1240)	238	Update on Optim [®] Lead Insulation
Endurity" DR (PM2160)	209	Update on Riata" Lead Performance
Endurity [®] VR (PM1160)	237	
Identity ADx [®] DR (5380)	224	
Identity ADx SR (5180)	247	
Identity ADx [®] XL DC (5286)	225	
Identity ADx [®] XL DR (5386)	225	
Integrity" ADx DR (5366)	223	
Microny [®] (2425T, 2525T, 2535K)	248	
Verity ADx [®] XL DC (5256)	222	
Verity ADx [®] XL DR (5356)	222	
Verity ADx [®] XL DR M/S (5357M/S)	222	
Verity ADx [®] XL SC (5056)	246	
Verity ADx [®] XL SR (5156)	246	
Verity ADx ^{**} XL SR M/S (5157M/S)	246	
Victory [®] DR (5810)	217	
Victory [®] SR (5610)	245	
Victory [®] XL DR (5816)	220	
Zephyr [®] DR (5820)	215	
Zephyr [*] SR (5620)	244	
Zephyr [®] XL DR (5826)	218	
Zephyr [®] XL SR (5626)	242	

PACING LEADS	PG
IsoFlex [®] Optim [®] (1944)	262
IsoFlex [®] Optim [®] (1948)	264
IsoFlex [®] P (1648T)	276
IsoFlex [®] S (1642T)	277
IsoFlex [®] S (1646T)	278
OptiSense" (1699T, 1699TC)	266
OptiSense" (1999)	260
Tendril (1782T, 1782TC)	272
Tendril [®] (1788T, 1788TC)	274
Tendril MRI ["] (LPA1200M)	257
Tendril [®] SDX (1688T, 1688TC)	280
Tendril" ST Optim" (1882T, 1882TC)	270
Tendril [®] ST Optim [®] (1888T, 1888TC)	268
Tendril [®] STS (2088TC)	258
FOCUS ON CLINICAL PERFORMANCE	PG
ICD Premature Battery Depletion Advisory Update	292
Update on Durata [®] Lead Performance	299

Index of Phased-out Models

Phased-out Models

As stated in the introduction of this Product Performance Report, product performance is plotted over a maximum range of 20 years, with a minimum of 500 registered implants required for inclusion in the report. As such, models that no longer meet the criteria for inclusion have been phased-out of the Product Performance Report over time. In order to provide our customers with information on these phased-out models, an index including the final edition for each phased-out model has been included. Previous Product Performance Reports can be viewed on the web at Product Performance Reports | Abbott (cardiovascular.abbott).

CRT DEVICES

Atlas" + HF (V-340) Atlas" II HF (V-365) Atlas" II + HF (V-366) Epic" HF (V-337) Epic" HF (V-338) Epic" II HF (V-355) Frontier" (5508) Promote" (3107-36) Promote" RF (3207-30)

ICDS

Atlas^{**} DR (V-240) Atlas[®] DR (V-242) Atlas" II DR (V-265) Atlas" VR (V-199) Contour" II (V-185, V-185AC, V-185B, V-185C, V-185D) Contour[®] MD (V-175, V-175AC, V-175B, V-175C, V-175D) Current[®] DR (2107-36) Current[®] DR RF (2207-30) Current" VR (1107-36) Current[®] VR (1207-30) Epic[™] + DR (V-236) Epic" + DR (V-239) Epic^{**} DR (V-233) Epic^{**} DR (V-235) Epic[™] II DR (V-255) Epic^{**} II DR (V-258) Epic[®] II VR (V-158) Epic^{**} + VR (V-196) Epic^{**} VR (V-197) Photon[®] DR (V-230HV)

FINAL EDITION

First Edition 2011 Second Edition 2015 Second Edition 2015 First Edition 2011 First Edition 2010 First Edition 2010 Second Edition 2010 First Edition 2010

FINAL EDITION

First Edition 2010 Second Edition 2014 First Edition 2010 Second Edition 2010 First Edition 2008 First Edition 2010 Second Edition 2010 Second Edition 2015 First Edition 2010 Second Edition 2013 First Edition 2010 First Edition 2014 First Edition 2011 Second Edition 2010 First Edition 2010 Second Edition 2013 Second Edition 2013 Second Edition 2015 Second Edition 2010 Second Edition 2007

ICDS

Photon" µ DR (V-232) Photon" µ VR (V-194) Profile" (V-186F, V-186HV3)

DEFIBRILLATION LEADS

Riata^{*} i (1560, 1561) Riata^{*} ST Optim^{*} (7030, 7031) TVL^{*} ADX (1559) TVL^{*} RV (RV01, RV02, RV03, RV06, RV07) TVL^{*} SVC (SV01, SV02, SV03) SPL^{*} (SP01, SP02, SP03 & SP04)

PACEMAKERS

AddVent^{**} (2060) Affinity^{TDC} (5230) Affinity[™] DR (5330, 5331) Affinity" SR (5130, 5131) Affinity" VDR (5430) Entity" DC (5226) Entity[®] DR (5326) Identity[™] (5370) Identity[™] SR (5172) Identity[™] XL (5376) Integrity[®] SR (5142) Integrity[™] µ SR (5136) Integrity ADx^{*} DR (5360) Integrity ADx^{**} SR (5160) Integrity" AFx DR (5342, 5346) Integrity^{*} µ DR (5336) Meta^{**} DDDR (1256) Meta[®] DDDR (1256D) Paragon[®] (2010, 2011, 2012) Paragon" II (2016)

FINAL EDITION

Second Edition 2009 First Edition 2010 Second Edition 2007

FINAL EDITION

Second Edition 2016 Second Edition 2013 Second Edition 2019 First Edition 2010 First Edition 2010 First Edition 2018

FINAL EDITION

First Edition 2010 First Edition 2019 First Edition 2019 First Edition 2019 First Edition 2010 First Edition 2019 First Edition 2019 Second Edition 2021 Second Edition 2021 Second Edition 2021 First Edition 2020 Second Edition 2013 Second Edition 2013 Second Edition 2013 First Edition 2020 Second Edition 2010 Second Edition 2008 Second Edition 2008 Second Edition 2010 Second Edition 2010

Phased-out Models

PACEMAKERS

Paragon[®] III (2304, 2314, 2315) Phoenix[®] II (2005, 2008, 2009) Phoenix[®] III (2204, 2205) Regency^{**} SC+ (2400L, 2402L) Solus^{**} (2002, 2003) Solus" II (2006, 2007) Synchrony^{*} II (2022, 2023) Synchrony^{**} III (2028, 2029) Tempo^{**} D (2902) Tempo^{**} DR (2102) Tempo^{**} V (1102) Tempo^{**} VR (1902) Trilogy[®] DC (2308) Trilogy^{**} DC+ (2318) Trilogy^{TDR} (2350) Trilogy^{**} DR+ (2360, 2364) Trilogy^{**} SR (2250) Trilogy^{**} SR+ (2260, 2264)

PACING LEADS

ACE" (1015M, 1025M) AV Plus" DX (1368) Fast-Pass" (1018T, 1028T) IsoFlex[®] P (1644T) Passive Plus[®] (1135K, 1143K, 1145K, 1235K, 1243K, 1245K) Passive Plus^{**} (1136T, 1142T, 1146T, 1222T, 1226T, 1236T, 1242T, 1246T) Passive Plus["] DX (1336T, 1342T, 1346T) Passive Plus[®] DX (1343K, 1345K) Permathane^{^m} ACE (1035M) Permathane[®] ACE (1036T, 1038T) Tendril^{**} (1148T, 1188T) Tendril[®] (1188K) Tendril[®] DX (1388K) Tendril[®] DX (1388T, 1388TC) Tendril⁻⁻ SDX (1488T, 1488TC) Unipolar Lead (1007)

FINAL EDITION

First Edition 2010 Second Edition 2010 First Edition 2009 First Edition 2010 Second Edition 2010 Second Edition 2010 Second Edition 2009 First Edition 2010 Second Edition 2008 Second Edition 2008 First Edition 2010 First Edition 2010 Second Edition 2006 Second Edition 2009 First Edition 2007 First Edition 2010 Second Edition 2009 Second Edition 2010

FINAL EDITION

Second Edition 2009 First Edition 2019 Second Edition 2009 First Edition 2011 First Edition 2010 Second Edition 2014

First Edition 2018 First Edition 2010 First Edition 2010 First Edition 2010 Second Edition 2015 First Edition 2010 First Edition 2010 First Edition 2020 First Edition 2010

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000 Abbott.com

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing indications, contraindications, warnings, precautions, potential adverse events and directions for use.

" Indicates a trademark of the Abbott group of companies.
 # Indicates a third party trademark, which is property of its respective owner.
 © 2021 Abbott. All Rights Reserved.
 SJM-ELP-90935371 REV A | Item approved for U.S. use only.

